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Abstract
Plasmodium falciparum is an obligate intracellular protozoan parasite and is the 
causative agent of malaria, which infects 270 million people and causes 2 - 3  million 
human deaths each year. During the erythrocytic stages of their life cycle the parasites 
are exposed to reactive oxygen species generated by the host and their own metabolism. 
As a result the parasites have developed efficient antioxidant defence mechanisms, 
which include the thioredoxin system. A key component of the thioredoxin system is 
the flavin adenine dinucleotide (FAD)-dependent disulphide oxidoreductase thioredoxin 
reductase (PfTrxR), which provides the reducing power for the system using NADPH. 
PfTrxR is a high Mr TrxR and has been genetically and chemically validated as a 
potential drug target by targeted gene dismption and the identification of several 
specific inhibitors. PfTrxR contains three redox active centres (FAD, Cys88/Cys93 and 
Cys535/Cys540) that are in redox communication.
This study examined the catalytic mechanism (i.e. the transfer of reducing equivalents 
between these redox active centres) of PfTrxR by employing pre-steady state kinetics of 
the reductive (reduction of PfTrxR by NADPH) and oxidative half reaction (oxidation 
of reduced PfTrxR by thioredoxin). This identified that the PfTrxR protein confonned 
to the catalytic mechanism for high Mr TrxR, which was proposed from studies on the 
Drosophila melanogaster TrxR (DmTrxR). However, a few key differences were 
observed between the proteins from the two organisms. Firstly, the reductive half 
reaction of PfTrxR was observed to proceed at a faster rate than that of DmTrxR. 
Secondly, the oxidative half reaction was obsei’ved to proceed at a slower rate than that 
of DmTrxR protein. Finally, PfTrxR was shown not to cycle between a two (EH2) and 
four (EH4) electron reduced species in vitro (as demonstrated in DmTrxR) and was 
observed to be almost fully oxidised following reaction with excess thioredoxin. 
However, the rate of oxidation from the two electron reduced (EH2) to oxidised (Eox) 
forms was extremely slow and would probably not be relevant in vivo due to the high 
NADPH concentration.
The role of conserved PfTi'xR active site residues was investigated by producing site 
directed mutants and analysing them by steady state kinetics, anaerobic static titrations 
and pre-steady state kinetics. Particular attention was paid to the residues (His509 and 
Glu514 in PfTrxR) contained in the acid/base catalyst motif (HPXXXE) that has been 
identified and investigated in other disulphide oxidoreductase proteins. This 
demonstrated that both of these residues played crucial, yet distinct, roles in the transfer
....................
of reducing equivalents between the redox aetive centres in PfTrxR. The His509 residue
was observed to be involved in the stabilisation of the thiolate flavin charge transfer
complex intermediate and Glu514 was involved in the transfer of reducing equivalents
.between the Cys88/Cys93 and Cys535/Cys540 redox active centres. Mutation of His509 
to glutamine and Glu514 to alanine resulted in 0.5 % and 7 % activity (relative to wild- 
type) with NADPH and thioredoxin as substrates, respectively. Analysis of another 
residue that had been previously proposed as an acid/base catalyst (His 137 in PfTrxR), 
demonstrated that PfTrxR activity was relatively unaffected by mutation of this residue.
The publishing of the P. falciparum  genome in 2002 led to the identification of two 
dihydrolipoamide dehydrogenase (LipDH) genes. LipDH is an essential component of
Ia  -  keto acid dehydrogenase complexes (KADH) and is also a member of disulphide
■
oxidoreductase protein family (along with TrxR and glutathione reductase). Both
LipDH  genes have been recombinantly expressed using the Escherichia coli system and 
the recombinant proteins were biochemically characterised showing that they displayed 
typical characteristics of LipDH proteins. The major difference between the two 
proteins was their turnover numbers.
In silico analyses of the genes suggested that the proteins were targeted to
different organelles in the parasite (one to the mitochondrion and one to the apicoplast).
This suggested that the KADH would also be localised in these organelles and the
■■'Ccomponents of three KADH were identified in the P. falciparum genome; an a  -  
ketoglutarate dehydrogenase complex (KGDH), a branched chain a  -  keto acid
'
dehydrogenase complex (BCKDH) and a pyruvate dehydrogenase complex (PDH).
.Targeting of proteins to both the mitochondrion and apicoplast has been previously 
shown to be due to N-terminal targeting sequences and we experimentally confirmed 
the in silico predictions by fusing N-terminal sections of the components of the three 
KADH with green fluorescent protein (GFP) and expressing the fusion protein in 
erythrocytic stage parasites. By analysing the fluorescent staining in these parasites we 
were able to demonstrate that P. falciparum does possess organelle specific LipDH 
proteins and that components of the KGDH and BCKDH were localised in the 
mitochondrion and components of the PDH were localised in the apicoplast.
The transcription and protein expression levels of components of the P. falciparum 
KADH were tested by RT-PCR and western blotting, respectively. This confirmed that 
these complexes were expressed during the erythi'ocytic stages of the parasite’s life
cycle and would therefore be likely to play important roles in the parasites metabolism. 
The presence of a single apicoplast localised PDH is novel as organisms (such as plants 
and algae) that contain mitochondrion and plastids usually possess distinct PDH in these 
organelles. The P. falciparum  PDH is likely to provide acetyl CoA in the apicoplast for 
fatty acid biosynthesis, but its absence from the mitochondrion raises further questions 
as to the function of the tricarboxylic acid cycle (TCA cycle) and the role of the 
mitochondrion in general. The presence of the KGDH and BCKDH in the 
mitochondrion is in line with their localisation in other organisms and suggestions for 
their roles are given.
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NADP^ Nicotinamide adenine dinucleotide phosphate, oxidised foim
NADPH Nicotinamide adenine dinucleotide phosphate, reduced form
NAD(P)H Either NADH or NADPH
nm Nanometres
N-terminal Amino terminal
O2 Superoxide
OD Optical density
ORF Open reading frame
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDH Pyruvate dehydrogenase complex
PfTrx Plasmodium falciparum thioredoxin
PfTrxR Plasmodium falciparum thioredoxin reductase
PMSF Phenylmethyl Sulphonyl Flouride
PVM Parasitophorous vacuole
Px Peroxiredoxin/thioredoxin peroxidase
RBC Red blood cell/erythrocyte
rpm Revolutions per minute
ROS Reactive oxygen species
RT-PCR Reverse transcriptase PCR
SD Standard deviation
SDS Sodium dodecyl sulphate
SOD Superoxide disniutase
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TCA Tricarboxylic acid
TIC Translocase of the inner chloroplast membrane
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1.1 Plasmodium falciparum
Plasmodium falciparum is one of four species of the genus Plasmodium (the others are 
P. ovale, P, malariae and P. vivax) that infect humans and are the causative agent of 
malaria (Sherman, 1998). Of the fom' species it is the infection with P. falciparum  that 
causes the most severe clinical symptoms resulting in 2 to 3 million deaths per annum 
primarily because the parasites have developed resistance against most of the 
antimalarial drugs in use. Chemotherapy is currently the only way to combat malarial 
infection, as a vaccine against the parasites is still elusive. Therefore the identification, 
validation and assessment of potential new targets for the design of antimalarials is 
urgently required.
Indeed the P. falciparum  genome project was completed in 2002 (Gardner et a l , 2002) 
and has been widely used by scientists as a powerful tool to further investigate the 
parasite that causes malaria. P. falciparum has 14 chromosomes that range from 0.643 
to 3.29 megabases (Mb.) and the complete genome size is 23 Mb. The genome wide A/T 
content is 80.6 %, which was the highest ever sequenced and much higher when 
compared to that of Saccharomyces cerevisiae and Arabidopsis thaliana with 61.7 % 
and 65.1 %, respectively. The over 7,000 intergenic regions were found to have an 
overall A/T content of 86.5 %. The genome was predicted to contain over 5,000 protein 
coding genes with approximately 60 % genes that encode hypothetical proteins when it 
was published (Gardner et a l, 2002).
The availability of the entire genome sequence has also enabled scientists to engage in 
functional studies such as transcriptome and proteome analyses. Transcriptome analyses 
demonstrated that transcription from the parasite genome is highly regulated with 
developmental stage specific regulation of pathways (i.e. transcription of genes required 
for transcription and translation in ring stages, glycolysis in trophozoite stages and 
merozoite invasion in late schizont stages). Genes that were adjacent in the parasite’s 
genome were rarely co-regulated, although transcription from the plastid genome was 
found to be highly co-regulated (Bozdech et a l,  2003). Proteome analyses further 
confirmed the stage specific expression of genes and also investigated the roles of 
expressed proteins in the sexual as well as the asexual stages of the parasites (Florens et 
a l, 2002).
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Other studies investigated sequence motifs that are involved in the targeting of proteins 
into the different organelles within the parasite and also locations outside the parasites 
such as the Maurer’s clefts and trafficking onto the erythrocytic surface (Przyborski et 
a l, 2005). Together these studies are highly informative and provide an excellent basis 
for future analyses that will help to better understand the metabolic processes governing 
parasite development and survival and thus offer fantastic opportunities to study these 
processes in more detail with the aim to find control measures against this disease.
1.1.1 Malaria
Malaria is estimated to infect approximately 270 million people resulting in around 2 - 3  
million deaths globally each year (Snow et a l, 2005). Ninety percent of this death toll 
occurs in sub-Saharan Africa (Figure 1.1 A), where most of the victims of the disease 
are young children and pregnant mothers (World health organisation, 
http://www.who.int/mediacentre/factsheets/fs094/en/1. It has been estimated that 40 % 
of the world’s population is at risk from malarial infection (Greenwood et al, 2002). In 
addition to being a major health threat the disease causes great economic losses -  in 
countries with high levels of malaria transmission the disease can account for up to 40 
% of public health expenditure, 30 ~ 50 % of inpatient admissions, and up to 50 % of 
outpatient visits (Source: World health organisation, 
http://www.rbm.who.int/cmc upload/0/000/015/363/RBMInfosheet 10.html.
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F igu re  1.1 -  O c c u rre n c e  o f t ra n s m is s io n  a n d  d ru g  re s is ta n c e  in m alaria
The worldwide distribution of malaria transm ission and resistance to anti-malarial drugs a re  
displayed. P an e l A displays the regions w here malaria transm ission occurs. The dark pink 
regions are  those  w here transm ission occurs, the light pink a re  regions with limited risk and the 
white regions have no m alaria transm ission. P an e l B displays the regions w here drug 
resistance  to anti-malarial drugs occurs. The a re a s  coloured in grey display chloroquine 
resistance  and th o se  circled a re  a re a s  w here resistance to other anti-m alarials occurs. This 
figure w as constructed from figures taken from the world health organisation w ebsite (Panel A; 
httD://rbm.who.int/rbm/Attachment/20040921/SP-M alaria2004 1 odfl and the cen tre  for d isea se  
control and prevention w ebsite (Panel 8; httD://www.cdc.Qov/ncidod/emeraDlan/box23.htmL
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1.1.2 L ifecycle
P. falciparum is an obligate intracellular protozoan parasite of the phylum Apicomplexa 
that are characterised by the presence of apical organelles called micronemes, rhoptries 
and dense granules (figure 1.2). These organelles are essential for the invasion of their 
host cells and the formation of the parasitophorous vacuole. The life cycle of P. 
falciparum consists of sexual and asexual stages (figure 1.3).
Mitocftondnon
Plastid Micfotutxjies
Dense granules
NucleusX
Plasma membrane
Microneme
Merozorteu
Polar rings
Apical prominence
Rhoptry
Ribosomes Pellicular asterna
Figure 1.2 -  The ultrastructure of a merozoite
This representation of the ultrastructure of a  Plasmodium falciparum m erozoite w as b ased  on 
analysis of serial electron m icroscope slides. The figure displays the apical organelles 
(M icronem es, rhoptries and d e n se  granules) that a re  involved in invasion of the m erozoite into 
the erythrocyte and the single mitochondrion and the plastid (apicoplast), which a re  usually 
observed  to be closely assoc ia ted  . This figure w as taken from Bannister et al. 2000.
The asexual stages of the life cycle (figure 1.3 A) begin with the injection of infective 
sporozoites into the human by a female Anopheles mosquito as she takes a blood meal 
(Greenwood et a l, 2002). These sporozoites circulate in the bloodstream and may be 
cleared from the system by the spleen; however sporozoites that avoid the spleen firstly 
infect liver cells where they multiply to form the exo-erythrocytic schizont, which can 
contain up to 30,000 merozoites. Once the exo-erythrocytic schizont bursts it releases 
the merozoites into the bloodstream and these are then able to infect the host’s 
erythrocytes/red blood cells (RBC). Invasion of the RBC by the merozoite is 
coordinated by the apical organelles of the merozoite (figure 1.2), and results in a 
parasite that is surrounded by what is termed the parasitophorous vacuole membrane
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(PVM) that produces a barrier between the parasite and the host cell. The asexual intra- 
erythrocytic stages of parasite infection are responsible for the symptoms associated 
with malaria infection including lactic acidosis and fever. During the 48 hour 
erythrocytic cycle of P. falciparum the parasites roughly undergo three stages of 
development; the ring stage, the trophozoite stage and the schizont stage. During the 
ring stage of infection, which occurs 0 - 1 5  hours following erythrocytic invasion, the 
parasites are considered to be in Go phase and are relatively metabolically inactive. The 
trophozoite stage of infection occur s between 15 and 28 hours after invasion and it is 
during this phase that the parasite ingests the host cells cytosol in order to extract the 
nutrients it requires to develop. During this ingestion the parasite is required to detoxify 
the haem, which is released upon haemoglobin digestion. This is achieved by a process 
of haem biomineralisation, which results in an inert crystalline material called 
‘haemozoin’. This digestion and crystallization occurs in an acidic vacuole called the 
‘food vacuole’ (Egan et a l, 2002). In the schizont stage of infection, which occurs 
between 28 and 48 hours after invasion, the parasites begin to replicate their DNA by 
mitotic divisions -  this process is called ‘schizogony’. The parasite replicates to produce 
up to 16 merozoites that can go on to invade further erytlirocytes (figure 1.3). It is this 
cyclic bursting of erythrocytes that causes the anaemia and cyclical fever associated 
with malaria infections. The asexual stage can continue for many cycles, although some 
merozoites will undergo gametocytogenesis which is thought to be triggered by innate 
and host defence factors and can take 9 - 1 2  days to be completed (Sinden, 1998). The 
gametocytes that are formed are infective to the mosquito vector where the later stages 
of sexual development of the parasites takes place (figure 1.3B). When gametocytes are 
taken up in a blood meal from an infected individual, they differentiate into male and 
females gametes. Fertilisation occurs within the gut of the mosquito producing a zygote, 
which develops into the so-called ookinete. The mobile ookinete traverses the 
mosquito’s midgut and migrates to the basal lamina, where it midergoes rounds of 
asexual replication to produce sporozoites. The sporozoites are released from the 
ookinete and enter the salivary glands, ready to be injected into the human host during 
the next blood meal taken by the insect vector, allowing the cycle of infection to 
continue between the insect and human host of the malaria parasite.
As it is the erythi'ocytic stage of infection that causes the primary symptoms of malaria, 
this is the stage that will be primarily considered in this study. The erythrocytic stage of 
infection with P. falciparum  leads to severe clinical manifestations, which is because 
these infections are capable of producing cerebral malaria, along with the lactic 
acidosis, fever and anaemia observed in the other human malarial infections. Cerebral
- 5 -
Chapter 1. Introduction
malaria can be caused by two phenomena that are specific to P, falciparum infections, 
which are called sequestration and rosetting (White, 1998; Miller et a l, 2002).
Sequestration is caused by the attachment of infected RBC to the vascular endothelium 
and is caused by the expression of a parasite encoded protein, called erythrocyte 
membrane protein 1 (EMP-1) on the surface of the RBC (Kriek et a l, 2003). It is 
anchored to the membrane via association with another parasite-encoded protein called 
knob associated histidine rich protein, which accumulates under the RBC membrane in 
structures that are called ‘knobs’. EMP-1 attaches to the vaseular endothelium by 
interacting with receptor proteins on the cell surface, such as CD36 and intracellular 
adhesion molecule (ICAM) (Kyes et a l, 2001). Sequestration occurs in the later stages 
of the erythrocytic stage and results in the removal of these later stages from the 
bloodstream (Miller et a l, 2002), and decreases the likelihood of infected RBC being 
cleared by the spleen. Sequestration can occur in many organs in the body (i.e. heart, 
liver and kidneys), but it is primarily a problem if it occurs in the capillaries of the brain 
where it can cause blockage and lead to cerebral malaria. Roseting can also cause 
cerebral malaria and is produced by the association of an infected RBC with uninfected 
RBC (Wahlgren et a l, 1998).
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Figure 1.3 -  The life cycle of Plasmodium falciparum
The life cycle of Plasmodium falciparum consists of both sexual and asexual s tag es . Panel A 
displays the asexual s tag e  of infection, which occurs in the hum an host. The sporozoites are  
injected into hum an tissue by the Anopheles mosquito, w here they invade hepatocytes. The 
parasites replicate to produce up to 30,000 m erozoites, which burst from the liver into the 
bloodstream  before infecting erythrocytes. The erythrocytic s tag e  of the infection can  cycle 
m any tim es a s  parasites replicate and re-infect the red blood cells. P arasites can  also  undergo 
gam etocytogenesis to produce gam etocytes, which are  the entry point for the sexual s ta g e  of 
infection. Panel B displays the sexual s tag e  of infection, which occurs in the  Anopheline 
m osquito. The g am etes  fuse in the  m osquitos midgut to produce a zygote which develops into 
an  ookinete. The ookinete traverses the midgut wall and becom es an oocyst in which 
sporozoites develop before entering the salivary glands ready to infect the hum an host again. 
This figure w as taken from Wirth, D.F., 2002.
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1.1.3 Chemotherapies
As malarial infections are so widespread (highlighted pink in figure 1.1 A) and cause so 
many infections and deaths globally it is necessary to have efficient anti-malarial 
chemotherapies (in order to keep the effect of the disease as low as possible). 
Chemotherapies that have been/are being used extensively include chloroquine, 
mefloquine, antifolate drugs and artemisinin, although drug resistant strains to many of 
these are now widespread (figure I.IB).
1.1.3.1_____Cuirent chemotherapies
Chloroquine has been the most widespread anti-malarial drug used over the last 50 
years and this has led to the emergence of widespread chloroquine resistance in malarial 
infections (White, 1996). Over the years a number of different mechanisms of action of 
this drug have been suggested. Currently the most favoured mode of chloroquine action 
is the blocking of degradation and biomineralisation of haemoglobin and haem, 
respectively (Egan et al, 1997; Leed et a l, 2002). The resulting increase in intracellular 
levels of toxic haem results in increased oxidative stress and membrane damage, which 
ultimately causes parasite death (Loria et al, 1999). Chloroquine resistance is 
associated with lower levels of the drug in the parasite’s food vacuole, which is thought 
to be mediated by an increased efflux of the drug from the parasites via a multi-drug 
resistance transporter (Volkman et al, 1998). A second mechanism that clearly is 
associated with chloroquine resistance not only in laboratory strains but also clinical 
isolates are mutations in the so-called chloroquine resistance transporter gene (Mu et 
al, 2003). The precise mechanism as to how this transporter confers resistance is not 
yet conclusively solved. Another theory is that chloroquine resistance correlates with 
increased levels of the tripeptide glutathione (Ginsburg et a l, 2003). The basis of this 
correlation is that free haem is detoxified by glutathione and that this process is 
inhibited by chloroquine thus arguing that increased levels of glutathione should lead to 
a protection of the parasites against the toxic action of free haem (Atamna et a l,  1995; 
Ginsburg et a l, 2003).
A second quinine derivative is mefloquine and this dmg has been in use since the late 
1970s (Davidson et al., 1975; Trenholme et a l, 1975). Like chloroquine, mefloquine 
resistance is rising in areas of Asia and Mauritius and the drug also causes numerous 
side effects such as nausea, vomiting and dizziness.
Chapter 1. Introduction
Antifolate drugs such as pyrimethamine and sulphonamides have been used 
successfully against Plasmodium species. However, resistances to these compounds are 
now widespread due to point mutations in both the dihydropterate synthase and 
dihydrofolate reductase (dehydrogenase) genes (Peterson et ah, 1988; Reeder et a l, 
1996).
Artemisinin is a naturally occun ing compound, which can be extracted from the shi’ub 
Artemesia annua and has been used in Chinese medicine for millennia. Unfortunately, 
artemisinin is an unstable compound (Dong et al, 2003) and many artemisinin 
derivatives, such as artemether and artesunate are now being used as treatments for 
malaria. Artemisinin is thought to act in a number of ways, like chloroquine it can 
inliibit production of haemozoin by alkylating haem but it also leads to alkylation of 
parasite proteins (Meshnick, 1998). It has been shown to act on the serco/endoplamic 
reticulum Ca^^ ATPase (Eckstein-Ludwig et al, 2003) and is also redox active and can 
produce reactive oxygen species that create oxidative stress and damage the cell (Dong 
et a l, 2003). Artemisinin based combination therapies (ACT) have now been 
introduced by the World Health Organisation for treatment of malaria due to the 
increasing prevalence of dmg resistance to the original dmgs of choice.
Other antimalarial treatments include the use of insecticide treated mosquito nets that 
can reduce transmission of the disease (World health organisation; 
http://www.rbm.who.int/cmc upload/O/OOO/015/368/RBMInfosheet 5.htm). These have 
been extremely successful, but are preventative cures that are logistically difficult and 
expensive to implement. It is because of this emerging dmg resistance and the relative 
expense of the ACT treatments that the search for new antimalarial drugs must 
continue.
1.2 Redox and antioxidant systems
During their intra-erythrocytic development Plasmodium parasites have to survive in a 
pro-oxidant environment that contains both oxygen and iron. Reactive oxygen species 
are produced by the parasites themselves when they degrade haemoglobin to haem (FP 
IX) in the food vacuole. The oxidation of haemoglobin results in the formation of 
superoxide anions (O2*'), which can spontaneously form hydrogen peroxide and 
oxygen. This reaction generates the substrates for the formation of the highly active and 
extremely toxic hydroxyl radicals. In addition, the presence of iron favours the Fenton 
reaction, which can result in the formation of hydroxyl radicals (figure 1.4). FP IX that
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is produced from the degradation of haemoglobin can be polymerised into an inert 
substance called ‘haemozoin’, although only between 50 % and 90 % of FP IX 
produced is stored as haemozoin, suggesting that the remaining 10 % to 50 % requires 
to be degraded in order to stop the production of reactive oxygen species (Atamna et al ,  
1993; Loria et a l ,  1999; Zhang et al ,  1999; Egan et al ,  2002; Becker et a l ,  2004b).
In order to cope with these reactive oxygen species the parasites have evolved highly 
efficient antioxidant and redox mechanisms including superoxide dismutases (SOD), 
the thioredoxin and the glutathione systems (figure 1.4 and figure 1.5) (Kmajski et al,  
2001; Becker et al,  2003; Sienkiewicz et al,  2004). However, the parasites lack 
catalase and a glutathione dependent peroxidase, both of which are important 
antioxidants in other organisms. Therefore it is currently believed that the thioredoxin 
system acts as the major antioxidant systems in the parasites whereas glutathione acts as 
major thiol redox buffer and acts as a co-factor for enzymes like glutathione S- 
transferase and glyoxalase (Harwaldt et a l ,  2002; Akoachere et al ,  2005).
HbO-Fe"Polymenzation into 
haemozoin Digestion by 
Proteases
R elease into cytosol - 
Membrane dam age/Redox active O, + 'OH OH
Lipid perpxidabpn
Fenton reaction ROOH RH
O, ♦ Fe" 
Fe‘*+*OH + 0 H “
Chain reaction
ROO'
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Figure 1.4 -  Production of reactive oxygen species In P. falciparum
This figure displays the production of reactive oxygen species in P. falciparum a s  a 
co n seq u en ce  of haem oglobin degradation and biomineralisation in the food vacuole. 
Haemoglobin (HbO-Fe^ ) is degraded  by p ro teases  releasing free haem  (FP IX), which is then 
mostly polymerised into haem ozoin in the  food vacuole. However, up to 50 % of this free haem  
is re leased  into the cytosol w here it can  produce reactive oxygen sp ec ies  that c a u se  m em brane 
dam age. Hydroxyl radicals can  form in the p resen ce  of free haem  via the Fenton reaction. 
Superoxide radicals (O2 ) that a re  produced by the oxidation of haem oglobin are  d ism utated to 
hydrogen peroxide (H2O 2) by superoxide d ism utase (SOD) or can react with H2 O 2 to 
spontaneously  form hydroxyl radicals (OH and OH). Hydrogen peroxide is detoxified by 
thioredoxin peroxidases that form part of the thioredoxin system . Figure w as taken from Müller, 
S., 2004.
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1.2.1 Thioredoxin system
As outlined above, it has been suggested that the thioredoxin system is of particular 
importance in the parasites antioxidant homeostasis (Becker et a l, 2004; Becker et a l, 
2004; Muller, 2004). The thioredoxin system comprises the NADPH-dependent 
disulphide oxidoreductase thioredoxin reductase (TrxR) and the ~ 12 kDa redox active 
protein thioredoxin (Trx). Trx acts as a redox messenger in the cell interacting with a 
wide variety of protein and peptide substrates such as transcription factors, 
ribonucleotide reductase, methionine sulphoxide reductase, peroxiredoxins and 
glutathione, and therefore plays an important role in cell proliferation, protection against 
reactive oxygen species and signal transduction (Powis et a l, 2001; Nakamoto et a l, 
2004; Baler et al, 2005; Kabe et al, 2005).
It is likely that the thioredoxin system has essential roles for P. falciparum  survival as 
the knockout of the TrxR gene has a lethal effect on the parasites (Krnajski et a l, 2002). 
This supports the finding that there is a single TrxR gene present in the parasite genome 
and supports the suggestion that the functions of the thioredoxin redox cycle cannot be 
replaced by another system such as the glutathione redox cycle as has been shown in 
other organisms. The parasites also contain only a single gene encoding a conventional 
thioredoxin with a number of genes encoding for thioredoxin-like proteins whose 
ffmction have not yet been established (Muller, 2004). Given that the peroxiredoxin- 
linked detoxification seems to be the major avenue for the parasites to detoxify ROS, it 
was expected that these proteins would be of crucial importance for parasite survival. 
However, there appears to be some redundancy between the different peroxiredoxins 
identified in the parasites, as the knockout of the cytosolic 2-Cys peroxiredoxin PfTrx- 
Px-1 merely renders parasites hypersensitive towards oxidative stress but does not have 
an effect on their viability (Komaki-Yasuda et a l, 2003). This emphasises that it is 
important to further dissect the precise roles of the different peroxiredoxins to be able to 
assign specific functions of these proteins that are key for parasite suivival and thus are 
potentially suitable for the design of inhibitors that might be developed into new 
antimalarials.
Both the thioredoxin and glutathione systems play extremely important but distinct roles 
in P. falciparum, with the reducing power for both of these redox cascades provided by 
their respective disulphide oxidoreductases, TrxR and glutathione reductase (OR) and it 
is those that I will introduce in the next section.
I!
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F igu re  1.5 -  T he th io red o x in  an d  g lu ta th io n e  s y s te m s  of P. falciparum
The thioredoxin and glutathione redox system s both consist of a  num ber of redox active 
proteins/peptides that produce a  c a sc a d e  of electrons from NADPH to accep to r m olecules. Both 
sy stem s contain com m on receptors such  a s  ribonucleotide reductase  and  transcription factors, 
although each  system  also  contains its own specific com ponents a s  well. This figure displays 
the thioredoxin and glutathione c a sc a d e s  with the oxidised forms (in yellow) and reduced forms 
(in orange) of the redox proteins/peptides. The th io red o x in  sy s te m  transfers reducing 
equivalents from NADPH via thioredoxin reduc tase  (TrxR) to thioredoxin (Trx) before finally 
reducing peroxiredoxins, glutathione (G SSG ) and the com m on accep to r m olecules. The 
g lu ta th io n e  sy s te m  transfers reducing equivalents from glutathione reduc tase  (GR) to 
glutathione (G SSG  in the oxidised form, GSH in the reduced form). Reducing equivalents can  
then be p assed  onto glutaredoxin (Grx) before reduction of plasm oredoxin and the com m on 
accep to r m olecules. Figure w as taken from Müller, S., 2004.
1.3 Disuiphide oxidoreductases
The family of flavoprotein disulphide oxidoreductases includes glutathione reductase 
(GR), dihydrolipoamide dehydrogenase (LipDH), thioredoxin reductase (TrxR), 
trypanothione reductase (TyrR) and mercuric ion reductase (MR) (Argyrou et al.,
2004). The proteins of this enzyme family have a high degree of amino acid sequence 
identity and they have very similar tertiary structures (Williams et a l ,  1982; Hirt et al ,  
2002; Argyrou et al ,  2004). All members of this protein family are characterised by the 
presence of a tightly bound flavin co-factor (FAD; figure 1.9), the formation of 
homodimers and the presence of at least one redox active disulphide. They can however 
be separated due to the presence of different amino acid domains that have distinct roles 
in catalysis (figure 1.6). The four most common domains are the FAD binding domain, 
the NADH/NADPFI binding domain, the central domain and the interface domain.
The FAD binding domain and NADH/NADPH (figure 1.6) binding domains contain the 
heptapeptide binding motif (usually but not always GXGXXG) for binding of their 
respective co-factor or substrate, with the FAD and the NADH/NADPH being bound to
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the proteins in an extended conformation (Pai et a l, 1983; Mattevi et a l,  1992; Lantwin 
et a l,  1994). The FAD binding domain also usually contains the redox active cysteine 
motif (CXXXC), although this motif is found in the NADPH domain of the low 
TrxR (see section 1.3.1.2 and figure 1.6). The central domain contains residues that are 
important in the binding of the FAD cofactor and also form part of the active site. The 
interface domain is responsible for dimer formation and contains the acid/base catalyst 
motif (HPXXXE), which is located in the active site of the homodimeric protein. Two 
active sites form in the homodimer with each active site containing residues from the 
FAD binding, NAD(P)H binding and central domains of one subunit with the interface 
domain of the other. The interface domain of some disulphide oxidoreductase contains a 
C-teiminal extension that possesses a second non-flavin redox centre (figure 1.6B; the 
extension of high Mr TrxR and the organism specific differences observed will be 
discussed in section 1.3.1.1).
(A) FAD NAD(P)H Central {interface
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(B) FAD NAD(P)H Central j interface
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Figure 1.6 -  Overview o f the domain s tructure  o f disulphide oxidoreductases
This figure demonstrates the domain structure of the disulphide oxidoreductases, which can be 
divided into a flavin cofactor binding domain (FAD), pyridine nucleotide binding domain 
(NAD(P)H), central domain (Central) and interface domain (Interface). Residues important for 
catalysis including disulphide forming cysteines and the acid/base catalyst motif are labelled 
below the domains. Panel A displays the domain structure for glutathione reductase and 
dihydrolipoamide dehydrogenase. Panel B displays the domain structure for mercuric ion 
reductase and high Mr thioredoxin reductase and demonstrates the organism specific 
differences observed at the C-terminal extension. Panel C display the domain structure for low 
Mr thioredoxin reductase. This figure was modified from Argyrou et al. 2004.
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Analysis of the tertiary structures of disulphide oxidoreductases also reveals a similarity 
in the organisation of the active site (except for in the low Mr TrxR; see section 
1.3.1.2), with the active site of GR being shown as an example in figure 1.7. The 
NADH/NADPH binding site is located on the re side of the isoalloxazine ring of the 
bound FAD cofactor. The region in which the nicotinamide ring of NADH/NADPH is 
located is occupied by an aromatic amino acid (which is usually a tyrosine; Tyrl97 in 
figure 1.7) in the oxidised protein and this is rotated out of position following binding of 
the pyridine nucleotide (Pai et al., 1983; Mattevi et a l, 1992; Biterova et a l,  2005). 
Reducing equivalents are passed from the reduced pyridine nucleotide (on the re side) 
to the flavin before being transferred to the redox active cysteine pair located on the si 
side of the isoalloxazine ring of FAD (Cys58 and Cys63 in figure 1.7). The residues of 
the acid/base catalyst motif (His467’ and Glu472’ in figure 1.7) are ideally located close 
to the N-terminal cysteine pair to promote the transfer of reducing equivalents through 
the active site to the substrate (or to the C-terminal redox active site). This transfer of 
reducing equivalents was initially suggested based on the crystal structm'e of human GR 
by Pai et a l and is now the accepted catalytic mechanism for GR and other disulphide 
oxidoreductases (Pai et a l, 1983). The flow of reducing equivalents in this mechanism 
and the presence of two distinct substrate binding sites suggest that disulphide 
oxidoreductases act via a ping-pong mechanism. For disulphide oxidoreductases, this is 
where one substrate binds, reduces the protein and is released before the second 
substrate binds and oxidises the protein. Studies into LipDH (Argyrou et a l, 2001), GR 
(Williams, 1992), TryR (Leichus et a l,  1992) and MR (Patel et a l, 1999) have 
confirmed this, although GR and LipDH at high substrate concentrations (GSSG for GR 
and NADH for LipDH) display sequential reactions (Mannervik, 1973; Tsai, 1980; 
Rakauskiene et a l,  1989; Tsai et a l, 1992).
Analyses of the spectral intermediates formed during catalysis have confirmed the 
proposed catalytic mechanism. Using pre-steady state kinetic analyses it is possible to 
identify the spectral intermediates formed during catalysis; the reaction of 
Mycobacterium tuberculosis LipDH is shown as an example (figure 1.8; Argyrou et a l, 
2002; Argyrou et a l, 2004). Following binding the pyridine nucleotide reduces the 
flavin and forms a FADH' NAD^ charge transfer complex (FADHz NAD"  ^box of figure
1.8) that can be obseived spectrally as absorbance at longer wavelengths (600nm -  700 
nm in figure 1.8). Reducing equivalents are passed via the flavin (a fully reduced flavin 
can be obseived in the main panel and in the EH4 box of figure 1.8) to the N-terminal 
cysteines producing the EH2 species (EH2 box of figure 1.8) that forms a charge transfer
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complex (CTC) between the flavin interacting thiol and the FAD (Cys63 in figure 1.7), 
which can be observed spectrally as a band centred around 500nm -  550nm (figure 1.8).
Several studies have investigated the role of the acid/base catalyst motif in the catalysis 
of disulphide oxidoreductases, although these have been primarily in GR and LipDH. 
Mutations of the conserved histidine, proline and glutamate residues lead to severe 
impairment of enzymatic activity (Deonarain et a l, 1989; Kim et a l,  1992; Gilberger et 
a l,  1997). The conserved histidine residue (His467’ in figure 1.7) acts as the acid/base 
catalyst by acting as a proton donor/acceptor in the dithiol/disulphide transfer reactions 
that occur during catalysis (Bauer et a l , 2003b). The proline residue is in the cis- 
conformation and acts to orientate the histidine residue so that the NE2 of the imidazole 
ring is positioned near the interchange thiol of the N-terminal cysteine pair (Cys58 in 
figure 1.7). The conserved glutamate residue (Glu472’ in figure 1.7) has been shown to 
form a hydrogen bond with the conserved histidine residue between the epsilon 
carboxyl of glutamic acid and the NDl of histidine (Pai et a l, 1983). The role of the 
conserved glutamate has also been studied by molecular dynamics and density function 
calculations, which predict its importance in making the histidine residue a better 
catalyst (Brandt et a l,  2005).
The following sections further introduce thioredoxin reductase and dihydrolipoamide 
dehydrogenase, as these are the members of the disulphide oxidoreductase family that 
will be investigated in this study.
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NADP
Figure 1.7 -  The active site of disulphide oxidoreductases
The active site of human GR is displayed as an example of the organisation of the pyridine 
nucleotide (NADP^) and FAD-blndIng and the positioning of the N-terminal redox active cysteine 
residues (Cys58 and Cys63) and the residues of the acid/base catalyst motif (His467’ and 
Giu472’). The tyrosine residue that shields the re side isoalloxazine ring in the oxidised protein 
is shown rotated outwards due to pyridine nucleotide binding, while the nicotinamide ring and 
isoalloxazine rings are stacked against each other. This figure was taken from Argyrou at al. 
2004.
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Figure 1.8 -  Spectral intermediates of LipDH during catalysis
The intermediates formed during catalysis of Mycobacterium tuberculosis LipDH are shown, as 
an example of those observed in all disulphide oxidoreductases (although high Mr TrxR are 
complicated by the presence of a second non-flavin redox active centre). The Main panel 
displays the spectra of the catalytic intermediates Eqx, FADH2 'NAD^. EH2  and EH4 . The 
formation of FADH2 'NAD'^ charge transfer complex can be observed as absorbance at longer 
wavelengths (600nm -  700 nm) and the formation of a flavin thiolate charge transfer complex 
can be observed as absorbance between 500nm -550 nm. Eqx box displays the isoalloxazine 
ring and N-terminal cysteine pair in the oxidised state. EH2  box displays the thiolate flavin 
charge transfer intermediate during the two electron reduced intermediate. EH4  box displays the 
full flavin and N-terminal cysteine reduction in the four electron reduced intermediate. FADHg' 
NAD'*' box displays the charge transfer complex intermediate formed following binding of NADH 
to the protein. This figure has been taken from Argyrou et al. 2004.
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L3.1 Thioredoxin reductase (TrxR)
Thioredoxin reductases catalyse the NADPH-dependent reduction of the 12 kDa 
thioredoxin protein, and therefore provides the reducing power for the thioredoxin 
redox cycle (figure 1.5, section 1.2.1). TrxR occur in two distinct forms in nature, the 
high and low Mr TrxRs that are distinguished by molecular weight (Mr), domain 
structure and enzyme mechanism as outlined below.
1.3.1.1____ High Mr Thioredoxin reductase
The high Mr TrxRs have a subunit molecular' size of -55 IcDa. They possess a similar 
domain structure as GR -  they have a protein bound FAD co-factor, an N-terminal 
redox active pair of cysteines (which is equivalent to GR) and they use NADPH similar 
to GR (figure 1.6B and figure 1.9). The high Mr TrxR are found in mammals, insects, 
worms and Plasmodium falciparum  (Gladyshev et al, 1996; Gilberger et a l, 1997; 
Gladyshev et a l, 1999; Williams et a l, 2000) and it has been shown by phylogenetic 
analyses that they are clearly related to GR (Hirt et a l, 2002). However, in addition to 
the two redox active centres that GR has, they contain a third redox active centre which 
resides on a C-terminal extension of 15 to 20 amino acids (relative to GR; figure 1.6B). 
The primary structure and nature of this redox active centre is organism specific and can 
either consist of a disulphide or a selenenylsulphide. Mammalian proteins contain a 
selenenylsulphide that forms between adjacent seienocysteine and cysteine residues 
(Gladyshev et a l, 1999; Lee et a l, 2000), while in insect TrxR a disulphide forms 
between adjacent cysteine residues (Bauer et a l, 2003b) and in P. falciparum  a 
disulphide forms between two cysteine residues separated by four amino acids (figure 
1.6B) (Gilberger et a l,  1998; Wang et a l,  1999).
The presence of a seienocysteine residue at the C-terminal redox active site of 
mammalian TrxR is an interesting obsei-vation. Not only is the seienocysteine residue 
much more reactive than its cysteine homologue, but the extra bond length (15 % 
greater in comparison to cysteine) allows for the formation of the selenenylsulphide 
bond between the adjacent seienocysteine and cysteine residues. This additional bond 
length is in contrast to the situation in insect TrxRs and other proteins, where a 
disulphide bond that forms from the adjacent cysteine residues is strained (Schulz et a l, 
1990; Wang et a l, 2000). Indeed, replacement of the seienocysteine with cysteine in the 
human TrxR (producing a GCCG motif) resulted In an almost inactive protein (Lee et 
a l,  2000; Zhong et a l,  2000). Replacement of the human Ti*xR GCUG motif (where U
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coiTesponds to seienocysteine) with that of the Drosophila melanogaster TrxR (SCCS), 
resulted in an even lower activity than that obseiwed for the GCCG motif (L. Johansson, 
unpublished data), which suggested that the local enviromnent around the C-terminus 
was important for catalysis.
An in depth study of the Drosophila melanogaster TrxR has led to the proposal of the 
catalytic mechanism of not only DmTrxR but of all high Mr TrxR (Bauer et a l, 2003b). 
By studying the spectral intennediates of the reductive half reaction (anaerobic 
reduction with NADPH/ sodium borohydride) and the oxidative half reactions 
(oxidation of the reduced protein by thioredoxin) of DmTrxR, Bauer et a l were able to 
propose the protein’s catalytic mechanism based on observations for the related protein 
GR (Bauer et a l, 2003b). Bauer et a l proposed that the protein was unable to be fully 
reduced (i.e. all tliree redox centres reduced to form an EHg species) by natural 
substrates under physiological conditions, but that the high Mr TrxR cycled in catalysis 
between a two electron reduced form (EH2) and a four electron reduced form (EH4) 
(Bauer et a l , 2003b).
The P. falciparum TrxR (PfTrxR) has been studied previously in some detail and these 
studies have shown that the three redox active centres (FAD, N-terminal disulphide 
(C88/C93) and C-teiminal disulphide (C535/C540) are in redox communication, which 
guarantees transfer of electrons through the enzymes active site and onto the protein 
substrate thioredoxin disulphide (Gilberger et a l, 1997; Gilberger et al, 1998; Wang et 
a l, 1999). The individual roles of each redox active cysteine residue have been 
investigated by mutagenesis, and have identified that Cys93 interacts with the flavin 
while Cys88 is the interchange thiol that forms a disulphide with one of the C-terminal 
cysteines (Gilberger et a l, 1997; Gilberger et a l,  1998; Wang et a l, 1999). The C- 
terminal cysteine that forms the disulphide has been suggested to be Cys540, although 
this has not been categorically proven and both C-terminal cysteines can accept 
reducing equivalents from the N-terminal thiols (Wang et a l, 1999).
In chapter 3 of this study I will fuither investigate the catalytic mechanism of PfTrxR by 
studying its reductive and oxidative half reactions and will concentrate primarily on the 
role that the acid/base eatalyst motif plays in the transfer of reducing equivalents 
between the redox active centres. The further information gained in this study may be 
an important aid in rational drug design against the PfTi-xR protein, which has 
previously been validated as a potential drug target as gene knockout studies have 
proved that the protein is essential for parasite survival (Kmajski et a l, 2002).
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Therefore, any targeted inhibition of the P. falciparum thioredoxin reductase (and/or the 
thioredoxin system) would be a potential candidate for an antimalarial dmg. The C- 
terminal disulphide has been proposed as a possible site of organism specific 
inactivation due to the organism specific differences observed there. Indeed, this has 
been shown to be the site of inactivation observed in P/frxR  inhibited with mannich 
base compounds (Davioud-Charvet et a l, 2003) and nitrophenyl compounds 
(Andricopulo et a l, 2006), and is therefore a plausible target for further studies in drug 
design.
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Figure 1.9 - Substrates and cofactors of disulphide oxidoreductases
This figure displays the redox active compounds that are involved in the catalytic reactions of 
LipDH (Panel A and 0) and many other disulphide oxidoreductases (Paneis B -  D). Panel A 
displays oxidised lipoic acid, with its sulphur groups at the 6  and 8  positions. Panel B displays 
oxidised flavin adenine dinucleotide cofactor of disuiphide oxidoreductases, with the picture 
drawn from the s/side of the isoalloxazine ring. Panel C displays reduced nicotinamide adenine 
dinucleotide (NADH) substrate that is involved in LipDH catalysis. Panel D displays reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) substrate that is involved in GR, TryR 
and TrxR catalysis. All structures were obtained from the SigmaAldrich website 
fwww.siqmaaldrich.coml.
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1.3.1. 2____ Low Mr Thioredoxin reductase
The low Mr TrxR are ~ 35 kDa and are found in Escherichia coli, funghi, plants and the 
protozoan parasite Trichomonas vaginalis (Williams et a l, 2000; Hirt et a l, 2002; 
Coombs et al, 2004; Gelhaye et a l, 2005). The low Mr TrxR possesses NADPH- 
binding, FAD-binding and central domains but lack the interface domain and C- 
terminal extension observed in the high Mr TrxR (Figure 1.6C). The redox active 
disuiphide is present in a CXXC motif that is located in the NADPH binding domain, 
which is in contrast to other disuiphide oxidoreductases that possess a CXXXXC motif 
in their FAD-binding domain (figure 1.6C). Analysis of the crystal structure from low 
Mr TrxR demonstrated that both the NADPH-binding domain and the redox active 
disuiphide were on the re side of the FAD (Kuriyan et a l, 1991), which is unlike the 
other disuiphide oxidoreductases where the NADPH-binding domain is on the re side 
and the redox active disuiphide is on the si side (Pai et al, 1983; Sandalova et al,
2001). This ari’angement requires a large conformational change to occur in the protein 
for Trx-reduction to occur as the redox active cysteines are buiied next to the FAD. 
Lennon et al. demonstrated that a 67° rotation of the NADPH-binding domain relative 
to the FAD-binding domain resulted in the transfer of the dithiols to a position where it 
can interact with thioredoxin (Lennon et a l, 2000). As they lack the interface domain 
the low Mr TrxR do not possess the acid-base catalyst motif (HPXXXE) that is found in 
other disuiphide oxidoreductase (Figure 1.6). Instead, it was determined that they 
utilised an aspartate residue as a acid/base catalyst during catalysis (Mulrooney et a l,
1994).
1.3.2 Dihydrolipoamide dehydrogenase (LipDH)
Dihydrolipoamide dehydrogenase (LipDH) is an essential component of the a  -  keto 
acid dehydrogenase complexes (KADH; see section 1.4) where it catalyses the 
oxidation of a dihydrolipoamide moiety (figure 1.10; section 1.4). This 
dihydrolipoamide moiety is produced from the covalent attachment of lipoic acid to a 
protein component of the KADH (see section 1.4). In Plasmodium, lipoic acid (figure
1.9) is produced by the introduction of two sulphurs at the 6 and 8 positions of a type 11 
fatty acid biosynthesis intermediate called octanoyl-acyl carrier protein. This step is 
catalysed by a lipoic acid synthase (LipA), which is an iron-sulphur protein that is 
located in the plastid of P. falciparum (Thomsen-Zieger et a l, 2003; Wrenger et a l, 
2004). The lipoic acid produced in the apicoplast can be attached to the KADH by the 
action of a lipoyl transferase (LipB) that is also located in the apicoplast (Thomsen-
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Zieger et a l, 2003; Wrenger et a l, 2004). Interestingly, P. falciparum  also contain a 
mitochondrially localised lipoate protein ligase (LplA) that can catalyse the attachment 
of salvaged lipoic acid to the KADH (Wrenger et a l, 2004). The presence of organelle 
specific lipoate transferase and ligase proteins suggest that P. falciparum may possess 
KADH in both the mitochondrion and the plastid. This would be reminiscent of the 
situation in plants and algae, where KADH are located in the mitochondrion and the 
plastid (Mooney et a l, 2002). As a component of the KADH, LipDH proteins are also 
required to be transported to the mitochondrion and plastids and as a result plastid- 
containing eukaryotes have developed two different LipDH isofoims (Lutziger et a l,
2000). The P. falciparum LipDH and components of the KADH will be described in 
chapter 4 (LipDH) and chapter 5 (KADH components) of this study.
LipDH shares the same domain structure as GR and TyrR, and contains a single redox 
active cysteine pair in a CXXXXC motif in the FAD domain and the acid-base catalyst 
motif in the interface domain of the protein (figure 1.6A). However, the protein displays 
substrate specificity for NADH (figure 1.9) rather than NADPH and although the 
catalytic mechanism is similar to that of GR, reducing equivalents run in the opposite 
direction to that of GR in the LipDH physiological reaction (Sahlman et a l, 1989). 
Reducing equivalents are passed from the reduced substrate dihydrolipoamide to the 
redox active cysteines on the si side of the isoalloxazine ring of FAD, then via the 
bound flavin cofactor to NAD^ on the re side of the isoalloxazine ring of FAD.
However, LipDH acts with a ping-pong reaction (similar to GR; see section 1.3) and the 
transfer of reducing equivalents can also be passed from NADH to lipoamide though the 
protein. An example of the spectral intermediates formed during catalysis of LipDH is 
shown in figure 1.8 and is discussed in section 1.3.
In addition to its role as a component of KADH, LipDH can also function as a possible 
antioxidant by reducing free lipoic acid. Lipoic acid (in free and protein bound forms) 
has been shown to interact with other redox active compounds, such as thioredoxin, 
glutathione, nitric oxide and ubiquinone (Jocelyn, 1967; Xia et a l,  2001; Bryk et a l, 
2002; Igamberdiev et a l, 2004). LipDH has also been implicated as a potential pro­
oxidant (Grinblat et a/., 1991; Sreider et a l, 1992) and as a result has been extensively 
studied as a potential drug target, especially in human parasites such as trypanosomatids 
(Krauth-Siegel et a l, 1995).
In humans, a genetic defect in LipDH activity produces a number of disorders due to the 
fact that the LipDH protein is shared between the mitochondrial KADH, and a
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deficiency in the LipDH activity affects all of the complexes. Indeed, targeted gene 
disruption of the mouse LipDH was found to induce a prenatal mortality phenotype 
(Johnson et a l, 1997). LipDH deficiency can occur as a result of mutations in all of the 
domains of the LipDH protein, with its clinical manifestations being wide-ranging and 
including severe and progressive neurological disorders, lactic acidosis, and maple 
syrup urine disorder (Liu et a l, 1993; Shaag et a l, 1999; Cerna et a l, 2001; Grafakou 
et a l,  2003).
1.4 g-Keto acid dehydrogenase complexes (KADH)
a-Keto acid dehydrogenase complexes (KADH) are large multi-enzyme complexes that 
can be up to 10 MDa in size. These complexes are formed by multimers of three 
independent proteins, which are a-keto acid dehydrogenase (El), acyl transferase (E2) 
and dihydrolipoamide dehydrogenase (E3/LipDH). There are three KADH that are 
located in the mitochondria of eukaryotes, the pyruvate dehydrogenase complex (PDH), 
the a  -  ketoglutarate dehydrogenase complex (KGDH) and the branched chain a  -  keto 
acid dehydrogenase complex (BCKDH) (Perham, 2000).
The a-keto acid dehydrogenase (E l) protein occurs as a homo-dimeric proteins of about 
100 - 120 kDa or as hetero-tetramerlc proteins that consist of two a and two p subunits 
(azpz) of between 35 kDa and 70 kDa. The homodimeric E l protein displays little 
sequence similarity to the El a  or E l p subunits except in the thiamine pyrophosphate 
binding motif (Hawkins et a l, 1989; Matuda et a l, 1991). The E la  subunit is 
responsible for the binding of the thiamine pyrophosphate cofactor, while the E l p 
subunit is involved in protein binding interactions with the E2 protein. The E l protein 
confers substrate specificity of the complexes, requires thiamine pyrophosphate and a 
magnesium ion as cofactors and is the rate-limiting step of the complexes.
The acy 1-transferase protein (E2) is organised into three domains, the lipoyl domain, the 
subunit-binding domain and the catalytic domain that are separated by flexible linker 
regions. The lipoyl domain contains a lipoic acid prosthetic group that is covalently 
attached to an s-amino group of a conserved lysine residue. E2 proteins can contain 
between 1 and 3 lipoyl domains depending on which complex they belong to (see 
sections 1.4.1, 1.4.2 and 1.4.3). The lipoyl domain aids in the orientation of the 
lipoamide moiety into a 20 A deep pocket that is the site of oxidative decarboxylation in 
the E l protein (Aevarsson et a l, 1999). The subunit-binding domain of E2 is
23 -
Chapter 1. Introduction
responsible for the interaction with E l and E3 proteins and is the pivot point for the 
‘swinging arm’ of the lipoyl domain(s). The catalytic domain catalyzes the transfer of 
the acyl group bound to the lipoamide cofactor of the lipoyl domain to coenzyme A, 
producing acyl Co A and dihydrolipoamide (figure 1.10). This part of the protein is also 
the region of self-association of E2 and is responsible for the generation of the E2 core 
-  the E2 protein forms homo-trimers that then associate to form 24 mers (cubic 
organisation) or 60 mers (pentagonal dodecahedron organisation) (Perham, 1991). The 
flexible linker regions that are found between the three domains are rich in alanine and 
proline residues and are approximately 20 to 30 amino acids in length (Perham, 1991). 
This linker region results in a ‘swinging arm’ that contains the lipoyl domain(s) and is 
responsible for transferring catalytic intermediates through the complex. This swinging 
arm produces a substrate channelling effect as the lipoyl domain transfers the acyl group 
produced by the E l protein to coenzyme A and then the resulting dihydrolipoamide to 
the LipDH protein to be oxidised (Aevarsson et a l, 1999; Mooney et a l, 2002).
The LipDH/E3 protein is a flavoprotein disuiphide oxidoreductase belonging to the 
same protein family as TrxR. The homodimer consists of two identical subunits of 
approximately 55 kDa and its role within the KADH is the re-oxidation of the 
dihydrolipoamide after it has reacted with coenzyme A (section 1.3.1.3; figure 1.10). 
Generally, the complexes share a single LipDH (Bourguignon et a l , 1996) but in some 
organisms it was shown that specific LipDH iso-enzymes exist and are integral to a 
specific KADH (Lutziger et a l, 2000). This protein has been described in more detail in 
seetion 1.3.1.3.
Each protein in the KADH plays a distinct role in the catalytic mechanism of the KADH 
(see figure 1.10 for an overview of what is detailed below). The a-keto acid 
dehydrogenase (El) is a decarboxylase that requires thiamine pyrophosphate as a 
cofactor and catalyses the oxidative decarboxylation of a-keto acids producing a 
hydroxyl-acyl thiamine diphosphate intermediate and CO2. The acyl group of the 
intermediate is then transferred to the lipoamide prosthetic group that is attached to the 
E2 protein. This acyl group is subsequently transferred to coenzyme A, producing acyl 
CoA and dihydrolipoamide. Dihydrolipoamide (that is attached to the E2 protein) is 
then oxidised by the action of the E3 protein, allowing the lipoamide to accept another 
acyl group from the E l protein.
KADH activity is regulated in a number of ways, which range from reversible 
phosphorylation, product inhibition, substrate levels and redox state sensing. The first
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three methods will be dealt with in other sections (see sections 1.4.1, 1.4.2 and 1.4.3), 
but the latter will be discussed here. The redox state of a cell can be thought of being 
determined by the ratio of redox active compounds such as thiol/disulphides and 
NAD(P)H/NAD(P)^, both of which are important factors in the activity of KADH. In 
addition to this the lipoamide that is covalently bound to the E2 protein of all KADH 
has been shown to be able to interact with other redox active molecules (Holmgren, 
1979). This suggests that thioredoxin can interact with KADH and can play a role in 
regulating the activity of the complexes during periods of low NAD'*' concentrations 
(Bunik et a l, 1999). This also suggests that in addition to their physiological functions, 
the KADH may also be able to play a role in defence against reactive oxygen species 
(Bryk et a l, 2002).
The KADH play a number of important roles in cellular metabolism and I will introduce 
the biochemical roles and organisation of each of the KADH in the following sections.
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Figure 1.10 -  The KADH catalytic mechanism
T he catalytic m echanism  of KADH involves the th ree proteins that form this complex; the a  -  
keto acid dehydrogenase  (E1), acyl tran sfe rase  (E2) and dihydrolipoamide d ehydrogenase  (E3 
or LipDH). The E1 protein is responsible for the oxidative decarboxylation of an a  -  keto acid 
using thiam ine pyrophosphate (TPP) a s  a  cofactor. This reaction produces hydroxyacyl- 
thiam ine pyrophosphate and COg. The acyl group from hydroxyacyl-thiamine pyrophosphate is 
transferred  onto the lipoamide moiety that is covalently attached  to the  E2 protein, before being 
transferred  onto coenzym e A producing and acyl CoA and dihydrolipoamide. The 
dihydrolipoamide is oxidised to lipoamide by E3, allowing it to accep t another acyl group from 
the  E l protein, with the reaction of E3 requiring a protein bound flavin cofactor (FAD) and 
producing NADH.
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1.4.1 a —Ketoglutarate dehydrogenase complex
The a-ketoglutarate dehydrogenase complex (KGDH) is located in the mitochondria of 
eukaryotic cells, where it is an integral component of the tricarboxylic acid cycle (TCA 
cycle). KGDH acts on the a  -  ketoglutarate that is provided by isocitrate dehydrogenase 
and produces CO2, succinyl-CoA and NADH. Succinyl-CoA is either fed into the next 
reaction of the TCA cycle or may be used for the biosynthesis of haem, whereas NADH 
is fed into the respiratory chain via complex I (NADH dehydrogenase).
The KGDH shares the multimeric structure of all KADH with some differences. The a  
-  ketoglutarate dehydrogenase (El protein; EC 1.2.4.2) is over 100 kDa and forms a 
homodimer, which is in contrast to the 012P2 hetero-tetramer found in BCKDH and 
PDH. The succinyl transferase (E2 protein; EC2.1.3.61) foims an octahedral core 
(24mer) that contains a single lipoyl domain. The dihydrolipoamide dehydrogenase is 
normally shared with the other mitochondrial KADH (Bourguignon et al., 1996; 
Lutziger et a l, 2001).
The activity of KGDH is not regulated by the reversible phosphoiylation of the E l 
protein, as is the case for BCKDH and PDH. Any regulation of KGDH activity is 
therefore likely to occur by transcription/translation control or by competition for 
substrates such as a  -  ketoglutarate, reduced coenzyme A (CoA SH) and the ratios of 
NAD^/NADH and lipoamide/dihydrolipoamide (Dry et a l, 1987). The KGDH activity 
can be inhibited by high levels of products such as NADH, which induces product 
inliibition of the LipDH protein (Hamada et a l,  1975; Lawlis et a l, 1981). Indeed, loss 
of KGDH activity by inhibition/inactivation or by genetic defects can have extreme 
effects. Genetic defects in KGDH activity in humans has been implicated in the 
development of many neurodegenerative diseases including Alzheimers disease and 
Parkinsons disease (Gibson et a l, 2000).
1.4.2 Branched chain a-keto acid dehydrogenase complex
The branched chain a-keto  acid dehydrogenase complex (BCKDH) is located in the 
mitochondria of eukaryotes and is involved in the degradation of the branched chain 
amino acids valine, leucine and isoleucine. The substrates for BCKDH are produced by 
branched chain amino acid transaminase (EC 2.6.1.42), which converts isoleucine, 
valine and leucine into a-keto acids (producing a-keto-p-methylvalerate, a-
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ketoisovalerate and a-ketoisocaproic acid, respectively). BCKDH acts on these 
substrates producing acyl CoA products (a-methylbutyryl-CoA, isobutyryl-CoA and 
isovalyryl-CoA, respectively) that can eventually lead to the production of acetyl CoA 
and/or succinyl CoA that could be used within the TCA cycle (Ward et a l, 1999; 
Holecek, 2002).
The a-keto acid dehydrogenase protein (El protein; EC 1.2.4.4) of the BCKDH are 
composed of E la  and E l (3 subunits. The acyl transferase protein (E2; EC 2.3.1.168) 
forms an octahedral core (24mer) and contains a single lipoyl domain. The 
dihydrolipoamide dehydrogenase (E3/LipDH; EC 1.8.1.4) is usually shared between the 
mitochondrial complexes.
In contrast to the KGDH, the activity of the BCKDH is regulated by the reversible 
phosphorylation of the E la  protein. This is catalysed by branched chain a  -  keto acid 
dehydrogenase kinase (EC 2.7.1.115) and phosphatase (EC 3.1.3.52), with two sites of 
phosphorylation occurring at conserved serine residues (Odessey, 1982). In spite of the 
fact that it acts on serine residues the branched chain a  -  keto acid dehydrogenase 
kinase has been shown to be related to histidine kinases rather than the 
serine/threonine/tyrosine kinases (Popov et al, 1992).
In humans, genetic defects that result in the loss of BCKDH activity produce an 
accumulation of branched chain a  -  keto acids in the body. This can lead to maple 
syrup urine disease, which produces severe clinical manifestations such as often fatal 
keto-acidosis and mental retardation (Chuang et a l, 2006).
1.4.3 Pyruvate dehydrogenase complex
The pyruvate dehydrogenase complex (PDH) utilises pyruvate, NAD**^  and Coenzyme A 
as substrates and produces acetyl CoA, NADH and CO2. The pyruvate dehydrogenase 
protein (El protein; EC 1.2.4.1) can exist as either a homodimeric protein with a subunit 
molecular mass of 100 kDa or as a hetero-tetramer (a2p2> of a  and p subunits with 
molecular masses of between 35 kDa and 70 kDa. The acetyl transferase (E2 protein;
EC 2.3.1.12) primarily forms a 60mer core in an icosahedral arrangement, and can 
contain between 1 and 3 lipoyl domains at its N-terminus. The dihydrolipoamide 
dehydrogenase protein (E3/LipDH; EC 1.8.1.4) can be shared between KADH or may 
be specific to the PDH, depending on the subcellular localisation of the PDH.
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There are a number of different fonns of PDH, which can be based on their submiit 
structure, organisation and cellular localisation.
The PDH of bacteria can be found in two forms depending on whether the bacteria are 
gram-positive or gram-negative. The PDH of gram-negative bacteria possess a pyruvate 
dehydrogenase protein (El protein; EC 1.2.4.1) that fonns from a homo-dimeric protein 
with a molecular mass of 100 kDa (Stephens et a l,  1983). The acetyl CoA transferase 
protein (E2) forms an octahedral core (24mer) and contains three lipoyl domains at its 
N-terminus (Schulze et a l,  1992). The PDH of gram-positive bacteria has a PDH that 
has a hetero-tetrameric (azpz) pyruvate dehydrogenase protein (El protein; EC 1.2.4.1) 
and an acetyl transferase protein (E2) that forms an icosahedral core (60mer) with one 
lipoyl domain (Henderson et a l,  1979; Packman et a l, 1984; Borges et a l, 1990).
In eukaryotes the PDH is located in the mitochondria, where it acts as a link between 
glycolysis and the TCA cycle. The mitochondrial PDH (mtPDH) is similar in structure 
and organisation to the PDH of gram-positive bacteria, as its pyruvate dehydrogenase 
(El protein) is composed from E la  and E ip  subunits and its acetyl transferase (E2) 
protein forms an icosahedral (60mer) core. However, the mtPDH E2 protein can contain 
between one and thr ee lipoyl domains and the complex contains a fourth component 
called protein X. Protein X has a high degree of sequence homology and domain 
structure to the E2 protein, but lacks the catalytic activity (Neagle et a l,  1989; HaiHs et 
a l, 1997). It is involved in forming the complexes core together with the E2 protein and 
is the site of LipDH/E3 association, while the E2 protein binds the E l protein (Maeng et 
a l,  1994; Sanderson e ta l ,  1996).
The activity of mtPDH is regulated by product inhibition, metabolic effectors and the 
action of a pyruvate dehydrogenase kinase (EC 2.7.1.99) and phosphatase (EC 3.1.3.43) 
on the E la  subrmit (Gudi et a l, 1995; Huang et a l,  1998). The pyruvate dehydrogenase 
kinase is a serine specific kinase, but lack signature domains of the serine/threonine 
kinase, but instead displays greatest sequence similarity to histidine kinases (Popov et 
al, 1993). The pyruvate dehydrogenase phosphatase (PDP) is a member of the 
mammalian PP2C class of phosphatases and occurs in two forms. The PDPl is an a|3 
heterodimer consisting of catalytic and regulatory subunits, while PDP2 is monomeric 
(Roche et a l, 2001).
Genetic defects in the human mtPDH are primarily caused by mutations in the E la  
subunit of pyruvate dehydrogenase, although defects in all proteins of the complex
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(including protein X) have been implicated (Ho et a l, 1989; Neagle et al., 1989; Marsac 
et a l, 1993; Yang et a l,  1997). A deficiency in PDH activity is the most common cause 
of congenital lactic acidosis and other symptoms vary from mild ataxia to severe lesions 
of the central nervous system (Patel et a l, 1992; Robinson, 1995)
In plants there are two distinct PDH that are organelle-specific and are located in the 
mitochondria and the plastid (Mooney et a l,  2002). The plastid located PDH produces 
acetyl-CoA and NADH for fatty acid biosynthesis (Camp et a l, 1985).
The plastid localised PDH has a similar subunit structure as the mitochondrial PDH.
The plastid PDH is composed of E la  and El |3 subunits (Johnston et a l,  2000) and 
requires a plastid localised E3 protein (see section 1.3.2). No protein X component of 
the plastid PDH has been identified, although a second E2 gene was identified in 
Arabidopsis thaliana. This predicted protein displayed 60 % sequence identity to the 
functional E2 protein, although its function has not yet been determined (B.P. Mooney, 
unpublished data). The plastid PDH is thought to be arranged around an icosahedral 
core (60mer) as the Mr (4 -  7 MDa) of both the mtPDH and plastid PDH are similar 
(Camp et a l, 1985).
The plastid PDH is not regulated by reversible phosphorylation (as obseived in the 
mitochondrial PDH and BCKDH) (Randall et al, 1989), even though the E la  
component of the plastid PDH contains one of the conserved serine residues required 
(Johnston et a l, 1997). Instead, the plastid PDH is thought to be controlled by substrate 
availability and product inhibition and is more sensitive to the NAD^/NADH ratio than 
the acetyl CoA/CoA SH ratio (Camp et a l, 1988).
1,5 Organelles in Plasmodium
Plasmodium falciparum  contain a number of organelles that play distinct and important 
roles in the life cycle of the parasite (see figure 1.2), The microneme, rhoptries and 
dense granules are called the apical organelles as they are located at the apical end of 
the merozoite and aie involved in the invasion of the host erythrocyte. Other organelles 
are involved in the cellular metabolism of the parasite and these include the food 
vacuole, mitochondrion and apicoplast. The food vacuole has been discussed previously 
(see section 1.2) and the role of the mitochondrion and the apicoplast will be discussed 
in more depth in the following sections.
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1.5.1 Apicoplast
The apicoplast is a non-photosynthetic plastid that is found in all Plasmodium species 
and most of the Apicomplexan parasites excluding for instance Cryptosporidium 
(Wilson et a l, 1994; Kohler et al, 1997). It was first observed by microscopy 
(McFadden et al, 1997) and has been shown to be surrounded by fom’ membranes 
(Kohler et a l, 1997; McFadden et a l, 1999; Cavalier-Smith, 2000). All plastids are 
derived from the endosymbiosis of cyanobacteria into a eukaryotic cell, which would 
usually produce two outer membranes and is called primary endosymbiosis (Gray,
1992). However, the four membranes of the apicoplast have foimed by a secondary 
endosymbiosis event, where the eukaryotic cell that was a product of primary 
endosymbiosis, itself becomes engulfed by the Plasmodium cell (van Dooren et a l,  
2001). The derivation of the apicoplast has been a contentious area for some time, with 
differing opinions on whether the plastid arose from engulfment of a red or a green 
algae, however it is now accepted that the apicoplast was most likely derived from a red 
algal lineage (Williamson et a l, 1994; McFadden et a l, 1997; Yap et al, 1997; 
Blanchard et a l, 1999).
The apicoplast has been shown to possess its own genome, which has been identified to 
be circular, 35 kb in length and exists in a copy number of between 1 and 15 (Fichera et 
al, 1997; Kohler et a l, 1997; Matsuzaki et al, 2001; Williamson et al, 2001). The 
apicoplast genome carries 60 open reading frames, of which only two are not involved 
in protein synthesis (Wilson et a l, 1996). The majority of the genes from the original 
endosymbionf s genome are thought to have moved to the Plasmodium nucleus by 
lateral gene transfer (Martin et a l, 1998; McFadden, 2001; Rujan et a l, 2001). This 
means that the nuclear encoded proteins that are expressed by the parasites require to be 
transported to, and imported into the plastid.
Due to the plastid lineage of the apicoplast it was assumed that the transport and import 
of the nuclear encoded proteins would be similar to that obseived in plant chloroplasts. 
The trafficking of nuclear encoded proteins to chloroplasts in plants requires the 
presence of an N-terminal extension known as a transit peptide (Vothknecht et a l,
2000; Jackson-Constan et a l, 2001). The transit peptide of plant chloroplasts are rich in 
hydroxylated amino acids such as serine and threonine and the transfer of the protein 
across the chloroplast membranes are mediated by import machinery called the TOC 
and TIC complexes (representing translocon of the outer/inner chloroplast membranes).
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The protein to be imported into the chloroplast, which has formed a complex with 
HSP70 and other chaperone proteins in the cytosol, binds to the TOC complex in a 
GTP-dependant manner. The protein is then transported across the outer and inner 
membrane using a mechanism that utilises both the TOC and TIC complexes. Once the 
transit peptide of the protein has passed the inner chloroplast membrane it is cleaved by 
a stromal processing peptidase, producing a chloroplast localised mature protein 
(Richter et a l, 1998).
The trafficking of nuclear encoded Plasmodium proteins is thought to function by a 
similar pathway, although the transfer into the plastid is complicated by the presence of 
the four membranes of the apicoplast. The targeting of protein to the complex plastids 
(those with 3 or 4 membranes) in many algae provided a clue to the requirements for 
transport of proteins into the apicoplast (Grossman et al, 1990; Pancic et al, 1993; Apt 
et a l, 1995; Caron et a l, 1996). In these complex plastids the transit peptide was 
preceded by a hydrophobic amino acid sequence known as the signal peptide thus 
forming a bipartite targeting peptide consisting of a signal peptide and a plastid transit 
peptide. Prediction programs have been developed to calculate the likelihood of a 
protein’s targeting based on the bipartite nature of proteins targeted to plant and algal 
plastids (TargetP; http://www.cbs.dtu.dk/services/TargetP/ and SignalP; 
http://www.cbs.dtu.dk/sei'vices/SignalP/ (Nielsen et a l, 1997; Emanuelsson O, 2000).
Analysis of the P. falciparum genome identified ~ 500 proteins that possessed a 
potential bipartite targeting peptide that also comprises a signal peptide followed by a 
possible apicoplast transit peptide (Foth et a l, 2003). The nature of this targeting signal 
was validated and dissected using green fluorescent fusion proteins with the respective 
parts of the targeting peptide (figure 1.11; Waller et al, 1998; DeRocher et a l, 2000; 
Waller et a l, 2000). These studies allowed Foth et a l  to derive an algorithm that can 
now be used to predict the possibility of a protein being targeted to the apicoplast (Foth 
et a l, 2003). Many studies have utilised GFP fusion proteins to test the signal transit 
peptides of potential plastid localised proteins in P. falciparum and the related 
apicomplexan parasite Toxoplasma gondii.
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Figure 1.11 -  Analysis of apicoplast localisation determinants
This figure displays the results genera ted  from the alignm ent of 68 putative apicoplast targeted  
proteins around their estim ated signal peptide (SP) cleavage sites (black arrow on the left side) 
and the estim ated boundary betw een the transit peptide (TP) and the m ature protein (MP; black 
arrow on the right side). This resulted in a  clear preference for hydrophobic residues in the 
signal peptide (yellow line, right hand y axis) and a relatively high occurrence of lysine and 
asp a rag in es  (black line, left hand y axis) and basic residues (blue line, left hand y axis) in the 
transit peptide. This figure w as taken from Foth et al., 2003
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The presence of a secondary endosymbiotic plastid obviously was of great interest to 
the scientific community particularly because it could be expected that this organelle 
was retained by the parasites to provide some metabolites necessary for their survival. 
The apicoplast was thought to be a possible drug target as drugs that inhibited the 
plastids genome replication, transcription and replication led to parasite death (Fichera 
et a l, 1997; Ralph et a l, 2001). A transgenic Toxoplasma gondii strain that displayed a 
segregation defect also resulted in the death of parasites lacking the organelle (He et a l,
2001). He et a l  produced a fusion protein containing GFP that was localised to the 
apicoplast, which was observed to block plastid segregation during endodyogeny {T. 
gondii equivalent of schizogony in P. falciparum) and resulted in parasites that 
displayed a delayed death phenotype (He et a l, 2001). This delayed death phenotype is 
observed in both the transgenic segregation mutant and in the inhibition studies. The 
parasites seem to develop normally in the host cell during treatment, but the merozoites 
produced are no longer viable to re-infect host cells. This delayed death phenotype may 
point towards an essential role for the apicoplast in the invasion of host cells, possibly 
in the production of the parasitophorous vacuole membrane (PVM).
Of the 500 proteins predicted to be localised in the apicoplast, almost 70 % have no 
known function. Of the 30 % with known functions a number have been identified to 
have housekeeping functions such as DNA replication/repair (8.8 %), transcription (2.9 
%), translation (25.9 %), transporters (5.3 %) and other roles (15.9 %). Three major 
pathways have been identified in the apicoplast proteome; fatty acid biosynthesis, 
isoprenoid precursor synthesis and a partial haem biosynthesis pathway (Gardner et a l , 
2002; Ralph et a l, 2004).
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Figure1.12 -  Biochemical pathways of P. falciparum
This figure gives an  overview of the biochem ical pathw ays of P. falciparum b ased  on the g e n e s  
identified in the  parasites genom e and w as taken from G ardner et al., 2002. This study is 
particularly interested the biochemistry of the  mitochondrion and the apicoplast, and this figure 
displays the pathw ays that a re  thought to be active in th ese  organelles. T he mitochondrion 
contains the tricarboxylic acid cycle (TCA cycle), oxidative phosphorylation and a  partial haem  
biosynthesis. The apicoplast contains a  type II fatty acid synthesis pathway, a  DOXP pathw ay 
(non-m evalonate isoprenoid biosynthesis) and  a  partial haem  biosynthesis pathway. The 
m etabolic s tep s  of pathw ays a re  indicated with red arrows, while m etabolic s tep s  with multiple 
intervening s tep s  a re  indicated by a dotted red arrow. Fushia coloured block arrow s indicate 
s tep s  that a re  inhibited by antim alarials. Abbreviations for mitochondrial and apicoplast 
pathways: AGP, acyl carrier protein; ALA, aminolevulinic acid; CoA, coenzym e A; DOXP, 
deoxyxylulose phosphate; PEP, phosphoenolpyruvate; UQ, ubiquinone/coenzym e Q.
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The type II fatty acid biosynthesis pathway that has been identified in the parasites is 
specific for bacteria and plant chloroplasts and requires acetyl CoA as an entry point 
(Harwood, 1996; Ke et a l,  2000). Acetyl CoA is provided from a plastid located 
pyruvate dehydrogenase complex (PDH; see section 1.4.3) and the presence of this 
complex will be investigated in chapter 5 of this study. Type II fatty acid biosynthesis is 
a cyclical pathway which adds two carbons per cycle and usually produces Cio -  C# 
fatty acids (Surolia et a l, 2001). The fatty acid elongation cycle occurs via four 
enzymatic steps; condensation, reduction, dehydration and reduction. Triclosan is 
thought to act specifically against enoyl-ACP reductase (second reduction step of the 
cycle) of the pathway and has also been shown to have potent antimalarial activity 
(McLeod et a l, 2001; Surolia et a l,  2001; Waller et a l, 2003).
The presence of the plant-specific non-mevalonate (DOXP) isoprenoid biosynthetic 
pathway, which uses pyruvate and glyceraldehyde-3-phosphate as precursors rather than 
mevalonate within the organelle and the absence of an alternative pathway providing 
isoprenoid units had significance particularly with respect to the design of new 
antimalarials (Jomaa et a l, 1999). Fosmidomycin, an antibiotic that acts against 1- 
deoxy-D-xylulose-5-phosphate (DOXP) reductoisomerase of the pathway is currently in 
clinical trials with some success, although recrudescent infections were observed 
following initial clearing of infection (Jomaa et a l, 1999; Lell et a l, 2003). Isoprenoids 
are composed of repeats of isoprene units and form the basis of ubiquinones, dolichols, 
modified tRNA and prenylated proteins.
P. falciparum appears to have a de novo haem biosynthesis pathway, even though it 
ingests large quantities of haem containing proteins during the erytlirocytic stage of its 
life cycle. The haem biosynthesis pathway in P. falciparum contains components in the 
apicoplast and the mitochondrion (van Dooren et a l, 2002; Ralph et a l,  2004; Sato et 
a l,  2004; Varadharajan et a l, 2004) and some components may also be imported from 
the host cell (Dhanasekaran et al, 2004). The mitochondrion and the apicoplast have 
been observed numerous times to be closely association (Hopkins et a l, 1999;
Bannister et al, 2000; van Dooren et al, 2005). This observation, when coupled with 
the suggested interchange of substrates between the two organelles (as predicted for 
haem biosynthesis) has led some researchers to suggest that they are metabolically co­
dependent (van Dooren et a l, 2005).
I
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1.5.2 Mitochondrion
P. falciparum contains a single mitochondrion and is generally considered to be 
achristate during the erythrocytic stages of the life cycle (Rudzinska, 1969; 
Leamgaramkul et ah, 1999). This is in contrast to the mitochondria obseiwed in 
gametocytes of P. falciparum, which are multiple and christate (Leamgaramkul et al, 
1999) and the mitochondrion of bird malaria parasites that have also been observed to 
contain chi'istae (Rudzinska, 1969). The single mitochondrion of P. falciparum (like all 
eukaryotes) was derived from a-protobacterial cells by primary endosymbiosis, which 
resulted in an organelle that is suiTounded by two outer membranes. The mitochondrion 
also contains a residual genome, which is 6 kb in length and contains fragmented genes 
encoding large and small ribosomal RNA and thr ee genes that encode cytochrome b, 
cytochrome oxidase I and cytochrome oxidase III. Therefore, the majority of the genes 
from the mitochondrial genome must have been passed to the parasites nucleus by 
lateral gene transfer (Adams et a l, 2003). This means that the proteins encoded by the 
nuclear genes require trafficking back to and into the mitochondrion, from the 
cytoplasm. The transport of nuclear encoded proteins to the mitochondrion can be 
mediated by a number of pathways although the most common utilises an N-terminal 
mitochondrial targeting peptide (Planner et al, 2001). The other methods for 
mitochondrial targeting include using transmembrane domains and internal signals, 
which have been poorly defined (Planner et al, 2001). The N-terminal mitochondrial 
targeting pre-sequences have been well characterised in other organisms and have led to 
the development of programs which can predict the likely mitochondrial localisation of 
a protein based on its N-terminal amino acids (Claros et al, 1996). These N-terminal 
pre-sequences have the general characteristics at the primary and secondary structure 
level. The amino acid sequence tends to be high in basic, hydioxylated and hydrophobic 
residues and an amphipathic a  helix with a hydrophobic face and a positive face (von 
Heijne et a l, 1989; Schatz et a l,  1996). The mitochondrial-targeted protein is 
transported into the mitochondria via a group of protein complexes called the TOM and 
TIM complexes (Truscott et a l,  2003). Indeed, homologues of two TOM complex 
proteins have been identified in the P. falciparum genome, which are TOM40 and 
TOM22 (Macasev et al, 2004). Homologues of two TIM complex associated chaperone 
proteins (Hsp60 and HsplO) have also been identified and shown to be localised in the 
mitochondrion by GFP fusion proteins (Sato et al, 2003; Tonkin et a l, 2004; Sato et 
al, 2005). It is highly likely that P. falciparum  possess other TIM/TOM complex
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'proteins although protein homologues have not been reported and require further
"'Iinvestigation.
i
A study that analysed a substantial number of mitochondrial or potential mitochondrial
protein sequences identified that the P. falciparum mitochondrial targeting pre-sequence ' swas relatively high in isoleucine, leucine, tyrosine and asparagines residues and 5
relatively low in glycine, alanine, tryptophan and arginine residues. The results of this 
study were used to develop a program that was specific for predicting mitochondrial 
protein in the P. falciparum genome (Bender et al, 2003). Analysis of the P. falciparum 
genome with the Plasmit program predicted between 381 and 1177 (7.1 % and 22 % of 
total genes) mitochondrial proteins depending on the stringency of the program (Bender 
et a l, 2003).
Studies into the single mitochondrion in P. falciparum have shown that despite being 
achristate the organelle is still metabolically active (figure 1.12). In mammalian cells 
the primary source of energy metabolism is via the production of ATP, which is driven
in the mitochondria by the tricarboxylic cycle (TCA cycle) and oxidative 
phosphorylation. Glucose is metabolised into pyruvate by glycolysis and is acted on by
a mitochondrial localised pyruvate dehydrogenase complex (PDH; see section 1.4.3 and
..IIchapter 5) to produce acetyl CoA, which can then feed into the TCA cycle.
However, energy metabolism in the erythrocytic stages of P. falciparum  is provided 
primarily by glycolysis, with up to 90% of the glucose being metabolised into lactic 
acid by lactate dehydrogenase (Bryant et a l, 1964; Scheibel et a l, 1970). This release 
of lactic acid is responsible for causing the lactic acidosis that is a clinical feature of 
Plasmodium infection. WI
It was therefore initially thought that Plasmodium did not therefore contain an active 
TCA cycle in their erytlirocytic stages. In spite of this, all of the genes necessary for an 
active TCA cycle have now been identified in the P. falciparum genome, although there 
are several key differences in the make up of the P. falciparum TCA cycle. Citrate 
synthase, which is the first step in the TCA cycle has been confirmed to be localised to 
the mitochondrion of P. falciparum  by GFP fusion protein (Tonkin et a l, 2004). The 
second protein in the TCA cycle is aconitase and a protein with homology to human | |
iron responsive element protein/aconitase has recently been identified in the P.
I
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falciparum genome and has been shown to be (at least partially) mitochondrially 
localised and active (Hodges et a l, 2005). The P. falciparum isocitrate dehydrogenase 
protein has been biochemically characterised and was shown to be active with NADP^ 
and isocitrate substrates (not NAD'*' specificity as in mammalian cells) and as a result 
was thought to be involved in mitochondrial redox control rather than in providing 
electrons for the electron transport chain (Wronger et al, 2003). The next step in the 
TCA cycle, the a-ketoglutarate dehydrogenase complex (KGDH; see section 1.4.1) will 
be investigated in this thesis (Chapters 4 and 5). P. falciparum are thought to require 
succinyl CoA, which is produced by KGDH, for continuing the TCA cycle and also as a 
precursor for haem biosynthesis. The succinyl CoA is converted to succinate via the 
succinyl-CoA synthetase /protein, which consists of a  and p subunits. Homologues of 
the succinyl-CoA synthetase of a  and P subunits have been identified in the P. 
falciparum genome as have the flavoprotein and iron-sulphur subunits (but not the 
CybS and CybL subunits) of succinate dehydrogenase (Suraveratum et al, 2000; Takeo 
et a l, 2000). Succinate dehydrogenase plays a role in oxidative phosphorylation (as 
complex II) and converts succinate into fumarate, which is then acted on by fumarate 
hydratase. The P. falciparum homologue of fumarate hydratase displayed homology to 
the iron sulphur containing Class I proteins of bacteria and archea rather than the class 
II proteins from yeast and mammalian cells (Flint et al, 1992), In the mammalian TCA 
cycle malate is then converted to oxaloacetate by a mitochondrial malate 
dehydrogenase, although the malate dehydrogenase that has been identified in P. 
falciparum  is not thought to be mitochondrial (Lang-Unnasch, 1992; Lang-Unnasch,
1995). However, a possible mitochondrially localised malate quinone oxidoreductase 
(MQO) homologue has been identified in the P. falciparum genome. MQO is a 
membrane bound flavoprotein, which is found in some bacteria and may contribute 
electrons via coenzyme Q into oxidative phosphorylation (Uyemura et a l, 2004).
The mitochondrion of Plasmodium species has been shown to maintain a membrane 
potential during their erythrocytic stages (Srivastava et a l, 1997). This is indicative of 
the mitochondrion having a functional electron transport chain/oxidative 
phosphorylation (figure 1.12). The antimalarial drug Atovaquone has been shown to 
collapse this membrane potential and was later found to interact specifically with the 
mitochondrial complex III (Srivastava et a l, 1997).
It has been proposed that the main role of oxidative phosphorylation in the 
mitochondrion of P. falciparum is to act as an electron sinlc for the dihydroorotate
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dehydrogenase protein that is involved in pyrimidine biosynthesis (Krungki’ai, 1995), 
This is an essential step in parasite biochemistry as P. falciparum are unable to 
scavenge pyrimidines and therefore must rely on de novo synthesis. Dihydroorotate 
dehydrogenase has therefore become an attractive drug target and high throughput drug 
screens have recently identified some potential Plasmodium specific inhibitors (Baldwin 
et a l,  2005).
The mammalian oxidative phosphorylation pathway is composed of a number of 
membrane associated protein complexes (complex I -  IV and an ATP synthase). Protein 
homologues of components from most of these complexes have been identified in the P. 
falciparum  genome (Gardner et a l, 2002). Activities of complex I (Krungkrai et a l,
2002), complex II (Fry et a l, 1991; Uyemura et a l, 2000; Takashima et a l, 2001; 
Uyemura et a l, 2004), complex III (Fry et a l, 1991) and complex IV (Krungkrai et a l, 
1993) have been shovm in a number of studies. Although homologues of the ATP 
synthase have been identified in the P. falciparum  genome (Gardner et a l, 2002), there 
have been no reports of any activity. It has been suggested that P. falciparum  possess 
and alternate oxidase (Murphy et a l, 1997), although no clear homologue has been 
identified in the genome (G. McFadden, personal communication). Two other proteins 
have also been suggested to be able to act as a complex III, these being dihydroorotate 
dehydrogenase (see above) and a malate-quinone oxidoreductase (Fry et a l,  1991; 
Uyemura et a l, 2000; Takashima et a l, 2001; Uyemura et a l, 2004).
Other biochemical functions that occur in the mitochondrion of P. falciparum  (figure 
1.12) are a partial haem biosynthesis pathway (see section 1.5.1), folate metabolism, 
coenzyme Q synthesis and iron-sulphur cluster biosynthesis. Folates are required in P. 
falciparum  as precursors for pyrimidines and methionine (Krungkrai et a l, 1990), 
although the functions of folate metabolism are poorly understood (Hyde, 2005; Nzila et 
a l, 2005a; Nzila et a l, 2005b). This pathway is clearly important for parasite 
biochemistry, as it is a target for a number of antimalarial drugs such as pyrimethamine 
and sulphonamides. The synthesis of Coenzyme Q (ubiquinone) is required in P. 
falciparum mitochondrion due its essential role as an electron carrier in oxidative 
phosphorylation. P. falciparum require the synthesis of iron-sulphur clusters due to the 
presence of many iron-sulphur cluster proteins such as ferredoxin, aconitase/iron 
regulatory protein, fumarate hydratase and proteins involved in isoprenoid biosynthesis 
and oxidative phosphorylation (Ralph et a l,  2004; Johnson et a l, 2005; Till et a l, 
2005).
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1.6 Aims of this study
This thesis can be separated into three distinct research projects. The first (presented in 
chapter 3) was to investigate the catalytic mechanism of P. falciparum thioredoxin 
reductase, the second (presented in chapter 4) was to investigate the P. falciparum 
dihydrolipoamide dehydrogenases and the last (presented in chapter 5) was to 
investigate the components of the a-keto acid dehydrogenase complexes. The aims of 
each of these projects are detailed below:
Chapter 3: P. falcivarum thioredoxin reductase fPfTrxRf
• Investigate the catalytic mechanism of the PfTrxR using pre-steady state and 
steady state kinetics of reductive and oxidative half reactions.
• Examine the role of acid/base catalysts in the catalysis of PfTrxR by 
mutagenesis followed by steady state and pre-steady state kinetics of reductive 
and oxidative half reactions.
Chapter 4; P. falciparum dihvdrohpoamide dehydrogenases (LipDH)
• Identify and analyse the genes encoding LipDH in the P. falciparum  genome.
• Investigate the transcription and protein expression of LipDH  genes and LipDH 
proteins in erythrocytic stages of the parasites.
• Analyse the subcellular localisation of LipDH proteins in P. falciparum.
• Biochemically characterise recombinant proteins expressed in the Escherichia 
coli system.
Chapter 5: P. falciparum a-keto acid dehydrogenase complexes (KADHI
• Identify and analyse the genes encoding for components of the KADH the P. 
falciparum genome.
• Investigate the transcription and protein expression of KADH  genes and KADH 
proteins in erythrocytic stages.
• Analyse the subcellular localisation of KADH proteins in P. falciparum.
• Biochemically characterise recombinant proteins expressed in the E. coli system.
40
Chapter 2. Materials and M ethods
Chapter 2 Materials and Methods
2.1 Materials
2.1.1 Companies from which chemicals, kits and equipment were 
purchased
Abgene: Reddymix
Amersham biosciences: ÀKTA FPLC, Hyperfilm ECL, HiTrap chelating HP column 
(1ml and 5ml), hypercassettes (18 x 24 cm), Sephadex S200 16/60 size exclusion 
column, Superose 6 10/30 size exclusion column, ECL-plus detection kit, protein A 
sepharose beads.
BDH; Giemsa stain, saponin, formamide, sodium acetate 
Beckman: J2-H5 centrifuge with JA-20 rotor 
BOC: Malaria culture gas (5% CO2, 1% O2 and 94% N2)
Biorad: Econopac columns, transblot SD semi-dry transfer cell, precision plus all blue 
protein standards, gel filtration standards, gene puiser electroporation cuvette (0.2 cm), 
gene puiser Xcell electroporator, protein assay reagent.
Blood transfusion service: Human A^ erythrocytes
Eppcndorf: Eppendorf microcentrifuge with F45-24-11 rotor
Eurogcntcc: Custom antibody production
Fisher scientific: 0.2 pM filtration units (500 ml and 1000 ml containers)
Hi-Tech scientific: SFA-20 rapid kinetics accessory, SF-61 DX2 double mixing 
stopped flow spectrophotometer, kinetasyst 3 software.
■
Invitrogcn: Accuprime Pfa Supermix, PCR supermix, TOPO TA cloning kit, ZERO 
BLUNT PCR cloning kit, chemically competent E.coli TOP 10 cells, RPMI 1640 (with 
25 mM HEPES, L-Glutamine, without NaHCOs), Albumax II, gentamycin, NuPAGE 4-
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12% Bis/Tris gels, NuPAGE 10 % Bis/Tris gels, 20 x MOPS buffer, Superscript II, 
DNase I, Random hexamers, dNTP mix, Xcell Sm'elock^” Mini-cell apparatus.
Jacobus pharmaceuticals: WR99210
Melford: Ampicillin, Isopropyl-beta-D-thiogalactopyranoside (IPTG).
Molecluar probes: MitoTracker CMXRos 
Nalgene: 1.0 ml cryotubes
New England Biolabs: All restriction endonucleases, T4 DNA ligase
Novagen: Bugbuster protein extraction solution, benzonase, pET28 expression vector, 
Chemically competent E.coli Novablue
Promega: 1 kb DNA ladder, 6 x DNA loading buffer
Qiagen: Qiaprep spin DNA miniprep columns, Hispeed plasmid maxi kit, Qiaquick gel 
extraction kit, Ni-NTA agarose, RNase A, pQE30 expression vector.
Roche: Complete mini protease inhibitor tablets, Complete EDTA free protease 
inhibitor tablets.
Sciquip: Sigma 6K 15 centrifuge with 11150 rotor.
Thermo electron: Custom produced oligonucleotides, Jouan CR3i centrifuge with T40 
rotor.
Sartorius: 0.2 pm syringe filters, 0.4 pm syringe filters.
Schleicher & Schuell: Protran nitrocellulose 
Shimadzu: UV-24Q1 and UV-2501 spectrophotometers 
Sigma: All chemicals unless otherwise stated.
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Stratagenei Chemically competent E.coli JM109, chemically competent E.coli XL 10 
GOLD, chemically competent E.coli BL21 (DE3), chemically competent E.coli BL21 
(DE3) RIL
Varian: Cary 300 spectrophotometer 
Zeiss: Axioplan 2 microscope
- 43  -
Chapter 2. Materials and Methods
2.1.2 Commonly used reagents
Electrophoresis buffers
1 X TAB: 40 mM Tris.Acetate pH 7.6, ImM Nai.EDTA.
6 X SDS-PAGE loading buffer: 62.5 mM Tris-HCl pH 6.8, 2 % (w/v) SDS, 10 % (v/v) 
glycerol, 0.001 % (w/v) bromophenol blue, 5 % (v/v) 2-mercaptoethanol.
MOPS buffer: 50 mM 3-[N-morpholino] propane sulphonic acid, 50 mM Tris base, 3.5 
mM SDS, 1 mM EDTA.
Coomasie stain: 40 % Methanol, 10 % Acetic acid, 0.1 % (w/v) coomasie brilliant blue 
R -2 5 0 .
Destain: 20 % Methanol, 10 % Acetic acid 
Western blotting buffers
To whin buffer: 25mM Tris, 192 mM glycine, 20 % Methanol
PBS: 4.3 mM Sodium phosphate (dibasic), 1.4 mM potassium phosphate (monobasic), 
137 mM NaCl, 2.7m M KCl.
PBS/tween: PBS containing 0.05 % Tween 20
Bacterial culture
LB media: 10 g/1 Bacto-Tryptone, 5 g/1 Bacto-yeast extract, 10 g/1 NaCl
TB media: 12 g/1 Bacto-tryptone, 24 g/1 yeast extract, 0.4% (v/v) glycerol, 1 X TB salts.
10 X TB s a l t s :  23.1 g/1 KH2PO4, 125.4 g/1 K2HPO4 ( p o t a s s i u m  p h o s p h a t e ,  d i b a s i c )
Ampicillin: Stock of 100 mg ml'^ in water. Filter sterilised, aliquoted and stored at -  
20°C.
Kanamycin: Stock of 50 mg mf^ in water. Filter sterilised, aliquoted and stored at -  
20°C.
Protein purification
Qiagen lysis buffer: 50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, pH 
8.0.
Qiagen wash buffer: 50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 
8.0.
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Qiagen elution buffer: 50 mM sodium phosphate, 300 mM NaCl, 500 mM imidazole, 
pH 8.0.
Denaturing Ni-NTA purification buffer (Change pH according to wash/elution): 100 
mM sodium phosphate, 10 mM Tris-Cl, 8M urea
Plasmodium culture
Complete RPMI medium: Blood wash media supplemented with 5 g litre'^ Albumax II.
Blood wash medium: 15.9 g/1 RPMI 1640, 2 g litre"  ^ Glucose, 1 g litre"’ Sodium 
bicarbonate, 0.01 mg ml"’ gentamycin, 0.03 mg ml"’ hypoxanthine, pH 7.4.
Saponin solution: 20 mg ml"’ Saponin in 1 x PBS
Sorbitol solution: 5 % (or 27 %) sorbitol (w/v) in 10 mM potassium phosphate buffer 
pH7.4
Cytomix: 120 mM KCl, 0.15 mM CaCh, 2 mM EGTA, 5 mM MgCh, 10 mM 
potassium phosphate (pH 7.6), 25 mM HEPES (pH 7.6).
Freezing solution: 1 x PBS, 30% glycerol
DNA lysis buffer: 50 mM Tris-HCl pH 8.0, 20 mM EDTA, 2% SDS.
2D lysis buffer: 100 mM Hepes, 5 mM MgCli, 10 mM EDTA, 0.5% Triton X-100, 5 p.g 
ml "’ RNAse A, 1 mM PMSF, 1 mM benzamidine, 2 pg ml"’ leupeptin, protease 
inhibitor cocktail (Roche, 1 tablet per 50 ml of buffer).
TE: 50 mM Tris-HCL pH 7.5, 1 mM EDTA
Immunoprécipitation buffers
IP lysis buffer: 50 mM Tris HCl 7.5, 600 mM KCl, 1% Triton X-100, complete protease 
inhibitor cocktail (Roche; 1 tablet per 10 ml)
IP wash buffer: 50 mM Tris HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% (v/v) 
Triton X-100, 0.25% (w/v) BSA
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2.2 Methods
2.2.1 Plasmodium falciparum  cell culture techniques
2.2.1. 1_____ General culturing
All solutions used for the culturing of P. falciparum  were filter sterilised using 0.2 pm 
filters (Fisher scientific) in a category 2 tissue culture hood. P. falciparum strains 3D7 
(The Netherlands) and DIO (Papua New Guinea) were cultivated in human A^ 
erythrocytes (Blood transfusion service, Glasgow) according to Trager and Jensen 
(Trager et a l, 1976). Erythrocytes were washed in RPMI 1640 containing 0.1% sodium 
bicarbonate, 11 mM glucose, 0.03 mg/ml hypoxanthine and 0.1 mg/ml gentamycin {Pf 
wash medium). Washing was carried out by centrifuging erythrocytes at 1500 rpm 
(Jouan CR3i centrifuge with T4 rotor), 4^C for 10 min and subsequently aspirating the 
supernatant and huffy coat/leukocyte layer from the top of the red blood cell pellet. The 
procedure was repeated 2 to 3 times until the supernatant appeared clear and no white 
blood cells were observed. Eiythi'ocytes washed in this manner were stored at 4°C and 
used for culturing for a maximum of 4 weeks following washing.
Parasite strains were cultured in complete RPMI 1640 (P/wash medium supplemented 
with 0.5% Albumax II) at a 5% haematocrit. Cultures were incubated at 37°C in a 
humidified atmosphere of 5% CO2, 1% O2 and 94% N2. Medium was exchanged daily 
and parasitemia was maintained between 0.1 and 10%. Parasitemia was determined by 
counting the percentage of infected erythrocytes in Giemsa stained blood smears.
2.2.1. 2_____Synchronisation
Parasite cultures were synchronised as described previously (Hoppe et a l, 1991). 
Cultures were centrifuged at 1500 rpm (Jouan CR3i centrifuge with T4 rotor), 25°C for 
10 min and the supernatant was discarded. The resulting pellet was resuspended in 5 
pellet volumes of 5% sorbitol (w/v in 10 mM potassium phosphate pH 7.2) at 37°C, 
incubated at 37°C for 5 min and centrifuged again. The supernatant was removed and 
the pellet was resuspended in complete RPMI 1640 medium at 37°C and cultured as 
described above (section 2.2.1.1). Parasite cultures were required to be synchronised for 
transfection protocols (see section 2.2.1.5).
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2.2.1. 3 Stabilates
Parasite stabilates were produced from 10 ml cultures with 10% parasitemia in mostly 
ring stages. Cultures were centrifuged at 1500 rpm (Jouan CRSi centrifuge with T4 
rotor), 4^C, 10 mins, before removing the supernatant and resuspending in one pellet 
volume of cold complete RPMI 1640 media. Two pellet volumes of ice cold stabilate 
freezing solution (30% glycerol in PBS) was added and 600 pi was transferred into a 
cryotube (Nalgene) and was incubated on ice for 15 min before storing in liquid 
nitrogen.
Stabilates were thawed with constant shaking in a 3TC  waterbath, and placed on ice 
immediately following thawing. The contents of the cryotube was transferred to a 15 ml 
falcon tube (usually 600 pi), and 2 volumes of 27% sorbitol (w/v in 10 mM potassium 
phosphate buffer pH 7.4) were added drop-wise with constant shaking, before being 
incubated on ice for 13 mins. A further two volumes of 5% sorbitol (w/v in 10 mM 
potassium phosphate buffer pH 7.4) was added in a similar way and was incubated on 
ice for 10 min. The solution was centrifuged at 1500 rpm (Jouan CR3i centrifuge with 
T4 rotor), 4^C for 5 min, and the supernatant was discarded. The resulting pellet was 
resuspended in 10 ml of cold complete RPMI 1640 medium, and was centrifuged as 
before. This wash step was repeated a second time before the pellet was resuspended in 
complete RPMI 1640 media at 37°C (containing washed RBC at 2.5% haematocrit). 
Parasites were then cultured as described in section 1.2.1.1, until they reached a 
parasitemia of 5 % when the appropriate drug selection was applied.
2.2.1. 4 Isolation of P. falciparum from host erythrocyte
Parasites were extracted from erythrocytes using saponin as described by (Umlas et al., 
1971). Parasites were freed from host erythrocytes by incubating cultures with 0.1 
volumes of saponin (20 mg/ml in PBS) on ice for 10 min. The solution was then 
centrifuged at 1500 rpm (Jouan CR3i centrifuge with T4 rotor), 4*^ 0 for 10 min before 
the supernatant was carefully removed; the parasite pellet was washed in 40 ml ice cold 
PBS to remove residual erythrocytes. The parasite/PBS mixture was centrifuged as 
described before, the supernatant discarded and the resulting parasite pellet was used for 
isolation of RNA, genomic DNA (gDNA) or protein and was resuspended in a solution 
consistent with the isolation necessary. Usually a minimum of 50 ml parasite culture
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with a -10  % parasitemia was necessary to obtain sufficient amounts of RNA, gDNA or 
protein for further analyses.
RNA isolation was perfoimed following saponin extraction by resuspending the parasite 
pellet in ten volumes of Trizol (Sigma); this was stored at -80°C until use. RNA was 
isolated from the Trizol by adding 0.2 volumes chloroform, mixing and centrifugation 
at 12,000 X g for 30 min at 4°C. The upper aqueous phase was removed and mixed with 
0.7 volumes isopropanol, and incubated at 4°C for at least 120 min. The RNA was then 
centrifuged at 12,000 x g, for 30 min at room temperature. The resulting supernatant 
was carefully removed and the RNA pellet allowed to air-dry, before being resuspended 
in 10-20 pi foimamide (BDH). The sample was heated to 60°C for 10 min (to aid 
re suspension) before being cooled on ice and placed at -80°C for long-term storage. The 
RNA concentration was determined by measuring the absorption at 260nm. The RNA 
concentration was calculated according to Abs26o x 40 = pg of RNA /ml of solution 
(Sambrook, 1989).
Isolation of genomic DNA from parasite was performed by thoroughly resuspending
parasite pellets in 1 ml (per 50 ml of parasite culture) of gDNA lysis buffer (50 mM
Tris-HCl pH 8.0, 20 mM EDTA, 2 % SDS). Proteinase K (Sigma) was added to a final
concentration of 100 pg/ml and the extraction mixture was incubated at 56°C for 2
hours. The suspension was cooled on ice for 10 min before 0.3 volumes of saturated
NaCl was added, mixed and incubated on ice for a further 5 min. The suspension was
centrifuged at 2500 rpm, 4°C for 15 min, with the resulting supernatant transfeired into
fresh tubes and centrifuged at 13000 rpm, 4°C for 15 min. The supernatant was again
removed into fresh tubes and RNaseA (Qiagen) was added to a final concentration of 20
pg/ml before being incubated overnight at 4°C. Following overnight incubation, one
volume of phenol/chloroform was added and mixed by vortexing. This was centrifuged
at room temperature for 10 min at 13000 rpm (Eppendorf microcentrifuge with F45-24-
11 rotor), before the aqueous phase was removed and 3 volumes of 100 % ethanol and
0.1 volumes of 3 M sodium acetate pH 5.2 were added, mixed and incubated at -20°C
for 60 min. This solution was then centrifuged to pellet the precipitated DNA at 13000
rpm (Eppendorf microcentrifuge with F45-24-11 rotor), 4^C for 15 min with the
resulting supernatant being carefully discarded. The pellet was washed in 200 pi 70%
.ethanol and centrifuged at 13000 rpm (Eppendorf microcentrifuge with F45-24-11 
rotor), 4°C for 5 min and the supernatant was again carefully discarded. The DNA pellet 
was allowed to air-dry and was resuspended in 100-200 pi sterile distilled water. DNA
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concentration was determined using the absorbance at 260 nm and visually by agarose 
gel electrophoresis. The DNA concentration was calculated according to Abs26o x 50 == 
pg DNA/ml of solution (Sambrook et ah, 1986).
Protein isolation was performed by resuspending parasite pellets in 10 volumes of 2D 
lysis buffer, with the resulting cell suspension being stored at -80°C until use. Protein 
extracts were prepared by five rounds of freeze/thawing (in liquid nitrogen and 37°C 
waterbath), followed by homogenisation using a micro-pestle and 0.7 mm glass beads 
(Sigma). Non-soluble proteins and membrane fiuctions were removed from the soluble 
proteins by centrifugation at 13000 rpm (Eppendorf microcentrifuge with F45-24-11 
rotor), 4”C for 20 min (supernatant fraction), and protein concentrations were 
determined by Bradford assay (see section 2.2.7.6).
2.2.1.5 Transfection techniques
There are two current methods for the transfection of plasmid DNA into P. falciparum', 
these are “the spontaneous uptake” and “the infected erythrocyte” methods. Each 
method requires 100 pg of plasmid DNA, tightly synchi’onised parasite cultures and 
uses the same Cytomix (25 mM HEPES pH 7.6, 10 mM potassium phosphate pH 7.6, 
120 mM KCl, 5 mM MgCk, 150 pM CaCli, 2 mM EGTA). 100 pg of plasmid DNA 
previously prepared using a Hi-speed plasmid maxi kit from Qiagen (see section 
2.2.7,2) was ethanol precipitated (see section 2.2.7.3) and the resulting DNA pellet was 
air-dried in the cell culture cabinet (i.e. under sterile conditions) and resuspended in 30 
pi TE buffer (10 mM Tris, 1 mM EDTA pH 7.5).
The spontaneous uptake method was modified from the previously published method 
(Deitsch et a l, 2001). The following details are those that are necessary for a single 
transfection. 500 pi erythrocytes were washed in 10 volumes cytomix and centrifuged at 
1500 rpm (Jouan CR3i centrifuge with T4 rotor), 25°C for 10 min with the supernatant 
being removed after spinning. 470 pi of erythrocytes and 30 pi of DNA/TE mix were 
combined and added to a 0.2 cm gene puiser electroporation cuvette (Biorad), and 
electroporated at 310V and 950 pF using a gene puiser Xcell electroporator (Biorad). 
This transfection method gave time constant values in the range of 18-20 ms. The 
electroporated erythrocytes were removed from the cuvette into a culture flask 
containing 10 ml complete RPMI 1640 medium and erythrocytes infected with late 
trophozoite stages (sorbitol synchronised) were added to a final parasitemia of 1% and
i
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cultured at 37°C for 4-6 hours after transfection. Following this incubation the culture 
media was replaced by fresh media containing the necessary drug selection.
The infected erythrocyte transfection method was modified fi’om the protocol published 
previously (Wu et a l, 1995). The following details are those that are necessary for a 
single transfection. Synchronous parasite cultmes with 8-10% ring stages were 
centrifuged at 1500 rpm (Jouan CR3i centrifuge with T4 rotor), 25°C for 10 mins and 
the resulting supernatant was discarded. The 30 pi plasmid/TE mix and 200 pi of 
infected erythrocytes were combined with 370 pi Cytomix and added to a 0.2 cm gene 
puiser electroporation cuvette (Biorad). The mix was electroporated at 310V and 950 pF 
using a gene puiser Xcell electroporator (Biorad). This transfection method gave time 
constant values in the range of 10-15 ms. The electroporated mix was removed from the 
cuvette into a culture flask containing 10 ml complete RPMI 1640 medium and 300 pi 
uninfected erytluocytes and cultured for 4-6 hours following transfection. Following 
this incubation, the culture media was replaced by fresh media containing the 
appropriate drug selection.
2.2.1.6 Fluorescent microscopy
The subcellular localisation of parasite proteins fused to green fluorescent protein were 
analysed using an Axioplan 2 microscope (Ziess) equipped with a HBOlOO digital 
camera.
Images were captured at lOOx magnification in phase-contrast for live cells. The 
subcellular localisation of the GFP-fusion proteins were observed using the fluorescent 
filters for GFP (excitation at 488 nm and emission at 505-530 nm) or FITC (excitation 
at 494 nm and emission at 518 nm). The parasite’s mitochondrion was selectively 
stained using MitoTracker CMXRos (Molecular Probes) and was visualised using the 
fluorescent filter for rhodamine (excitation at 570 nm and emission at 590 nm).
Staining of the mitochondrion was perfonned by incubating 1 ml of culture (10 % 
parasitemia, 5% haematocrit) with 25 nM MitoTracker CMX ROS (Molecular Probes) 
for 5 min at 3TQ, before washing in 10 ml of warm culture medium (at 3TC). The 
resulting culture was centrifuged at 1500 ipm (Jouan CR3i centrifuge with T4 rotor), 10 
min, 25®C and the supernatant was removed and the erythrocyte pellet was resuspended 
in 1 ml of warm media (at 37°C) before being analysed as described above.
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2.2.2 Bioinformatics
2.2.2. 1____ Identifying genes in the P. falciparum genome
The component genes of the KADH were identified in the P. falciparum genome by 
TBlastN searching the Plasmodium genome database PlasmoDb (The Plasmodium 
genome database collaborative (Collaborative, 2001), http://www.plasmodb.org/) with 
human or yeast protein sequences.
2 .1 2 2____ Multiple sequence alignments
Multiple protein alignments of the identified sequences were performed using ClustalW 
rhttp://www.ebi.ac.uk/clustalw/I with predicted P. falciparum protein sequences and 
those encoding homologous proteins from other organisms, which were identified by 
EC numbers in the Expasy database (http : //us. expasv.org/enz vme/t.
2.2.2. 3_____Subcellular localisation predictions
Subcellular localisation predictions using the N-terminal targeting sequences of each 
protein was performed using SignalP (Nielsen et a l,  1997) 
http://www.cbs.dtu.dk/services/SignalP/. TargetP (Emanuelsson O, 2000) 
http://www.cbs.dtu.dk/services/TargetP. MitoProt (Claros et a l,  1996) 
http://mips.biochem.mpg.de/cgi-bin/proi/medgen/mitofilter and PlasmoAP (Foth et a l,
2003) http://www.PlasmoDB.org/restricted/PlasmoAPcgi.shtml.
2.2.3 Amplification of Plasmodium falciparum genes
2.2.3. 1_____Designing constructs
Constructs designed for recombinant expression in the E. coli system were sub-cloned 
into one of three expression constructs; pQE30, pJC40 and pET28. Recombinant 
expression of gene products in these vectors is under the control of the T7 promoter and 
is therefore inducible upon the addition of IPTG. The expression plasmid pQE30 
(Qiagen) contains a multiple cloning and ampicillin resistance cassettes, with the 
LipDH 1 expression construct cloned into Bam HI / Hind III sites (figure 2.1). 
Expression with the pQE30 vector produces a recombinant protein with a (His)e tag 
attached to it N-terminus. The expression plasmid pJC40 (Clos et a l,  1994) contains a
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multiple cloning site and ampicillin resistance cassette (figure 2.2). The LipDH2 
expression construct was cloned into Nde I / Bam HI sites. Expression using the pJC40 
vector produces a recombinant protein with a (His)io tag attached to its N-terminus. The 
expression plasmid pET28 (Novagen) contains a multiple cloning and kanamycin 
resistance cassette (figure 2.3) and the KGDH-E2 expression construct was cloned into 
Nhe I / Hind III sites which resulted in a (His)e tag at the N-terminus.
§.^6-8^5-
PT5 -  lac O  -  Iqc O -  RBS -| ATG Stop Codons
pQE-30
pQE-31
pQE-32
pQE-30, pQE-31, 
pQE-32 3.4 kb
ColEl
Figure 2.1- pQESO recombinant expression
This figure displays the important fea tu res of the pQESO recom binant expression plasmid; th e se  
include the ampicillin resistance  c a sse tte  and the multiple cloning site (MCS) that contains the 
Bam H\/Hind III sites used  for subcloning of the LipDHI expression construct. R ecom binant 
expression  using this plasm id is under the control of a  PT5 prom oter and a ttach es  a  HiS(g) tag at 
the N-terminus of the ex p ressed  protein. This figure w as taken from the Q iagen w ebsite 
fw w w .aiaaen.com ).
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A T C C  8 7 1 1 4
p M B 1  o r i
pJC40
2402 bp
T 7  p r o m o t e r  
Xbi 1(114)
S O  S E Q  
Nco I (153)
oly HIS 1 0 
XA c le e v a g a  s ite
Nd« 1(218)
Hind 111(221)
Boo R I (227)
W  1(232)
H I (237) 
Sm a 1(243)
TP HI term
M C S
Bgl 1(1272)
\  Pwu I (1021) 
a m p R
Figure 2.2 -  pJC40 recombinant expression plasmid
This figure displays the important fea tu res of the pJC 40 recom binant expression plasmid; th e se  
include the ampicillin resistance  c a sse tte  (m arked in red) and the multiple cloning site that 
contains the Nde UBam HI sites used  for subcloning of the LipDH2 expression construct. 
R ecom binant expression using this plasmid is under the control of a  T7 prom oter and a ttach es 
a  HiS(io) tag at the N-terminus of the ex p ressed  protein.
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T7 p rom oter 370-386
T7 tnm scrip tlon  s ta r t 369
His*Tag coding  sequence 270-287
T7*Tag coding  sequence 207 239
M ultiple cloning sites 
(Asndil-AAoI) 158-203
His*Tag coding sequence 140-157
T7 term inato r 26-72
i s c /  coding sequence 773-1852
pBR322 origin 3286
Kan coding sequence 3995-4807
f l origin 4903-5358
The m aps for pET  28b(+) and  pET-28c(>) 
a re  the  sam e as  pET 28a(+) (shown) w ith 
th e  following exceptions: pET-28b(+) Is a 
5368bp plasm id: sub trac t Ibp  from  each  s ite 
beyond Aa/nH I a t 198. pET 28c(+) Is a 
5367bp plasm id: su b trac t 2bp from  each  site 
beyond BairUA 1 a t 198.
Ora nKsi27)
XhoKiM)
a& tss.
K»i)
ZK»«l Bgl 18401) SgrA8442)
Sph8aw)
Bpu1102 8ao)
MhJ 81123) 
Bd 81137)
BetE 181304)
81334)
EC057 83772)
AlwN 83640)
PVU8442S)Sgf8443S)
Sma 1(4300)
Cla 84117) 
Nru 84083)
8(1834)
EcoRVt«73)
Hpa8i«zt)
BasS 83307) 
BapLUn ^
PahA8iOM)
83100)
Bst1107 1(2006) n h i n  1(2960)
Bgl 1(2107) Fop 82206) Pap6 8(2230)
Figure 2.3- pET28 recombinant expression plasmid
This figure displays the important fea tu res of the pET28 recom binant expression plasmid; th e se  
include the kanamycin resistance  c a sse tte  and the multiple cloning site. The KGDH-E2 
expression construct w as subcloned using Nhe UHind III. Recom binant expression  using this 
plasmid is under the  control of a  T7 prom oter and a ttaches a HiS(6> tag at the  N-terminus of the 
ex p ressed  protein. This figure w as taken from the Novagen w ebsite fww w .novaaen.com T
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Constructs designed for expression of P. falciparum genes in transfected P. falciparum 
cells were sub-cloned into the pHH2 vector (Crabb et a i, 2004). This vector employs 
Avr 11/ Bgl II restriction sites to clone an insert in frame with green fluorescent protein 
(GFP), producing C-terminally GFP-tagged proteins that are expressed following 
transfection of the plasmid DNA into P. falciparum. Expression of the GFP-fusion 
protein is under the control of the heat shock protein 86 promoter. pHH2 also contains 
the calmodulin promoter that controls expression of human dihydrofolate reductase 
(hDHFR) (figure 2.4), which confers resistance to the antifolate drug WR99210 and 
was used to select for the presence of the episomal vector following P. falciparum 
transfection (Fidock et a l,  1997).
PbDT3
XhoI(8s5)
GFP
Awn (1597)
PHH2 1I \  dgtn ( 1 6 6 7 )  
7 3 3 6  b p  J \ JftoI(i67i)
hspM 5
Hrp2 3 y  CAM 9
hDHFR
Figure 2.4- pHH2 Plasmodium expression plasmid
This figure displays the important fea tu res of the pHH2 Plasmodium expression  plasmid. The 
hum an dihydrofolate red u c tase  (hDHFR) g en e  is under the control of the Calmodulin prom oter 
(CAM 5’), confers resistance  to the pyrim etham ine derivative W R99210 and is used  a s  a 
selec tab le  m arker in parasite  cultures. An ampicillin resistance c a sse tte  (not shown) is used  
during subcloning of G FP fusion constructs into the AvrWIBgl II sites. This resulted in proteins 
that w ere tagged a t C-term inus with green  fluorescent protein (GFP), with expression under the  
control of the heat shock protein 86 prom oter (MSP 86 5’).
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2.2.3.2 Preparation of oligonucleotide primers
Oligonucleotide primers were designed for cloning of expression constructs (full and 
possible mature lengths), site directed mutagenesis and internal sequencing of 
constructs. Oligonucleotides designed for amplification of PCR products for 
recombinant expression/gene knockout studies contained 5’ extension that included 
restriction enzyme recognition sites, to allow cloning into the relevant destination 
plasmid. Oligonucleotides designed for use in site directed mutagenesis contained 
nucleotide changes designed to specifically incoiporate single amino acid mutations in 
the open reading frame. The oligonucleotides (Thermo electron) used in this study are 
shown in table 2.1.
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2.2.3.3 Reverse transcriptase (RT-PCR)
P. falciparum cDNA was reversed transcribed from RNA isolated from P. falciparum 
strain 3D7 using Superscript II (Invitrogen). All solutions were stored and all additions 
occurred on ice. 10 pg RNA was incubated at 25°C for 15 min with final concentrations 
of 5 mM DTT, 1.25x superscript II buffer and 50 units DNase I (Invitrogen) in DEPC 
treated water with a final volume of 20 pi. The DNase I in the reaction mix was 
inactivated by incubation at 70°C for 5 min, before the solution was cooled on ice for 10 
min. 250 ng of random hexamers (Invitrogen) were added, mixed well and denatured at
70°C for 5 min followed immediately by incubation on ice and addition of dNTP mix
(to a final concentration of 0.5 mM for each dNTP) and 200 units of Superscript II 
(Both Invitrogen). This solution was incubated at 50°C for 45 min and stored at for 
second strand synthesis.
Second strand synthesis was caiTied out using oligonucleotides specific for the 
components of the P. falciparum KADH (see table 2.1 for details of oligonucleotides 
used for these reactions). 1 pi of the products from the first strand synthesis was used 
with 50 ng of forward and reverse oligonucleotides, in a 25 pi reaction volume with 
PCR supermix supplemented with PJx polymerase (Invitrogen). A gradient PCR was set 
up to enable a range of annealing temperatures between 40 and 65°C, with the PCR 
reaction run as follows:
Step 1 95 °C, 3 minutes
Step 2 95 °C, 1 minute
Step 3 40-65 “C, 30 seconds
Step 4 60 “C, 2 minutes per kb
Repeat steps 2-4 for 30 cycles 
Step 5 60°C, 4 minutes per kb
Step 6 4 ^C, indefinitely
PCR products were analysed by agarose gel electrophoresis, and were cloned into the 
Zero blunt TOPO PCR kit (Invitrogen) for DNA sequencing using M13F and M13R 
sequencing primers.
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2.2.3. 4____ PCR from P. falciparum genomic DNA
Genes were amplified from genomic DNA (gDNA) isolated from parasites as described 
in section 2.2.1.4. 100 ng gDNA was mixed with 200 ng of forward and reverse 
oligonucleotides in PJx supermix or PCR supeimix (Invitrogen). The reaction was 
performed in a gradient PCR as detailed below:
Step 1 95°C, 3 minutes
Step 2 95®C, 30 seconds
Step 3 40 - 60°C, 30 seconds
Step 4 60°C, 2 minutes per kb to be amplified
Repeat steps 2 -  4 for 30 cycles
Step 5 60°C, 4 minutes per kb to be amplified
Step 6 Store at 4®C
The resulting PCR products were analysed by agarose gel electrophoresis before being 
cloned into the Zero blunt TOPO PCR cloning kit or TOPO TA cloning kit (Invitrogen; 
figures 2.5 and 2.6). DNA sequences were verified using M13F and M13R sequencing 
primers, with reactions being performed by The Sequencing Service, University o f 
Dundee ('www.dnaseq.co.uk'). Clones with correctly verified sequences were sub-cloned 
into their relevant destination vector as described in section 2.2.4.2.
2.2.3. 5____ Site directed mutagenesis
Site directed mutagenesis was carried out according to the method of Papworth et a l 
(Papworth, 1996). The method requires both forward and reverse oligonucleotides 
(containing the required mutation) of the same stretch of sequence; this allows the PCR 
of the entire template plasmid in both directions, producing complete plasmids 
containing the desired mutation. The template used in the mutagenesis PCR was the 
pJC40 PJTrxR wild type construct described previously (Gilberger et al., 1997).
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10 ng of double stranded plasmid DNA (pJC40 iyfrxR ) was used with 50 ng of forward 
and reverse oligonucleotides, in a 25 pi reaction volume with Accuprime PJx supermix 
(Invitrogen). A gradient PCR was set up to enable a range of annealing temperatures 
between 40 and 65°C. The mutagenesis reaction was run in the gradient PCR block as 
follows:
Step 1 95 ^C, 5 minutes
Step 2 95 “C, 30 seconds
The Dpn I-digested PCR products were then transformed into E. coli strain TOP 10 
cells (Invitrogen), selected on Luria-Bertani plates containing 100 pg/ml Ampicillin 
(LB/Amp) and incubated overnight at 37°C. Single colonies were selected and DNA 
was extracted using the Qiagen miniprep kit (Qiagen), with mutants determined by 
DNA sequence analyses using relevant sequencing primers (table 2.1).
Step 3 40-65 ”C, 15 seconds
■IStep 4 68 *^ C, 5 minutes
Repeat steps 2-4 for 15 cycles |
Step 5 68 °C, 10 minutes
Step 6 4°C, indefinitely
The PCR products were subsequently treated with 20 units Dpn I at 37°C overnight, to 
digest any template DNA. Dpn I is a restriction endonuclease that is specific to the 
sequence GATC, but only when adenine is methylated. This méthylation occurs in the 
bacterial host of the template plasmid, but not in the products of the PCR; therefore 
digestion with Dpn I degrades only the template DNA and not the PCR products thus
>1:,resulting in a positive selection for the mutated plasmid.
j
?î
2.2.3.6 Colony PCR
Colony PCR was necessary for the identification of correctly ligated clones from the 
ligation of small inserts (up to 300 bp) from TOPO clones into the 7.3 kb destination 
vector pHH2. Therefore, transformation plates that contained more than one hundred 
colonies were analysed by colony PCR to identify possible positive clones. Colony PCR 
uses a single bacterial colony as the template for the polymerase reaction that is
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performed using Reddymix (ABgene). Reddymix is a -based polymerase that 
contains a DNA loading dye that allows direct loading of agarose gels after completion 
of the PCR. An extended first dénaturation step assists in release of DNA from the 
colony allowing the PCR reaction to proceed using oligonucleotides that are specific for 
insert (the forward oligonucleotide) and vector (the reverse oligonucleotide). By using 
this combination of oligonucleotides only a colony containing a correctly ligated insert 
will produce a PCR product.
The PCR was set up using a stock solution for the PCR reaction mix, the total 
volume of this depended on the number of colonies to be screened, with 10 pi of the 
stock solution used per colony:
1 colony 20 colonies 60 colonies 
Oligonucleotide F (0.1 mg/ml) 0.5 10 30
Oligonucleotide R (0.1 mg/ml) 0.5 10 30
2 X Reddymix 4.5 90 270
UaÙ___________________________________ 4A_________90___________270
Total Volume 10 pi 200 pi 600 pi
Once the mix was made it was aliquoted into numbered PCR tubes, and a fresh 
LB/Amp plate was labelled with a numbered grid corresponding to the numbered tubes.
A single colony was selected from the transformation plate using a sterile 2 pi tip, and 
the colony inoculated onto the gridded plate at the relevant position (i.e. position 1) 
before being placed into the relevant tube (i.e. tube 1). This was repeated for all 
colonies that were to be screened, with particular attention being paid to matching the 
grid position with the PCR tube. The tips were removed from the tubes and discarded 
after 5 mins of incubation at room temperature. Appropriate negative controls were 
necessary to disregard unspecific binding, for instance by using a colony from an
'
unrelated cloning experiment. The gridded plate was incubated overnight at 37^C and
the PCR reaction was run as follows;
6 4 -
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Step 1 94 °C, 7 minutes 22'«
"is
Step 2 94 °C, 60 seconds /i
Step 3 45 °C, 60 seconds :i:
Step 4 60 °C, 2 minutes per kb to be amplifed i
Repeat steps 2-4 for 29 cycles '"i
Step 5 60 °C, 3 minutes per kb to be amplified
Step 6 4 °C, indefinitely ■ '■ t
2.2.4 Cloning techniques
2.2.4.1 TOPO cloning of PCR products
TOP 10 cells (Invitrogen) and selected on LB plates containing 50 pg kanamycin/ml.
PCR products were analysed by agarose gel electrophoresis, with possible positive |
elones identified by the presence of a PCR product at the correct size. Positive clones 
were subsequently analysed by DNA miniprep, restriction digestion and DNA 
sequencing.
All PCR products were initially cloned using a TOPO PCR cloning kit (Invitrogen); two 
types of vectors were used depending on the polymerase used. PCR products amplified 
using Taq based polymerases produce adenine overhangs on the 3’ ends of PCR 
products and required the TOPO TA® PCR cloning kit (Invitrogen; figure 2.5). While I
products generated using Pfa/Pfu based polymerases amplify as blunt ended products 
and required the Zero Blunt® TOPO® PCR cloning kit (Invitrogen; figure 2.6). Both kits 
provide linearised vectors with topoisomerase I covalently bound to the 3’ end of the 
vector. This topoisomerase catalyses the ligation of the PCR product into the vector at %
room temperature in 5-10 mins, and disrupts the ccdB lethal gene, allowing for further 
selection of correctly ligated products. The ligation reaction was performed as per
' ■“Imanufacturer’s instructions and was transformed into chemically competent E. coli
A number of single bacterial colonies were selected from the transformation plates and 
plasmid DNA was isolated using the Qiaprep spin miniprep kit (Qiagen) following the 
manufacturer’s guidelines. 500 ng of isolated DNA was digested using 4 units EcoPl at I
37°C for 2-3 hours before being analysed by agarose gel electrophoresis. Possible I
- 65 -
Chapter 2. Materials and Methods
positive clones were determined by the presence of the correct banding pattern and 
verified by DNA sequencing using M l3 F, M l3 R or internal sequencing primers.
/acZaATGM13 Reverse Wmef | *** I I Sarrtl I !
CAG GAA ACA GCT ATC A cb  ATG ATT ACG CCA AGO TEG GTA COG AGC TOG GAT CCA CTA GTC CTT TGT CGA TAC TG Î  TAC TAA TGC GGT TOG AAC CAT GGC TCG AGC CTA GGT GAT
BsfXI ECORI
GTA ACG GCC GCC AGT GTg ' c TG GAA TTC GCC CT' 
CAT TGC CGG CGG TCA CAC GAC CTT AAG CGG
£coRI
,G GGC GAA TTC TGC 
TTC CCG CTT AAG ACG
EcoRV SsfXI AWl X h o l N sU X bai A psiI I I I  I I  T  ______AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT 
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
TTPromofer M13 Fonwtrd (-20) Prinwr
CTG' GCC GTC GTT TTA dAA CGT CGT GAC TGG GAA AACGAC CGG CAG CAA AAT GTT GCA GCA CTG ACG CTT TTG
AGT GAG TCG TAT AAT TCATCA CTC AGC ATA A TTA AGT
pCR®2.1-TOPO*
3.9 kb
Comments for pCR*2.1-TOPO®
3931 nucleotides
LacZa fragment: bases 1-547 
MIS re v e re  priming site: b ases  205-221 
Multiple cloning site; bases  234-357 
T7 promoter/priming site: bases 364-383 
Ml 3 Forward (-20) priming site; b ases  391-406 
f1 origin: b ases  548-985 
Kanamycin resistance ORF: b ases  1319-2113 
Ampicillin resistance ORF: b ases  2131-2991 
pUC origin: b a se s  3136-3809
Figure 2.5 -  pCR2.1- TOPO plasmid (TOPO TA cloning)
This figure displays the important features of the pCR2.1 TOPO plasmid, which was used to 
clone PCR products amplified with Taq based polymerases. Key features of this plasmid include 
the ampicillin and kanamycin resistance cassettes, the multiple cloning site and the position of 
M IS forward and reverse primers that were used for sequence verification by DNA sequencing.
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M13 Rsverse priming sHe
2 0 1  CACf CAGGAA ACAGCTATGA CCATGATTAC GCCAAGCl AT TTAGGTGACA CTATAGAATA 
GTGljGTCCTT TGTCGATACT QGTACTAATG CGGTTCGATA AATCCACTGT GATATCgTAT
SP6 promoter^ming
Nall Mndlll A^TIBI ^ ^ 1  ÉW136HS*îtS|OT(HI $ ^ l
CTCAAGCTAT GCATCAAGCT TGGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT 
GAGTTCGATA CGTAGTTCGA ACCATGGCTC GAGCCTAGGT GATCATTGCC GGCGGTCACABmRI
GCTGGAATTC GCCCTTi 
CGACCTTAAG CGGGAAI
NoTI
B l u n t  P C R  PI  o  d  u  c t
6c«Rt f y i  ÊCORV
lAAGGGCGAATTCT GCAGATA
I t t c c c g c t t a a g a  CGTCTAT
;cr»iI AWObalL OmllJ - T7 promotorApriming siteTCCATCACAC TGGCGGCCGC TCGAGCATGC ATCTAGAGGG CCCAATTCGC CCTATAGTGA 
AGGTAGTGTG ACCGCCGGCG AGCTCGTACG TAGATCTCCC GGGTTAAGOG GGATATCACT
M13 Forward (-20) priming site
GTCGTATltAC A A TT C Æ TG G 'T C G T C G T T^T Â 3V A C G TC G T GACTGGGAAA ACCCTGGCGT 4 7 6  
CAGCATAAfFG TTAAG’qGACC GGCAGCAAAA TGjTTGCAGCA CTGACCCTTT TGGGACCGCA^ V— ................ . ................. ... . ........ . ........ ..................... .......... ..............
pCR-Blunt II TOPO
3519 bpComments for pCR«-Blunt ll-TOPO®3S19 nucleoHdes
fac promoter/operator region: bases 95-216 M13 Reverse priming ate ; bases 205-221 LacZ-aipha ORF: bases 217-576 SP6 promoter priming site: bases 239-256 Multiple Cloriing Site: bases 269^399 TOPO^-Clonlng site: bases 336-337 T7 promoter pnming site: bases 406-425 Ml 3 (-20) Forward prirning site: bases 433-448 Fusion joint: bases 577-585 ccdB leteal gene ORF: bases 586-888 kan gene: bases 1099-2031 kan promoter: bases 1099-1236 Kanamycin resistance geiw ORF: bases 1237-2031 Zeocin re^stance ORF: bases 2238-2612 pUC origin: bases 2724-3397
Figure 2.6 -  pCR-Blunt II- TOPO plasmid (TOPO cloning)
This figure displays the important features of the pCR-Biunt II TOPO plasmid, which was used 
to clone PCR products amplified with polymerases with proof reading abilities (e.g. Pfx 
supermix). Key features of this plasmid include the kanamycin resistance cassette, the multiple 
cloning site and the position of M13 forward and reverse primers that were used for sequence 
verification by DNA sequencing.
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2.2.4.2 Sub-cloning into destination vectors
TOPO clones which have had their sequences verified by DNA sequencing were then 
sub-cloned into their respective destination plasmid. The inserts were digested from the 
TOPO vector, gel purified and ligated together. The resulting ligation reactions were 
transformed into either E. coli strains JM109, TOP 10 or XL-10 gold (see section
2.2.7.1).
Restriction digests of 3 pg of isolated DNA (fr om both destination vector and TOPO 
clone plasmids) were performed overnight using 10 units each of the relevant restriction 
enzymes (table 2.1). The digests were separated by agarose gel electrophoresis and 
digested products (inserts or plasmids) were isolated by gel purification.
Gel purification of digested DNA was performed on both destination vector and insert 
bands excised following agarose gel electrophoresis using the Qiaquick gel extraction 
kit (Qiagen) according to manufacturers guidelines. Samples were eluted from the gel 
purification columns in 30 pi sterile distilled water, with 3 pi being analysed for purity 
and visually quantified by agarose gel electrophoresis.
Ligation of isolated vector and insert DNA were performed using T4 DNA ligase 
(NEB) with molar vector to Insert ratios ranging from 1:3 to 1:10. Ligation reactions 
were incubated in a 14°C waterbath overnight, and were subsequently transformed into 
E. coli TOP 10 cells and selected on LB/Amp plates. Possible positive clones were 
identified by DNA miniprep and digested with the relevant restrictions enzymes (table
2.1). Clones with the correct destination vector and insert band size were verified by 
DNA sequencing.
2.2.5 Recombinant protein expression and purification
In order to maximise the parameters for recombinant protein expression in E. coli, test 
expressions were set up and analysed using the Bugbuster protein extraction reagent 
(Novagen). Single colonies were selected and grown in 2 ml LB (containing the 
relevant antibiotic) cultures overnight at 37 with shaking at 200 rpm. Overnight 
cultures were diluted 1:50 into 10 ml LB/Amp (in 50 ml falcon tubes) and were 
incubated at 37 °C with shaking at 200 rpm. Once the cultures reached mid-log phase 
(ODôoo = 0.4 - 0.8), the expression of the proteins was indueed by adding IPTG 
(Melford) to a final concentration of ImM. The cultures were then incubated overnight
-6 8  -
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at various temperatures (37 ‘^ C, 25 °C and 15 "C) with 200 rpm shaking. 1 ml aliquots of 
cultures were removed immediately after induction, 4 h after induction and after 
overnight expression. These 1 ml aliquots were centriftiged at 13,000 rpm (Eppendorf 
microcentrifuge with F45-24-11 rotor), 4 °C for 4 mins and the supernatant was 
discarded. The resulting cell pellets were stored at -  20 "C until further analyses was 
performed.
Bacterial pellets were resuspended in 50 pi Bugbuster protein extraction reagent 
containing 0.5 pi benzonase (Novagen). The Bugbuster solution contains a mixture of 
non-ionic detergents to aid the lysis of the bacterial cells, while the benzonase degrades 
the DNA and RNA released following this lysis. The cell lysates were mixed at room 
temperature for 15 min before being centrifuged at 13,000 rpm (Eppendorf 
microcentrifuge with F45-24-11 rotor), 4 °C for 20 min. The soluble fraction 
(supernatant) was transferred to a fresh tube and 10 pi of 6 x SDS loading dye was 
added. The pellet was resuspended in 50 pi 1 x SDS loading dye. The soluble and pellet 
mixes were heated for 5 min at 100 °C, and then separated by SDS-PAGE followed by 
Coomassie staining or western blotting (see sections 2.2.7.7 and 2.2.7.9).
2.2.5.1 Thioredoxin reductase (PflrxR)
PfTrxR (wild type and mutants) was expressed as described previously (Gilberger et a l,
1997) with modifications. pJC40 cloned expression constructs were transformed into E.
coli BL21 (DE3) chemically competent cells (Stratagene) for expression. Starter
cultures were inoculated from a glycerol stock and were incubated for 18 h at 31°C with
constant shaking at 200 rpm. The starter cultui'es were diluted 1:50 into IL LB media
containing 50 pg ml’  ^ ampicillin in a 2L Erlenmeyer flask and incubated at 31°C with
shaking at 200 rpm. The recombinant expression was then induced by the addition of 1
mM IPTG when the cultures had reached an ODôoo of 0.4 -  0.8, before being incubated
for 18 h at 31°C with constant shaking. Bacteria were pelleted by centrifugation at 4,000
rpm (Sigma 6K15 centrifuge with 12500 rotor), 15 min, 4°C and pellets were
re suspended in Qiagen lysis buffer and were stored at -80 C for purification.
.Recombinant PfTrxR was purified using Ni-NTA batch purification (see section
2.2.6.1) and was quantified using an extinction coefficient of 11,300 mM'* cm'* at 460 
nm (except for PfTrxR C88A and C93A mutants, which used an extinction coefficient 
of 12,800 mM'* cm'* at 451 nm and 12,620 mM'* cm'* 456 mn, respectively).
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2.2.5. 2____ Thioredoxin fPfTrx)
PfTrx was expressed and purified as described previously (Krnajski et a l,  2001) with 
some alterations. pJC40 eloned PfTrx was expressed in E. coli BL21 (DE3) by 
inoeulating a LB/Amp starter culture from a glycerol stock and incubating it at 3TC  
overnight with shaking at 200 rpm. The starter culture was diluted 50 fold in a IL 
LB/Amp eulture (in 5L Erlenmeyer flask) and incubated at 31°C with shaking at 200 
rpm until the culture reached an ODeoo of between 0.4 and 0.8. The expression of 
recombinant PfTrx was induced by the addition of ImM IPTG and the culture was 
incubated for a further 14 hours at 28®C, with shaking at 200 rpm. The bacterial culture 
was harvested at 3000 rpm (Sigma 6K15 centrifuge with 12500 rotor), 4®C for 20 mins 
and the resultant bacterial pellet was resuspended in Qiagen lysis buffer (10 ml of buffer 
per L of culture) and stored at -80°C until purification. Recombinant PfTrx was purified 
by Ni-NTA batch purification (see section 2.2.6.1), with purified PfTrx concentration 
being measured spectrally at 280 mn using the extinction coefficient 11,700 mM'* cm"* 
(Krnajski et a l, 2001) and was confirmed using the Bradford assay.
2.2.5.3 LipDHl
LipDHl was recombinantly expressed in the pQE30 expression vector producing a 
recombinant protein with a His(6)-tag at the N-terminus. The expression construct was 
transformed into chemically competent E, coli Novablue cells, and single colonies were 
used to produce a starter culture in LB/Amp media, which was incubated at 37“C 
overnight with shaking at 200 rpm. The starter culture was diluted 50 fold into IL 
LB/amp medium (5L Erlenmeyer flasks), and incubated at 31°C with shaking at 200 
rpm until ODôoo reached 0.4 -  0.8. Expression of the recombinant protein was induced 
with the addition of ImM IPTG and the cultures were incubated for a further 14 hours 
at 30^C. Bacteria were pelleted by centrifugation at 4,000 rpm (Sigma 6K15 centrifuge 
with 12500 rotor), 15 min, 4°C and pellets were resuspended in Qiagen lysis buffer and 
were stored at -80°C for purification. Recombinant LipDHl was purified by Ni-NTA 
batch purification (see section 2.2.6.1) and purified LipDHl was quantified spectrally 
using an extinction coefficient of 11,300 mM"* cm"* at 460 nm.
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2 2 .5 .4  L ip D H l
LipDH l expression was carried out in E. coli BL21 (DE3) RIL cells transformed with 
the pJC40 cloned LipDH2 expression construct. A single colony was inoculated into a 
starter culture containing LB/Amp media and was incubated overnight at 31°C with 
shaking at 200 rpm. The starter culture was diluted 50 fold into IL LB/Amp media (in 
5L Erlenmeyer flasks) and incubated at 31°C with shaking at 200 rpm until the culture 
reaehes an ODôoo of 0.4 -  0.8. Expression of recombinant protein was induced by the 
addition of ImM IPTG and the cultures were incubated for a further 14 hours at 31°C 
with shaking at 200 rpm. The bacterial cultui'e was harvested at 3000 rpm (Sigma 6K15 
centrifuge with 12500 rotor), A°C for 20 min and the resultant bacterial pellet was 
resuspended in Qiagen lysis buffer (10 ml of buffer per L of cultme) and stored at -  
80°C until purification. Recombinant LipDH2 was purified in a two-step method using 
Ni-NTA affinity chromatography. The first step utilised Ni-NTA batch purification (see 
section 2.2.6.1), with the elution sample being extensively dialysed into Qiagen lysis 
buffer. The second step utilised a Ni-NTA purification with a linear imidazole gradient 
performed on a FPLC (see section 2.2.6.2) to obtain purified LipDH2. The purified 
protein was quantified spectrally using an extinction coefficient of 11,300 mM'* cm'* at 
460 nm.
2.2.5.5____ g-Ketoglutarate succinvltransferase (KGDH-E2)
The recombinant expression of KGDH-E2 was performed in E. coli BL21 (DE3) cells 
(Novagen) transformed with the pET28 KGDH-E2 expression construct. A single 
colony was used to inoculate a LB/Kan starter culture that was incubated overnight at 
31°C with shaking at 200 rpm. The starter culture was diluted 50 fold in a IL LB/Amp 
culture that was incubated at 31°C for 24 hours, with the addition of ImM IPTG when 
the culture reached an O D ôoo of between 0.4 and 0.8. The baeterial culture was 
harvested at 3000 rpm (Sigma 6K15 centrifuge with 12500 rotor), 4°C for 20 mins and 
the resulting pellet was resuspended in Qiagen lysis buffer (10 ml per IL of bacterial 
culture) and stored at -80°C for purifieation. Recombinant KGDH-E2 proteins were 
purified using Ni-NTA batch pmification (see section 2.2.6,1) and purified proteins 
were quantified using Bradford assay (see section 22.1.6).
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2.2.6 Purification techniques
Bacterial pellets were flash thawed in running warm water to lyse bacterial cells before 
being incubated on ice for 30 min with 50 pg ml"* lysozyme. ImM of the protease 
inliibitor PMSF (and lOOpM FAD for purifications of disulphide oxidoreductases) was 
added to the bacterial lysate, before centrifuging at 20,000ipm (Beckman J2-H5 
centrifuge with a JA-20 rotor), 4°C for 60 min. The resulting bacterial supernatant was 
removed and filtered through a 0.4 pm syringe filter before the recombinant protein was 
purified by one of the methods below.
2.2.6. 1____ Batch Nickel affinity chromatography
Batch Ni-NTA purification was performed using Ni-NTA agarose (Qiagen) according 
to manufacturers instructions with some modifications. Briefly, 1 ml Ni-NTA agarose 
per litre of bacterial culture was mixed with the filtered bacterial supernatant (see 
previous section) at 4°C for 60 min using a blood wheel. The lysate/Ni-NTA mix was 
poured through an econopac column (Biorad) and the flow-through fraction was 
collected by gravity flow. The resulting Ni-NTA pellet was washed twice in 5 pellet 
volumes of Qiagen lysis buffer (which contains 10 mM Imidazole). A subsequent wash 
was performed with 5 pellet volumes of Qiagen wash buffer (containing 20 mM 
Imidazole) and a third wash (only for proteins expressed by pJC40) was performed in 
50 mM Imidazole. The recombinant proteins were eluted from the Ni-NTA beads by 
Qiagen elution buffer (containing 500 mM Imidazole) and collected by gravity flow. 
Eluted proteins were quantified spectrally as described in section 2.2.5. All fractions 
(bacterial pellet, bacterial lysate, Ni-NTA flow-through, washes and elutions) were 
stored at 4°C for analysis by SDS-PAGE or western blot following eompletion of 
purification. LipDH2 was further purified by FPLC nickel chromatography.
2.2.6. 2____ Denaturing Nickel affinity chromatography
Denaturing Ni-NTA purification was performed using Ni-NTA (Qiagen) according to 
manufacturers guidelines with some modifications. Recombinant expression cultures 
were harvested as described in section 2.2.6.1, but were resuspended in denaturing Ni- 
NTA purification buffer (at pH 8.0) rather than Qiagen lysis buffer. This suspension 
was mixed for between 1 5 -6 0  min at room temperature with occasional vortexing. The 
lysate was then centrifuged at 20,000rpm (Beckman J2-H5 centrifuge with a JA-20 B'
rotor), 4°C for 30 min to remove cellular debris. Ni-NTA (1 ml per litre of culture) was
-72
2.2.6.3 FPLC Nickel affinity chromatography
2.2.6.4 Gel filtration chromatography
Gel filtration chromatography was employed in order to investigate the oligomeric state
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added to the resulting supernatant and incubated at room temperature of constant 
shaking (an a rotary shaker) for 60 min. The Ni-NTA/lyaste mix was then applied to an 
econopac column (Biorad) and the flow-thi'ough was collected by gravity flow. The 
resulting Ni-NTA pellet was washed twice with 2 pellet volumes of denaturing Ni-NTA 
purification buffer at pH 6.3 and once with 2 pellet volumes of denaturing Ni-NTA 
purification buffer at pH 5.9. The recombinant protein was eluted in three times in 2
■Ipellet volumes of denaturing Ni-NTA purification buffer at pH 4.4. All fractions were 
collected to be analysed by SDS-PAGE.
■3|
FPLC nickel affinity chromatography used HiTrap chelating HP columns (either 1 ml or
1
■3|
5ml; Amersham biosciences). HiTrap columns were washed sequentially with sterile 
distilled water, 100 mM NiS04, sterile distilled water and Qiagen lysis buffer before 
protein samples were pre-loaded onto a HiTrap chelating column (Amersham 
bioseiences). The column was then attached to an ÂKTA FPLC (Amersham 
biosciences), washed with five column volumes of Qiagen lysis buffer before the 
sample was eluted using a linear gradient of 10 mM -  500 mM imidazole. The linear 
gradient of imidazole was prepared by the ÂKTA FPLC (Amersham biosciences), by 
mixing Qiagen lysis buffer (lOmM imidazole) with Qiagen Elution buffer (500 mM 
imidazole). The elution profile of the proteins loaded onto the HiTrap chelating HP | |
column was followed spectrally at 280 nm. Samples from OD280 peaks were analysed
by SDS-PAGE and western blotting.
j
of the recombinantly expressed protein. A Sephadex S200 16/60 or Superose 6 10/30
column was attached to an ÀKTA FPLC (All Amersham biosciences) and pre­
equilibrated with 50 mM potassium phosphate pH 7.6, 150 mM NaCl with a flow rate 
of 1 ml min*. The protein elution profile of samples was followed at 280 nm. Before 
samples were separated the columns were calibrated in the same buffer with gel 
filtration standards (Biorad), with elution profiles of the standards used to produce a
■tcalibration curve. The calibration curve was produced by plotting the logio of the 
proteins molecular mass (on the y-axis) against the Ve/Vo (on the x-axis), where Ve is 
the elution volume of the protein and Vo is the void volume of the column. This
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resulted in the calibration curves of y = 7.9844 + (-1.8492x) for the Sephadex S200 
16/60 and y = 7.8235 4- (-1.5140x) for the Superose 6 10/30 column.
1.4 mg of the purified LipDHl protein was loaded onto the Superose 6 10/30 column 
(Amersham biosciences) and 300 pg of the pmified LipDH2 protein sample was loaded 
onto the Sephadex S200 16/60 column (Amersham biosciences) and the resulting 
elution profiles were used to calculate the apparent molecular size of the proteins using 
the calibration curves.
2.2.7 Molecular biology techniques
2.2.7.1 E. coli transformation
Plasmid DNA was transformed into chemically competent E. coli strains JM109 
(Stratagene), XL 10 gold (Stratgene) and TOP 10 (Invitrogen) for general cloning and 
sub-cloning; BL21(DE3) and BL21(DE3) RIL (both Stratagene) and Novablue cells 
(Novagen) were used for recombinant expression. The genotypes of the E. coli strains 
used aie displayed in table 2.2. Transformations were performed to manufacturers 
guidelines with modifications. Transformations were performed with either whole 
ligation reactions (maximum of 30 pi) or 100 ng of destination plasmid DNA, with 
transformations being plated onto LB agar plates with the appropriate antibiotic 
selection and incubated overnight at 37®C. Possible positive clones were identified by 
DNA miniprep and digested with the relevant restrictions enzymes (table 2.1). Clones 
with the correct destination vector and insert band size were verified by DNA 
sequencing.
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2.2.7.2 Plasmid DNA isolation from E. coli
Plasmid DNA was isolated from transformed E.coli eultures using two methods that 
depended on the levels of plasmid DNA required.
Small-scale isolations were carried out using the Qiaprep spin miniprep kit (Qiagen). 
DNA was isolated from single colonies on transformation plates by inoculating them
into 2 ml LB media containing either 50 pg/ml kanamycin (for TOPO clones) or 100 
pg/ml ampicillin (for destination clones) antibiotics; these cultures were incubated at 
3TC  overnight with shaking at 200 rpm. DNA was isolated from the resulting cultures 
using the Qiaprep spin miniprep kit (Qiagen) by following the manufacturers 
guidelines, with the DNA eluted In 50 pi sterile distilled water. Miniprep plasmid DNA 
was analysed by either restriction digests followed by agarose gel electrophoresis or by 
DNA sequencing using the appropriate primers.
3Large-scale isolations were carried out using the Hi-speed plasmid maxi kit (Qiagen) 
and were performed following the manufacturers guidelines. It was necessary to 
perform large-scale isolations on eonstructs, which were due to be transfected into 
parasites (pHH2 constructs; see section 2.2.3.1). Isolated plasmid DNA was quantified 
by spectrophotometric analyses, using the absorbance at 260 nm to calculate DNA f
concentration as described in section 2.2.1.4. Using this kit, 250 ml of culture usually -I
yielded 200 - 400 pg of purified DNA, which provided enough DNA for 2 -  4 ■ | |
transfections (see section 2.2.1.5). #12.2.7.3____ Ethanol precipitation of DNA
■i
The preeipitation of DNA was required as part of the transfection protocol (to
concentrate and buffer exchange the DNA solution) and was also utilised during sub-
cloning as a buffer exchange method for restriction enzyme digests with two non- f |
compatible enzymes.
'■•f:
' IEthanol precipitation was performed by mixing the DNA solution with 0.1 volumes of 
3M NaAc pH 5.2 and 3 volumes of 100% ethanol. The resulting mix was incubated at - 'I20°C or -SO^ ^C for at least an hour before being centrifuged at 13,000 rpm (Eppendorf 
microcentrifuge with F45-24-11 rotor), 4 C for 30 min. The supernatant was carefully 
removed and the pellet was washed in 70% ethanol before being centrifuged at 13,000 
rpm (Eppendorf mierocentrifuge with F45-24-11 rotor), 4°C for 10 min and the
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supernatant was again carefully removed. The pellet was allowed to air-dry before being 
resuspended in the appropriate buffer by gently pipetting and storing at 4°C overnight to 
aid resuspension.
2.2.7.4____ DNA sequencing
2.2.7.5 Agarose gel electrophoresis
77 -
DNA sequencing was performed by the sequeneing service, School of Life Sciences, |
University of Dundee f http ://www. dnaseq. co .uk/home.htmh using Applied Biosystems 
big-dye version 3.1 chemistry on an Applied Biosystems 3730 automated capillaiy 
DNA sequencer. This reaction required 200-300 ng of plasmid and 3.2 picomoles of
sequencing primer per reaction. All relevant sequencing primers, except for sequencing 
primers for pQE30 and pHH2 (table 2.1), were provided by the sequencing service.
DNA was routinely examined by electrophoresis in 1.0% (w/v) agarose gel that
contained TAB buffer with 0.5 pg/ml ethidium bromide. The DNA sample of interest U
was mixed with 6 x DNA loading buffer (Promega) and electrophoresis was performed i;
at 100 V for 30-60 min in TAE buffer. 1 kb ladders (Promega) were routinely run
’Ialongside samples to allow size determination of the bands visualised by UV
illumination at 302 nm or 365 nm. DNA was visualised at 365 nm when subsequent gel 
extraction was required because under this condition DNA damage was minimised. !:|
2.2.7. 6____ Determining protein concentration 1
The protein concentration of purified and isolated proteins was analysed by the 
Bradford assay (Bradford, 1976), using the Biorad protein assay reagent (Biorad).
Protein concentration was observed spectrally as the absorbance at 595 nm and was S
determined in reference to a standard curve produced by the addition of 1 -  20 pg ml f
bovine serum albumin (BSA) to a 1 x Bradford solution (Biorad).
,2.2.7. 7____ Sodium dodecvl sulphate polyacrylamide gel electrophoresis
Protein samples were separated by sodium dodecyl sulphate polyacrlamide gel 
electrophoresis (SDS-PAGE) using the NuPAGE Bis/Tris electrophoresis system 
(Invitrogen). Novex Bis/Tris pre-cast gels (either 10 % or 4 -12 % polyacrylamide) 
were used in Xcell Surelock™ Mini-cell apparatus with 1 x MOPS running buffer (all
C hap ter 2. M aterials and M ethods
Invitrogen). Proteins to be run on SDS-PAGE were commonly quantified by Bradford 
assay and gels were loaded with 10 pg protein in 1 x SDS loading buffer following 
heating at lOO^C for 5 min (see section 2.2.7.6). Electrophoresis was performed 
according to manufacturers guidelines and SDS-PAGE gels were stained by incubation 
(with shaking) in Coomasie stain for 10 mins and washed in destain.
2.2.7. 8____ Generation of polyclonal antibodies
Polyclonal antibodies were generated from purified recombinantly expressed proteins 
by Eurogentec fhttp://uk.eurogentec.com/code/en/hp.aspi. 400 pg of recombinant 
LipDH2, BCKDH E2 and KGDH E2 proteins were separated by SDS-PAGE, gel 
excised and sent to Eurogentec using their standard immunisation protocol 
(Eurogentec). Each bleed was analysed on recombinant protein and P. falciparum 
extract to test for specificity.
2.2.7. 9____ Western blot analyses
Following protein separation by SDS-PAGE (see section 2.2.7.S) the proteins were 
transferred to Protran nitrocellulose (Schleicher & Schuell) using a Transblot semi-dry 
blotting system (Biorad) according to manufacturers instructions. Transfer was in a 
downward direction in a sandwich of To whin buffer soaked blotting paper, SDS-PAGE 
gel, nitrocellulose and blotting paper (from top to bottom in the sandwich). The transfer 
was canied out at a fixed voltage of 20V for 30 min per gel. The nitrocellulose 
membrane was subsequently stained using Ponceau S stain (Sigma) to allow analyses of 
transfer and marking of the gel lanes with a blunt pencil. Ponceau S was removed by 
washing the blot in PBS with 0.05% Tween 20. Following washing the blot was 
blocked by incubating (with shaking) in PBS containing 5 % Marvel milk powder for 
either 60 min at room temperature or overnight at 4°C. Primaiy antibodies were diluted 
to the necessary concentration (table 2.3) in 1% (w/v) Marvel in PBS, and incubated on 
the blot at room temp for 60 min with constant shaking. The blots were then washed in 
PBS containing 0.05% (v/v) Tween 20 for three washed of 10 min with constant 
shaking. Secondary antibodies were then incubated at the necessary dilution at room 
temperatuie for 60 min in 1% (w/v) Mai*vel in PBS, before the wash step was repeated 
as before. The HRP conjugated secondary antibodies were detected using the ECL-plus 
detection kit (Amersham biosciences), and the blots were exposed to ECL film
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(Amersham biosciences) for the necessary time in a hyperfilm cassette (Amersham 
bioscienees).
Primary antibody Dilution Secondary antibody Dilution
anti - His(ô) Tag 1 : 5,000 anti -  Mouse 1 : 5,000
anti -  GFP I : 5,000 anti -  Rabbit 1 : 5,000
anti - LipDH2 1 : 500 anti -  Rabbit 1 : 1,000
anti - KGDH-E2 1 : 100 anti -  Rat 1 : 10,000
anti - BCKDH-E2 1 : 500 anti -  Rabbit 1 : 1,000
Table 2.3 -  Antibody dilutions for western blots
This table displays the dilutions factors of the commonly used primary and secondary 
antibodies.
2.2.7.10 Immunoprécipitation
Parasites were isolated from IRBC by Saponin lysis (see section 2.2.1.4), before being 
resuspended in 5 pellet volumes of IP lysis buffer. This was flash frozen at -80°C before 
being thawed at room temperature, and then incubated on iee for 30 min. The lysed 
solution was then cleared by centrifugation at 12,000g for 30 min at 4°C. A 50% slurry 
(v/v) of protein A sepharose beads (Amersham biosciences) in IP wash buffer was then 
added to the lysate in order to pre-dear the solution of any proteins that un-specifically 
bind to the beads. Simultaneously, 5 pg of antibody were added to a 50% slurry (v/v) of 
Protein A sepharose beads in IP wash buffer in a separate tube. Both the pre-cleared and 
antibody/bead mix were mixed on a blood wheel at 4°C for 60 min. The beads were 
pelleted at 10,000g, 4°C for 4 min and the supernatant from the antibody/beads 
incubation was removed and replaced with the supernatant from the pre-clear 
incubation. This was incubated on a blood wheel at 4°C for 2 hours. The beads were 
pelleted again by centrifugation at 10,000g and washed in IP wash buffer, this step was 
then repeated a further 3 times. Finally the beads were washed a further 2 times in PBS 
and eluted from the beads in 2x SDS loading buffer. Samples were then separated on 
SDS-PAGE and detected by either Coomassie staining or western blotting.
- 7 9 -
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2.2.8 Spectral analyses of disulphide oxidoreductases
The spectral features of the reeombinantly expressed PfTrxR (wild-type and mutants) 
and LipDH proteins were analysed by reduction with either NADH, NADPH or sodium 
dithionite (all Sigma).
2.2.8. 1_____ Reductive half-reaction of dihvdrolipoamide dehydrogenase
Reduction of LipDH was measured under aerobic conditions by the addition of excess 
NADH. Spectra between 300 and 700 nm were measured before and immediately after 
addition of 20 molar excess of NADH to a LipDH solution (11 - 22 pM) on a UV-2401 
spectrophotometer (Shimadzu). The LipDH concentration was calculated using the 
extinction coefficient for protein bound FAD at 460 nm of 11,300 mM cm'* and the 
NADH concentration was calculated using the extinction coefficient of 6,200 mM cm'* 
at 340 nm.
2.2.8. 2_____Reductive half-reaction of thioredoxin reductase
The reductive half-reaction in thioredoxin reductase was analysed under anaerobic 
conditions in order to counteract the enzyme re-oxidation observed under aerobic 
conditions. PfTrxR solutions were made anaerobic in an anaerobic cuvette by 8 -  10 
cycles of vacuum and ultrapure nitrogen. The solution was left to equilibrate in 
ultrapure nitrogen before an air tight Hamilton syringe, containing the reductant, was 
attached to the euvette. The anaerobic PfTrx R solution was titrated with the reductants 
NADPH or sodium dithionite at 25°C under anaerobic conditions; each addition was 
analysed between 350 and 700 nm in a Cary 300 spectrophotometer (Varian). P/TrxR 
solutions were quantified using the extinetion coefficient for protein bound FAD at 460 
nm of 11,300 mM'* cm'*, except for PfTrxR C88A and C93A which used the extinction 
coefficients of 12,800 M'* cm"* at 451 nm and 12,620 M"* cm'* at 456 mn respectively 
(Gilberger et a l, 1997).
2.2.8.2.1 NADPH reduction
Freshly prepared 1.5 mM NADPH was quantified using an extinction coefficient at 340 
mn of 6,220 mM'* cm'*, and degassed by bubbling in ultrapure nitrogen for 10 min in a 
glass syringe. The anaerobic NADPH solution was drawn into an airtight Hamilton
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syringe and titrated (in 2 |_il additions) into an anaerobic cuvette containing an anaerobic 
10-15 jiM P/TrxR solution.
2.2.8.2.2 Sodium dithionite reduction
Sodium dithionite was freshly prepared and quantified by reduction of lumifiavin-3- 
acetic acid, before iy frxR  reduction was performed. A 1.5 mM stock solution of 
sodium dithionite (Sigma) was prepared in anaerobic 50 mM pyrophosphate buffer pH 
9.0. Anaerobisis was achieved by 10 cycles of purified nitrogen and vacuum, the buffer 
was equilibrated with ultrapure nitrogen before being mixed with the sodium dithionite 
powder.
The dithionite solution was then quantified by anaerobic static titration with lumifiavin- 
3-acetic acid (LF-3-AA). 1 ml of a 20 pM LF-3-AA solution was prepared in 50 mM 
pyrophosphate pH 9.0, and was made anaerobic (as in section 2.2.8.2) in an anaerobic 
cuvette. The dithionite solution was titrated in 5 pi steps using an airtight Hamilton 
syringe; the dithionite solution was quantified using the reduction of LF-3-AA at 443 
nm with an extinction coefficient of 12,400 mM"  ^ cm"\
The anaerobic dithionite solution was drawn into an airtight Hamilton syringe and 
titrated into an anaerobic 15 pM P/TrxR solution in an anaerobic cuvette. Dithionite 
titrations were performed in the presence of 1.5 pM methyl viologen to act as an 
electron mediator between the dithionite and TrxR.
2.2.9 Steady state kinetic analyses of LipDH
The kinetic parameters of recombinant LipDH proteins were analysed for both forward 
and reverse reactions by varying the substrates used in the assay. The reactions were 
measured using a stopped flow fast kinetic system (SFA-20, Rapid kinetics accessory, 
Hi-Tech scientific) in order to measure initial rates as described previously (Akerman et 
a l,  2003). The reactions were measured using the consumption/production of NADH at 
340 nm with the extinction coefficient of 6,220 mM'^ cm '\
2.2.9.1 Forward reaction
The forward reaction of LipDH uses the substrates dihydrolipoamide and NAD’*’. 
Dihydrolipoamide was produced from lipoamide (Sigma) by reduction with 100 fold
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molar excess of sodium borohydride, as modified from previous studies (Reed et a l , 
1958). A stock solution of 60 mM lipoamide was prepared in 100% ethanol, before 
sodium borohydride was added to the solution to a final concentration of 600 mM and 
nitrogen was bubbled into the solution until it was clear. The solution was diluted to the 
necessary concentration in 50 mM potassium phosphate, 1 mM EDTA, pH 8.0, and was 
used for assays following complete hydrolysis of the sodium borohydride.
NAD’*' was freshly prepared in reaction buffer and quantified at 340 nm using the 
extinction co-efficient of 6,200 mM'^ cm"\ The reaction was performed with 1 pg of 
protein at 25^C in 50 mM potassium phosphate, 1 mM EDTA, pH 8.0 in order to 
prevent spontaneous oxidation of dihydrolipoamide. The i^ j^ ’^hydrohpoamide determined 
by holding the NAD^ concentration constant at 2mM and varying dihydrolipoamide 
between 50 pM and 2 mM. The was determined by holding the
dihydrolipoamide concentration constant at 2 mM and varying NAD^ between 62.5 mM 
and 2mM.
constant at 200 pM and varying lipoamide between 50 pM and 4 mM. The was
determined by holding the lipoamide 
NADH between 10 pM and 200 pM.
2.2.9.3 Analysing pH optimum
The pH optimum of both the forward and reverse reactions were measured using the 
assays detailed above over a range of pH values. Buffers were prepared between pH 5.5 
and 10.0 using a mixture of 50 mM bicine/Bis Tris Propane/MES buffers.
"3
2.2.9.2 Reverse reaction
The reverse reaction of LipDH uses the substrates lipoamide and NADH. Stock 
solutions of 60 mM lipoamide were prepared in 100% ethanol and it was necessary to «àheat to 37 C and vortex to make the lipoamide soluble. NADH was freshly prepared in
1 Ireaction buffer and quantified at 340 nm using the extinction co-efficient of 6,200 mM' | |
cm"\ The reaction was performed at 25°C in 50 mM potassium phosphate, 1 mM 
EDTA, pH 7.0. The was determined by holding the NADH concentration I 
.concentration constant at 2 mM and varying
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(10 pM, 20 pM, 40 pM),
2.2.10 Determination of thioredoxin reductase steady state kinetic
parameters
2.2.9.4 Determining catalytic mechanism
The reverse reaction of LipDH was utilised to investigate the catalytic mechanism of 
LipDH2. Reactions were performed as described previously and measured over a range 
of lipoamide concentrations (0.5 mM to 2 mM) at three different NADH concentrations
The kinetic parameters of PfTrxR can be analysed using NADPH as reductant and
either PfTrx (the natural substrate) or DTNB as electron acceptors. The activity assays
were followed spectrophotometrically (Shimadzu UVPC 2501) at diagnostic
wavelengths. g;
2.2.10.1 Thioredoxin/insulin assay
y
The TrxR activity with the natural substrates NADPH and thioredoxin was determined
as described previously (Luthman et a l, 1982). The reaction was performed at 25°C in
150 mM potassium phosphate, 1 mM EDTA, 0.2 mg ml' human insulin (Sigma), pH 7.6, 
with 1 -  20 pg PffrxR  (depending on mutant), 200 pM NADPH and 50 pM PfTrx. The 
reaction was followed at 340 nm for the oxidation of NADPH using the extinction 
coefficient of 6220 M'^ cm '\ A 10 mM NADPH stock solution was prepared in 2 mM 
Tris pH 10.0 and stored at 4°C. The was determined by holding the NADPH
concentration at 200 pM and varying PfTrx between 2 pM and 50 pM.
■t i
I2.2.10.2 DTNB assay
The DTNB assay follows the release of TNB anions at 412 nm using the extinction 
coefficient of 13,600 M'^ cm"^  per TNB released as described previously (Holmgren, 
1977). The reaction was performed at 25°C in 50 mM potassium phosphate, 1 mM 
EDTA, pH 7.6, with 1 -20 pg PfTrxR (depending on variant assayed), 200 pM NADPH 
and 3 mM DTNB. The Km^™® was determined by holding the NADPH concentration 
constant at 200 pM and varying DTNB between 25 pM and 3 mM. The was
determined by holding the DTNB concentration constant at 3 mM and varying NADPH 
between 0.5 pM and 200 pM. A stock solution of 100 mM DTNB was prepared in
- 8 3 -
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DMSO, with the final DMSO concentration in the assay being held constant at 3%
(v/v). A 10 mM NADPH stock solution was prepared in 2 mM Tris pH 10.0 and stored
at rc.
2.2.11 Pre-steady state kinetic analyses of P. falciparum  TrxR
Pre-steady state kinetics of the iyT rxR  reductive and half-reactions were analysed 
using a SF-61 DX2 double mixing stopped flow spectrophotometer (Hi-tech scientific). 
The stopped flow spectrophotometer was operated in either photodiode a iT a y  (Spectra) 
or photomultiplier (Single wavelength) modes. The kinetic traces collected during the 
reactions were analysed and quantified using the kinetasyst 3 program (Hi-tech 
scientific), with data fitted using the Marquadt algorithm for solving differential 
equations (Press, 1992).
2.2.11.1 Reductive half-reaction
/y frxR  reduction with NADPH was observed in the stopped flow spectrophotometer in 
both photodiode array (Spectra) or photomultiplier (Single wavelength) modes. The 
reaction was followed at the wavelengths 355, 440, 540 and 670 nm in photomultiplier 
mode. All solutions were made anaerobic as described previously (see section 2.2.8.2) 
in tonometers (anaerobic vessels). The tonometers were attached to the stopped flow 
spectrophotometer, and the reactions were followed until completion after mixing of 10 
- 15 pM PJTvxR (concentration after mixing) with 6 molar equivalents NADPH at 5°C.
2.2.11.2 Oxidative half-reaction
The oxidative h a lf  reaction of P /TrxR  was followed in double mixing mode (4 
syringes) in the stopped flow spectrophotometer at 5 °C or 25 °C depending on the rate 
of reaction. All solutions were made anaerobic as described previously in anaerobic 
tonometers (see section 2.2.8.2), and attached to the stopped flow spectrophotometer. 40 
pM P/FrxR was pre-reduced with 2.2 molar equivalents NADPH and was incubated 
until completion of reductive h a lf  reaction. The reduced P fTrxR  (EH4) was then mixed 
with between 0.5 and 20 molar equivalents PJTrx, with data being acquired in 
photomultiplier mode at 490 and 540 nm until the reaction was complete.
-84
Chapter 3. The role of acid-base catalysts in the catalytic mechanism of P. /a/c/pamm TrxR 
Chapter 3 The role of acid-base catalysts in the catalytic mechanism
of Plasmodium falciparum thioredoxin reductase.
3.1 Introduction
3.1.1 Plasmodium falciparum  thioredoxin reductase (PfTrxR)
Thioredoxin reductase (TrxR) is a component of the thioredoxin redox system and a 
member of the disulphide oxidoreductases family that includes glutathione reductase, 
dihydrolipoamide dehydrogenase, trypanothione reductase and mercuric ion reductase 
(Williams, 1992). TrxR acts as an electron donor in the thioredoxin redox system and 
therefore plays an important role in cell proliferation, defence against reactive oxygen 
species and signal transduction (Powis et a l, 2001; Nakamoto et a l, 2004; Baier et a l, 
2005; Kabe et a l,  2005). Indeed, gene knockout studies of the TrxR gene of 
Plasmodium falciparum  demonstrated this protein to be essential for parasite survival 
during erythrocytic stages (Kmajski et al, 2002), and therefore genetically validated it 
as a potential drug target.
TrxR from P. falciparum (PfTrxR) belongs to the high Mr TrxRs and contains tliree 
redox-active centres that are involved in catalysis; a protein bound FAD cofactor, an N- 
terminal disulphide (Cys88 and Cys93) and a C-terminal disulphide (Cys535 and 
Cys540). It is at the C-terminal disulphide that the most notable differences can be 
observed between high Mr TrxRs. In P. falciparum TrxR the redox active cysteines are 
separated by four amino acids, while the Drosophila melanogaster TrxR disulphide is 
formed by two adjacent cysteine residues and the mammalian and worm TrxRs form a 
selenenylsulphide from adjacent cysteine and selenocysteine residues (Williams et a l, 
2000).
The catalytic mechanism of high Mr TrxR has been investigated previously with the D. 
melanogaster TrxR (DmTrxR). This resulted in a proposed reaction mechanism for the 
high Mr TrxRs, and demonstrated that the enzyme cycled between the two (EH2) and 
four (EH4) electron reduced states in catalysis (Bauer et a l, 2003b).
The transfer of reducing equivalents between the redox active centres in the related 
proteins glutathione reductase and dihydrolipoamide dehydrogenase has been shown to 
require an acid-base catalyst, which is in a conserved motif (HPXXXE) in all disulphide 
oxidoreductase of this protein family (Benen et al, 1991; Benen et a l, 1992; Rietveld et
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al, 1994). The role of the potential acid-base catalyst has however not been investigated 
in high Mr TrxR. A recent study by Gromer et al. suggested an additional acid-base 
catalyst present in high Mr TrxR (Gromer et a l, 2003). This appeared to be an 
appealing hypothesis because during catalysis thr ee instead of two dithiol-disulphide 
interchange reactions take place, which need to be supported by acid-base catalysis.
3.1.2 Aims
The aims of this part of the study were to investigate the catalytic mechanism of the P. 
falciparum  TrxR and examine the role of the active site residues and those located in the 
acid-base catalyst motif in catalysis. A site directed mutagenesis approach was taken to 
investigate the roles of the chosen residues, whereby analyses of the characteristics of 
these mutated residues would allow investigation of their role in catalysis. The mutants 
were to be analysed by steady state kinetics, static anaerobic titrations with reductants 
and by stopped-flow rapid reaction kinetics of their reductive and oxidative half­
reactions.
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3.2 Results
3.2.1 Identification of conserved active site residues
In order to analyse the conserved active site residues I performed a ClustalW alignment 
of the PffrxR  amino acid sequence with those of other high Mr TrxR (figure 3.1). The 
P. falciparum  TrxR amino acid sequence displayed 45% sequence identity to the other 
proteins in the alignment. The amino acid sequences of high Mr TrxR can be separated 
into three domains; the FAD binding, NADPH binding and interface domains 
(Sandalova et al, 2001).
The FAD binding domain, which is located between residues 1 - 1 9 3  and 320 - 388 
contains the conserved FAD binding motif (GGGXXG; highlighted yellow in figure
3.1) for binding of the pyrophosphate moiety of FAD in part of a Rossman-like fold 
(p a p a p a  units that form parallel p sheets; Schierbeek et al, 1989; Mattevi et a l,
1991). The N-terminal cysteine pair that is consei'ved in all the high Mr TrxR 
(highlighted red in figure 3.1) is also located within this domain. This domain also 
contains a proposed acid-base catalyst (Gromer et a l, 2003), which corresponds to 
His 137 in the P. falciparum  TrxR and is shown to be conserved in the alignment with 
high Mr TrxR (highlighted blue in figure 3.1). Alignment of the P. falciparum  TrxR 
with P. falciparum  glutathione reductase and both dihydrolipoamide dehydrogenase 
(see chapter 4) shows that this residue is not conserved between these related disulphide 
oxidoreductase and suggests that it may play a role only in the high Mr TrxR (data not 
shown).
The NADPH domain forms a Rossman-like fold, is located between residues 194 and 
319 and is the site of association with the NADPH substrate. Two arginine residues, 
con'esponding to Arg253 and Arg258 in PfTrxR (highlighted pink in figure 3.1), are 
involved in binding of the 2’ phosphate moiety of NADP’*' and are therefore imparting 
substrate specificity (Sandalova et a l, 2001). The NADPH domain also contains a 
conserved tyrosine residue (Tyrl45 in PfTrxR; highlighted orange in figure 3.1) that is 
responsible for shielding the isoalloxazine ring of FAD in the oxidised protein; this 
residue has been shown to be displaced by the nicotinamide ring of the bound NADPH 
substrate in the reduced protein (Biterova et a l, 2005).
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Figure 3.1 - ClustalW alignment of high Mr TrxR
ClustalW  a lignm ent of am ino acid se q u e n c e s  from the high Mr TrxR from Plasmodium 
falciparum (Pf; NC_004330), Homo sapiens (Hs; Q 16881), Rattus norvegicus (Rn; 089049), 
Anopheles gambiae (Ag; A J459821) and  Drosophila melanogaster {Dm] AAM51940). The 
C lustalW  program aligns identical {*), conserved  (:) and sem i-conserved (.) residues and 
disp lays conserved  residues and motifs tha t are  associa ted  with the d isulphide 
ox idoreduc tases. The FAD binding motif is highlighted in yellow; active site cy s te ines are  
highlighted in red (se lenocys te ines are  rep resen ted  by the letter U); acid -base  ca ta lyst motif is 
highlighted in green; a  possib le second  ac id -base  ca ta lyst residue is highlighted in blue; a 
conserved  tyrosine residue involved in NADPH binding is highlighted orange and two arg inine 
residues tha t confer subs tra te  specificity for NADPH are  highlighted in pink.
The interface domain is located between residues 389 and 541 and is the site of subunit 
interactions. This domain contains the C-terminal disulphide and the acid-base catalyst 
motif. The ClustalW alignment displays the differences observed between members of 
the high Mr TrxRs at the C-terminal disulphide, with PfTrxR containing two cysteine 
residues separated by four amino acids, whereas the other proteins contain adjacent 
cysteines or adjacent cysteine/selenocysteines (highlighted red in figure 3.1). The acid- 
base catalyst motif (HPXXXE) is conserved in all high Mr TrxR proteins and 
corresponds to amino acids 509 to 514 in the P. falciparum sequence (highlighted green 
in figure 3.1).
C93
C88
— I-----NADPH
■ FAD
- S S i
s-
H137
C 540
C 535 I ] Trx
I I
H509 E514
Figure 3.2 -  Overview of conserved active site residues
The PfTrxR active site consis ts of m any conserved  residues and binding sites. PfTrxR con tains 
substra te-binding dom ains (NADPH and PfTrx), along with the redox active cen tres tha t consis t 
of a  bound FAD cofactor, N-term inal cys te ine pair (Cys88 & Cys93) and  C-term inal cys te ine pair 
(Cys535 & Cys540). The catalytic m echanism  is proposed to a lso  involve acid -base  ca ta lysts 
(His 137, His509 & G lu514). The active site consis ts of residues from both subunits of the 
homodimeric protein; residues from each  m onom er are  labelled with a  different colour (green for 
one and red for the o ther m onomer).
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Figure 3.2 displays an overview of the residues that were to be investigated in this 
study, and demonstrates that the active site is generated by residues from both subunits 
of the homodimer. Residues are coloured in red or in green according to the subunit 
they belong to. The residues coloured in green include those responsible for NADPH 
and FAD-binding, along with the N-teiininal cysteine pair, while the other subunit 
(residues coloured in red) provides the C-terminal cysteine pair and acid-base catalyst 
motif and is responsible for passing electrons to the thioredoxin substrate.
The PffrxR  active site cysteine residues (Cys 88, Cys 93, Cys 535 & Cys 540) and the 
histidine residue in the acid-base catalyst motif (His 509) had been mutated previously 
to either alanine for cysteine residues or glutamine for histidine residue and these 
mutants were further analysed in this study (Gilberger et a l, 1997; Gilberger et a l,
1998). Site directed mutants were also generated for the glutamate residue in the acid- 
base catalyst motif (Glu 514) and the proposed acid-base catalyst (His 137). Glutamate 
514 was mutated to alanine, while histidine 137 was mutated to asparagine (N), 
glutamine (Q), serine (S) and alanine (A).
3.2.2 Recombinant expression and purification
The recombinant expression of both PffrxR  and Pffrx were carried out as described 
previously (Gilberger et a l, 1997; Krnajski et al, 2001) and resulted in 2 -  5 mg of 
purified proteins per litre of bacterial culture. PffrxR  was purified in the oxidised form, 
which was unlike the insect forms of Ti’xR {Anopheles gambiae and Drosophila 
melanogaster) that were purified in a reduced form (Bauer et a l, 2003a; Bauer et a l, 
2003b). An example of the purified samples used for these analyses is given in figure 
3.3 and multimers that could not be resolved by reducing SDS-PAGE can be observed 
in all lanes. The P ffrx  sample (Lane 1 in figure 3.3) displays a monomeric band at 14 
kDa and a dimeric band at 28 kDa, which is consistent with samples observed in 
previous purifications (Kmajski et a l, 2001). The PffrxR wild-type and mutant 
proteins all display a major band at 63 kDa and also higher bands that correspond to 
homodimers at 126 kDa (Lanes 2 to 8 in figure 3.3).
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Figure 3.3 -  Purification of PfTrxR & PfTrx
An exam p le of the purified sam p les used  in th e se  stud ies w ere ana lysed  on 4 -  12 % SD S -  
PAGE and stained with C oom assie  blue. The gel w as loaded with 2 pg of each  of the following 
recom binan t proteins; PfTrx (lane 1), PfTrxR (lane 2), PfTrxR H509Q (lane 3), PfTrxR E514A 
(lane 4), PfTrxR H137N (lane 5), PfTrxR H I3 7 0  (lane 6), PfTrxR H137S (lane 7) and PfTrxR 
H137A (lane 8). Lane M con tains precision protein m arkers (Biorad). Lane 1 disp lays a  major 
band a t 14.2 kDa tha t corresponds to m onom eric PfTrx and a band a t 28.4 kDa tha t 
corresponds to dimeric PfTrx. Lanes 2 - 8  disp lay a major band a t 63 kDa tha t corresponds to 
m onom eric PfTrxR and a num ber of minor bands of higher molecular m ass, tha t correspond to 
dim ers and o ther multimers of PfTrxR.
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3.2.3 Effect of mutations on tertiary structure
Before in-depth characterisation of the mutant proteins could occur it was necessary to 
analyse if the mutations had affected the folding of the purified proteins. Although all 
proteins were purified with FAD bound and displayed spectral properties of oxidised 
fiavoprotein disulphide oxidoreductase, their tertiary structure and protein folding was 
analysed by circular dichroism spectrometry (CD). The CD analyses of the wild-type 
and mutant forms of PffrxR  were canied out by Dr. Sharon Kelly of the Protein 
Characterisation Facility, Institute of Biomedical and Life Sciences, University of 
Glasgow.
Analyses of the CD spectra observed in the far UV (panel A in figure 3.4) and near 
UV/visible ranges (panels B and C in figure 3.4) demonstrated that there have been no 
gross structural changes of the mutants in comparison to the wild-type protein. Further 
analysis o f the far UV spectra demonstrates that most of the spectra are unchanged, 
however the spectra of PffrxR  E514A (red line in panel A of figure 3.4) and H137S 
(blue line in panel A of figure 3.4) display increases in CD intensity at 222 mn 
(compared to wild-type; black line in panel A of figure 3.4) of 18.7% and 12.3%, 
respectively. The near UV/visible spectra (panel B and C in figure 3.4) display that 
there may be small re-arrangements in the enviromnents around the FAD and disulphide 
chromophores. This was observed between 300 and 500 nm for the FAD chromophore 
and at 260 nm for the disulphides, and demonstrates that all mutants display greater 
intensities at these wavelengths than the wild-type protein. This suggests that the protein 
structure around these chromophores are more rigid in the mutants than in the wild-type 
protein.
Overall the CD analyses displays that the mutated proteins do not produce any major 
structural changes, but that small changes in the micro-environment of the active site 
can be observed. This would be expected, as the residues being analysed are conserved 
active site residues.
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F igure  3.4 -  C ircu lar d ich ro ism  (CD) a n a ly s e s  of PfTrxR v a ria n ts
T he circular dichroism spec tra  of the w ild-type and m u tan t forms of PfTrxR w ere ana lysed  a t far 
UV and near UV/visible w ave lengths in order to investigate the effect of the m utations on the 
tertiary structure of the proteins. T h ese  experim en ts w ere carried out by Dr. Sharon Kelly of the 
Protein C harac terisa tion Facility, Institute of Biological and Life Sciences, University of 
G lasgow. Data w ere co llected in a  JASCO J-180 instrum en t with protein sam p les a t 0.5 mg/ml. 
P an e l A d isp lays the  far UV CD spec tra  of wild-type and m utant proteins. Most spec tra  overlay 
with w ild-type (black line), a lthough two outliers corresponding to E514A (red line) and H137S 
(blue line) a re  shown. P an e l B d isp lays a  com parison of visible/near UV CD spec tra  of wild-type 
(black line), H509Q (red line), E514A (blue line), H137N (green line). P an e l C d isp lays a 
com parison of visib le/near UV CD spec tra  of wild-type (black line), H137Q (red line), H137S 
(blue line) and  H137A (green line) proteins.
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3.2.4 Steady state kinetic analyses
PfTi-xR enzymatic activities were determined for wild-type and mutant forms of the 
enzyme using either DTNB or thioredoxin disulphide as electron acceptors. The steady 
state kinetic parameters of the wild-type and mutant proteins were analysed using both 
of these assay systems and are summarised in table 3.1.
The catalytic activities obseiwed for the wild-type proteins were similar to those 
reported previously (Gilberger et a l, 1997). Mutation of His509 to glutamine resulted in 
the largest decreases in activity of the mutants studied. The H509Q mutant retained only 
0.06 % (with iy irx ) and 8 % (with DTNB) activities, when compared to those of wild- 
type P/TrxR; this was consistent with the previously published activities for PfTrxR 
H509Q (Gilberger et al, 1997). Replacement of Glu514 with alanine resulted in 
activities of 7.5 % and 48 % for P/Trx and DTNB, respectively. These data confirm that 
glutamate 514 plays an important role in the catalysis of PfTrxR. Mutation of the His 
137 residue had the smallest effect on catalytic activity, with mutants retaining between 
102 and 60 % activity in the P/Trx assay. Analyses of these mutants with DTNB 
displayed that H137N retained the most activity (145 %) and H137A the least (81 %). 
The greater specific activity obseiwed in the H137N (also observed in H137Q and 
H137S) mutants may be due to a change in the extinction coefficient of these proteins as 
subsequent analysis has shown that H137N acts essentially as wild-type PfTrxR (see 
sections 3.2.6.4 and 3.2.7.4).
The Michaelis-Menten graphs and Lineweaver-Burk plots of the data collected for the 
wild-type and mutant proteins with DTNB, NADPH and PfTrx substrates are displayed 
in figures 3.5, 3.6 and 3.7, respectively. The Km for DTNB was altered from 212 pM in 
the wild-type to 50 pM in H509Q and 80 pM in E514A, but was not drastically altered 
in the His 137 mutants (Figure 3.5; Table 3.1). This change in Km may arise as a
consequence of the interaction of DTNB with both the N and C-terminal cysteines, 
unlike PfTrx that only accepts reducing equivalents from the C-terminal cysteines 
(Fuji war a et al., 2001; Bauer et a l,  2003b). The Km for NADPH was determined to be
2.0 pM for wild-type PffrxR  using the DTNB assay system and did not change 
drastically with mutation of the active site residues studied (Figure 3.6; Table 3.1). The 
Km for PfTrx was determined to be 3.4 pM for the wild-type protein and was again not 
altered by the mutation o f the active site residues (Figure 3.7; Table 3.1).
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F ig u re  3.5 - T he s te a d y  s ta te  k ine tic  p a ra m e te rs  o f PfTrxR w ith  DTNB
The kinetic parameters for DTNB were determined using the DTNB assay, which was 
performed at 25°C in 50mM potassium phosphate buffer pH 7.6, 1 mM EDTA. The reaction mix 
contained 1 - 2 0  pg of protein (depending on the mutant), 100 pM NADPH and varying 
concentrations of DTNB (25 pM to 3 mM) in a final volume of 1 ml. The reaction was followed at 
412 nm for the production of TNB' with specific activities calculated using an s 4 1 2  nm of 13,600 
M’  ^ cm'^ per TNB' released. Michaelis-Menten curves and Lineweaver-Burk are displayed with 
each point being the mean ± standard deviation of 2 - 4  independent measurements. Kinetic 
parameters of PfTrxR E514A (P ane l A), H137N (pane l B), H137Q (pane l C), H137S (pane l D), 
H137A (pane l E) are displayed, with and Vmax values (Table 3.1) determined using the Graf it
5.0 software (Erithacus software).
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Figure 3.6 -  The steady state kinetic parameters of PfTrxR with NADPH
The kinetic p aram e te rs for NADPH w ere determ ined using the DTNB assay , which w as 
perform ed a t 25°C in 50mM po tassium  phospha te  buffer pH 7.6, 1 mM EDTA. The reaction mix 
con tained 1 -  20 pg of protein (depending on the mutant), 3 mM DTNB and  varying 
concen tra tions of NADPH (0.5 jiM to 200 pM) in a  final volume of 1 ml. The reaction w as 
followed a t 412 nm for the production of TNB' with specific activities ca lcula ted using an e 4 1 2  nm 
of 13,600 M"^  cm'^ per TNB' re leased . M ichaelis-M enten curves and Lineweaver-Burk plots are  
disp layed with each  point the  m ean +- standard  deviation of 2 ~ 4 Independen t m easurem en ts. 
The kinetic param e te rs for PfTrxR wild-type (panel A), H509Q (panel B), E514A (panel C), 
H137N (panel D), H137Q (panel E), H137S (panel F), H137A (panel G) are  disp layed with 
ap p aren t Km and Vmax va lues (Table 3.1) determ ined using the Graf it 5.0 softw are (Erithacus 
software).
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F igure  3.7 - T he s te a d y  s ta te  k ine tic  p a ra m e te rs  o f PfTrxR w ith PfTrx
The kinetic param e te rs for reduction of PfTrx w ere de term ined using the insulin assay , which 
w as perform ed a t2 5 °C  in 50mM po tassium  phospha te  buffer pH 7.6, 1 mM EDTA, 0.2 mg mi'^ 
insulin. The reaction mix con tained 0.5 ~ 20 pg of protein (depending on the  mutant), 200 pM 
NADPH and  varying concen tra tions of PfTrx (2 pM to 60 pM) in a  final vo lum e of 1 ml. The 
reaction w as followed a t 340 nm for the consum p tion of NADPH with specific activities 
ca lcula ted using an s 3#  nm of 6,200 M"^  cm'V M ichaelis-Menten curves and Lineweaver-Burk 
plots a re  disp layed with each  point the  m ean  ± standard  deviation of 2 -  4  independen t 
m easurem en ts. Kinetic p aram e te rs for PfTrxR wild-type (pane l A), H509Q (pane l B), E514A 
(pane l C), H137N (pane l D), H137Q (pane l E), H137S (pane l F), H137A (pane l G) are  
disp layed with apparen t Km and Vmax va lues (Table 3.1) determ ined using the Graf it 5.0 softw are 
(Erithacus software).
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3.2.5 Spectral features of oxidised and reduced proteins
The wild-type and mutant proteins were anaerobically titrated with either NADPH or 
sodium dithionite, to analyse how the mutations affected the distribution of electrons 
within the redox active centres and the formation of charge transfer complexes.
Spectral analysis of the oxidised PfTrxR wild-type protein demonstrated that it 
exhibited the characteristic shape of a disulphide oxidoreductase (Gilberger et a l, 1997; 
Farber et al, 1998), with peaks at around 460 and 380 nm (black line in figure 3.8A). 
Oxidised spectra of the mutant forms display the same characteristic shape with minor 
changes in the position of the flavin peak around 460 nm (Gilberger et al, 1997).
Reduction of wild-type PfTrxR with 6 eq NADPH (blue line in figure 3.8 A) produced 
several spectral differences when compared to the oxidised protein (black line in figure 
3.8A). The absorbance of the flavin peak at 462 nm decreases and shifts to shorter 
wavelengths (445 nm) as the flavin becomes reduced. Two charge transfer complexes 
were observed in the spectral features; the flavin thiolate charge transfer complex band 
(CTC l) was centred around 540 nm and a small absorbance at longer wavelengths (670 
-  700 nm) associated with the NADP^ FADH' charge transfer complex (CTC2) was 
also observed in the reduced protein. This spectral pattern was consistent with those 
features described in previous studies (Gilberger et al, 1997). Reduction with sodium 
dithionite, which reduces the protein via the FAD cofactor, removes the spectral 
features associated with NADPH binding and reaction (red line in figure 3.8A). The 
spectrum of the sodium dithionite reduced protein displays the reduced flavin peak at 
444 nm and the CTCl peak at 540 nm, but lacks the absorbance at longer wavelengths 
associated with CTC2 and the peak produced at 340 nm which is a result of excess 
NADPH; an isobestic point is also observed at approximately 355 nm, which will be 
used for calculations in the pre-steady state kinetic studies.
Reduction of the H509Q mutant with NADPH (blue line in figure 3.8B) resulted in a 
spectrum that displays several different properties to those observed in the wild-type 
protein (blue line in figuie 3.8A). The CTCl absorbance had decreased to 8540nm 2.09 
mM'^ cm'* in the mutant from S540nm 3.42 mM'* cm'* in the wild-type. The flavin peak 
appears more reduced at 5.81 mM'* cm'* in the mutant when compared with 6.86 mM'* 
cm'* in the wild-type (at 440 nm), although the peak retains a partially oxidised shape 
(presence of two clear shoulders on the flavin peak). The CTC2 absorbance (at 670 nm) 
displayed no significant changes with an absorbance of 1.58 mM'* cm * in comparison
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to 1.55 mM"* cm"* in the wild-type. Reduction of H509Q with sodium dithionite (red 
line in figure 3.8B) showed remarkable differences to the wild-type protein reduced 
with sodium dithionite (red line in figure 3.8A); the charge transfer absorbances (CTCl 
and 2) between 540 and 700 nm were almost completely lost (c540nm = 1.08 mM"* cm"*
& S670nm "  0.42 mM"* cm"*) in the H509Q protein upon reduction. The flavin peak was 
more reduced (s440nm of 6.85 mM"* cm"*), although it retained a more oxidised shape 
than that in the dithionite reduced wild-type protein (compare red lines in figure 3.8A 
and B), A small quantity of flavin anion semi-quinone can also be observed at 405 nm 
in the dithionite reduced H509Q spectrum (red line in figure 3.8B). Analysis of the 
effects of the H509Q mutation suggests that His509 has a crucial role in stabilising 
CTCl, and is therefore also required for electron transfer between the redox active 
centres.
Reduction of the E514A mutant with NADPH (blue line in figure 3.8C) led to an 
increase in the CTCl absorbance (at 540 nm) formed, from 3.42 mM * cm"* in wild-type 
to 3.78 mM"* cm"* in the E514A mutant. The CTC2 absorbance (at 670 nm) was slightly 
increased in the mutant to 1.79 mM * cm"* compared with 1.55 mM"* cm"* in the wild- 
type protein. The flavin peak resembles that of the NADPH reduced wild-type protein 
and the absorption coefficients are also very similar (6.91 mM"* cm"* in the mutant 
compared with 6.86 mM"* cm * in the wild-type (at 440 mn). Reduction of the E514A 
protein with sodium dithionite displays a spectrum (red line in figure 3.8C) with major 
changes to the con'esponding wild-type speetrum (red line in figure 3.8A). The flavin 
peak (440 nm) is reduced in shape and yet has a higher absorbance (S440nm of 10.1 mM"* 
cm"* compared to an S444nm of 8.3 mM * cm"* in the wild-type protein). The CTCl 
absorbance is also increased in the mutant with a S540nm of 4.7 mM"* cm * compared to 
an S540nm of 3.0 mM"* cm * in the wild-type protein. The mutation of glutamate 514 
therefore seems to enhance the level of CTCl observed in the static titrations. This is 
presumably due to the mutation favouring the formation of CTCl (being stabilised by 
His509), but also conferring an inhibition of the transfer of reducing equivalents beyond 
CTCl to the C-terminal cysteines.
Replacement of the second proposed acid-base catalyst residue His 137 to an asparagine 
residue produced only minor changes when compared with the wild-type protein. 
Reduction of H137N with NADPH (blue line in figure 3.8D) produced minor increases 
in both CTCl (8540nm from 3.42 mM'* cm* in the wild-type to 4.06 mM"* cm"* in the 
mutant), CTC2 (8670nm from 1.55 mM"* cm"* in the wild-type to 2.2 mM"* cm"* in the
- 1 0 0 -
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mutant), and flavin peak (8440nm from 6 . 8 6  mM‘* cm'* in the wild-type to 7.45 mM'* cm * 
in the mutant) absorbances (blue line in figure 3.8D), although the increases in 
absorbances for each diagnostic wavelength may be due to a fine precipitate that formed 
during titration with NADPH. The reduction of the H137N mutant with sodium 
dithionite (red line figure 3.8D) again yielded a spectrum that was similar to that 
observed in wild-type PfTrxR. The CTCl absorbance was £540nm 2.9 mM * cm * in the 
mutant compared to 3.0 mM * cm * in the wild-type protein, the CTC2 absorbance was 
E670nm 0.8 mM * cm * in the mutant (compared to 8670nm 0.7 mM * cm * in the wild-type) 
and the flavin peak was 8 . 6  mM * cm *at 444 nm in the mutant (compared with 8.3 mM'
* cm *at 444 nm in the wild-type enzyme. The mutation of Hisl37 with three other 
amino acids (glutamine, serine and alanine) led to only minor spectral changes, with the 
NADPH reduced spectra of all Hisl37 mutants being essentially identical to wild-type 
(figure 3.9).
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F igure  3.8 -  S ta tic  a n a e ro b ic  red u c tiv e  titra tio n s  of Pf TrxR
Visible absorp tion spec tra  of 15 pM PfTrxR wild-type and m utant forms w ere m easured  a t 25°C 
under anaerobic conditions in 50 mM po tassium  phospha te, 1 mM EDTA pH 7.6. S pec tra w ere 
recorded for the wild-type oxidised (black line) and either NADPH (blue line) or dithionite (red 
line) reduced forms of the proteins. NADPH reduction w as achieved by the addition of 6  eq 
NADPH; dithionite spec tra  w ere se lec ted  for maximum abso rbance  a t 540 nm during titration of 
dithionite be tw een 0 -  8  eq. P an e l A w ild-type PfTrxR; Pane l B PfTrxR H509Q mutant; P an e l C 
PfTrxR E514A mutant; P an e l D PfTrxR H137N mutant.
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Figure 3.9 -  Anaerobic static titrations of H137 mutants with NADPH
Visible absorp tion spec tra  of 15 pM PfTrxR N is i37 m u tan ts w ere m easu red  be tw een 350 nm 
and 700 nm a t 25°C under anaerobic  conditions in 50 mM po tassium  phospha te , 1 mM EDTA 
pH 7.6. Spec tra  w ere recorded be tw een for the oxidised (black line) and NADPH reduced 
H137Q (green line), H137S (blue line), and H137A (red line). NADPH reduction w as achieved 
by the  addition of 6  eq NADPH.
Mutation of the N-terminal cysteine pair affected the NADPH reduced spectra of the 
proteins drastically. Replacement of the charge transfer thiol (Cys93) with an alanine 
residue produced spectra (blue line in figure 3.10A) with a highly reduced flavin peak 
(G440nm = 4.36 mM'' cm'*), a long wavelength peak associated with CTC2 (8670nm = 1.79 
mM'' cm'') and very little absorbance for the CTCl peak (S540nm = 1.48 mM'' cm '). 
Replacement of the interchange thiol (CysSS) with an alanine residue resulted in a 
spectrum (red line in figure 3.10A) displaying a reduced flavin peak with higher 
absorbance than observed in the wild-type protein (8440nm of 7.77 mM'' cm'' in the 
mutant, compared with 6 . 8 6  mM'' cm'' in the wild-type spectra), while the CTCl 
(G540nm = 1.35 mM'' cm'') absorbance was similar to that observed in the C93A spectra. 
The CTC2 absorbance (G670nm = 1.42 mM'' cm ') was essentially similar to wild-type 
spectra. The flavin peaks of both N-terminal cysteine mutants maintained partially 
oxidised shape, unlike that observed in the wild-type spectra. This is in agreement with 
previous reports, which investigated the static titrations of the C8 8 A and C93A mutants 
(Gilberger ef ûf/., 1997).
Mutation of the C-terminal cysteines to alanine residues resulted in only minor changes 
to the reduced spectra of the proteins. The NADPH reduced C535A spectrum (blue line 
in figure 3.10B) displayed a more reduced flavin peak (8440nm = 5.89 mM'' cm '), less 
CTCl absorbance (8540nm of 3.1 mM'' cm'') and less CTC2 absorbance (8670nm = 1.28
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mM"' cm’') than was observed in the wild-type protein. The NADPH reduced spectra of 
the C540A mutant (red line in figure 3.1 OB) displayed almost identical features to the 
C535A mutant, with the values observed for C540A of flavin reduction (8440nm = 6.09 
mM'' cm '), CTCl (8540nm = 3.15 mM’' cm ') and CTC2 (8670nm = 136 mM*' cm ') being 
extremely similar. This is in agreement with previous reports, which investigated the 
C535A and C540A mutants (Wang et al,  1999).
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F igure  3.10 -  A n aero b ic  s ta t ic  titra t io n s  o f PfTrxR c y s te in e  m u ta n ts  w ith  NADPH
Visible absorp tion spec tra  of 15 pM PfTrxR cyste ine m u tan ts w ere m easu red  be tw een 350 nm 
and 700 nm a t 25°C under anaerobic  conditions in 50 mM po tassium  phospha te , 1 mM EDTA 
pH 7.6. S pec tra w ere recorded for the oxidised (black line) and NADPH reduced proteins 
(achieved by the  addition of 6  Eq NADPH). P an e l A disp lays the reduced spec trum  of PfTrxR 
C93A (blue line) and C 8 8 A (red line). P an e l B d isp lays the reduced spec trum  of PfTrxR C535A 
(blue line) and C540A (red line).
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3.2.6 The pre-steady state reductive half-reaction
The reduction of PfTrxR wild-type and mutant proteins with six molar equivalents of 
NADPH was studied under anaerobic conditions using a stopped-flow 
spectrophotometer; this allowed me to study the spectral intermediates formed during 
catalysis from PfTrxR Box to PfTrxR EH4 and therefore the effect that the mutations 
have on catalysis.
3.2.6.1 Reductive half-reaction of PfTrxR wild-type
The reductive half-reaction of the wild-type protein with NADPH displayed similar 
kinetics to the D. melanogaster TrxR (DmTrxR) that has been studied previously; this 
was not surprising as the reaction mechanism proposed for DmTrxR is thought to be 
relevant for all high Mr TrxR (Bauer et a l, 2003b). The reductive half-reaction of 
PfTrxR wild-type protein was fitted to three phases with the first phase being dependent 
on NADPH concentration and reaching a saturating rate of 700 -  800 s“' (table 3.2). The 
first phase corresponds primarily to the formation of FADH' - NADP^ charge transfer 
complex (CTC2; observed at 440 nm and 670 nm), which can be observed in the 
spectrum taken 5 ms following reduction (red line in figui'e 3.11). This phase can also 
be observed in the kinetic traces as an increase of absorbance at 670 mn (blue line in the 
inset of figure 3.11) and a decrease in absorbance at 440 nm (red line in the inset of 
figure 3.11) in the inset. This phase also demonstrates the consumption of NADPH, 
which is observed as a decrease in absorbance at 355 nm (black line in the inset of 
figure 3.11).
The phases following the first phase proved difficult to resolve when PfTrxR was 
reacted with more than 2 molar equivalents of NADPH. During the second phase 
(which was determined to proceed at an observed rate constant of 360 s ''; Table 3.2) the 
reducing equivalents are passed from CTC2 to the N-terminal disulphide, producing a 
thiolate flavin charge transfer complex between Cys 93 and the bound FAD cofactor 
(CTC l; observed at 540 nm). This formation of CTCl was observed by the increase in 
absorbance at 540 nm in the spectrum taken 36 ms following reduction (green line in 
figure 3.11) and in the 540 nm trace in the inset (green line in the inset of figure 3.11). 
The formation of CTCl can also be obseived by an increase in absorbance at 440 nm 
and a shifting of the flavin peak to a shorter wavelength (green line in figure 3.11 and 
the red line in the inset of figure 3.11).
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In the third phase the reducing equivalents are passed from the N-terminal cysteines to 
the C-teiininal cysteines. This transfer occurs by the interchange thiol (Cys88) reacting 
with the C-terminal disulphide to form a transient mixed disulphide probably between 
Cys88 and C540, which is followed by the transfer of reducing equivalents to the C- 
terminal cysteine pair. Phase three was associated with an increase in absorbance at 440 
nm and a further shifting of the FAD peak to a shorter wavelength (blue line in figure 
3.11 and red line in the inset of figure 3.11). The CTCl absorbance (observed at 540 
nm) was also enhanced during this phase due to the displacement ofNADP^ by a 
second molecule of NADPFl producing a decrease in CTC2, and therefore a shift of the 
equilibrium to CTCl (blue line in figure 3.11 and green line in the inset of figure 3.11). 
The third phase was determined to proceed at an observed rate constant of 20 s '' and 
produced an endpoint spectrum (blue line in figure 3.11) that was similar to the 
spectrmn observed in the static NADPH titrations (blue line in figure 3.8A).
Comparison of the NADPH reduced spectra from the static titration and stopped-flow 
analysis identified an increase in the CTCl absorbance in the latter when compared to 
the former (S540nm of 3.0 mM"' cm"' in the static titration compared with 4.2 mM"' cm"' 
in the stopped-flow analysis). This was probably due to the different temperatures that 
these experiments were performed at modulating the pKa of active site residues and 
therefore the equilibria that were formed. Comparison of static titrations perfoimed at 
25°C and 4^C confirmed that this was a possible explanation, as spectra from the 4“C 
experiment displayed higher CTCl absorbances than those collected at 25“C using the 
same equipment (data not shown).
The NADPH consumption was analysed using the data collected for 355 nm (black line 
in figure 3.11). This wavelength was used as it is an isobestic point between the PfTrxR 
Box and BH4 species (red line in figure 3.8 A). The consumption of NADPH can be 
observed by a decrease in absorbance at 355 nm and seems to proceed in a biphasic 
manner (although it was fitted to 3 phases), which would fit well with the priming of the 
oxidised protein to BH% (in the first phase) followed by a subsequent production of EH4 
(in phase 3), which is consistent with the proposed catalytic mechanism.
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F ig u re  3.11 -  R ed u c tiv e  h a lf-reac tio n  o f vyild-type PfTrxR
Reduction of 15.6 pM PfTrxR wild-type with 6  eq of NADPH w as perform ed under anaerobic 
conditions a t 5°C. S pec tra a re  show n before (Eox, black line) and 5 m s (red line), 36 m s (green 
line) and 10 s (blue line) following mixing with NADPH. The 5 m s spec trum  (red line) disp lays 
the FADH'-NADP* charge transfer com plex (CTC2) a t 670 nm and 460 nm. The 10 s  spec trum  
d isp lays the  thiolate-flavin charge transfer com plex (CTC1) at 540 nm and 440 nm. In se t 
d isp lays kinetic traces  of the reaction a t d iagnostic w ave lengths 355 nm (black line), 440 nm 
(red line), 540 nm (green line), and  670 nm (blue line). The kinetic traces  w ere fitted to three 
distinct p h a se s  using the K inetAsyst 3 softw are (Hi-Tech scientific) (Table 2).
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3.2.6.2 Reductive half-reaction of PfTrxR H5Q9Q
The reductive half-reaction of PfTrxR H509Q was fitted to tliree phases, which was 
similar to the situation in the wild-type, although the data collected were considerably 
different. This would be expected as the steady state kinetic and static titration data for 
this mutant were very different to those observed for the wild-type protein. These data 
had suggested that His509 would be important in the formation and stabilisation of the 
thiolate flavin charge transfer complex (CTCl), and the reductive half-reaction of 
PfTrxR H509Q was analysed in order to confirm this.
The first phase seen in the reductive half-reaction was assignable to production of CTC2 
and was essentially the same as that obseiwed in the wild-type protein. The first phase 
was also dependent of NADPH concentration (as observed for the wild-type protein) 
and was determined to proceed at 567 s '\  which was slightly slower than the maximum 
rate in the first phase of the wild-type protein (table 3.2; 700 -  800 s'^). The spectrum 
taken 20 ms following reduction displayed a decrease in flavin absorbance (440 nm) 
and an absorbance band at longer wavelengths (650-700 nm), which was indicative of 
CTC2 production (green line in figui'e 3.12). However, this spectmm also displayed 
much less absorbance at 440 nm (S440 of 4.6 mM‘  ^cm'Hn H509Q compared with 5.2 
mM"  ^cm'^ in wild-type) and the flavin peak had not shifted to shorter wavelengths and 
also maintained an oxidised-like shape, which suggests that the primary species is 
CTC2 after reaction with NADPH (green line in figure 3.12).
The second phase in the reductive half-reaction proceeded much slower (by 1000 fold) 
than in wild-type reductions (figure 3.12 inset). This second phase is normally assigned 
to transfer of electrons from the flavin to the N-terminal cysteines and the subsequent 
formation of CTCl (Bauer et al 2003). In the wild-type protein this phase proceeds at 
an observed rate constant of 360 s '\  while the H509Q proteins reaction was slowed to 
0.37 s'  ^ (table 3.2). This phase is characterised by an increase in absorbance at 440 nm 
(figure 3.12 inset) and a decrease in CTC2 and is postulated to involve the transfer of 
reducing equivalents from the flavin to the N-terminal cysteines without the formation 
of CTC l.
The effect of pH on the reductive half-reaction of H509Q was investigated as the pH 
optimum of this mutant has been shifted from pH 7.6 (the wild-type optimum) to pH 8.2 
(data not shown). The second phase was observed to proceed faster at pH 8.2 (blue line 
in figure 3.13) than at pH 7.6 (red line in figure 3.13; table 3.2), presumably as the
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solvent partially compensated for the loss of the base (His509). This did not however 
result in an increase in the CTCl formed (observed at 540 nm) at higher pH (up to pH 
8.2, data not shown) confirming that the reducing equivalents were passing between the 
flavin and the N-terminal cysteines without the formation of a CTCl intermediate. The 
higher rate observed in the second phase of the reaction performed at pH 7.0 (table 3.2) 
may be due to the formation of a different set of intermediates.
The third phase of the PfTrxR H509Q reductive half-reaction produced an endpoint 
spectrum (blue line in figure 3.12) that was similar to the spectrum observed in the 
static titration of H509Q with NADPH (blue line in figure 3.8B). This phase proceeds at 
0.071 s"^  (table 3.2) and was not affected by altering the pH of the reaction. The 
production of absorbance at 540 nm (blue line in figure 3.12) that occurs during this 
phase may be due to displacement ofNADP^ with NADPH and also the generation of a 
small amount of CTCl. This small degree of CTCl formation was also observed in the 
sodium dithionite titration of H509Q (red line in figure 3.8B).
Analysis of the NADPH consumption appeared biphasic (as observed in the wild-type) 
with each phase consuming 0.9 equivalents, which is consistent with the reduction of 
the protein to the EH% and then EH4 species. Utilising the rate of the first phase at 
different NADPH concentrations allowed me to analyse the Kd app for NADPH, with 
H509Q yielding a higher Kd app (59 pM; table 3.2) than wild-type protein ( 25 pM; table 
3.2). This is in contrast to the Km app data determined for H509Q, which was not 
different from that of the wild-type protein (table 3.1) and may be a function of the 
effect of the mutation on the observed rate constants altering the dissociation of the 
substrate.
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F igure  3.12 -  R ed u c tiv e  h a lf-reac tio n  o f PfTrxR H509Q
Reduction of 17.9 pM PfTrxR H509Q with 6  eq of NADPH w as perform ed in 50 mM po tassium  
phospha te  pH 7.6, 1 mM EDTA under anaerobic  conditions a t 5°C. S pec tra a re  shown before 
(Eox, black line) and 1m s (red line), 20m s (green line) and 140s (blue line) following mixing with 
NADPH. In se t d isp lays rapid reaction kinetic traces  of 440 nm for 15.6 pM PfTrxR wild-type 
(black line) and 17.9 pM PfTrxR H509Q (red line) reduced with 6  eq  of NADPH. The kinetic 
traces of the H509Q reductive half-reaction w ere fitted to three exponen tial p h ases , using the 
K inetAsyst 3 softw are (Hi-Tech scientific), with the second and third p h a se s  of the reductive 
half-reaction being much slower than with wild-type enzym e (table 3.2).
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F igure  3.13 -  E ffec t of pH on  th e  red u c tiv e  ha lf-reac tion  o f PfTrxR H509Q
PfTrxR H509Q w as reduced a t 5°C with 6  eq  of NADPH. The reaction w as followed a t 440 nm 
in 50 mM po tassium  phospha te , 1 mM EDTA a t pH 7.0 (black line: 9.7 pM PfTrxR H509Q), pH
7.6 (red line; 13.5 pM PfTrxR H509Q) and pH 8.2 (blue line; 12.1 pM PfTrxR H509Q). The 
reductive half-reaction p roceeds m uch fas ter a t higher pH, suggesting tha t the protonation s ta te  
of the residue a t position 509 is crucial for the formation and stabilization of the thiolate-flavin 
CTC and for the dithiol-disulfide in terchange reactions. R a tes observed  with w ild-type enzym e 
are  m uch less sensitive to pH in this range (tab le 3.2).
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3.2.6.3 Reductive half-reaction of PfTrxR E514A
The reductive half-reaction of the PfTrxR E514A mutant was fitted to tliree phases, as 
observed for both wild-type and H509Q forms. The first phase was again associated 
with formation of FADH" NADP^ charge transfer complex (CTC2) and was determined 
to proceed at an observed rate constant of 803 s"^  (essentially the same as wild-type; 
table 3.2). However, the flavin reduction observed in this phase proceeds much further 
than those of either wild-type or H509Q proteins, with the absorbance at 440 rmi 
reaching 4.5 mM‘* cm'^ (green line in figure 3.14 and inset of figure 3.14) when 
compared with an 844011m of 5.2 mM'^ cm'* in wild-type (figure 3.14 inset). The resulting
11.2 ms spectrum resembles that of reduced flavin (FADH2)as it was observed in the 
titration of PfTrxR wild-type with 6 eq of sodium dithionite (data not shown; see EH4 
spectrum in figure 1.8 for an example). The second phase was slowed by 32 fold 
relative to wild-type (table 3.2), with the slower formation of the thiolate flavin charge 
transfer complex (CTCl) allowing for more of the CTC2 species to be observed (green 
line in figure 3.14). The third phase of the reductive half-reaction was slowed by 20 fold 
relative to the wild-type reaction (table 3.2) and resulted in an endpoint spectrum that 
displayed a much more pronounced CTCl absorbance at 540 nm ( S 540 nm  of 4.9 mM'* 
cm'* in E514A compared with 4.2 mM'* cm'* in the wild-type protein). This is 
consistent with the spectrum obtained in the static titrations although more CTCl 
absorbance is observed in the stopped-flow experiment due to the lower temperature 
that the experiment was performed at (see section 3.2.6.1 for an explanation).
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F igure  3.14 -  R ed u c tiv e  h a lf-reac tio n  o f PfTrxR E514A
Reduction of 12.4 pM PfTrxR E514A with 6  eq of NADPH w as perform ed under anaerobic 
conditions a t 5°C in 50 mM po tassium  phospha te  pH 7.6, 1 mM EDTA. Spec tra  shown are  
taken before (Eox, black line) and 3.7 m s (red line), 11.2 m s (green line), 101.2 m s (fuchsia line) 
and 7.12 s  (blue line) following mixing with NADPH. In se t d isp lays rapid reaction kinetic traces  
of 440 nm for 15.6 pM PfTrxR wild-type (black line) and 12.4 pM PfTrxR E514A (red line) 
reduced with 6  eq  of NADPH. The kinetic trace  of the E514A reductive half-reaction w as fitted to 
th ree exponen tial p h ases , using the K inetAsyst 3 software (Hi-Tech scientific), with the second  
and third p h a se s  of the reductive half-reaction being much slower than in the c a se  of wild-type 
enzym e (table 3.2).
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3.2.6.4 Reductive half-reaction of PfTrxR H137N
The reductive half-reaction of the PfTrxR H137N mutant was essentially the same as 
that for the wild-type protein (inset of figure 3.15), and could be fitted with the same 
three phases. Analysis of the different phases demonstrated the same features observed 
in the wild-type protein, with phase 1 being the formation of FADH' NADP^ charge 
transfer complex (CTC2; red line in figure 3.15), phase 2 corresponding to the 
formation of the thiolate flavin charge transfer (CTCl; green line in figure 3.15) and 
phase 3 being the transfer of reducing equivalents to the C-terminal cysteine pair and an 
enhancement of CTCl (blue line in figure 3.15).
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F ig u re  3.15 -  R ed u c tiv e  h a lf-reac tio n  o f PfTrxR H137N
Reduction of 14.7 |iM PfTrxR H137N with 6  eq of NADPH w as perform ed under anaerobic 
conditions a t 5°C in 50 mM po tassium  phospha te  pH 7.6, 1 mM EDTA. Spec tra  shown are  
taken before (Eox, black line) and 3.7 m s (red line), 30.7 m s (green line) and  1.43 s (blue line) 
following mixing with NADPH. In se t d isp lays rapid reaction kinetic traces  of 440 nm for 15.6 pM 
PfTrxR wild-type (black line) and 14.7 pM PfTrxR H137N (red line) reduced with 6  eq  of 
NADPH. The kinetic trace  of the H137N reductive half-reaction w ere essen tia lly  the sa m e  a s  
wild-type.
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3.2.6.5 Reductive half-reaction of PfTrxR C93A
Analysis of the reductive half-reaction of PfTrxR C93A mutant served as a control for 
the analyses of the acid base motif mutants, as mutation of Cys93 (the charge transfer 
thiol) means that no thiolate flavin charge transfer (CTC 1 ) can be formed (blue line in 
figure 3.10A). Comparison of the flavin reduction (at 440 nm) in the C93A and wild- 
type reductive half-reactions shows that no further reduction occurs after the first phase 
(figure 3.16). This suggests that the C93A mutant can form FADH' NADP^ charge 
transfer complex (CTC2) which can be observed at longer wavelengths (650 -  700 nm), 
by the decrease in flavin absorbance at 440 nm and the oxidised like shape of the flavin 
peak (green and blue lines and inset of figure 3.16). This also confirms that there is a 
small amount of absorbance displayed at 540 nm, even in a protein that cannot form the 
CTCl, which is also the case (although to a greater degree) in the H509Q reductive 
half-reaction.
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F igure  3.16 -  R ed u c tiv e  h a lf-reac tio n  of PfTrxR C93A
Reduction of 19.8 pM PfTrxR C93A with 6  eq  of NADPH w as perform ed under anaerobic 
conditions a t 5°C in 50 mM po tassium  phospha te  pH 7.6, 1 mM EDTA. S pec tra show n are  
taken  before (Eox, black line) and 7.5 m s (red line), 22.5 m s (green line) and  14.25 s  (blue line) 
following mixing with NADPH. In se t d isp lays rapid reaction kinetic traces  of 440 nm for 15.6 pM 
PfTrxR wild-type (black line) and 19.8 pM PfTrxR C93A (red line) reduced with 6  eq of NADPH. 
The spec tra  and kinetic traces  of the C93A reductive half-reaction dem ons tra ted  tha t this 
m u tan t could form the FADH' NADP* charge transfer complex (CTC2; observed  a t 670 nm and 
460 nm), but w as unab le to form the thiolate flavin charge transfer com plex (C TC l; observed  a t 
540 nm and 440 nm).
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3.2.7 The pre-steady state oxidative half-reaction
The oxidative half-reaction of PfTrxR was studied by pre-reducing the enzyme to EH4 
with 2.2 equivalents of reductant (either sodium dithionite or NADPH), before adding 
between 1 and 20 equivalents of PfTrx and following the reaction in a stopped-flow 
spectrophotometer. These reactions were performed under anaerobic conditions at 5°C, 
and the data collected have been corrected to remove the baseline shift caused by the 
addition of excess PfTrx. Traces were collected at 490 nm and 540 nm as these 
wavelengths were where the largest changes occm for flavin redox and thiolate flavin 
charge transfer (CTCl), respectively.
3.2.7.1 Oxidative half-reaction of PfTrxR wild-type
The oxidative half-reaction of PfTrxR wild-type was initially performed by reducing the 
protein with 2.2 eq of sodium dithionite before analysing the oxidation of the enzyme 
after addition of 6 eq PfTrx. Spectra were taken of the oxidised protein (Eox; black line 
in figure 3.17A), the sodium dithionite reduced protein (EH4; red line in Figure 3.17A) 
and following oxidation of the reduced protein by PfTrx (blue line in Figure 3.17A).
The sodium dithionite reduced spectrum (red line in Figure 3.17A) was characteristic of 
the spectrum observed during static titration of the protein with the reductant (data not 
shown). The spectrum taken 16 minutes after addition of PfTrx (to the reduced protein), 
displayed that the protein had almost returned to its oxidised state. This was shown by 
the similarity of the Eox spectrum (black line in figure 3.17A) and PfTrx oxidised 
spectrum (blue line in figure 3.17A) between 350 nm and 530 nm, although some long 
wavelength absorbance (530 -  700 nm) remained in the PfTrx reduced spectrum. The 
oxidative half-reaction of the sodium dithionite reduced protein was further analysed by 
rapid reaction kinetics and the data collected (at 490 nm and 540 nm; figure 3.17B) 
were fitted to three exponential phases, with the observed rate constants of 40 s '\  0.016 
s"^  and 0.003 s'^  (table 3.3). The first phase displayed no dependence on PfTrx 
concentration, which suggested that PfTrx is bound rapidly and that we are only 
observing the re-oxidation of the enzyme due to reduction of the bound PfTrx. The 
second and third phases are thought to be due to the slow reaction of the resultant EH% 
species with a second molecule of PfTrx disulphide.
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F igure  3.17 -  O x ida tive  h a lf-reac tio n  o f PfTrxR w ild-type (d ith ion ite  re d u c e d )
W ild-type PfTrxR (16.1 pM) reduced with 2.2 eq  of dithionite w as reac ted  with PfTrx under 
anaerobic conditions a t 5 °C in 50 mM po tassium  phospha te  pH 7.6, 1 mM EDTA. P an e l A 
d isp lays spec tra  w ere recorded before (Eox: black line) and after reduction (EH^; red line), and 
16 m inu tes after the addition of 6  eq of PfTrx (blue line). Pane l B d isp lays kinetic traces  from 
the oxidative half-reaction using 6  eq of PfTrx. T races for 490 nm (red line, right hand y-axis) 
and 540 (black line, left hand y-axis) w ere m easured  for 10 minutes. The kinetic traces  w ere 
fitted with th ree exponen tial p h a se s  with observed  ra tes of 40 s '\  0 .016 s'^ and 0.003 s ' \  Note: 
the apparen t d ec re a se  in ab so rb an ce  from 1 to 3 m s of the 490 nm trace  is due to a  flow 
artefac t in this experim en t.
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The oxidative half-reaction of PfTrxR wild-type was also analysed following reduction 
with 2.2 eq NADPH and subsequent reaction with 10 eq PfTrx. Again spectra were 
taken of the oxidised protein (Eox; black line in figure 3.18 A), after reduction with 2.2 
eq NADPH (EH4; red line in figure 3.ISA) and 16 min following addition of PfTrx 
(blue line in figure 3.ISA). The NADPH reduced spectrum was similar to those 
observed at 2.2 eq NADPH during the static titration of the protein (data not shown), 
and the PfTrx oxidised protein displayed a spectrum very similar to that of the Eox 
protein (compare black line with blue line in figure 3.ISA). The major differences 
observed between the Eox and PfTrx reacted spectra are observed at longer wavelengths 
(530 nm -  700 nm), which was likely to be due to the presence of protein bound NADP^ 
or NADPH. This spectral feature was also similar to that observed in the static titration 
of PfTrxR H509Q with NADPH (Figure 3.S). The oxidative half-reaction of the 
NADPH reduced protein was analysed by rapid reaction kinetics with the data collected 
(at 490 nm and 540 nm; Figure 3.1 SB) being fitted to three exponential phases with 
observed rate constants of 20-2S s '\  3.1 s"^  and 0.05 s'*. The first phase of the NADPH 
reduced protein was slower than those determined for the sodium dithionite reduced 
protein (table 3.2), which was probably due to the presence of bound NADP^ in the EH4 
reduced protein stabilising the reduced flavin (via FADH" NADP^ charge transfer 
compiex/CTC2).
The return of both sodium dithionite and NADPH reduced protein to near Eox species 
suggests that PfTrxR may not cycle between the EH2 and EH4 species, as is the situation 
in the D. melanogaster TrxR (Bauer et al.  ^2003b). From these experiments it can be 
deduced that PfTrxR is rapidly reduced to a PfTrxR EH2 species, which can be obseiwed 
after 200 ms in the sodium dithionite experiment and after 2 seconds in the NADPH 
experiment. The oxidation of this EH2 species to an Eox species proceeds at a much 
slower rate, which may not be catalytically relevant due to the high NADPH 
concentration in the cytosol (50 - 100 qM in humans; H, Schirmer, personal 
communication).
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F igure  3.18 -  O xida tive  h a lf-reac tio n  o f PfTrxR w ild-type (NADPH red u ced )
Wild-type fVTrxR (10 pM) pre-reduced with 2.2 eq of NADPH w as reac ted  with PfTrx under 
anaerobic  conditions a t 5 ®C in 50 mM po tassium  phospha te  pH 7.6, 1 mM EDTA. P an e l A 
d isp lays spec tra  recorded before (Eo*: black line) and after reduction (EH4 : red line), and 16 
m inu tes after the addition of 10 equiva len ts of Pn"rx (blue line). P an e l B d isp lays kinetic traces 
from the oxidative half-reaction using 10 eq of PfTrx. T races for 490 nm (red line, right hand y- 
axis) and 540 (black line, left hand y-axis) w ere m easured  for 16 m inutes. The kinetic traces 
w ere fitted with th ree exponen tia l p h a se s  with observed  ra tes of 20-28 s ' \  3.1 s'^ and 0.05 s '\
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3.2.7.2 Oxidative half-reaction of PfTrxR H5Q9Q
The oxidative half-reaction of PfTrxR H509Q was analysed following reduction with
2.2 eq NADPH and subsequent reaction with 19 eq PfTrx. Spectra were taken of the 
oxidised protein (Eox; black line in figure 3.19A), the NADPH reduced protein (EH4; 
red line in figure 3.19A) and the protein following reaction with PfTrx (blue line in 
figure 3.19A). The NADPH reduced spectrum was similar to those observed during the 
static titration of the protein with NADPH (data not shown). The spectmm following 
reaction with PfTrx displays similar featiues to those observed in the Eox protein.
The oxidative half-reaction of PfTrxR H509Q was further analysed by rapid reaction 
kinetics with the data collected at 490 nm (red line in figure 3.19B) being fitted to three 
exponential phases; 11,1 s'^ 0.0181 s'  ^ and 0.00013s'^ (table 3.3). The first phase of the 
PfTrxR H509Q oxidative half-reaction represented only 10% of the total extinction 
change at 490 nm. This suggests that flavin oxidation does not occur during this phase, 
but that it is more likely to be due to NADP"*" dissociation and/or reduction of the first 
equivalent of thioredoxin. Phases two and three, which are slower and are responsible 
for 90% of the extinction change at 490 nm, are more likely responsible for flavin 
oxidation as reducing equivalents pass to the C-teiminal redox centre to react with the 
second equivalent of Trx (figure 3.19A).
The oxidative half-reaction of PfTrxR H509Q was 100 fold slower than that of the wild- 
type protein (compare black line and red lines in figure 3.19A). This confirms that the 
mutation of His509 to glutamine severely affects not only the reductive half reaction but 
also the oxidative half-reaction of PfTrxR, by perturbing formation of CTCl and 
therefore the transfer of reducing equivalents between the redox active sites.
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F igure  3.19 -  O x ida tive  h a lf-reac tio n  o f PfTrxR H509Q (NADPH red u ced )
The oxidative half-reaction of 10.1 |iM PfTrxR H509Q, reduced with 2.2 eq  of NADPH, w as 
mixed with 19 eq PfTrx under anaerobic conditions at 5 °C in 50 mM po tassium  phospha te  pH 
7.6, 1 mM EDTA. P an e l A d isp lays spec tra  recorded before (Eoxi black line) and after reduction 
(EH4 : blue line) and 16 m inu tes after the addition of 19 equivalen ts PfTrx (red line). P an e l B 
disp lays kinetic traces  from the oxidative half-reaction with PfTrx. T races a t 490 nm are  shown 
for PfTrxR wild-type reac ted  with 10 eq of PfTrx (black line) and PfTrxR H509Q reac ted  with 19 
equ iva len ts PfTrx (red line). The PfTrxR H509Q 490 nm trace w as fitted with th ree exponen tial 
p h a se s  with observed  ra tes of 11.1 s ‘\  0.0181 s '’ and 0.00013 s ’’ (tab le 3.3).
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3.2.7.3 Oxidative half-reaction of PfTrxR E514A
The oxidative half-reaction of PfTrxR E514A was analysed following reduction with
2.2 eq NADPH and subsequent addition of 18 eq PfTrx. Spectra were taken for the 
oxidised protein (black line in figure 3.20A), after reduction with NADPH (red line in 
figure 3.20A) and 16 min after reaction with PfTrx (blue line in figure 3.20A). The 
NADPH reduced spectrum was similar to those observed in the static NADPH titrations 
with this mutant (data not shown). The spectrum of the PfTrx reacted sample did not 
display features of the Eox protein, as had been observed in the wild-type protein reacted 
with PfTrx (figure 3.20A). The E514A PfTrx oxidised spectrum was consistent with the 
presence of the thiolate flavin charge transfer (CTCl), with a high absorbance at 540 
nm (2.2 mlVT^  cm"^) and a partially reduced flavin peak with a maximum at 450 nm.
This suggested that, similar to the spectra obseived in the reductive half-reaction of 
E514A (figure 3.14A), the mutant formed a stable CTCl. This prevented the production 
of an Eox species during the oxidative half-reaction (as observed in the wild-type and 
H509Q proteins) and resulted in a spectrum that appeared closer to an EHa species than 
an Eox species.
The oxidative half-reaction of PfTrxR E514A was further analysed by rapid reaction 
kinetics with the data collected at 490 nm (red line in figure 3.20B) being fitted to three 
exponential phases; 10 s '\  0.14 s"^  and 0.004 s'  ^ (table 3.3). The oxidative half-reaction 
of PfTrxR E514A was affected in a similar manner as that of the H509Q mutant, in that 
the first phase was representing flavin re-oxidation, but was most likely associated with 
NADP^ dissociation, with phases two and three being responsible for the majority of the 
flavin re-oxidation. The oxidative half-reaction of PfTrxR E514A was 20 fold slower 
than the wild-type reaction (compare black line with red line in figure 3.20B), which 
confirms that Glu514 plays an important role in the transfer of reducing equivalents 
between the redox active centres; although it plays a clearly distinct role to that of the 
His509 residue.
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F ig u re  3.20 -  O xida tive  h a lf-reac tio n  o f PfTrxR E514A (NADPH red u ced )
8 . 6  pM PfTrxR E514A, reduced with 2.2 eq of NADPH, w as mixed with 18 eq  PfTrx under 
anaerobic  conditions a t 5 ®C in 50 mM po tassium  phospha te  pH 7.6, 1 mM EDTA. P an e l A 
d isp lays spec tra  recorded before (Eox! black line) and after reduction (EH4 ; red line) and 16 
m inu tes after the addition of 19 equiva len ts PfTrx (blue line). P an e l B d isp lays kinetic traces  a t 
490 nm for reduced PfTrxR wild-type reac ted  with 10 eq of PfTrx (black line) and PfTrxR E514A 
reac ted  with 18 eq of PfTrx (red line). The PfTrxR E514A 490 nm trace w as fitted with th ree 
exponen tial p h a se s  with observed  ra tes  of 10 s*\ 0.14 s '’ and 0.004 s '’ (tab le 3.3).
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3.2.7.4 Oxidative half-reaction of PfTrxR H137N
The oxidative half-reaction of PfTrxR H137N was analysed following reduction with
2.2 eq NADPH and subsequent addition of 10 eq PfTrx. The reaction was analysed by 
rapid reaction kinetics at 490 nm and the observed trace (red line in figure 3.21) 
displayed the same features as those observed in the corresponding wild-type trace (red 
line in figure 3.21). The increase in absorbance 10 seconds after addition of the PfTrx 
was due to the formation of a fine precipitate in the reaction mix; this precipitation 
made analysis of the spectra collected very difficult (data not shown). From this 
experiment, as also observed in the static titration and reductive half-reaction, it was 
concluded that mutation of His 137 to glutamine resulted in no change to the proteins 
catalytic activity. Although the kinetics of the H137N mutant were essentially the same 
as that of the wild-type protein, the mutant was prone to precipitation as observed in 
both the NADPH static titration and oxidative half-reaction.
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Figure 3.21 -  Oxidative half-reaction of PfTrxR H137N (NADPH reduced)
9.5 pM PfTrxR H137N, reduced with 2.2 equ iva len ts NADPH, w as mixed with 10 eq PfTrx under 
anaerobic  conditions a t 5 ®C. The 490 nm kinetic traces from the oxidative half-reaction with 
PfTrx are  shown for PfTrxR wild-type reac ted  with 10 equiva len ts PfTrx (black line) and PfTrxR 
H137N reac ted  with 10 eq  of PfTrx (red line). The kinetic trace w as essen tia lly  the sa m e  a s  tha t 
of wild-type PfTrxR. Note: the increase  in ab so rb an ce  observed after 10 seco n d s w as due  to 
the formation of a  precipitate.
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3.3 Discussion
3.3.1 Crystal structure of high Mi- TrxR
In this study I have investigated the role of a number of the key active site residues 
involved in catalysis of the PfTrxR. Although there is no crystal structure of the PfTrxR 
protein, structural studies on rat TrxR and mouse mitochondrial TrxR identified that the 
bound NADPH, FAD and active site residues were all well positioned to aid transfer o f the 
reducing equivalents between the redox active centres (Sandalova et a l, 2001; Biterova et 
al, 2005). For example, in the rat TrxR structure the charge transfer thiol in the N-terminal 
cysteine pair (Cys93 in PfTrxR) is within 3.6 Â of the isoalloxazine ring of FAD 
(Sandalova et al, 2001) allowing it to form the thiolate flavin charge transfer complex 
(CTCl).
The C-terminal disulphide is located on a 16-21 amino acids extension (21 amino acids in 
PfTrxR) when compared to glutathione reductase. Studies in the rat TrxR identified several 
residues involved in glutathione binding as being conserved in the TrxR structure and 
postulated that the presence of the C-terminal tail conferred substrate specificity for 
thioredoxin in the TrxR protein (Kanzok et a l, 2000; Sandalova et a l, 2001), In both high 
Mr TrxR structural studies the C-terminal tail had to be modelled into the structure as this 
region was not ordered in either structure. This flexibility of the C-terminal tail was also 
suggested by Gromer et a l who demonstrated that the C-terminal tail could be cleaved (by 
proteases) in the reduced but not the oxidised human TixR (Gromer et a l, 1998). These 
findings supported the idea that the flexibility of the C-terminal tail in high Mr TrxR may 
play some role in catalysis, although this needs to be investigated further. This C-terminal 
flexibility also raises questions to the validity of thioredoxin docking models that have 
been proposed (Sandalova et a l, 2001; Brandt et al, 2005). In order to elucidate the 
interaction of thioredoxin with TrxR it may be necessary to form a stable mixed disulphide 
between the two proteins, and try to solve the structui e of the protein-protein complex.
3.3.2 The acid-base catalyst diad is essential for catalysis
The crystal structures of both mammalian TrxRs also confirmed the acid-base catalyst 
residues (equivalent to His509 and Glu514 in PfTrxR) to be suitably located to perform 
their postulated role within the active site. This was reminiscent to the studies on human 
glutathione reductase that initially proposed these residues as being important in catalysis 
(Pai et a l, 1983). Pai et al identified that the histidine and glutamate residues of the acid-
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base catalyst were closely associated and foimed a hydrogen bond in the oxidised protein. 
They also demonstrated that the imidazole ring of the histidine residue was closely 
associated with the bound FAD and the distal cysteine (equivalent to Cys88 in PfTrxR) 
was therefore ideally placed to act in catalysis. Mutagenesis studies on the histidine residue 
from glutathione reductase (from various organisms) confirmed that this residue was 
essential for catalysis, as mutants displayed highly reduced enzymatic activities (below 1% 
of wild-type) and demonstrated altered Km values for both substrates (Beny et al., 1989; 
Deonai'ain et a l, 1989; Scrutton et a l, 1990; Deonarain et al, 1992).
Studies on dihydrolipoamide dehydrogenase have concentrated on the histidine and the 
glutamate residues with mutation studies confirming their crucial role by showing the loss 
of enzymatic activity, alteration of Km values for the substrates and a change in catalytic 
mechanism (Williams et a l, 1989; Benen et al, 1991; Benen et a l, 1992; Kim et a l,
1992). The change in catalytic mechanism, from ping-pong to sequential, was obsei-ved in 
a protein with the glutamate residue mutated to glutamine and was probably due to the 
alteration of Km producing a slower release of substrates than that observed in the wild- 
type protein (Kim et a l, 1992). Mutants of the glutamate residue 'm Azotobacter vinelandii 
LipDH produced a shift in equilibrium in favour of the thiolate flavin charge transfer 
complex (Benen et a l, 1991), which was also observed in this study on the analogous 
residue (E514A) of PfTrxR.
These results reported on GR and LipDH were similar to those presented in this thesis and 
to studies previously carried out on PfTrxR, where mutation of His509 to glutamine 
resulted in 95 % loss of enzymatic activity relative to wild-type (Gilberger et a l, 1997). 
Overall the previous studies strongly suggest that the residues of the acid-base catalyst had 
a key role in catalysis with the histidine residue acting to stabilise catalytic intermediates 
and the glutamate residue acted to modulate the pKa value of the histidine residue during 
catalysis.
The predicted second acid-base catalyst (His 137 in PfTrxR), which was proposed to 
stabilise the C-teiminal cysteines during thiol-disulphide exchange (Gromer et a l, 2003), 
has been shown in this study to not act as an acid-base catalyst. This was also confiimed by 
Jacob et a l, who mutated the corresponding residue in the Drosophila melanogaster TrxR 
into asparagines, glutamine and phenylalanine (Jacob et a l, 2005). These mutants 
displayed a marked decrease in activity with DmTrx (90% reduction for the glutamine 
mutant), although the substrate Km and pH optima of the mutants were not altered from 
that of wild-type (Jacob et a l, 2005). Jacob et al. postulated that the residue was more
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likely to have a structural role in the protein than act as an active site acid-base catalyst. A 
closely associated tyrosine residue (equivalent to TyiT45 in PfTrxR) has also been studied 
as a possible acid-base catalyst in E. coli glutathione reductase, although the residue was 
not observed to play any such function in catalysis (Deonarain et a l, 1989).
3,3.3 The catalytic mechanism of PfTrxR
High Mr thioredoxin reductases contain three redox active centres; a bound FAD cofactor, 
an N-terminal disulphide and a C-terminal disulphide. Previous studies on the P. 
falciparum  TrxR have demonstrated that these centres are in redox communication (Wang 
et a l, 1999; Williams et a l, 2000). The catalytic mechanism of the high Mr TrxR has been 
proposed based on studies carried out on the Z). melanogaster TrxR protein (Bauer et a l, 
2003b) and I have modified this model to explain the data obsei-ved during my studies on 
the PfTrxR (figure 3.22).
In the proposed catalytic mechanism the oxidised protein is reduced to an EH] species by 1 
molar equivalent of NADPH. This reduction initially forms a FADH" NADP"^ charge 
transfer complex (CTC2) on the re side of the flavin that is visible as a spectral 
intermediate in the reductive half reaction. This was attributable to the first phase in the 
reductive half reaction of all PfTrxR forms and proceeded at a faster rate than that 
observed for the D. melanogaster TrxR (Bauer et a l, 2003b). The reductive half-reaction 
of both proteins were complete after 200 ms, however if one takes into account the 
temperatui'e that the experiment was performed at (5“C for PfTrxR and 10°C for DmTrxR), 
the PfTrxR has a much faster reductive half-reaction than DmTrxR.
Reducing equivalents are then passed to the si side of the flavin and form a thiolate flavin 
charge transfer complex (CTCl; EH] (B) in figure 3.22) with Cys93. Analysis of the C93A 
mutant’s reductive half reaction displayed that it was able to form CTC2 but not CTCl, 
confirming this residue as the charge transfer residue (figure 3.16). Another residue 
important in the formation of EH] (B) is His509 of the acid/base catalyst motif, as mutation 
of this residue to glutamine resulted in a loss of the CTCl spectral intermediate during the 
reductive half reaction. This was most dramatically demonstrated in the static reduction 
with sodium dithionite as the resulting spectrum lacked the spectral properties of the bound 
NADP(H) (figure 3.8). The His509 residue is therefore postulated to stabilise the CTCl by 
de-protonating the Cys93 thiol foimed in this charge transfer complex. Mutation of the 
Glu514 residue of the acid/base catalyst motif resulted in an enhancement of the EH] (B) 
spectral intermediate during the reductive half reaction. This may be due to the loss of the
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negative charge of Glu514 favouring the de-protonation of the Cys93 thiol, which results 
in an accumulation of the EH] (B) species (figure 3.22). Reduction of PfTrxR wild-type by 
one equivalent of NADPH results in an equilibrium of EH] species (A -  D), although the 
major species is EH] (B). Formation of EH] (B) was attributable to the second observed 
phase in the reductive half reactions of PfTrxR proteins and this phase proceeded much 
slower in H509Q and E514A forms than in PfTrxR wild-type, confirming the crucial roles 
that both these residues play in this part of the catalytic mechanism.
Reaction of a second equivalent of NADPH results in the further enhancement of CTCl 
spectral intermediate and produces a four electron reduced form (EH4 A -  B in figure
3.22). This was attributed to the third obsei-ved phase of the reductive half reaction and this 
phase also proceeded slower in the H509Q and E514A mutants. This was postulated to be 
due to the inhibition of CTCl formation (obsei-ved in EH] B, EH] C and EH4 B in figure
3.22) in H509Q or the accumulation of CTCl in E514A resulting in a slower transfer of 
reducing equivalents through the active site of the mutant forms. The faster reaction of the 
PfTrxR H509Q mutant at higher pH (coupled with the lack of wild-type pH dependency) 
was further evidence that this residue acted as an acid/base catalyst.
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Figure 3.22 -  The proposed catalytic mechanism of PfTrxR
This model of the catalytic cycle of RfTrxR h as been  adap ted  from B auer et al. T he oxidised protein 
is ‘prim ed’ by NADPH forming a  Michaelis com plex (MG) which leads to a  two e lectron reduced 
sp ec ie s  (EHg A-D). EHg B d isp lays the th iolate flavin charge transfer com p lex (CTC1; d ash ed  
arrow s indicate charge-transfer interactions), and reducing equ iva len ts a re  p assed  from the N- 
term inai cys te ines (EH2 B) to the C-term inal cy s te ines (EH2 D) via the  formation of a  disulphide 
bond be tw een Cys88 and C ys540 (EH2 C). A second  NADPH then form s a  second Michaelis 
com p lex (MC2) which resu lts in the four electron reduced form of the protein (EH4 A -  B). The 
thioredoxin su bs tra te  then binds to the protein and  oxidises the C-term inal cy s te ines via the 
formation of a  mixed disu lphide (MDS), before the reduced thioredoxin is re leased  and the PfTrxR 
re turns to the two e lectron reduced s ta te  (EH2 B). The reductive half-reaction involves the  s tep s  
designa ted  by ra te cons tan ts ki-ki6, and the oxidative half-reaction by the  ra te  cons tan ts ki7 -k2 o-
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Analysis of the reaction of PfTrxR EH4 species with Trx (the oxidative half reaction) 
demonstrated three observable phases. The first phase was attributable to the reduction of 
Trx (via a mixed disulphide; MDS in figure 3.22) and subsequent production of a PfTrxR 
EH] species (equilibrium of EH] A -  D). The steps involved in oxidation of the EH4 
species (such as Trx SH] dissociation and formation of EH] equilibrium) are first order 
reactions and this can therefore explain the independence of the rate (of the first phase) on 
Trx concentration. The second and third phases proceeded much slower than the first and 
represented the oxidation of PfTrxR EH] to Eox by Trx (represented by kio, kg, ke, iQ and k] 
in figure 3.22). The slower rate of EH] oxidation to Eox suggests that PffixR , like 
DmTrxR, cycles in catalysis between EH] and EH4 (Bauer et a l, 2003b). This is further 
likely to be true due to the high cytosolic NADPH concentration that would readily reduce 
any Eox that does form back to EH]. The oxidative half reactions of wild-type PfTrxR 
reduced with sodium dithionite and NADPH display major differences. The sodium 
dithionite reduced EH4 species reacts much faster with Trx than the NADPH reduced EH4 
species (compare figure 3.17B with figure 3.18B). This is thought to be due to the different 
equilibria that form during reduction of the proteins (i.e. the formation of a FADH' NADP^ 
intermediate in the NADPH reduced and not in the sodium dithionite reduced). The 
oxidative half reactions of the H509Q and E514A mutants reduced with NADPH are also 
slower than that of the wild-type PfTrxR (compare figui'es 3.19 and 3.20 with figure 3.18). 
The oxidative half reaction of PfTrxR H509Q is substantially slowed but oxidises to near 
the same extent as the wild type reaction (compare wild-type and H509Q extinctions at 
1000s in figure 3.19). This is likely to be due to impaired transfer of reducing equivalents 
from the N-terminal to the C-terminal redox centres. The E514A mutant does not oxidise 
to the extent that the wild-type and H509Q forms do (compare figure 3.20 with figures 
3.18 and 3.19). This is probably due to the loss of the negative charge of Glu514 
encouraging the formation of CTCl and therefore ‘trapping’ reducing equivalents in this 
intermediate. This results in an inhibition of transfer of reducing equivalents between N- 
terminal and C-terminal redox centres and can be observed in the oxidative half reaction as 
well as the reductive half reaction.
From these experiments it can be concluded that the residues of the acid/base catalyst motif 
play crucial roles in the transfer of reducing equivalents between the redox active centres 
and that the PfTrxR protein in likely to cycle between EH] and EH4 in vivo.
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3.3.4 Importance of the C-terminal tail in high Mr TrxR
The C-teiminal tail of the high Mr TrxR is located in the interface domain and is the site of 
Trx binding and reduction. The flexibility observed in this tail has been suggested to be 
important for the catalytic mechanism (Gromer et al, 1998). Mutation of residues (outwith 
the active site cysteine/selenocysteine residues) within this C-terminal tail have also been 
shown to alter the enzymatic activity of the protein, and have identified that the 
distribution of residues in this tail is tailored to the active site cysteine/selenocysteine 
residues involved in catalysis (Gromer et a l, 2003).
It may therefore be possible to utilise the major differences observed at the C-terminal 
redox centres to specifically inhibit a TrxR from one organism, while not inhibiting those 
from other organisms. The development of an inhibitor that would work specifically 
against the PflrxR  (but not the human TrxR), may result in a potent antimalarial. Indeed, 
the C-terminal disulphide in P. falciparum has already been shown to be a site of inhibition 
by Mannich bases (Davioud-Charvet et a l, 2003). Mannich bases are intermediates o f the 
Mannich reaction, and is the reaction product of carbonyl and an amine compound that 
engage in a nucleophilic addition reaction followed by elimination to the imine salt. These 
Mamiich bases were initially identified in high throughput screens of the Pfizer compound 
library as having possible anti-thioredoxin reductase activity and are dependent on the 
enzyme mechanism. The inactivation at the C-terminal disulphide was proven by the loss 
o f enzymatic activity with PfTrx as a substrate and is a result of chemical modification of 
the C-terminal cysteines by the inliibitor (Davioud-Charvet et a l, 2003),
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3.4 Conclusions
In this study I have investigated the reaction mechanism and role within that mechanism of 
an acid-base catalyst motif in the high Mr TrxR from Plasmodium falciparum.
My studies have shown that the PfTrxR reaction mechanism is similar to that proposed for 
other high Mr TrxR based on previous studies on the D. melanogaster protein. Although 
some major differences in the catalysis of the DmTrxR and PfTrxR proteins were 
observed:
1, PfTrxR appears to have a faster reductive half-reaction
2, PfTrxR has a slower oxidative half-reaction
3, PfTrxR appears to be able to return to Box following oxidation with PfTrx {in vitro).
Investigations into the proposed acid-base catalyst residues have shown that H509 and 
E514 of the conserved motif are crucial for the efficient transfer of electrons thi'ough the 
redox active centres and also display distinct roles.
1. The H509Q mutant inhibited formation of the thiolate flavin charge transfer 
complex (CTCl) and this confirmed that the histidine residue was vital in 
stabilising the formation of this reaction intermediate.
2. The E514A mutant enhanced the level of CTCl observed and is thought to be 
involved in modulating the pKa of the histidine residue during catalysis.
Analysis of a proposed acid-base catalyst (His 137) demonstrated that this residue does not 
form a function important in catalysis as observed by the wild-type like parameters of 
His 137 mutants.
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Chapter 4 Plasmodium falciparum  possesses two distinct
dihydrolipoamide dehydrogenases
4.1 Introduction
4.1.1 Dihydrolipoamide dehydrogenase
Dihydrolipoamide dehydrogenase (LipDH) is a member of the disulphide 
oxidoreductase family that includes thioredoxin reductase, glutathione reductase, 
trypanathione reductase and mercuric ion reductase (Williams, 1976). LipDH is an 
essential component of a-keto acid dehydrogenase multi-enzyme complexes (Perham et 
a l, 1996; Douce et al, 2001; Mooney et a l, 2002), where it is responsible for the re­
oxidation of dihydrolipoamide covalently bound to the complexes (figure 1,10; figure
4.1).
LipDH is a homodimeric protein that uses a bound flavin (FAD) cofactor and a redox 
active cysteine pair to transfer reducing equivalents from dihydrolipoamide to NAD"  ^
producing NADH and lipoamide (figure 4.1).
4.1.2 Aims
The aims of this part of the study were to identify and characterise the genes that encode 
dihydrolipoamide dehydrogenase in the Plasmodium falciparum genome. The genes 
were then to be amplified and cloned for recombinant expression, biochemical 
characterisation and subcellular localisation studies.
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F ig u re  4.1 -  T he  ca ta ly tic  m e c h a n ism  o f d ih y d ro lip o am id e  d e h y d ro g e n a s e  (LipDH)
T he physiological reaction of LipDH ca ta ly ses the  oxidation of dihydrolipoamide, which resu lts in 
the production of lipoamide and NADH. The LipDH protein can a lso  ca ta ly se  the  reduction of 
lipoamide by NADH in the reverse  reaction. LipDH is a  m em ber of the d isu lphide 
oxidoreduc tase family and requires a  protein bound flavin cofactor (FAD) for transfer of reducing 
equ iva len ts from one subs tra te  to the other.
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4.2 Results
4.2.1 Identification of two distinct dihydrolipoamide dehydrogenase 
genes.
The Plasmodium falciparum genome database (www.plasmodb.orgl was searched by 
TBLASTN using the human (P09622) and yeast (P09624) LipDH amino acid sequences 
as queries. These searches identified two LipDH open reading frames (ORFs) located 
on chromosomes 8 and 12, which I named LipDHÎ and LipDH2, respectively. LipDH 1 
had BLAST scores of 211 and 191 with the human and yeast proteins, respectively. 
LipDH2 had BLAST scores of 316 and 332 with the human and yeast proteins, 
respectively. TBLASTN searches identified the related disulphide oxidoreductases 
glutathione reductase (with BLAST scores of 135 and 139 for the human and yeast 
LipDH proteins, respectively) and thioredoxin reductase proteins (with BLAST scores 
of 150 and 132 for the human and yeast LipDH proteins, respectively) from P. 
falciparum  as the next best hits.
4.2.1. 1_____ Sequence analyses of LipDH 1
The LipDHl gene identified on chromosome 8 (which was later annotated PF08 0066 
in PlasmoDB) was 2001 bp in length and displayed 21 % and 23.3 % amino acid 
identity to human and yeast LipDH  genes respectively. The gene encodes a 667 amino 
acid protein with a predicted molecular mass of 75.6 kDa (figure 4.2). Comparison o f P. 
falciparum  LipDHl with predicted homologues from other Plasmodium species 
confirmed the predicted start site (data not shown). Homologues identified in P. 
gallinecium, P. yoelii yoelii, P. berghei, P. knowlesi and P. vivax had 74 %, 60 %, 59 %, 
56 % and 53 % amino acid identity, respectively.
When the LipDHl deduced amino acid sequence was subjected to BLAST? analysis, it
displayed greatest amino acid identity to the plastid isoforms of Oryza sativa (Japanese
rice; 36 % identity), Arabidopsis thaliana (Thale cress; 35 % identity), Trichodesmium
.erythraceum (Cyanobacteria; 38 % identity) and Nostocpunctiforme (Cyanobacteria; 37 
% identity). This observed homology to plastid isoforms of LipDH suggests that 
LipDHl may be localised to the apicoplast in P. falciparum. The observation of a large 
N-teiminal extension in the LipDHl deduced amino acid sequence (when compared 
with the human and yeast proteins; data not shown) suggests the presence of the 
bipartite signal/transit peptide that is responsible for apicoplast targeting in P.
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falciparum (Foth et a l,  2003). In order to further investigate the possible subcellular 
localisation of LipDH l, I analysed the amino acid sequence using sub-cellular 
predictions programs (see section 2.2.2.3). The results obtained from these programs 
confirmed the possible apicoplast localisation for LipDHl with good confidence (95%) 
and a predicted signal peptide cleavage site after amino acid 33 (table 4.1; highlighted 
blue in figure 4.1).
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ATGGTCATAAGGCAAAATATTAAACATATCGTTAAACTTAACGTCGTTACTCTAATTTGG 6 0 
M V I R Q N I K H I V K L N V V T L I W  2 0
TTATCTTATCTTTTTCTTCTTAAACCTCATGGAACTTTGAAAi\ATATGATGGTGTGTAAT 1 2 0
L S Y L P L L K P H G T K N M M V C N 4 0
GCTGTCCTTCTTCCATTTAATGAGAAAAATAAAGGCATAAATAATTTTGTGTATATTAAC 1 8 0  
A V L L P F N E K N K G I N N F V Y I N  60
CCAAAGAATATTATTTTGAATAAAATAAAAAAAGATGTCATAAAACTAGAAAAAGATAAT 2 4  0
P K N I I L N K I K K D V I K L E K D N 8 0
ATCATCCTCTGCCAACACAATAGAAAAAGAGATAACTATATTAAACAACAAAAACGAAAA 3 0  0
I I L C Q H N R K R D N Y I K Q Q K R K 1 0 0
GAAAAAAACGCGAATAATTTTACATTTATGTTAAAAGGAAGTACACAAAATATTATGAAC 3 6 0
E K N A N N F T F L K G S T Q N I M 1 2 0
ATTAATGAAAAAGAATATGATCTTGCTATAATCGGTTGTGGTGTTGGAGGACATGCGGCC 4 2 0
I N E K E Y D L A I I G C G V G G H A A 1 4 0
GCAATTAATGCTATGGAAAGAAATTTAAAAGTCATTATATTTGCAGGGGATGAAAATTGT 4 8 0  
A I N A M E R N L K V I I F A G D E N C  1 6 0
ATTGGAGGAACATGTGTTAATGTTGGCTGTATACCAAGCAAAGCGCTATTATACGCTACA 54  0
I G G T C V N V G C I P S K A L L Y A T 1 8 0
AATAAATATAGAGAATTAAAAAATTTAGATAAATTATATTATTATGGTATCCATAGCAAT 6 0  0 
N K Y R E L K N L D K L Y Y Y G I H S N  2 0 0
ATTTTTCAAAATAATAAAAATACAGAAATTGAAAATAATCAACTCGTTTCAAACAGCTTC 6 6 0  
I F Q N N K N T E I E N N Q L V S N S F  2 2 0
CAAATTAATATTACGAAATTGAAAGAATACACACAAAGTGTTATTGACAAATTAAGAAAT 72  0
Q I N I T K L K E Y T Q S V I D K L R N 2 4 0
GGAATTTCACATGGATTTAAAACATTAAAATTTAATAAAAATTCTGAACATGTTCAGGTA 7 8 0
G I S H G F K T L K F N K N S E H V Q V 2 6 0
ATTTATGAACATGGTCAGCTATTAGATAAAAATACTATAAAAAGTAAAAAAAGTGGTAAT 84 0
l Y E H G Q L L D K N T I K S K K S G N 2 8 0
ACATATAAAGTAAAAAATATCATTATAGCAACAGGATCTGTACCTAATATTCCAAATAAC 9 0 0
T Y K V K N I I I A T G S V P N I P N N 3 0 0
GTTGAGATAGATGACAAGAGTGTTTTTACAAGTGATATGGCAGTAAAATTAGTTGGTTTA 9 6 0  
V E I D D K S V F T S D M A V K L V G L  3 2 0
AAAAATTATATGAGTATAATTGGTATGGGAATAATTGGTTTAGAATTTGCTGATATATAT 1 0 2  0 
K N Y M S I I G M G I I G L E F A D I Y  3 4 0
ACAGCCTTAGGTTCAGAAATAACATTTTTGGAATATTCTTCTGAATTATTACCAATAATT 1 0 8 0  
T A L G S E I T F L E Y S S E L L P I I  3 6 0
GATAATGATGTTGCAAAATATTTTGAAAGGGTATTTTTAAAAAATAAACCTGTAAATTAC 1 1 4 0
D N D V A K Y F E R V F L K N K P V N Y 3 8 0
C ATTTAAATACAGAGGTTAAATATATAAAGGCTTCTAAAAATAATAATCCGGTTATTATT 1 2  00  
H L N T E V K Y I K A S K N N N P V I  I  4 0 0
GGAT ATTCACATAGAACTGGTAATGATGATAATGAAAAAAAAAATATGAC AGATGTTAAA 1 2 6 0
G Y S H R T G N D D N E K K N M T D V K 4 2 0
GAATTATATGTTGATAGTTGTTTAGTTGCTACTGGACGAAATCCAAATACACAAAACTTA 1 3 2 0
E L Y V D S C L V A T G R M P N T Q N L 4 4 0
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GGTTTGGAAAAATTAAAAATACAAATGAATAGAGGATATGTTTCAGTAAATGACAATTTA 13  8 0
G L E K L K Ï Q M N R G Y V S V N D N L 4 6 0
CAAGTAAAAATGGAAAATAATGAAATTTATGATAATATATTTTGTAT AGGAGATGCAAAT 1 4 4  0
Q V K M E N N E Y D N I F C I G D A N 4 8 0
GGGAAACAAATGTT AGCAC AC AC AGC ATC AT ATC AAGC ATTAAAAGTC ATTGATTTT ATT 1 5 0 0
G K Q M L A H T A S Y Q A L K V I D F 5 0 0
GAAAAGAAAGAAAAAAAGAATGTAAACATAAATGTTGAAAATAATTTGAGTAAACCCATA 1 5 6  0
E K K E K K N V N I N V E N N L S K P 5 2 0
TTATATAAAAATATACCTTCTGTTTGTTATACAAATCCTGAATTAGCTTTTATCGGATTA 1 6 2 0  
L Y K N I P S V C Y T N P E L A F I G L  5 4 0
ACAGAAAAAGAAGCAAAAGTATTATATCCAGATAATGTCGGTGTTGAAATTTCATATTAT 1 6 8 0  
T E I C E A K V L Y P D N V G V E I S Y Y  5 60
AAATCAAATTCAAAAATATTGTGTGAAAATAATATTTCCTTAAATAATAATAAAAAAAAT 1 7 4  0
K S N S K I L C E N N I S L N N N K K N 5 8 0
AATTCATATAATAAAGGACAATATAACATAAATGATAATACAAATGGTATGGTAAAAATA 18  0 0
N S Y N K G Q Y N I N D N T N G M V K I 6 0 0
ATATATAAAGAAGACACAAAGGAAATATTAGGAATGTTCATAGTTGGAAATTATGCTTCC 1 8 6 0
l Y K E D T K E I L G M F I V G N Y A S 6 2 0
GTTTTAATTCATGAAGCAGTATTGGCAATTAATCTGAAATTATCAGCATTCGATTTGGCA 1 9 2 0  
V L I H E A V L A I N L K L S A F D L A  6 4 0
TATATGGTTCATTCTCATCCAACAGTAAGTGAAGTTCTGGACACAGCTTTTAAATCTATA 1 9 8 0
Y M V H S H P T V S E V L D T A F K S 6 6 0
TCAAAAATAAGAACTCACTAA 
S K I  R T H *
2 0 0 1
6 6 7
F igure  4.2 -  LipDH l n u c le o tid e  an d  am in o  ac id  s e q u e n c e
The cDNA sequence of PfLipDHI,  with the deduced amino acid sequence displayed 
underneath. Amino acid numbering includes the initiator methionine: the termination codon is 
marked with an asterisk. This figure also highlights the amino acids of the predicted signal 
peptide cleavage site (highlighted in blue), the predicted start site of the mature protein used for 
recombinant expression (highlighted in red) and the last amino acid before attachment to GFP 
in the GFP-fusion construct (highlighted in green).
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4.2.1.2 Sequence analyses of LipDH2
The LipDH2 gene identified on chromosome 12 (which was later annotated PFL1550w 
in PlasmoDB) was initially identified to be 1497 base pairs in length. This gene (named 
LipDH2A) encoded a protein comprising of 499 amino acids with a predicted molecular 
mass of 55.6 kDa. However, ClustalW alignment of this deduced amino acid sequence 
with the predicted open reading frames of homologues from other Plasmodium species 
suggested the presence of an intron at the N-tenninus of the gene. This prediction was 
due to the un-conseiwed nature of the LipDH2A translation initiation site (Met) and the 
apparent loss of identity in the N-terminal 1 0 -2 0  amino acids (figure 4.3 A). Analyses 
of the genomic DNA sequence from P. falciparum LipDH2 identified possible 
intron/exon boundaries in the 5’ end of the gene. The predicted intron produced a shift 
of frames between the two exons, from frame +1 in exon 1 to frame +3 in exon 2 (figure 
4.3B) and displayed a much higher A/T content (86.6 %) when compared to that of 64.8 
% and 72.1 % for exons 1 and 2, respectively. The positions of the intron/exon 
boundaries were conseiwed in the amino acid sequences between the Plasmodium 
species (figure 4.3C), although the length of the predicted intron did vary between the 
species; with the introns being 216 bp for P. falciparum, 182 bp for P. berghei, 185 bp 
for P. chabaudi, 239 bp for P. vivax and 187 for P. yoelii yoelii.
I named the P. falciparum  gene that contained the intron, LipDH2B. The genomic 
sequence of the LipDH2B gene was 1763 bp in length, while the complementary DNA 
(following removal of the intron from mRNA) was 1539 bp and encoded for a protein 
containing 513 amino acids with a predicted molecular mass of 57.2 kDa (figure 4.4). 
The deduced amino acid sequence of LipDH2B displayed high levels of amino acid 
sequence identity with homologues from other Plasmodium species P. yoelii yoelii (79 
% identity), P. vivax (73 % identity), P. chabaudi (79 % identity) and P. bergheiÇ?^ % 
identity).
Subsequent BLAST? analyses of the predicted amino acid sequence displayed that 
LipDH2B had greatest amino acid identity to mitochondrial isoforms of LipDH from 
Euglena gracilis (Protist; 40 % identity), Dictyostelium discoideum (Slime mould; 38 %
identity), Pisum sativum (Pea plant; 38 % identity), Lycopersicon esculentum (Tomato
plant; 38 % identity). Solarium tuberosum (potato plant; 37 % identity) dead Aspergillus 
fumigatus (Fungi; 38 % identity).
fI
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As LipDH2B had greatest amino acid identity with mitochondrial isoforms of LipDH, I 
investigated this possible mitochondrial localisation further by analysing the LipDH2B 
amino acid sequence using sub-cellular localisation prediction programs. The results of 
these programs suggested that LipDH2 was predicted to be localised to the 
mitochondrion with the level of confidence depending on the start site used (table 4.1 ). 
Analysis of LipDH2A led to poor confidence levels (2 %) and no cleavage site 
predictions, while the predictions for LipDH2B produced a mitochondrial prediction 
with 61% confidence and a possible cleavage site after amino acid 27 (highlighted 
yellow in figure 4.4).
A)
P b e r g
P y o e l
P c h a b
P f a l
P v i v a x
B )
 ELKYLSHFIFFHLY lYDVIVIGGGPGGYVCSIRCGQNKLKVLNVNDDNKLGGT 53
 NIFIIFFFFFYLYWYDVIVIGGGPGGYVCSIRCGQNKLKVLNVNDDKKLGGT 52 — ................- k y l s h f i f f s f c I y d v iv ig g g p g g y v c s ir c g q n k l k v l n v n e d k k l g g t  5 1 -................. ............... m y i f f p f f c I y d v iv ig g g p g g y v c s i r c a q n k l n v l n v n e d k k l g g t  4 8
w a t l p l y s l p n s p l p l l l p p h I y d v iv ig g g p g g y v c s i r c a q n k l n v l n v n e d k k l g g t  60
E Q R Y F * S T L F F S A I A * M L L N + 3  
* T A L F L E H I V F F S H C V D A S Q + 2  
M N S V I F R A H C F F Q P L R R C F S  +1
a c t a a g a a a g a H a t a c a a a t a g a a a a t t a a a a a a t a a g c a t a a t t t a c t t g t a c a t a g a
* E R V Y K * K I K K * A * F T C T * K + 3  
L R K S I Q I E N * K I S I I Y L Y I E + 2  
T K K E Y T N R K L K N K H N L L V H R  +1
AAAAAAAAAATATACATATATATAAATATATATATATATCTATTTATATATATATATATT 
K K N I H I Y K Y I Y I S I Y I Y I Y L + 3  
K K K Y T Y I * I Y I Y I Y L Y I Y I F + 2  
K K K I Y I Y I N I Y I Y L F I Y I Y I  +1
Y I C I F F F F Y F V P H L H Y H T H I + 3  
I Y M Y I F F F L F C P T F T L S H A H + 2  
Y I Y V Y F F F S I L S H I Y I I T R T  +1
TATATATATATATATATATATAATATArGTATATATTTTTTCCTTTTTTTTG lMCTATG 
y i y i y i * y | y i f f p f f c s  Ü I  +3  
I Y I Y I Y I I Y V Y I F S F F L * L * + 2  
Y I Y I Y I Y N I C I Y F F L F F V A M  +1
ATGTTATAGTCATTGGAGGAGGGCCAGGTGGTTACGTGTGCAGTATTCGATGTGCTC
C Y S H W R R A R W L R V Q Y S M C S  
M L *  S L E E G Q V V T C A V F D V L
+3 
+2  
+ 1
C )
P b e r g
P y o e l
P c h a b
P f a l
P v i v a x
MNGFFSKTNKVFFYPLRRNFSTNI' 
M NSFFSKTNKVFFYPLRRNFSTNf 
MKGIFSKTNKIFFYPVRRNFSTNE 
M NSVIFRA-HCFFQPLRRCFSTKÎ 
M SA W SRT - RVAFFPGRRHFSSKÎ
DVIVIGGGPGGYVCSIRCGQNKLKVLNVNDDNKL 60  
DVIVIGGGPGGYVCSIRCGQNKLKVLNVNDDKKL 60 
OVIVIGGGPGGYVCSIRCGQNKLKVLNVNEDKKL 60  
DVIVIGGGPGGYVCSIRCAQNKLNVLNVNEDKKL 59  
DVIVIGGGPGGYVCSIRCAQNKLNVLNVNEDKKL 59
P b e r g
P y o e l
P c h a b
P f a l
P v i v a x
GGTCLNRGCIPSKALLHIAHNYYESKNKFKECGILIDNVKLDIEQVHKHKNKCMGSLADG 1 2 0  
GGTCLNRGCIPSKSLLHIAHNYYESKNKFKECGILIDNVKLDIEQVHKHKNKCMGNLADG 1 2 0  
GGTCLNRGCIPSKSLLHIAHNYYESKNKFKECGILVDNVKLDIEQLHKHKNKCMGNLADG 1 2 0  
GGTCLNRGCIPSKSLLHISHNYYEAKTRFKECGILVDNVKLDlETMHKHKNKCMGNLSDG 1 1 9  
GGTCLNRGCIPSKALLHIAHKYYEAKNKFKQSGIIIDSVHLDVEAIHKQKNKCMGNLADG 1 1 9  * * * * * * * * * * * * * . * * * * . * . * * * . *  . * * .  * * • • *  * • * * • *  . * * . * * * * * *  * . * *
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PbergPyoelPchabPfalPvivax
ISFLYKKNNVKHIIGRGSIIDSNTILVKTENEGQKKYTAERIVIATGSKPIEIPLKKLND 180 ISFLYKKNNVKHIIGRGSIIDGNTILVETENEGQKKYTAERIVIATGSKPIEIPLKKLDD 18 0 ISFLYKKNNVKHIIGRGSIVDGNTILVETENEGQKKYTAERIVIATGSKPIEIPLKKLDD 180 INFLYKKNNVWHIIGHGSLVDEHTVLIKTEKE-EKKVTAERIVIATGSKPIEIPLKKLND 178 ITYLYKTNKVWHLVGHGSIVDGNTVLVNSSGK-EKLVTAERIVIATGSKPIEIPLKKLNE 178 * , * * * .* . * . * . . . * . . * *********************. .
PbergPyoelPchabPfalPvivax
DNIMDVETVKDILEYDHKLIQTSDDILNFKEIPKTMSIIGGGVIGLEIGSVFSKFGSDVT 240 NNINDVENVICDILEYDHKLIQTSDDILNFKEIPKTMSIIGGGVIGLEIGSVFSKFGSDVT 240 3SIKIKDVENVKDILEYDHKILQTSDDILNFKE1PKTMSIIGGGVIGLEIGSVFSKFGSDVT 240 NNFNDADNVNDILEYDHSIIQNSDDILNFKKVPHNISIIGGGVIGLEIGSVFSKLGSDVT 23 8 DTAKEAETVEELLQYDHQVIQTSDDILNFKKIPKKISIIGGGVIGLEIGSVFAKMGSDVT 23 8 ♦ ♦ ♦ * * • . . * ******** . .*. , **************** . * * *****
PbergPyoelPchabPfalPvivax
VYEYNSRLCGFLDPDVSKVLQKVLEKVKIKFMFNTSIVGGNLNTTNNEAILYARDNKTNK 300 VYEYNSRLCGFLDPDVS KVLQKVLE KIKIKFMPNTSIIGGNLNTTNNEAILYARDNKTNQ 3 00 VYEYNSRLCGFLDPDVSKVLQKVLEKIKMKFMFNTSIIGGNLNTSNNEAILYARDNKTNQ 300 VFEYNERLCGFLDADVSIWLQKTLEKIKMKFVFNTSVIGG--NIENNQAALFAKNKKTNB 2 95 IFEYUSRLCTFLDADVSKVLQKTLEICVKIKFAFNSSWGG- -SVQNGEATLPAKNAKTKE 296 ***** *** * * * ******** ******** **,*..** * . * *.*.. * * , *
PbergPyoelPchabPfalPvivax
IKICVKSDIVLVCVGRKANLENINLEKLNIELNKNKKIQVDEYFNVKSQPTIKAIGDAIDG 360 IKKVKSDIVLVCVGRKANLENINLEKLSIELNKNKKIQVDEYFNVKSQPTIKAIGDAIDG 3 60 INKIKSDIVLVCVGRKANLBNINLBNLSIELNKNKKIQVDEYFNVQSQPTIKAIGDAIDG 360 IKKTTSEIVLICIGRKANFDNLNLHLLNIELNKNKKIPVDEYFNVIAQPTIKAIGDAIDG 3 56 IQKVTSDWLVCVGRRPNFDDLNLEKLNVQLGQNKRLQVDASFGVASHPTIKAIGDAIDG 3 56 
* * * * • • * * . * . * * .  * , . . . * *  * . . *  • * * . »  * *  * * . * * * * * * * * * * * * *
PbergPyoelPchabPfalPvivax
SMLAHKAEEEGYIVADMIFNELKNNKKKKNHINYDLIPSVIYTHPEVASVGYNEQKCKEL 420 SMLAHKAEEEGYIVADMLFNELKNNKKKKNHINYDLIPSVIYTHPEVASVGYNEQKCKEL 420 AMLAHKAEEEGYIVADMIPNELKMNNKKKNHINYDLIPSVIYTHPEVASVGYTBQKCKEL 420 PMLAHKAEEEGYLLANILFDBLKNNKKKKAHINYDLVPSVIYTHPEVATVGYNEAKCKEL 416 PMLAHKAEEEGYILANILLSELKLKKPKKSHLNYDLVPSVIYTHPEVASVGLNEERCKQR 416 ************ .*. . . . * * * ** * * * . **** . *********** * ** * .**.
PbergPyoelPchabPfalPvivax
KLNYKTVSFPFAANSRSRTIDDYDGLIKLIVEKDTNVILGSQIIGNNASDLILPLSIYAS 4 80 KLNYKSVSFPFAANSRSRTIDDYDGLIKLIVEKDTNVILGSQIIGNNASELILPLSIYAS 4 80 KLNYKAVSFPFAANSRSRTIDDYDGLIKLIVEKDTNWLGSQIIGNNASELILPLSIYAS 4 80 NMNFKSVSFPFAANSRSRTIDDYDGLIKLIVEKDTNRILGSQIIGNNASDLILPLSIYVA 476 NLPYKAVTFPFAANSRSRTIDDFDGVIKLLVESNSNKILGSQIVGNNASDLILPLSIYVA 4 76
: Î . * . * . * * * * * * * * * * * * * *  « * * . * * * . * *  . . *  . * * * * * , * * * * *  . * * * * * * * *
PbergPyoelPchabPfalPvivax
HKGTSKNLSKIIYPHPTFSEVIKEVALQSFDKAIHM 516 HKGTS KNLSKIIYPHPTFSEVIKEVALQSPDKAIHM 516 HKGTSKNLSKIIYPHPTFSEVIKEVALQSFDKAIHM 516 NNGSSKSLSKIIYAHPTFSEVIKEVALQSFDKPIHM 512 NGGSSKSLSKVIYAHPTFSEVIKEVALQSFDRAIHM 512 > * . * *  *  *  *  . *  *  * * * * * * * * * * * * * * * * *  , *  *  *
F igure  4,3 -  C lusta lW  a lig n m e n t o f LlpDH2 h o m o lo g u e s  from  Plasmodium  s p e c ie s .
The P. falciparum LipDH2 deduced amino acid sequence was compared by ClustalW alignment 
with homologues from Plasmodium berghei (Pberg), Plasmodium yoelii yoelii (Pyoel), 
Plasmodium chabaudi (Pchab) and Plasmodium vivax (Pvivax). (*) Identical residues, (:) 
conserved residues, (.) homologous residues. P an e l A displays an N-terminal section of the 
ClustalW alignment of the open reading frames (ORF) of exon 2 of LipDH2A homologues from 
Plasmodium species genomes. This displays that the in-frame methionine present in the P. 
falciparum exon 2 ORF is not conserved among the different Plasmodium LipDH2 sequences 
which suggests the presence of a possible Intron. The most likely site for the position of the 
intron/exon boundary is highlighted in grey. P an e l B displays the LipDH2 genomic DNA 
sequence with the deduced amino acid sequence for each of the three frames. Exon 1 starts in 
frame +1 and is highlighted in yellow; exon 2 starts in frame +3 and is highlighted in dark blue. 
The predicted intron/exon boundaries are highlighted in red and were found to be conserved 
between Plasmodium species. The translation initiation methionine for LipDH2A (green) and 
LipDH2B (yellow, at the start of exon 1) are displayed. Pane l C displays a ClustalW alignment 
of the predicted amino acid sequences of LipDH2B and homologues from other Plasmodium 
species following splicing of the potential intron. The position of the intron/exon boundary is 
highlighted in grey, and displays that splicing of the intron produces a change in residue from 
serine to aspartate (compare panel A with panel C).
«
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ATGAACAGCGTTATTTTTAGAGCACATTGTTTTTTTCAGCCATTGCGTAGATGCTTCTCA 6 0
M N S V I F R A H C F F Q P L R R C F S
G T C L N R G C I P S K S L L H I S H N
Y Y E A K T R F K E C G I L V D N V K L
D I E T M H K H K N K C M G N L S D
N F L Y K K N N V N H I  I G H G S L V D
V I A T G S K P I E P L K K L N D N N
F N D A D N V N D I L E Y D H E I I Q N
S D D I L N F K K V P H N I S I I G G G
V I G L E I G S V F S K L G S D V T V F
E Y N E R L C G F L D A D V S K V L Q K
20
ACTAAGAAAGACTATGATGTTATAGTCATTGGAGGAGGGCCAGGTGGTTACGTGTGCAGT 12  0 
T K K d | d V I V I G G G P G G Y V C S  4 0
ATTCGATGTGCTCAAAATAAACTAAACGTTTTGAACGTGAACGAAGACAAGAAACTAGGA 1 8 0  
I R C A Q N K L N V L N V N E D K K L G  60
GGCACATGTTTAAATAGAGGATGCATTCCATCCAAATCTCTATTACACATTTCTCATAAT 2 4  0
80
TATTATGAAGCAAAGACTAGATTCAAAGAATGTGGTATATTAGTTGATAATGTTAAGTTG 3 0 0
100
GATATAGAGAC TATGCATAAACATAAAAATAAGTGCATGGGTAATTTATCTGATGGAATT 3 6 0
120
AATTTTTTATACAAAAAGAACAATGTGAATCATATTATAGGCCATGGGAGTTTAGTAGAT 4 2 0
1 4 0
GAACATACTGTTTTAATAAAAACCGAAAAAGAAGAAAAGAAGGTAACAGCTGAACGTATT 4 80  
E H | v L I K T E K E E K K V T A E R I  1 6 0
GTTATAGCTACTGGATCCAAACCGATTGAAATACCTTTAAAAAAATTAAATGATAATAAT 5 4  0
1 8 0
TTTAATGATGCTGATAATGTGAACGATATATTAGAATATGACCATGAAATAATACAAAAT 6 00
20 0
TCAGATGATATTTTAAATTTTAAAAAGGTTCCTCATAATATATCTATTATTGGAGGTGGT 6 6 0
2 2 0
GTTATAGGGTTAGAAATTGGATCTGTGTTTTCAAAACTTGGTTCTGATGTTACTGTATTT 7 2  0
2 4 0
GAATATAATGAAAGGTTATGTGGTTTTCTTGATGCTGATGTAAGTAAAGTTTTACAAAAA 7 80
2 6 0
ACATTAGAAAAAATAAAAATGAAATTTGTATTTAATACTTCAGTAATAGGTGGAAATATA 84  0 
T L E K I K M K F V F N T S V I G G N I  2 8 0
GAAAATAACCAAGCTGCTTTATTTGCTAAAAATAAAAAAACTAATGAAATAAAAAAAACA 9 0 0
E N N Q A A L F A K N K K T N E I K K T 3 0 0
ACATCAGAAATTGTACTTATATGTATTGGTAGGAAAGCTAACTTTGATAATTTAAATTTA 9 6 0  
T S E I V L I C I G R K A N F D N L N L  3 2 0
C ATTTACTTAATATAGAATTAAATAAAAATAAAAAAATACCTGTAGATGAATATTTTAAT 1 0 2  0
H L L N I E L N K N K K I P V D E Y F N 3 4 0
GTAAT AGCAC AACCAACTATTAAAGCAATTGGCGATGCTATAGATGGACCTATGTTGGCC 10  8 0
V I A Q P T I K A I G D A I D G P M L A 3 6 0
CATAAAGCAGAAGAAGAAGGATATTTATTAGCTAACATCTTATTTGATGAATTAAAAAAT 1 1 4  0
H K A E E E G Y L L A N I L F D E L K N 3 8 0
AATAAGAAAAAAAAAGCACATATAAATTATGACCTAGTTCCAAGTGTTATATATACACAT 1 2 0 0
N K K K K A H I N Y D L V P S V I Y T H 4 0 0
CCTGAGGTAGCTACTGTAGGATATAATGAAGCAAAATGTAAAGAACTCAATATGAATTTC 1 2 6 0  
P E V A T V G Y N E A K C K E L N M N F  4 2 0
AAATCAGTTAGTTTTCCCTTTGCTGCTAACAGTAGATCAAGGACAATTGATGATTATGAT 1 3 2 0
K S V S F P F A A N S R S R T I D D Y D 4 4 0
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GGACTCATAAAATTAATTGTAGAAAAAGATACTAACAGAATTTTAGGTTCTCAAATTATA 13 80  
G L I K L I V E K D T N R I L G S Q I I  4 6 0
GGAAATAATGCTAGTGATTTAATATTACCTTTGTCAATATATGTCGCTAATAATGGCTCA 1 4 4  0
G N N A S D L I L P L S  l Y V A N N G S 4 8 0
TCTAAAAGTCTGAGTAAAATTATATATGCGCATCCAACATTTTCAGAAGTAATCAAAGAA 1 5 0  0 
S K S L S K I I Y A H P T F S E V I K E  5 0 0
GTGGCTTTACAATCTTTTGATAAACCTATACACATGTAA 1 5 3  9
V A L Q S F D K P I H M *  5 1 3
F ig u re  4.4 -  LlpDH2B n u c le o tid e  an d  am in o  ac id  s e q u e n c e
The proposed cDNA sequence of LipDH2B following splicing of the potential intron is shown, 
with the deduced amino acid sequence shown underneath. Amino acid numbering includes the 
initiator methionine; the termination codon is marked with an asterisk. The amino acid residues 
highlighted are the predicted mitochondrial cleavage site (highlighted yellow), the start site of 
the recombinantly expressed protein (highlighted red) and the GFP-fusion sites (highlighted 
green) for LipDH2A (Thr143) and LipDH2B (Gly119).
Gene Chromosome Prediction Score" Cleavage site
LipDHl
LipDH2A
LipDH2B
8 Apicoplast
12 Mitochondrion
12 Mitochondrion
1.95 %' 
60.7%'
33^ *
n.d.
27'
T ab le  4.1 - S u b c e llu la r lo ca lisa tio n  p re d ic tio n s
Predictions for the presence of potential mitochondrial targeting sequences or the presence of a 
potential signal peptide and apicoplast transit peptide were performed using PlasMit, MitoProt, 
TargetP, SignalP and PlasmoAP (Claros etal., 1996; Nielsen etal., 1997; Emanuelsson O, 
2000; Bender et al., 2003; Foth et al., 2003) Bender et al., 2003; Foth et al., 2003)®. Prediction 
scores refer to PlasmoAP'^ and MitoProt' predictions. Cleavage site predictions were provided 
by Mitoprot' and SignalP*^.
-143 ~
Chapter 4. P/asmod/um fa/c/pamm possesses two distinct dihydrolipoamide dehydrogenase
4.2.2 Identification of conserved motifs
The identified amino acid sequences were further analysed by ClustalW alignment with 
LipDH proteins from other organisms to analyse the conserved motifs. Alignment of 
both P. falciparum LipDH amino acid sequences identified several regions of conserved 
motifs and residues, despite the low level of overall identity (20%) between the two 
full-length proteins. This low level of identity may be partially due to the presence o f a 
long N-terminal extension (the predicted bipartite plastid targeting sequence) in the 
LipDHl amino acid sequence, and the amino acid identity was increased to 24 % when 
the N-terminal sequence was omitted from the alignment.
The conserved motifs displayed in the alignment are characteristic of this class of 
disulphide oxidoreductases and include motifs for the binding of the FAD-cofactor and 
NADH, as well as residues important in catalysis such as active site cysteines and acid 
base catalysts (figure 4.5). The LipDH amino acid sequence can be separated into four 
domains in analogy with those identified in glutathione reductase (Thieme et a i,  1981; 
Argyrou et a l, 2004); the FAD-domain, the NADH-domain, the central domain and the 
interface domain (Toyoda et a l, 1998).
The FAD-domain is located at positions 2 0 -1 6 4  and 110-291 in the LipDH2 and 
LipDHl respectively. The FAD-domain contains a conserved motif (GXGXXG) for 
binding of the pyrophosphate moiety of FAD in part of a Rossman-like fold (Schierbeek 
et a l, 1989; Mattevi et al, 1991), and is located at positions 132-137 in the LipDHl and 
31-36 in the LipDH2 (highlighted blue in figure 4.5). The FAD-domain also contains 
the redox active cysteine motif (Thorpe et a l, 1976) that is present in a CV/LXGC 
motif that is located at positions 165-170 in the LipDHl and 63 -  68 in the LipDH2 
(highlighted yellow in figure 4.5).
The NADH-domain is located at positions 111 -4 3 5  and 165 -  295 in the LipDHl and 
LipDH2, respectively and contains a conserved dinucleotide-binding motif 
(GXGXIGXEXXXV/IXXXXG). This NADH-binding motif (Mattevi et a l, 1992; 
Bocanegra et a l, 1993; Brautigam et al., 2005) is located at positions 328 -  344 in 
LipDHl and 219 -  235 in LipDH2 (highlighted green in figure 4.5).
The central domain is located at positions 436 -  517 and 296 -  391 in LipDHl and 
LipDH2, respectively. This domain also contains further residues that are important for 
binding of the flavin co-factor.
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The interface domain is located at positions 518 -  667 and 392 -  513 in the LipDHl and 
LipDH2, respectively and is the site of dimérisation. The interface also contains the 
acid/base catalyst motif (HPTXXE) which is an essential component of the active site 
(Williams, 1976) and is located at positions 646 -  651 in LipDHl and 491 -  496 in the 
LipDH2 (highlighted red in figure 4.5).
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Figure 4.5 - CiustalW alignment of LipDH proteins
C lustalW  alignm ent of the deduced  of am ino acid seq u en ces  from P. falciparum LipDHl & 
LipDH2B, Homo sapiens (Human; P09622), Saccharomyces cerevisiae (Yeast; P09624), Pisum 
sativum m itochondrion (Pea; P41023) and  O ryza sa tiva chlorop last (Rice; NM_183915) are  
disp layed. The conserved  motifs for FAD binding (blue), NADH-binding (green), active site 
cys te ines (yellow) and acid b a se  ca ta lyst (red) are  highlighted. (*) Identical residues, (:) 
conserved  residues, (.) hom o logous residues.
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4.2.3 Both LipDH are expressed in erythrocytic stages
In order to test if both of the LipDH genes/proteins were expressed in the blood stages, I 
investigated their transcription and translation by reverse transcriptase PCR (RT-PCR) 
and western blot analyses,
RT-PCR analyses were earned out on total RNA isolated from erythrocytic stage 
parasites and confirmed the transcription of both LipDH g&ncs in these stages of the life 
cycle (figure 4.6) Negative controls that tested for the presence of genomic DNA in 
total RNA preparations were observed to be blank, suggesting that the bands amplified 
were exclusively from the isolated RNA. The presence of the predicted intron in 
LipDH2 was experimentally verified by DNA sequencing of the LipDH2 RT-PCR 
product, suggesting that LipDH2B was the protein expressed by the parasites (and not 
LipDH2A).
Protein expression analysis was carried out on parasite protein extracts by Western 
blotting using polyclonal antibodies raised against recombinantly expressed LipDH2 
(See section 4.2.6). This analysis identified a single band of an estimated size of 55 
kDa, which was in good agreement with the predicted mature LipDH2 size of 54 kDa 
(table 4.1). The protein expression of LipDHl was not analysed by western blotting, as 
polyclonal antibodies have not yet been raised against the recombinant LipDHl protein. 
The combined data fi’om the RT-PCR and western blot analyses confirmed that both 
LipDH were expressed during in the erythrocytic stages.
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F igure  4.6 -  E x p re ss io n  o f LipDH in e ry th ro c y tic  s ta g e s
The transcription of both LipDH g e n e s  in the erythrocytic s tag e s  of P. falciparum w as 
investiga ted by RT-PCR (Pane l A) and w estern blotting (Panel B). P an e i A disp lays the resu lts 
of RT-PCR on total RNA isolated from parasites, with PCR perform ed in the  p re sen ce  (+) or 
a b se n c e  (-) of reverse  transcrip tase. Both LipDH transcrip ts w ere amplified from the RNA and  
resu lted in products of 2 kb and 1.6 kb for LipDHl and LipDH2, respectively. The produc ts w ere 
verified by DNA sequencing and confirmed the p resen ce  of the pred icted intron in LipDH2. 
Sam p les amplified in the ab se n c e  of reverse  transcrip tase (-) w ere used  a s  nega tive controls, in 
order to te s t for genom ic DNA con tam ination in the RNA prepara tions. P an e i B disp lays the 
result of a  w estern blot with lOpg of parasite  protein ex trac t using polyclonal an tibodies raised 
agains t recombinantly ex p re ssed  LipDH2. The antibody reac ted  with a  protein of 56 kDa, which 
is in good agreem en t with the pred icted size  LipDH2 after the c leavage of the potential 
m itochondrial targeting seq u en ce .
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4.2.4 Confirming localisation with GFP-fusion proteins
The homology of the two LipDH proteins to different isoforms (plastid or 
mitochondrial) combined with the predicted subcellular localisations suggested that the 
LipDH proteins might be targeted to different organelles in the parasites. LipDHl 
displayed highest amino acid identity with plastid isoforms of LipDH (see section
4.2.1.1) and was predicted to be localised to the apicoplast (table 4.1), while LipDH2 
displayed highest amino acid sequence identity with mitochondrial isoforms (see 
section 4.2.1.2) and was predicted to be localised to the mitochondrion (table 4.1).
These predicted localisations were experimentally tested by fusing their respective N- 
terminal targeting sequences in frame with green fluorescent protein (GFP) and 
expressing the fusion protein in P. falciparum cells. Four constructs were designed to 
analyse the subcellular localisation of both LipDH, one for LipDHl and tliree for 
LipDH2. The reason that three constructs were necessary to investigate the subcellular i
localisation of LipDH2 was because of the presence of two possible translation 
initiation sites. 1 have already confirmed LipDH2B as being the correctly spliced 1
product of the LipDHl gene (see section 4.2.3), but wanted to investigate the 
localisation of an incorrectly spliced gene product that used the in-frame methionine 
that is located in the confirmed intron (LipDF12A). The four constructs designed were as 
follows:
1. The LipDHl fusion protein consisted of amino acids 1 -  120 in frame with the 
GFP ORF (highlighted green in figure 4.2).
2. LipDH2A was designed to use the in-frame methionine contained within the 
confirmed intron and consisted of the first 129 amino acids from the resultant 
protein (highlighted green in figure 4.4).
3. LipDH2B (C) used the methionine identified in exon 1, but was amplified from 
total RNA by RT-PCR and therefore lacked the predicted intron. This consisted 
of the first 119 amino acids from the LipDH2B protein (highlighted green in 
figure 4.4)
4. LipDH2B (G) used the methionine identified in exon 1, but was amplified from 
isolated genomic DNA and would contain the intron and both possible 
translation initiation sites.
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The inserts were amplified by PCR, cloned into the TOPO TA cloning vector and 
finally sub-cloned into P. falciparum transfection vector pHH2. Cloning into pHH2 was 
laborious due to the large size of the destination vector (7.3 kb), therefore positive 
pHH2 clones were initially identified by colony PCR to allow high throughput 
screening of clones (figure 4.7). Typically it was necessary to screen over a hundred 
colonies by colony PCR to identify a positive clone. Positive clones were verified by 
DNA sequencing and were transfected into P. falciparum under drug selection 
(WR99210) and parasites were observed in Giemsa stained blood smears between 6 and 
12 weeks following transfection.
A)
kb M l  2 3 4 5 6 7 8 9  10 11 12 1314
B) kb M
F igure  4.7 - C loning  of pHH2 tra n s fe c t io n  c o n s t ru c ts
P an e l A d isp lays an  exam p le of colony PCR screening for pHH2 LipDH l-GFP c lones. Lane M 
con tains 1kb ladder (Prom ega); Lanes 1 and 2 a re  negative controls; L anes 3 - 1 4  contain 
produc ts from co lonies sc reen ed  by colony PCR, with colony 11 identified a s  a  possib le positive 
c lone with the expected  product size  of 567 bp. P an e l B displays an  overview of pHH2-GFP 
fusion cons tructs digested  with Avril I Bgl II. Lane M con tains 1 kb ladder (Prom ega); Lane 1 
con tains the d igest of pHH2-LipDH1 displaying the 360 bp insert; Lane 2 con tains the pHH2- 
LipDH2A digest and disp lays the 387 bp insert; Lane 3 con tains the d igest of pHH2-LipDH2B 
(C) and disp lays the 357 bp insert; Lane 4 con tains the d igest of pHH2-LipDH2B (G) and 
disp lays the insert of 581 bp. Lanes 1 -  4 all contain a 7.3 kb band tha t corresponds to d igested  
pHH2.
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The suhcellulai' localisations of the GFP-fusion proteins were visualised in live parasites 
by fluorescent microscopy under lOOx magnification. Each image contains an 
erythrocyte containing a single parasite, whose mitochondrion was selectively stained 
using Mitotracker CMXRos (Molecular probes). Images of transfected parasites were 
taken in phase-contrast and using the fluorescent filters for rhodamine (excitation at 570 
nm and emission at 590 nm) and GFP (excitation at 488 nm and emission at 505-530 
nm) or FITC (excitation at 494 nm and emission at 518 nm).
The localisation of the LipDHl-GFP fusion protein was closely associated to the 
mitochondrial staining, but showed no clear co-localisation (figure 4.8). Analysis of the 
LipDHl-GFP fusion protein fluorescence through the ring (figure 4.8 A), trophozoite 
(figure 4.8B) and schizont (figure 4.8C) stages of the erythrocytic life cycle were 
consistent with those observed in previous studies using GFP fusions and immuno­
fluorescence analyses with known apicoplast markers (Foth et a l, 2003; Tonkin et al, 
2004; van Dooren et al, 2005).
In the ring stages of the parasite’s erythrocytic cycle (0 -1 5  hours following invasion) 
the apicoplast appears small, rounded and is closely associated with the mitochondrion 
(figure 4.8A). During the trophozoite stage the apicoplast elongates (15 -28  hours post­
invasion) and has few points of association with the elongated mitochondrion (figure 
4.8B). In the schizont stage (28 - 48 hours post-invasion) the apicoplast begins to 
branch and has many points of association with the branched mitochondrion, in a 
process which allows each resultant daughter merozoite to contain both an apicoplast 
and a mitochondrion (figure 4.8C). These images are duplicated and discussed further in 
a more in depth investigation into organelle development in chapter 5 (figure 5.16). 1
The three LipDH2-GFP fusion proteins all displayed mitochondrial localisation, as 
determined by the observed co-localisation of the GFP-fluorescence with that of the
Mitotracker (figure 4.9). The mitochondrial co-localisation of the LipDH2A-GFP fusion 
construct was extremely interesting, as it was not predicted to contain a mitochondrial
targeting peptide (table 4.1). However, the targeting of the LipDH2A-GFP fusion 
protein was less efficient than that observed for either LipDH2B construct, as revealed 
by the lower number of parasites that exhibited GFP-expression and mitochondrial co- 
staining (data not shown). Both the LipDH2B constructs display co-localisation with the 
elongated mitochondrion of trophozoite stage parasites. Both of these constructs were 
commonly co-localised with the mitochondrion and the majority of cells expressed
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GFP, unlike the situation in the LipDH2A-GFP fusion protein, further confirming that 
LipDH2B is the correct product of the LipDHl gene.
UVE GFP MTTO \ 1£R G £
A
B
Figure 4.8 - Subcellular localisation of LipDHl
The subcellular localisation of LipDHl w as Investigated by fusing the first 120 am ino acids in 
fram e with G FP and expressing the resulting protein in erythrocytic s tag e  P. falciparum. The 
p arasites mitochondrion w as selectively s tained with M itotracker CMXRos (m olecular probes) 
and im ages of live cells w ere ob tained using a  Z eiss Axioplan 2 m icroscope a t 100 x 
magnification. The parasites w ere ana lysed  using p h ase  con trast (LIVE), GFP/FITC (GFP) and 
rhodam ine (MITO) fluorescen t filters. Overlays of the im ages ob tained from each  channe l are  
disp layed for determ ination of co-localisation of the  two fluorescen t signa ls (MERGE). The 
f luorescence pattern is disp layed for ring (A), trophozoite (B), and schizon t (C) s ta g e s  in the 
erythrocytic cycle. The fluorescen t signa ls show  a  c lose associa tion but not c lear co-localisation 
throughou t the erythrocytic life cycle of the parasites.
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F igure  4.9 - S u b c e llu la r lo ca lisa tio n  o f LipDH2
The subcellular localisation of LipDH2 w as investigated using th ree different GFP-fusion 
proteins. P an e l A d isp lays the resu lts ob tained with the LipDH2A-GFP fusion protein. The 
LipDH2A-GFP fusion construct utilises the  in-frame methionine within the intron (highlighted 
green in figure 4.3B) and con tained the  first 129 am ino acids from LipDH2A (ana logous to 
Thr143 in LipDH2B; highlighted green in figure 4.4). Pane l B d isp lays the resu lts ob tained with 
the LipDH2B (C)-GFP fusion protein. The LipDH2B (C)-GFP fusion construct utilises the in­
fram e m ethionine identified a t the  start of exon 1 in the LipDH2B g ene  (highlighted light blue in 
figure 4.3B) and w as amplified from total RNA by RT-PCR. The construct therefore lacked the 
pred icted intron and con tained the first 119 am ino acids of the LipDH2B protein (highlighted in 
green in figure 4.4). P an e l C d isp lays the resu lts ob tained with the LipDH2B (G)-GFP fusion 
protein. The LipDH2B (G)-GFP fusion construct starts a t position 1 of LipDH2B and con tains the 
following 581 nucleo tides including the pred icted intron to allow the  parasites to “ch o o se” 
be tw een the potential start codon in the pred icted exon 1 or the potential start codon in the 
pred icted intron of the gene. The parasites mitochondrion w as selectively stained  with 
M itotracker CMXRos (molecular probes) and  im ages of live cells w ere ob tained using a  Z eiss 
Axioplan 2 m icroscope a t 100 x magnification. The parasites w ere ana ly sed  using p h ase  
con tras t (LIVE), GFP/FITC (GFP) and rhodam ine (MITO) fluorescen t filters. Overlays of the 
im ages ob tained from each  channe l are  disp layed for determ ination of co-localisation of the  two 
fluorescen t signa ls (MERGE). The fluorescence pa tterns are  disp layed for ring (A), trophozoite 
(B), and schizon t (C) s ta g e s  in the erythrocytic cycle. The fluorescen t signa ls for all three 
constructs display a  c lear co-localisation.
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4.2.5 Cloning of both LipDH for recombinant expression
Previous studies in our laboratory had identified that in order for soluble recombinant 
expression to occur in E. coli it was necessary to prepare recombinant expression 
constructs without the hydrophobic N-terminal targeting sequences.
The LipDHl expression construct was designed by utilising the LipDHl-GFP fusion 
protein to allow me to estimate the size of the mature protein. By immuno-precipitating 
the fusion protein with anti GFP-antibodies (AbCam), I could determine the 
approximate size of the mature protein and therefore the potential cleavage site of the 
bipartite signal/transit peptide. The full-length LipDHl-GFP fusion protein had a 
predicted molecular weight of 42 kDa and the GFP protein of 27 kDa (figure 4.10A); 
the mature LipDHl-GFP fusion protein isolated by immunoprécipitation was estimated 
to be 29 kDa (Lane 4; figure 4.1 OB). This mature protein size corresponded to a transit 
peptide cleavage site around amino acid 110 (highlighted red in figure 4.2). Therefore 
the construct for recombinant expression in E. coli was designed to be 1674 bp in length 
and ran from amino acid 111 -  667, which when cloned into pQE30 (a vector that 
attaches a Hisô-tag to the N-terminus of the protein) would result in a recombinant 
protein of 64 kDa.
The LipDH2 expression construct was designed taking into account the predicted 
cleavage site obtained from the sub-cellular predictions programs for the LipDH2B 
protein. These predictions suggested a mitochondrial targeting sequence cleavage site 
near the intron/exon 2 boundary (table 4.1). I therefore designed an expression construct 
from the start of exon 2 (figure 4.3B; highlighted red in figure 4.4) that was 1470 bp in 
length, encompassing amino acids 2 5 -5 1 3  (from the LipDH2B sequence) that, when 
cloned into pJC40 (a vector that attaches a Hism-tag to the N-terminus of the expressed 
protein) would produce an expressed protein of 57 kDa.
Both expression constructs were amplified by PCR, cloned into TOPO and sub-cloned 
into their relevant expression plasmid (figure 4.11).
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F igure  4.10 - Im m u n o p réc ip ita tio n  o f LipDH l G F P -fusion  p ro te in
The possib le size of the  m a ture LipDH l, following cleaving of the signal peptide and transit 
peptide w as de term ined by immunoprécipitation of the LipDHl GFP-fusion protein. P an e l A 
d isp lays a schem a tic  overview of the 42 kDa fusion protein tha t w as genera ted  by the pHH2 
LipDH l-GFP transfec ted  parasites. This consisted  of the 27 kDa G FP protein, fused with the 15 
kDa LipDHl N-term inal section (amino acids 1 -  120). P ane l B d isp lays the 
immunoprécipitation experim en t w here pro teins ex trac ted from parasites (lane 1) w ere initially 
pre-cleared in protein A sep h a ro se  CL-4B b ead s (without an tibodies bound) to rem ove any 
unspecific binding (lane 2). The lysa te w as then incubated in b ead s (with anti G FP an tibodies 
bound) and sam p les being sep ara ted  into flow through fractions (lane 3) and the  elution fraction 
(lane 4). All fractions w ere run on SDS-PAGE for w estern blotting with anti G FP an tibodies; 
Lane M con tains M agicmark protein s tan d ard s (Invitrogen). M ature length G FP fusion pro te ins 
(with N-term inal signal/transit peptides c leaved) can be observed in both lysate (Lane 1) and 
elution (Lane 4) fractions, and w as estim a ted  to be 29 kDa in size; no full-length (42 kDa) 
pro te ins w ere observed  in the w estern blots.
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F igure  4.11 - C loning of PfLlpDH fo r re c o m b in a n t  e x p re s s io n
Both LipDH g e n e s  w ere amplified from gDNA using Taq superm ix (Invitrogen) and specific 
o ligonucleo tides (table 2.1). P an e l A d isp lays an overview of the cloning of LipDHI for 
recom binan t expression. The amplified PGR product w as initially cloned into the TORO TA PGR 
cloning vector for seq u en ce  verification before being sub-cloned into the recom binan t 
expression vector pQE30. Lane 1 con tains 10 pi Ikb  DNA ladder (Prom ega); lane 2 con tains 
the  1.7 kb PGR product of LipDH1\ lane 3 con tains the  Bam HI / Hind III d igest of the TORO TA 
clone used  for sub-cloning which resu lted in a  3.5 kb band corresponding to the pG R 2 .1 -T 0 P 0  
vector and a 1.7 kb band corresponding to LipDHI] lane 4 con tains a Bam HI / Hind III d igest of 
the pQE30 recom binan t expression c lone and  resu lted in a  3.5 kb band corresponding to the 
pQE30 vec tor and a 1.7 kb band corresponding to LipDHI. P ane l B d isp lays an overview of the 
cloning of LipDH2 for recom binan t expression. The amplified PGR produc t w as initially cloned 
into the  TOPO TA PGR cloning vector for seq u en ce  verification before being for sub-c loned into 
the recom binan t expression vector pJG40. Lane 1 con tains 10 pi Ikb  DNA ladder (Prom ega); 
lane 2 con tains the 1.5 kb PGR product of LipDH2] lane 3 con tains the Nde I / Xho I d igest of 
the TOPO TA clone used  for sub-cloning which resu lted in a  3.5 kb band corresponding to the 
pG R 2 .1 -T 0 P 0  vector and a 1.5 kb band corresponding to LipDH2] lane 4 con tains a  Nde I / 
Xho I d igest of the pJG40 recom binan t expression c lone and resu lted in a  2.4 kb band 
corresponding to the pJG40 vec tor and a 1.5 kb band corresponding to LipDH2.
-156
Chapter 4. P/asmod/um /a/c/pamm possesses two distinct dihydrolipoamide dehydrogenase
4.2.6 Recombinant expression and purification of both PfLipDH
4.2.6. 1 Recombinant expression of PfLipDH
In order to maximise parameters for the expression of both LipDH proteins, test 
expressions were set up to analyse the E. coli strains and temperatures following 
induction that led to the best expression levels. The use of terrific broth (TB) allowed 
the bacterial expression clones to grow to higher densities, therefore producing more 
recombinant protein.
The highest levels of expressions in LipDHI test expressions were observed in E. coli 
strain Novablue (Novagen) in TB/Amp with expression induced with ImM IPTG 
during mid-log phase and an overnight incubation at 30°C, 200 rpm (data not shown).
Although test expressions of LipDH2 initially suggested that no expression had 
occurred, it was later discovered that expression of LipDH2 was below the levels of 
detection for this method (see section 2.2.5). Larger scale expressions were required and 
LipDH2 expression analysed by purifying protein from these test expressions. The 
parameters determined to be optimal for LipDH2 were expression in temfic broth with 
E, coli strain BL21 (DE3) RIL with ImM IPTG induction during mid-log phase and 
overnight expression at 37°C, 200 rpm (data not shown).
Large-scale expressions were then performed using the optimal conditions identified 
during the test expressions, to express sufficient recombinant proteins for 
characterisation of both LipDH proteins. The next section presents the purification of 
recombinant proteins from these large-scale expressions.
4.2.6. 2____ Purification of PfLipDH
The vectors used for the expression of both LipDH attach N-terminal His-tags to the 
recombinant proteins allowing purification using Ni-NTA affinity chromatography. 
Initial purification of both LipDH was carried out by batch purification using Ni-NTA 
agarose.
LipDHI was purified to 95% homogeneity by the Ni-NTA batch purification process, 
with the purification process and pmity of recombinant LipDHI being analysed by 
SDS-PAGE (figure 4.12A). Expression levels of LipDHI was in the range of 1-2 mg of
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purified pro tein per IL  E.coli expression, although purified L ipD H I was found unstab le
w ith  storage (greater than two weeks) at 4°C and m ay be susceptible to proteolysis.
-1 5 8 -
LipDH2 was further purified after batch purification (following dialysis) by Ni-NTA 
affinity chromatography utilising an ÂKTA FPLC (Amersham biosciences) to elute 
proteins across a linear gradient of imidazole (10 -  500 mM), with the LipDH2 protein
-H'eluting between 400 - 500 mM imidazole (figure 4.12C). The purification process and f
■ipurity of LipDH2 was analysed by SDS-PAGE (figuie 4.12B). Expression levels of 
LipDH2 were extremely low, with 100 pg LipDH2 purified from a IL E. coli n
expression.
IPurification and activity levels of both LipDH proteins were found to be increased by 
the addition of 100 pM FAD (Sigma) to the haivested E. coli pellets. This addition 
increased the yield of enzymatically active LipDH2 from 57% to 87%, based on a  ;ïcomparison of the total protein (observed at 280 nm) to that of FAD containing protein J
(observed at 460 nm).
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F igure  4.12 - P urifica tion  o f reco m b in an tiy  e x p re s s e d  PfLipDH
Both LipDH pro teins w ere purified from soluble E. coli extrac t by Ni-NTA affinity 
chrom a tography. P an e l A d isp lays an  overview of the batch purification of LipDHI, run on 15 % 
SDS-PAGE and stained with C oom assie  stain. The gel displays the B enchm ark protein ladder 
(Lane M; Invitrogen) and lOpg of the  so lub le E. co//fraction (Lane 1), insoluble E. co//fraction 
(Lane 2), Ni-NTA b ead s  flow through fraction (lane 3) and elution fraction (Lane 4). The elution 
fraction con tains a  main band of 64 kDa tha t is in good agreem en t with the pred icted size  of the 
recom binan t LipDHI protein. P an e l B d isp lays an  overview of the tw o-step Ni-NTA batch and 
FPLC purification of LipDH2, run on 4 -1 2  % SDS-PAGE and stained with C oom assie  stain. 
The gel w as loaded with lOpg of the insoluble E. coli fraction (Lane 1), so lub le E. coli fraction 
(Lane 2), batch purification elution fraction (Lane 3) and elution fraction from FPLC purification 
(Lane 4); Lane M con tains B enchm ark protein s tandards (Invitrogen). P an e l C d isp lays the 
FPLC purification of LipDH2 following d ialysis of the batch binding elution. T he sam p le  (lane 3 
in panel B) w as loaded onto a  1 ml HiTRAP Ni-chelating column (Am ersham  pharm acia) and 
w as run on an ÂKTA purifier FPLC (A m ersham  pharm acia) to e lute the recom binan t protein 
over a  linear range be tw een 10 mM and 500 mM imidazole. R ecom binan t LipDH2 w as e luted 
be tw een 450 -  500 mM Imidazole (small peak eluted after 16 ml), and the purified protein w as 
ana ly sed  on SDS-PAGE (lane 4 in pane l B).
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4.2.7 Characterisation of LipDH
In order to confirm that the recombinantiy expressed proteins were functional as 
LipDH, I analysed their oligomeric state, spectral properties, kinetic parameters and 
catalytic mechanism.
4.2.7.1 Analyses of oligomeric state
The oligomeric state of both LipDH was studied in order to confiim whether or not they 
formed homodimers. Purified samples of LipDHI and LipDH2 were separated 
according to molecular weight by applying to gel filtration chromatography columns 
(either Sephadex S200 16/60 or Superose 6 10/30). The columns were also calibrated 
with molecular weight markers (Biorad), and the resulting calibration curve allowed the 
calculation of the molecular size of the recombinant proteins (insets in figure 4.13).
The gel filtration of LipDHI produced two observed peaks; the first peak eluted after 46 
ml and the second after 74 ml (figure 4.13 A), The first peak corresponded to the void 
volume of the column and presumably consisted of large multimers or precipitated 
protein, while the second peak (which contained the majority of the protein) had a 
calculated molecular weight of 126 kDa. This second peak was close to the expected 
size for a homodimeric LipDHI protein (130 kDa including the Hisg tag), confirming 
that LipDHI was likely to form homodimers.
The gel filtration of LipDH2 produced one major peak that eluted after 14.5 ml. This 
elution volume coiTesponded to a calculated molecular weight of LipDH2 of 77.6 kDa, 
unfortunately this lay between the sizes expected for monomeric (57 kDa) and 
homodimeric (114 kDa) proteins.
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Figure 4.13 - Oligomeric state analyses of recombinant LipDH
The oligomeric s ta te  of both purified LipDH pro teins w as ana lysed by either gel filtration. Panel 
A disp lays the gel filtration elution of 1.5 mg of purified LipDHI on a  S ephadex  820 0  16/60 size 
exclusion column. The inse t d isp lays the calibration curve for the column b ased  on the elution 
vo lum es of protein s tan d ard s (Filled circles; Biorad) with the position of the  eluted LipDHI 
protein (Open circle). Panel B d isp lays the  gel filtration elution of 300 pg of purified LipDH2 on a  
S u p ero se  6 10/30 size exclusion column. The inset d isp lays the calibration curve b ased  on the 
elution vo lum es of protein s tan d ard s (Filled circles; Biorad) with the position of the eluted 
LipDH2 protein (Open circle).
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4.2.7.2 Spectral properties of PfLipDH
The spectral properties of the purified proteins were analysed in order to confirm their 
role as active LipDH (figure 4.14). Both proteins were purified in the oxidised form and 
displayed characteristic spectra of flavoprotein disulphide oxidoreductases (Ghisla et 
al., 1974). The peak observed at 460 nm along with the shoulders at 430 nm and 480 
nm are consistent with the presence of a bound flavin adenine dinucleotide (FAD) 
cofactor.
The absorption spectra of the purified proteins change following reduction with 20 
molar equivalents of NADH (figure 4.14; line 2). The maximum at 460 nm decreases in 
absorbance and shifts to a shorter wavelength (approximately 450 nm), which is 
consistent with reduction of the FAD prosthetic group. Another peak in the reduced 
spectra is centred around 530 nm and is due to the formation of a charge transfer 
complex between the FAD and a thiolate formed on one of the active site cysteine 
residues. Both of these spectral features are consistent with those observed for other 
members of the disulphide oxidoreductases (Ghisla et al, 1974; Thorpe et a l, 1976). 
The large absorption increase at shorter wavelengths, which has a maximum centred at 
340 nm (off scale, figure 4.14) was due to the presence of excess NADH used as the 
reductant. The lower level of flavin reduction and thiolate-flavin charge transfer 
observed in reduced LipDHI (figure 4.14A; line 2) than that observed in reduced 
LipDH2 (figure 4.14B; line 2), was due to rapid re-oxidation of the flavin by oxygen. 
Ideally this experiment should have been performed under anaerobic conditions.
162
Chapter 4. P/asmod/um fa/c/paa/m possesses two distinct dihydrolipoamide dehydrogenase
Ê.a3
S
II
0.15
0.10
0.05
0
0.25
0.20
0.15
0.10
0.05
0
300 400 500 600 700
Wavelength (nm)
F ig u re  4 .14 - O x id ised  an d  re d u c e d  s p e c t ra  o f PfLipDH
Purified PfLipDH was analysed spectrally between 300 nm and 700 nm using a UV-2501 PC 
spectrophotometer (Shimadzu). Purified recombinant protein were analysed in the oxidised 
state (line 1) and reduced state (line 2); following reduction with a 20 molar excess (NADH/FAD) 
of NADH under aerobic conditions. P an e l A displays spectra for 11 pM LipDH2.; P an e l B, 
displays spectra for 21.8 pM LipDHI
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Chapter 4. P/asmod/um fa/c/pan:/m possesses two distinct dihydrolipoamide dehydrogenase
4.2.7. 3____ Kinetic analyses of LipDHI
In order to confirm that LipDHI was enzymatically active, I tested the recombinant 
protein with LipDH-specific substrates. Before kinetic analyses could be carried out I 
verified the pH-optimum for the LipDHI reverse reaction. Analyses of the activity of 
LipDHI between pH 7.0 and pH 8.0 revealed a broad shoulder with a peak at 
approximately pH 7.6 (data not shown). LipDHI displayed Michaelis-Menten kinetics 
for both substrates that lead to K„i app of 15.5 ± 3.0 |aM and Km app 1211 +
260 pM (figure 4.15). The calculated apparent kcat was determined to be between 27.3 
and 37.1 s'  ^ (table 4.2).
4.2.7. 4____ Kinetic analyses of LipDH2
In order to confirm that LipDH2 was enzymatically active 1 tested the recombinant 
protein with LipDH-specific substrates. Before in depth kinetic analyses could be 
caiTied out on LipDH2 it was necessary to determine the pH-profiles for both the 
forward (physiological) and reverse reactions (non-physiological). The forward reaction 
enzymatic activity was maximal at pH 9.0 and the reverse reaction enzymatic activity 
was maximal at pH 7.0.
The kinetic parameters of the LipDH2 forward reaction were determined using stopped
flow fast kinetics to measure initial rates as the reaction was inhibited by NADH 
(Sahlman et a l, 1989). The apparent Km values for both substrates (dihydrolipoamide 
and NAD"^) and the apparent kcat were calculated for the forward reaction at pH 8.0 and
25^C; pH 8.0 was used to minimise the spontaneous oxidation of dihydrolipoamide
.observed at pH 9.0 (Reed et a l, 1958). The apparent kcat was calculated to be between 
135.5 and 337 s'  ^ (depending on enzyme preparation), the apparent was
146 ±15 pM and the apparent Km '^^^^ was 450 ± 30 pM (figure 4.16; table 4.2).
The pH-optimum determined (pH 7.0) for the reverse reaction was used in all activity 
and kinetic studies of this reaction. The assay measured the oxidation of NADH at 340 
nm using stopped flow fast kinetics. The apparent Km for both substrates (NADH and 
lipoamide) and the kcat were calculated for the reverse reaction at 25“C. The apparent 
kcat was calculated to be 448 s '’ and the Km app and Km app were 20.8 ±5.6
pM and 870 ± 270 pM, respectively (figure 4.17 and table 4.2).
I
- 1 6 4 -
Chapter 4. Pfasmodfum fa/cfpaa/m possesses two distinct dihydrolipoamide dehydrogenase 
The catalytic mechanism of LipDH2 was investigated using the reverse reaction. By 
measuring enzyme activity over a range of lipoamide concentrations (between 0.5 and 2 
mM) at three NADH concentrations (10, 20 and 40 pM) it is possible to deteimine the 
enzyme mechanism of LipDH2. A Lineweaver-Burk (double reciprocal) plot of the 
resultant activities produces data that can be fitted with parallel lines, suggesting that 
LipDH2 acts through a ping-pong mechanism (figure 4.18; in a sequential reaction these 
lines will converge on a single point). In a ping-pong mechanism a reduced substrate (in 
this case NADH) must first bind and reduce the enzyme before the second substrate (in 
this case lipoamide) can bind and oxidise the enzyme. Further analysis of the data from 
this experiment allowed me to calculate the true Km for both substrates. The calculated 
is 28 ± 4 nM, is 1,720 ± 230 nM (table 4.2).
LipDHI LipDH2 H. sapiens^^
pH optimum (forward) n.d. pH 9.0 n.d.
pH optimum (reverse) pH 7.6 pH 7.0 n.d.
Km app NAD n.d. 0.45 ± 0.03 mM 0.29 mM
Km app NADH 15.5 ± 3.0 qM 20.8 ± 5.6 pM n.d.
Km NADH n.d. 28 ± 4 pM 51 pM
Km app Lipoamide 1.21 ± 0.26 mM 0.87 ± 0.27 mM n.d.
Km Lipoamide n.d. 1.72 ±0.23 mM 1.01 mM
Km app Dihydrolipoamide n.d. 146 ±15 pM 570 pM
kcat forward n.d. 135.5-337.0 s'*’’ 382 s"’
kcat reverse 27.3-37 .1  s '“ 448 s"' 167 s’’
Table 4.2 - Kinetic parameters of LipDH
Overview o f the determined kinetic parameters for both LipDH proteins, compared to those of 
the human mitochondrial isoform. ® Kinetic data for the Human LipDH was taken from Kim e t al 
1991 and are true Km. The kcat determined for the LipDH2 forward reaction was dependent on 
the enzyme preparation and the assay system used. The kcat determined for the LipDHI 
forward reaction was dependent on the parameters o f the reaction used to determine it. n.d. 
parameter was not determined.
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F ig u re  4 .15 -  D eterm in ing  th e  k ine tic  p a ra m e te rs  o f th e  LipDHI re v e rse  reac tio n
T he kinetic param e te rs of the LipDHI reverse  reaction w ere determ ined a t 25 °C in 50 mM 
po tassium  phospha te , 1 mM EDTA pH 7.6. The a ssa y  w as followed a t 340 nm for the oxidation 
of NADH using the extinction coefficient of 6220 M'  ^ c m '\  Each point rep re sen ts  the m ean  + 
s tandard  error for 2 to 3 independen t m easurem en ts, with apparen t Km and Vmax de term ined 
using the Graf it 5.0 softw are {Erithacus software). P an e l A d isp lays the  M ichaelis-M enten plot 
of LipDHI reverse  reaction for lipoamide. The reaction mixture con tained sa tura ting levels of 
NADH (200pM) and variab le concen tra tions of lipoamide (50 pM to 4 mM). P an e l A in se t  
d isp lays the  Lineweaver-Burk (Double reciprocal) plot of the da ta. The apparen t Km and 
the Vmax of LipDHI w ere de term ined to be 1210 ± 260 pM and 37.1 units m g"\ respectively. 
P an e l B d isp lays the  M ichaelis-M enten plot of the LipDHI reverse  reaction for NADH. The 
reaction mixture con tained 2 mM lipoamide and  variab le concen tra tions of NADH (5 pM to 
200pM ) lipoamide. P an e l B in se t  d isp lays the Lineweaver-Burk (Double reciprocal) plot of the 
d a ta  ob tained. The apparen t Km and the Vmax of LipDHI w ere de term ined to be 15.5 ± 3.0 
pM and 27.3 units m g '\  respectively.
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F ig u re  4.16 -  D eterm in ing  th e  k ine tic  p a ra m e te rs  o f th e  LipDH2 fo rw ard  reac tio n
The kinetic param e te rs of the LipDH2 forward reaction w ere de term ined a t 25°C in 50 mM 
po tassium  phospha te , 1 mM EDTA pH 8.0. T he activity of 1 pg of recom binantiy ex p ressed  
LipDH2 w as followed a t 340 nm for the reduction of NAD^ using the  extinction coefficient of 
6220 M"^  c m '\  Each point rep resen ts the m ean ± s tandard  error for 3 to 5 independen t 
m easu rem en ts, with apparen t Km and Vmax determ ined using the Graf it 5.0 software 
(Erithacus software). P an e l A d isp lays the  M ichaelis-M enten plot of LipDH2 forward reaction for 
dihydrolipoamide. The reaction mixture con tained 2 mM NAD"" and variab le concen tra tions of 
dihydrolipoamide (50 pM to 2mM). P an e l A in se t  displays the Lineweaver-Burk (Double 
reciprocal) plot of the  da ta  ob tained. T he apparen t Km and the Vmax of LipDH2 w ere
de term ined to be 146 ± 15pM and 240 ± 6 units m g '\  respectively. P an e l B d isp lays the 
M ichaelis-M enten plot of the  LipDH2 forward reaction for NAD^. The reaction mixture con tained 
sa tura ting levels of dihydrolipoamide (2mM) and variable concen tra tions of NAD'’ (62.5pM to 
2mM). P an e l B in se t  d isp lays the  Lineweaver-Burk (Double reciprocal) plot of the da ta  
ob tained. The apparen t Km and the Vmax of LipDH2 w ere de term ined to be 450 ± SOpM and 
368 ± 8 units m g"\ respectively.
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F igure  4.17 -  D eterm in ing  th e  k ine tic  p a ra m e te rs  o f th e  LipDH2 re v e rs e  re a c tio n
The kinetic param e te rs of the LipDH2 reverse  reaction w ere determ ined a t 25 °C in 50 mM 
po tassium  phospha te , 1 mM EDTA pH 7.0. The activity of 1 pg of recom binantiy ex p ressed  
LipDH2 w as followed a t 340 nm for the oxidation of NADH using the extinction coefficient of 
6220 M'  ^ cm \  Each point rep resen ts the  m ean  ± s tandard  error for 3 to 5 independen t 
m easu rem en ts, with apparen t Km and Vmax de term ined using the  Graf it 5.0 software 
(Erithacus software). P an e l A d isp lays the  M ichaelis-M enten plot of LipDH2 reverse  reaction for 
lipoamide. The reaction mixture con tained sa tura ting levels of NADH (200pM) and variab le 
concen tra tions of lipoamide (50 pM to 2 mM) lipoamide. P ane l A in se t  d isp lays the  Lineweaver- 
Burk (Double reciprocal) plot of the da ta  ob tained. The apparen t and the Vmax of
LipDH2 w ere de term ined to be 870 ± 270pM  and 351 ± 50 units m g '\  repectively. P an e l B 
d isp lays the  M ichaelis-M enten plot of the LipDH2 reverse  reaction for NADH. The reaction 
mixture con tained 2 mM lipoamide and variab le concen tra tions of NADH (10 pM to 200pM). 
P an e l B In se t d isp lays the  Lineweaver-Burk (Double reciprocal) plot of the da ta  ob tained. The 
apparen t Km and the  Vmax of LipDH2 w ere de term ined to be 20.8 ± 5.6pM and 181 + 11 
units mg'^ units m g '\  respectively.
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The catalytic mechanism of LipDH2 was analysed using the reverse reaction. Specific activities 
were measured for a range of lipoamide concentrations (between 0.5 and 2 mM) at three NADH 
concentrations (o 10 pM; # 20 pM; □ 40 pM), in all combinations. The kinetic data determined 
was in good agreement with those observed in previous experiments (table 4.2, figures 4.16 & 
4.17), with determined as 1.72 ± 0.23 mM and was estimated to be 28 ± 4 pM.
The calculated Vmax of LipDH2 was 489 ± 45 units mg'V
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Both P. falciparum proteins exhibited N-terminal extensions that contained targeting 
peptides required for targeting to their respective organelles. The P. falciparum  LipDHI 
amino acid sequence contained a bipartite signal/transit peptide, in which the 
hydrophobic signal peptide was responsible for placing the protein into the secretory
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4.3 Discussion
4.3.1 P. falciparum  possess two distinct LipDH  genes
The completion of the Plasmodium falciparum  genome sequencing project has provided 
researchers with a large number of resources to aid their research of this human parasite 
Cwww.Dlasmodb.orsT Using these resources I have identified and characterised two 
genes that encode LipDH proteins in the P. falciparum genome. The presence of two 
LipDH  in the P. falciparum  genome is in contrast to the single ZzpD//identified 
in the genome of the human host.
One of these genes {LipDHI) was found to contain an intron at its 5’ end separating two 
exons; the first of which contained the predicted mitochondrial targeting sequence. 
Analyses of the P. falciparum  genome displayed that 53.9 % of predicted genes 
contained introns and that the predicted intron sequences displayed a higher A/T content 
(86.5 %) than exon (76.3 %) sequences (Gardner et a l, 2002). This higher A/T content 
of introns was also observed in the LipDH2B gene and was further confirmed in a 
recent study into the splice sites from P. falciparum. This study identified that the 
parasites use the canonical GT-AG boundaries with a high preference for A/T rich 
sequences in the intervening intronic sequences (Szafranski et a l, 2005).
4.3.2 P. falciparum  LipDH proteins are organelle specific
The predicted LipDH proteins displayed greatest homology to different LipDH isofoims
(mitochondrial or plastid), suggesting that the proteins were organelle specific. This
theory was further strengthened by detailed phylogenetic analysis of both LipDH
proteins with those from other species (Foth et al, 2005). This study confirmed that the
LipDHI was grouped with other plastid isoforms and those of Cyanobacteria, while the 
.LipDH2 was grouped with mitochondrial isoforms and those of a-protobacteria (Foth et 
al, 2005). This suggested that these nuclear encoded genes arose by lateral gene 
transfer from the endosymbionts that were the origins of these organelles (Maitin et al, 
1998; Zhu et a l, 2002; Adams et a l, 2003).
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system (via the endoplasmic reticulum) and the transit peptide was responsible for the 
transport of the protein into the apicoplast. The features of the bipartite signal/transit 
peptide have been investigated in depth and have led to the production of the subcellular 
localisation prediction programs used in this study (Nielsen et aA, 1997; Emanuelsson 
O, 2000; Foth et a i, 2003). The P. falciparum LipDH2 protein contained a 
mitochondrial targeting peptide, which was consistent with studies into mitochondrial 
targeting sequences for Plasmodium (Bender et al, 2003) and other species (Claros et 
al, 1996).
I have experimentally determined that LipDHI is localised in the apicoplast and that 
LipDH2 is localised in the mitochondrion and these subcellular localisations have also 
been confirmed independently in another lab (using both GFP-fusion protein and 
immuno-fluorescence analyses; Foth & McFadden personal communication). However, 
the localisation of the LipDH2A-GFP fusion protein (which was predicted not to 
contain a targeting peptide) to the mitochondrion identified the possibility that further 
signals may be responsible for transfer of proteins to this organelle. This was consistent 
with previous studies that have identified mitochondrial-localised proteins that lack the 
classical N-terminal targeting peptide (Stan et al, 2003). In these cases internal 
targeting sequences have been proposed to be sufficient for mitochondrial localisation 
(Planner et a l, 1987; Truscott et a l, 2001).
The obseiwed organelle specific subcellular localisations of the P. falciparum LipDH 
proteins was reminiscent of the situation in plants, where cells contain both 
mitochondria and plastids. In Pisum sativum (Pea plant) two LipDH proteins have been 
identified, one of which is located in the mitochondrion and the other in the plastid. The 
P. sativum mitochondrial LipDH is shared between the mitochondrial KADH 
(Bourguignon et al, 1996), while the P. sativum plastid LipDH is a component of the 
plastid PDH (Conner et a l, 1996). However, the situation is complicated in Arabidopsis 
thaliana, by the presence of two mitochondrial and two plastid LipDH isoforms 
(Lutziger et a l, 2000; Lutziger et a l, 2001). Gene knockout studies demonstrated that 
one mitochondrial LipDH was able to substitute for the loss of the other, suggesting that 
the two mitochondrial LipDH can be shared between the mitochondrial KADH 
(Lutziger et a l, 2001). The two plastid LipDH isoforms identified in the A. thaliana 
genome have 81% amino acid sequence identity and their subcellular localisation was 
confirmed by chloroplast import assays (Lutziger et al, 2000). The predicted 
localisation of organelle-specific LipDH proteins would suggest that there are likely to 
be KADH located in both organelles (Johnston et al, 1997; Lutziger et a l, 2000). The
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localisation o f  KA DH and the consequences o f  their distribu tion w ill be investigated
and discussed in detail in  chap ter 5.
4.3.3 Recombinantiy expressed PfLipDH are active
Both LipDH from P. falciparum were recombinantiy expressed and displayed 
enzymatic activity using LipDH-specific substrates. The kcat of the LipDHI reverse 
reaction was determined to be more than ten fold lower than that of the LipDH2. The 
lower specific activity of the plastid LipDH when compared to its mitochondrial 
counterpart was analogous to the situation obseived in Pisum sativum (pea plant), where 
the plastid LipDH has a 5 fold lower specific activity to that of the mitochondrial 
LipDH (Conner et al, 1996). The pea plastid LipDH also displayed a 7 fold higher 
affinity for NAD"  ^than its mitochondrial isofomi (G. Lindsay, personal 
communication). The steady state kinetic parameters determined for both LipDH were 
in good agreement with those determined previously for LipDH from other organisms 
(Kim et al, 1991; Else et a l, 1994; Schoneck et al, 1997; Argyrou et al, 2001) and the 
inhibition of LipDH2 by NADH that was observed in the forward reaction, has also 
been reported previously (Sahlman et a l, 1989).
The apparent instability displayed in the recombinantiy expressed LipDHI suggests that 
this recombinant protein may be susceptible to proteolysis. The correct folding of these 
proteins is essential for catalysis and this was confirmed by the findings of Lindsay et 
al„ where they displayed that FAD-binding was essential for the correct folding of 
denatured LipDH and enzymatic activity (Lindsay et al, 2000). Further analyses of the 
mature forms of both P. falciparum  LipDH would perhaps allow for more stable protein 
expression; this may be achieved by Edman sequencing (N-terminal sequencing) or 
tryptic digestion of immuno-precipitated GFP-fusion proteins, and could be tested by 
circular dicliroism of the recombinant proteins. Re-cloning of the both LipDH 
constructs into a different expression system, perhaps using a C-terminal His-tag or a 
Streptavidin-tag, may also result in higher levels of protein expression.
Other factors important for LipDH-activity could be analysed from the mutations 
observed in patients displaying LipDH-deficiency, which leads to numerous clinical 
symptoms including lactic acidosis, neurological dysfunctions and maple syrup urine 
disease (Liu et a l, 1993; Hong et al, 1996; Hong et al, 1997; Shany et al, 1999; Cerna 
et a l, 2001; Grafakou et a l, 2003). Ten of the mutations that caused LipDH deficiency 
were investigated in the crystal structure of the human LipDH, with nine of them
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observed to cluster in three areas; the homodimer interface, the FAD and NAD^ binding 
sites and the disulphide interface (Brautigam et al, 2005); the other produced a 
nonsense mutation that truncated the human LipDH protein at tyrosine 35 (Hong et al, 
1996).
The clinical manifestations of LipDH-deficiency result from a decrease in activity of the 
KADH, with maple syrup urine disease the product of an accumulation of branched 
chain a-keto acids brought about by the loss of BCKADH activity (Kuhara et a l,
1983). As an essential component of the a-keto acid dehydrogenase complexes, LipDH 
plays an important role in the biochemistry of the parasites during their erythrocytic 
stages. Although the main roles of KADH in these stages will be fmther discussed in 
chapter 5, it has also been suggested that LipDH/KADH may also interact with other 
pathways.
Indeed, LipDH has been shown to act with one of the major antioxidant systems in the 
human pathogen Mycobacterium tuberculosis. This interaction has been determined to 
involve a LipDH (Lpd), an acetyl transferase (DlaT), a thioredoxin-like protein (AhpD) 
and a peroxiredoxin-like protein (AhpC) and results in the NADH-specific reduction of 
hydroperoxides and peroxynitrite (Bryk et a l, 2002; Koshkin et a l, 2004; Tian et al, 
2005). The LipDH transfers reducing equivalents, via the protein bound lipoamide, to 
the AhpD and onto the AhpC, in a system analogous with the thioredoxin cascade 
(figure 4.19).
The presence of an antioxidant function in the Plasmodium mitochondrion would be 
required, because of the presence of an active electron transport chain that may produce 
reactive oxygen species (Krungkiai, 2004; Uyemura et a l, 2004). A mitochondrially 
localised superoxide dismutase has already been identified (Sienkiewicz et a l, 2004), 
that could produce hydrogen peroxide (H2O2) from superoxide (O2"). 
Immunofluorescence studies have recently identified a mitochondrially localised 
thioredoxin peroxidase (Yano et a l, 2005) and a possible mitochondrial thioredoxin has 
been proposed (Muller, 2004), which may be involved in a peroxiredoxin linked 
antioxidant system similar to those identified in humans and yeast (Miranda-Vizuete et 
al, 2000). No mitochondrially localised thioredoxin reductase (homologous to those 
identified in mammals) has yet been identified, suggesting that the LipDH/KADH 
antioxidant function may play an important role in the mitochondrion. Work is ongoing 
in our laboratory to try and identify possible proteins involved in antioxidant functions 
in the parasites organelles.
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In addition to acting on protein bound lipoamide, LipDH may also use free lipoic acid 
as a substrate. Although the level of free lipoic acid is usually extremely low, 
exogenous stressing of the parasites with hydrogen peroxide resulted in a 10-fold 
increase in protein bound lipoic acid and equivalent levels of free lipoic acid (T. Smith 
and S. Müller, unpublished data). Many studies have identified the antioxidant functions 
of both the oxidised and reduced forms of lipoic acid. The oxidised form (lipoic acid) 
can be reduced by thioredoxin reductase (Amer et a l, 1996), glutathione reductase 
(Pick et al, 1995) and can also scavenge hydroxyl radicals, hypochlorous acid, singlet 
oxygen and chelates iron, copper and other transition metals (Moini et a l,  2002a). The 
reduced form (dihydrolipoic acid) has been shown to reduce other antioxidants such as 
glutathione disulphide, thioredoxin, vitamin C and vitamin E (Jocelyn, 1967; Packer et 
a l, 1995). Dihydrolipoic acid may also act as a pro-oxidant via the reduction of iron 
(Fe^ "^  to Fe^^) producing hydroxyl radicals (Moini et al., 2002b).
SOD 2
NADH^
e2.k-|!j
Trx-(SH).
ROOM
Mitochondrion
Figure 4.19 -  Mitochondrial antioxidant function
The p resen ce  of an  active electron transport chain can produce reac tive oxygen sp ec ies  tha t 
need  to be detoxified. T he e lectron transport chain is represen ted  in this figure by com p lexes 
and III (C1 & C3), tha t both utilise ubiquinone (UbQ) a s  a  substra te . Both of th e se  com p lexes 
leak superoxide an ions (O'), which can  be dism u ta ted to hydrogen peroxide (H2O 2 ) by a  
mitochondrially localised superoxide d ism u tase  (S0D 2). The Plasmodium genom e con tains 
g en es  tha t encode  for a  mitochondrial peroxiredoxin (Trx-Px) and a potential m itochondrially 
localised thioredoxin (Trx) tha t can  reduce the  H2O 2 produced by S 0 D 2 . However, the 
Plasmodium genom e lacks a  mitochondrially localised thioredoxin reduc tase  and  therefore a 
reducing partner for the thioredoxin. W e postula te tha t the m itochondrially localised LipDH2 
(LipDH E3) and acyl tran sfe rases  of the  KADH (E2) may be ab le to provide the  reducing 
equ iva len ts for the pathw ay to be functional.
I.:-(ïI»
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4.3.4 Inhibition of LipDH
LipDH plays a major role in integral biochemical processes of the P. falciparum 
parasite via its involvement in the KADH (see chapter 5) and the possible anti-oxidant 
role proposed earlier. Any inliibition of LipDH may have extreme consequences for the 
parasite. Inhibition of LipDH activity has been observed by NADH (Sahlman et a l, 
1989) and has been proposed to be involved in regulation of KADH activity (Tovar- 
Mendez et a l, 2003). This regulation has also been observed in the inhibition of a -  
ketoglutarate dependent mitochondrial respiration by competitive inhibition by sub­
micromolar levels of zinc (Brown et a l, 2000). The zinc (in the form of Zn^^) interacts 
with the reduced active site thiols (where it competes with lipoamide) and increases the 
NADH oxidase activity of the LipDH protein, thereby producing reactive oxygen 
species (Gazaryan et a l, 2002).
The inhibition of LipDH proteins (along with other disulphide oxidoreductases) has also 
been investigated to provide chemotherapeutic drugs against human pathogens. Possible 
drug inhibitors of the disulphide oxidoreductases have been extensively investigated in 
the Trypanosome species (due to the presence o f the parasite specific trypanothione 
reductase) as well as in P. falciparum (Krauth-Siegel et a l, 2005). In addition to the 
numerous inhibition studies that have investigated trypanothione reductase as a drug 
target (Krauth-Siegel et a l, 2005), many studies have also investigated the inhibition of 
LipDH in Trypanosomes. Trivalent arsenicals such as melarsenoxide have been 
demonstrated to interact with the active site cysteines in the reduced form of the protein 
(Fairlamb et al, 1992; Cunningham et a l, 1994). Nitrosoureas such as carmustine also 
act via covalent inhibition of the protein by carbomylation of the interchange thiol 
(Lohrer et a l, 1990). Several other compounds display what has been termed turncoat 
inhibition, where they are substrates for the protein that induce one electron transfer to 
oxygen, which leads to the production of reactive oxygen species; examples of turncoat 
inhibitors active against LipDH are napthoquinones/benzoquinones derivatives (Cenas 
et a l, 1994; Cenas et a l, 1994) and nitrofurans such as nifurtimox (Cenas et a l, 1994; 
Blumenstiel et al, 1999). Phenothiazine radicals were also shown to produce inhibition 
by irreversible modification of the LipDH protein structure (Gutierrez-Correa et al, 
2003).
In Plasmodium, these disulphide oxidoreductase inhibition studies have been based on 
thioredoxin reductase and glutathione reductase (see chapters 1 & 3), as the 
dihydrolipoamide dehydrogenase had not been recombinantiy expressed until now.
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Therefore the recombinant LipDH proteins that I have generated may also now be 
utilised for anti-malarial drug screening. I am currently working to validate whether 
both LipDH proteins are essential for parasite survival by targeted gene knockout, 
although the analyses are at too early a stage to be included in this thesis.
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4.4 Conclusions
I have identified two LipDH genes in the Plasmodium genome, one o f which (LipDH2) 
contains an intron. The two LipDH proteins were determined to be organelle-specific 
using GFP-fusion proteins, with one LipDH located in the apicoplast (LipDHI) and the 
other in the mitochondria (LipDH), This organelle-specific localisation suggests that 
there should be KADH located in both organelles and this theory will be further 
investigated in Chapter 5.
Analyses of the mature forms o f both LipDH allowed me to generate constructs that 
display soluble recombinant expression o f both LipDH proteins using the E. coli 
system, although the observed instability o f LipDHI and low expression levels o f  
LipDH2 requires fuither optimisation.
Analysis o f both purified LipDH proteins demonstrated that they were enzymatically 
active with typical LipDH substrates and displayed the relevant biophysical parameters 
o f LipDH proteins. Although the specific activity o f the plastid isoform was obseiwed to 
be lower than that observed for the mitochondrial isoform, this was consistent with 
previous studies on the two different isoforms. Further studies are necessary to 
investigate the basis of the reduced activity in the plastid isoforms.
177-
Chapter 5. The a  -  keto acid d eh yd rogen ase com p lexes (KADH) of P /asm od/um  fa/c/pam m
Chapter 5 The a-keto acid dehydrogenase complexes (KADH) of
P la s m o d iu m  f a lc ip a r u m  
5.1 Introduction
5.1.1 a-Keto acid dehydrogenase complexes
There are thi'ee a-keto acid dehydrogenase complexes (KADH) in humans that are all 
located in the mitochondrion. The pyruvate dehydrogenase complex (PDH) acts as a 
link between glycolysis and the citric acid cycle (TCA cycle), the a-ketoglutarate 
dehydrogenase complex (KGDH) acts within the TCA cycle and the branched chain a  - 
keto acid dehydrogenase complex (BCKDH) acts in the catabolism of branched chain 
amino acids such as valine, leucine and isoleucine. The KADH are large multi-enzyme 
complexes that form from multimers o f thi'ee independent enzymes.
The first enzyme o f the KADH (referred to as E l) is a decarboxylase that catalyses the 
oxidative decarboxylation o f a-keto acids using a thiamine diphosphate cofactor 
forming a hydroxyl-acyl thiamine diphosphate intermediate. It is this protein that 
confers the substrate specificity o f the complexes and its activity can be regulated by 
phosphorylation and de-phosphorylation (Randall et a l,  1977; Odessey, 1982). The El 
protein can occur as a homodimeric protein o f about 100 - 120 kDa or as a hetero- 
tetrameric protein that consist o f two a and two p subunits (a 2p%) of between 50 kDa 
and 70 kDa.
The second enzyme (referred to as E2) is a dihydrolipoamide acyl transferase and forms 
the catalytic core o f the KADH. The protein is organised into three domains, the lipoyl 
domain, subunit binding domain and catalytic domain that are separated by flexible 
linker regions. The lipoyl domain contains a lipoic acid moiety covalently attached to an 
s-amino group o f a conserved lysine residue, which accepts the acyl group transfened 
from the hydroxyl-acyl thiamine diphosphate o f E l. The subunit-binding domain o f E2 
is responsible for the attachment o f E l and the third component o f KADH, a LipDH 
protein. The catalytic domain is the region o f self-association o f E2 and is responsible 
for the generation o f the E2 core -  the E2 protein forms homo-trimers that associate to 
form 24 mers (KGDH) or 60 mers (PDH). The catalytic domain also catalyzes the 
transfer o f the acyl group bound to the lipoamide cofactor of the lipoyl domain to 
coenzyme A, producing acyl CoA and dihydrolipoamide (see figure 5.1 & section 1.4).
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Mammalian PDH also contains a fourth component, the so-called protein X that has a 
high degree of homology to the E2 protein but lacks the catalytic activity (Harris et a i,
1997). Protein X is involved in forming the core of the PDH together with the E2 
protein and is the site of LipDH association (McCartney et a l, 1997).
The third enzyme (referred to as LipDH, dihydrolipoamide dehydrogenase) is 
responsible for the re-oxidation of dihydrolipoamide producing lipoamide and NADH 
(figure 5.1). The P. falciparum LipDH proteins have been investigated/discussed in 
depth in chapter 4.
5.1.2 Aims
The aims of this part of the study were to identify the genes encoding the a-keto acid 
dehydrogenase complexes (KADH) in the Plasmodium falciparum genome and 
determine whether they have a role during the erythrocytic development of the parasite. 
These studies included investigation of their expression levels, subcellular localisation 
and preliminary biochemical analyses utilising recombinantiy expressed protein.
- O H T h iam inep y ro p h o sp h a te  , , — L i p — s h  h s — c o a
K e . 0  "  -
ac id  , i .  E 1  E 2
O H
IC O , 1 r A ^  ^  Lip^
T I P  ! ^ s — C o A
FADHg E 3  f a d
NAD+ NADH
Figure 5.1 -  Catalytic mechanism of KADH
The catalytic m echanism  of KADH involves the th ree proteins tha t form this complex; the a  -  
keto acid dehydrogenase  (E1), acyl tran sferase  (E2) and dihydrolipoamide dehyd ro g en ase  (E3 
or LipDH). The E1 protein is responsib le for the oxidative decarboxy lation of an a  -  keto acid 
using th iam ine pyrophospha te  a s  a cofactor. This reaction produces a  hydroxyl-acyl th iam ine 
pyrophospha te  and CO 2 . The acyl group from hydroxyl-acyl thiamine pyrophospha te  is 
transferred  on to the lipoamide moiety tha t is covalently a ttached to the E2 protein, before being 
transferred  onto coenzym e A producing acyl CoA and dihydrolipoamide. The dihydrolipoamide 
is oxidised to lipoamide by E3, allowing it to accep t ano ther acyl group from the E l protein, with 
the reaction of E3 requiring a protein bound flavin cofactor (FAD) and producing NADH.
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5.2 Results
5.2.1 Identification of components of KADH in the P. falciparum  genome
The P. falciparum  genome database (www.Dlasmodb.org) was searched by TBLASTP 
using the human, yeast or E. coli amino acid sequences as queries to identify possible 
homologues in the P. falciparum  genome. These searches identified that the P. 
falciparum  genome contained components o f all three KADH:
1. Three genes were identified that encoded components o f the a-ketoglutarate 
dehydrogenase complex (KGDH); an a-ketoglutarate dehydrogenase (KGDH- 
E l), a succinyl transferase (KGDH-E2) and one o f the LipDH described in 
chapter 4.
2. Four genes were identified that encoded components o f the branched chain a  -  
keto acid dehydrogenase complex (BCKDH); the a  and p subunits o f the 
BCKDH dehydrogenase (BCKDH-Ela & BCKDH-Eip), a branched chain 
acyl transferase (BCKDH-E2) and one o f the LipDH described in chapter 4.
3. The pyruvate dehydrogenase complex (PDH) was found to be encoded by four 
genes; the a  and p subunits o f the PDH dehydrogenase (PDH-Ela and PDH- 
Eip), the acetyl transferase (PDH-E2) and one o f the LipDH described in 
Chapter 4. The searches failed to identify a homologue for the protein X  
(000330) component, suggesting this does not form a part o f the parasite PDH.
The following sections detail the sequence analyses o f the Plasmodium genes and 
proteins identified in these searches. This does not include the LipDH components o f 
the complexes, as these have already been analysed/discussed in Chapter 4.
5.2.1. 1_____ g-Ketoglutarate dehydrogenase
Searching the Plasmodium genome with the a  - ketoglutarate dehydrogenase (KGDH- 
E l) amino acid sequences o f Homo sapiens (Q02218) and E. coli (P07015) identified a 
P. falciparum  homologue with 39 % and 38 % identity respectively. The P. falciparum  
gene I identified is located on chromosome 8 and was later annotated PF08_0045 in 
PlasmoDB (www.plasmodb.org) .
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Alignment o f the P, falciparum  KGDH- E l with open reading frames o f homologues 
identified in other Plasmodium species {P. yoelii yoelii, P. berghei and P. vivax) 
demonstrated that the predicted start site for the P. falciparum  protein was not 
conserved in the proteins identified in the other species (figure 5.2A). Comparative 
analyses o f the genomic sequences o f all the Plasmodium genes identified a possible 
intron/exon boundary that was consei*ved at the same amino acid position in all 
Plasmodium proteins analysed (highlighted grey in figme 5.2A and red in figure 5.2C). 
Alignment o f the resulting proteins (with the intron removed) produced proteins with 
conserved sequences and in-fiame translation initiation sites (figure 5.2B). The 
predicted intron (boundaries are highlighted red in figure 5.2C) resulted in a P. 
falciparum  KGDH-El gene that consisted o f a 157 bp exon 1 (highlighted yellow in 
figure 5.2C; 74.7 % A/T), a 190 bp intron (85.2 % A/T) and a 2958 bp exon 2 
(highlighted grey in figure 5.2C; 71.6 % A/T). The 3306 bp a-ketoglutarate 
dehydrogenase gene (which contains the single intron) encoded a protein consisting o f  
1038 amino acids with a predicted molecular size of 121.2 kDa.
ClustalW alignment with homologues identified in the other Plasmodium species P. 
berghei, P. yoelii yoelii, P. chabaudi confirmed the predicted start site and displayed 
amino acid identities of 85 %, 84 % and 86 %, respectively (data not shown).
Reciprocal BLAST? analyses o f the KGDH-El amino acid showed that the P. 
falciparum  protein had the highest amino acid identity with slime mould (Dictyostelium 
discoideum; 45 %), plant (Arabidopsis thaliana; 44 % and Oryza sativa; 44 %), fungi 
{Aspergillus nidulans; 43 % and Neurosporra eras sa; 42 %) and yeast {Saccharomyces 
cerivisiae; 43 %). Comparison o f the P. falciparum  KGDH-El with amino acid 
sequences o f KGDH-El from other organisms identified the conserved thiamine 
pyrophosphate binding motif (Koike, 1998) is present in the parasite protein sequence. 
Further identification o f residues important in the catalysis o f the KGDH-El protein has 
been limited due to the inherent difficulties in recombinantly expressing this large 
protein from other soui'ces.
Analysis o f the KGDH-El amino acid sequence in subcellular prediction programs (see 
section 2.2.2.3) suggests that the KGDH-El is localised to the mitochondrion, with a 
relatively high level of confidence (74 %), although the programmes did not predict a 
mitochondrial targeting peptide cleavage site (table 5.2).
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A )
P y o e l
P b e r g
P f a l
P v i v
P y o e l
P b e r g
P f a l
P v i v
     HFLTFFMICTYIFFYWHFLSDLFRNTLDKSWDRYFT 3 6
FKKKNYVRVNEEYTFFCIINLNCSYFLIFFM ICTYIF F YYHFLSDLLRNTLDKSWDRYFT 6 0
-------------------------Y L Y IC T L--------LH IY IY IY IY V Y IFFFFFFFFL PFR N N LH K SW D SL FS 44
---------------------------------------------------------------------------------------------------------------------  - GAPPRDTPDVLLPLLNAA.LPLPYPLRRNSLHKSWDVYFA 3 9
: : : * * * * * * *  * .
NICNGMPN-------NSLLDENSRIIYKNCDREYG--ERHNNLRITYVNEEM IEKGKTGNIYDI 91
NICNGMPN-------NSLIDENSRVIYKNRDREYG--ERHNNLRITYVNEEM IEKGKTGNIYDI 1 1 5
MYPHAEMDN-YNNPIKINRKTDNYNNSNCFQDVLKNNNLRITYVNNEMLEKGKTENIYDL 1 0 3  
EMAEEAGPLGSAPPRVLSTREVRSRMGASVPQNRSSSNLRITYVNKEMLDKGRMGNIYDI 9 9
* * * * * * * * * * * * . * * .  * * * * *
B )
P y o e l
P b e r g
P f a l
P v i v
 MQTS RKNGNNIK-KYIHTSSVLYNEEFNPSMASYLENVYRLWKSDKNTLDKSW 52
 MQTS RKNGNNIK-KYIHTSSVLYNEEFNPSMASYLESVYRLWKSDRNTLDKSW 52
MRKFFYTNNLVRNNGKDIRTRSFHLSSCLYDYNFNPSMTSYIENTYKIWKEDRNNLHKSW 6 0 
MRKILHSNKLLKENGDMLR-RRFHVGGCAGSDNFNPSMAAYIEGAYRMWRQDRNSLHKSW 59
* * * * * *  . * , *  * . . * .  * * * * * * *
P y o e l
P b e r g
P f a l
P v i v
C )
DRYFTNICNGMPN NSLLDENSRIIYKNCDREYG--ERHNNLRITYVNEEMIEKGKTG 1 0 7
DRYFTNICNGMPN NSLIDENSRVIYKNRDREYG--ERHNNLRITYVNEEM IEKGKTG 1 0 7
DSLFSMYPHAEMDN-YNNPIKINRKTDNYNNSNCFQDVLKNNNLRITYVNNEMLEKGKTE 1 1 9  
DVYFAEMAEEAGPLGSAPPRVLSTREVRSRMGASVPQNRSSSNLRITYVNKEMLDKGRMG 1 1 9* * * * * * * * . * * . . * * .
DNA: 
+3 : +2 : + 1:
E K I F L H K * F G K K * W K R Y K N T I I S
* E N F F T Q I I W * E I M E K I * E H D H F
M R K F F Y T N N L V R N N G K D I R T R S F
DNA: CATTTAAGTTCTTGCTTATATGATTATAATTTTAACCCAAGTATGACCTCGTATATTGAGAATACATAT 
+ 3 :  F K F L L I * L * F * P K Y D L V Y * E Y I *
+2 :  I * V L A Y M I I I L T Q V * P R I L R I H I
+ 1 : H L S S C L Y D Y N F N P S M T S Y I E N T Y
DNA : AAGATATGGAAAGAAGACAGgATAATGTGCAACAGGCACAACATAGAAATAAACTTTCATGTATACAT 
+ 3 :  D M E R R Q V * C A T G T T * K * T F M Y T Y
+2 :  R Y G K K T G I M C N R H N I E I N F H V Y I
+ 1 : K I W K E D R Y N V Q Q A Q H R N K L S C I H
DNA 
+3 +2 + 1
ATATATATATATATTTATAACTATACATACCTATATTTATATTAATATTTATATATATGTACATTGTTG
I Y I Y L * L Y I P I F I L I F I Y M Y I V A
Y I Y I F I T I H T Y I Y I N I Y I Y V H C C
I Y I Y I Y N Y T Y L Y L Y * Y L Y I C T L L
DNA:
+ 3 :  Y I Y I Y I Y I C I Y F F F F F F F F F T F *
+2 :  l Y I Y I Y I Y M Y I F F F F F F F F F Y L L
+ 1 : H I Y I Y I Y I Y V Y I F F F F F F F F L P F
DNA : U a a a c a a t t t a c a c a a a t c g t g g g a c t c t t t a t t t a g c a t g t a t c c a c a t g c a g a a a t g g a t a a t t a t
+ 3 :  K Q F T Q I V G L F I * H V S T C R N G * L *
+2 ;  E T I Y T N R G T L Y L A C I H M Q K W I I I  
+ 1 : R N N L H K S W D S L F S M Y P H A E M  D ^ N  Y
F igure  5.2 -  D eterm in ing in tro n /ex o n  b o u n d a r ie s  fo r KGDH-E1
The in tron/exons boundaries of P. falciparum KGDH-E1 w ere determ ined by C lustalW  
a lignm en t with hom o logues identified in the o ther Plasmodium species, P. yoelii yoelii, P. 
berghei and P. vivax. {*) Identical residues, (:) conserved residues, (.) hom o logous residues. All 
a lignm en ts display only the N-term inus of the pred icted proteins. P an e l A) ClustalW  alignm en t 
open reading fram es of KGDH-E1 hom o logues from Plasmodium species. The predicted 
intron/exon boundary is highlighted in grey. P an e l B) ClustalW alignm en t of the predicted 
pro teins of the Plasmodium KGDH-E1 with the intron rem oved, with the intron/exon boundary 
highlighted in grey. P an e l C) The intron/exon boundaries of the P. falciparum KGDH-E1 are  
m arked in red with exon 1 highlighted in yellow and exon 2 highlighted in grey.
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DNA: ATGAGAAAATTTTTTTACACAAATAATTTGGTAAGAAATAATGGAAAAGATATAAGAACA 60 
+ 1 :  M R K F F Y T N N L V R N N G K D I R T  20
DNA: CGATCATTTCATTTAAGTTCTTGCTTATATGATTATAATTTTAACCCAAGTATGACCTCG 1 2 0  
+ 1 :  R S F H L S S C L Y D Y N F N P S M T S  4 0
DNA: TATATTGAGAATACATATAAGATATGGAAAGAAGACAGAAACAATTTACACAAATCGTGG 1 8 0  
+ 1 : Y I E N T Y K I W K E D R N N L H K S W  60
DNA: GACTCTTTATTTAGCATGTATCCACATGCAGAAATGGATAATTATAATAACCCAATAAAA 2 4  0 
+ 1 :  D S L F S M Y P H A E M D N Y N N P I K  80
DNA: ATAAATCGAAAGACTGATAATTATAATAATAGTAATTGTTTTCAAGATGTGCTTAAGAAT 3 0 0  
+ 1 :  I N R K T D N Y N N S N C F Q D V L K N  1 0 0
DNA: AATAATCTTCGAATTACATATGTGAATAATGAAATGCTTGAAAAAGGGAAAACAGAAAAT 3 6 0  
+ 1 : N N L R I T Y V N N E M L E K G K T E N  1 2 0
DNA: ATTTATGATCTAGCTAGGATTGTTCAATTAATTAGATGGTATCAAAAGAAAGGACATTTA 4 2  0 
+ 1 : I Y D L A R I V Q L I R W Y Q K K G H L  1 4 0
DNA: TATGCTAATATAAATCCTTTGCCATTACCAAAAGAACCTCCCTATAGTAGTGTTTGTTAT 4 80  
+ 1 :  Y A N I N P L P L P K E P P Y S S V C Y  1 6 0
DNA: GAACCTTGTAAAAGGAAAATGTCTTACGTGGATTTTGGTTTTAATGAGGATGATTTAGAT 54 0 
+ 1 :  E P C K R K M S Y V D F G F N E D D L D  1 8 0
DNA: AAAGAGTTTTTTTTTGATTTGCCGTCGATTAGTGGTTTTTCAAGTAATGGTATGAAAAAA 6 0 0  
+ 1 :  K E F F F D L P S I S G F S S N G M K K  2 0 0
DNA: TGTAATTTAAGAAATTTATTAAAAAGATTAGAAGAAACATATTGTGGTACTATTGGTTTT 6 6 0  
+ 1 :  C N L R N L L K R L E E T Y C G T I G F  2 2 0
DNA: GAATATATGCATATAACAAATGAAAATATAGTAAATTATATAATACAAAGAATAGAGAAG 7 2 0  
+ 1 - . E Y M H I T N E N I V N Y I  I Q R I E K  2 4 0
DNA: GACAAAAAATATGAATATGATACAAAGATGAAAAAAAGAATTTTAGAATATACTGCTCGA 7 8 0  
+ 1 :  D K K Y E Y D T K M K K R I L E Y T A R  2 6 0
DNA: GCATTTATATTTGAAAATTATATGGCAGCTAAATTTGCTACAACAAAAAGATTTGGAGTT 84  0 
+ 1 :  A F I F E N Y M A A K F A T T K R F G V  2 8 0
DNA: GATGGATGTGAAACATTAATTACTGGTATGAAAGCATTAATAAAAAGGGCTGCTCAGTTA 9 0 0  
+ 1 :  D G C E T L I T G M K A L I K R A A Q L  3 0 0
DNA: GATGTAGATAGTGTATTGATGAGTATGTCTCATCGAGGTCGATTGAATGTTTTATTTAAT 9 6 0  
+ 1 :  D V D S V L M S M S H R G R L N V L F N  3 2 0
DNA: GTATTACATAAACCATTAGAACAAATGATGTCAGAATTTCGAGGGAAAACTGGTTTTAGT 1 0 2  0 
+ 1 :  V L H K P L E Q M M S E F R G K T G F S  3 4 0
DNA: GATAATATATGGGGAAATACCGGAGATGTAAAATACCATTTAGGTGTTGAAATTGATTAT 1 0 8 0  
+ 1 :  D N I W G N T G D V K Y H L G V E I D Y  3 6 0
DNA: TATGATGAAGATTCACAAAGATATATACATATGGGTATAGTAGACAATTCGTCTCATTTA 1 1 4  0 
+ 1 :  Y D E D S Q R Y I H M G I V D N S S H L  3 8 0
DNA : GAATCTGTTGATCCTATTTTAATGGGTCAAGCTAGAGCACAACAATATTATTGTAATGAT 1 2 0 0  
+ 1 :  E S V D P I L M G Q A R A Q Q Y Y C N D  4 0 0
DNA : AAAGAAAAAAAGAAAGTGTTACCAATAACTATACATGGAGATGCTTCAATCGCTGGACAA 1 2 6 0  
+ 1 : K E K K K V L P I T I H G D A S I A G Q  4 2 0
DNA: GGAATTGCATATGAAACATTTCAAATGTCTAAATTACCAAGTTATAATGTGGGTGGTACT 1 3 2 0  
+ 1 : G I A Y E T F Q M S K L P S Y N V G G T  4 4 0
DNA : ATACATATTGTGGTTAATAATCAAATAGGATTTACCACATATCCAATAGATGCAAGGTCA 1 3 8 0  
+ 1 : I H I V V N N Q I G F T T Y P I D A R S  4 6 0
DNA : GGAAAATATTGTACAGACATAGCTAAATGTATAGATATACCAATTATACATGTAAATGCA 1 4 4  0 
+ 1 : G K Y C T D I A K C I D I P I I H V N A  4 8 0
DNA : GATGATCCAGAAGCTGTAACATATGTATTTGAATTAGCATTAGATATTCGAAATAAATTT 1 5 0 0  
+ 1 :  D D P E A V T Y V F E L A L D I R N K F  5 0 0
DNA: AATATTGATACAATTATTGATATTGTAGGTTATAGGAGATTTGGGCATAACGAATTAGAT 1 5 6 0  
+ 1 :  N I D T I I D I V G Y R R F G H N E L D  5 2 0
DNA : ATGCCAAAATTTACGAATCCATTATTATATGATGTAATAGCTAGACATAAATCTGTTTTA 1 6 2  0 
+ 1 :  M P K F T N P L L Y D V I A R H K S V L  5 4 0
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DNA: GATATATATAGTAAAAAATTAATTGATGAAAATATTATTAGTCTTAAAGAATTTGAAGAT 1680 + 1 : D I Y S K K L I D E N I I S L K E F E D  560
DNA : AATAAAACTGAAATATTTAATTTTTATGAACAAGTGTATGAGAAATCCAAATCATTTGTA 174 0 + 1: N K T E I F N F Y E Q V Y E K S K S F V  580
DNA ; CCAACACCTAAGGAAAAATATTTACCTCAATGGGAACATATGGTAACACCCCAAAAATTT 180 0+ 1 : P T P K E K Y L P Q W E H M V T P Q K F 600
DNA: TCTCCCTCACGAAAAACAGGAGTAGAAAAAGATGTATTAATAAATCTTGGGAAAAAGATA 1860+ 1; P S R K T G V E K D V L I N L G K K I 620
DNA: TTTACATTACGTGAAAATTTCACTGCTCATCCAATAATAACAAAATTATTTAAAAGTAGA 1920 + 1 : F T L R E N F T A H P I I T K L P K S R  640
DNA: ATAGATAGTTTAGAAACAGGCAAAAATATAGATTTTGGTACCGCTGAATTATTAGCTTAT 1980 + 1: I D S L E T G K N I D F G T A E L L A Y  660
DNA : GCAACTTTATTATCTGATGGATTCCATGCACGTTTATCTGGTCAGG ATTC ACAAAGAGGA 2040 + 1: A T L L S D G F H A R L S G Q D S Q R G  680
DNA : ACTTTTTCTCATCGACACGCAGTATTACATGATCAAATAACATATGAATCATATAATATA 2100+ 1 : T F S H R H A V L H D Q I T Y E S Y N I 700
DNA ; TTTGATTCATTAAAAACACCACATACCATAGAAGTAAATAATTCTCTTTTATCTGAATAC 2160 + 1 : F D S L K T P H T I E V N N S L L S E Y  720
DNA: GCATGTTTAGGTTATGAGATAGGATATAGTTATGAACATCCAGATGCTCTTGTTATTTGG 2220+ 1 : A C L G Y E  I G Y S Y E H P D A L V I W 740
DNA; GAAGCTGAATTTGGTGATTTTGCTAATGGAGCTCAGGTTATGATTGACAATTATATTGCA 22 80 + 1; E A Q F G D F A N G A Q V M I D N Y I A  760
DNA : TCTGGTGAAACAAAATGGAATAAACAATCGGGTATTGTTATGTTATTACCTCATGGATAT 234 0 + 1 : S G E T K W N K Q S G I V M L L P H G Y  780
DNA : GATGGACAAGGTCCTGAGCATTCATCTGCTCGGATAGAACGTTTTTTACAATTGTGTGAT 24 00 + 1 : D G Q G P E H S S A R I E R F L Q L C D  800
DNA: GATAGAGAAGATATAGCTACCTATTCTGTTGAAAAAGATAATAAGATTATTCAGCAGCAT 24 60 + 1 : D R E D I A T Y S V E K D N K I I Q Q H  820
DNA: AATATGCAGGTTATAAATTGTAGTAAACCATCTAATTTTTTCCATGCATTAAGAAGACAA 252 0 + 1 : N M Q V I N C S K P S N F F H A L R R Q  840
DNA: ATGCATAGATCTTTTAGGAAACCATTAATTGTAATAACACCTAAGAAAATGTTGAAAATG 25 80 + 1 : M H R S F R K P L I V I T P K K M L K M  860
DNA: AGAATGGCATTTGATAAGATTGAAAATTTTTTAACGAACACTGAATTTTTACCTTATTTA 2 64 0 +1: R M A F D K I E N F L T N T E F L P Y L  880
DNA: CCAGAAGAAGTTG6TCATAAATTGAAAGATAAAAAAGAAATCAAAAGAATTATATTATGT 2 700 + 1 ; P E E V G H K L K D K K E I K R I I L C  900
DNA; TCAGGACAAGTATATTATGATTTATTAAATTATAGATATACAAATAAAATTGATGATGTA 2 760 + 1: S G Q V Y Y D L L N Y R Y T N K I D D V  920
DNA: GCTATTGCCAGAATAGAACAATTATCTCCTTTCCCCTTTAAACAAATAATGAATGATCTG 2 820 + 1: A I A R I E Q L S P F P F K Q I M N D L  940
DNA : CAAACTTATCCAAATTTGAGAGATATTATATGGGCACAAGAAGAACATATGAATATGGGT 2 880 + 1 : Q T Y P N L R D I I W A Q E E H M N M G  960
DNA : CCATGGTTTTATGTCTCTCGTCGTATTGAAGCATCTATAAAACAATTAAAAAAAGATAAA 2 94 0 + 1 : P W F Y V S R R I E A S I K Q L K K D K  980
DNA : CCAAAATGGAATATTCAAATTCCTCAGGTACGTTATTCAGGAAGGGATGTATATGCAGCG 3 000+ 1: P K W N I P Q V R Y S G R D V Y A A 1000
DNA : CAATCAGCAGGTGATCTTAATTTACATCTTTATCAATTAGATGAATTTTTAGTTGATGCA 3160+ 1 : Q S A G D L N L H L Y Q L D B F L V D A 1020
DNA : TTTAATTTGGATAAAAAATATAACATGCATGTTCAAAAATATACCGATGCGTTATAA + 1 : F N L D K K Y N M H V  Q I C Y T D A L  * 32171039
Figure 5.3 -  Plasmodium falciparum KGDH-E1
The complementary DNA sequence (with the intron removed) is displayed with the resulting 
amino acid sequence shown below it. The conserved domain involved in thiamine 
pyrophosphate is highlighted in grey.
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5.2.1.2 Succinvl transferase
The deduced amino acid sequence o f the open reading frame o f P. falciparum succinyl 
transferase (KGDH-E2) gene displayed 42 % and 39 % identity to the human (P36957) 
and E. coli (P07016) proteins, respectively; I named this gene KGDH-E2A. However, 
ClustalW alignment o f the predicted protein with open reading frames identified in 
other Plasmodium species (P. berghei, P. knowlesi, P. gallinecium and P. vivax) 
identified the presence o f two possible introns in the 5’region o f the gene (see below). 
The P. falciparum KGDH-E2 gene is located on chromosome 13 and was later 
annotated PF13 0121 inPlasmoDB (www.plasmodb. oral .
Intron 2 was predicted because the initiator methionine identified in the P. falciparum  
KGDH-E2A protein (highlighted green in figure 5.4A) was not conserved in the 
predicted proteins from the other Plasmodium species. Analyses o f the genomic 
sequence o f  KGDH-E2 from P. falciparum  and other Plasmodium species identified the 
possible intron/exon boundaries (highlighted grey in figure 5.4A and B, and red in 
figure 5.4D), with their position being conserved in the sequences o f all the Plasmodium 
species investigated.
Intron 1 was identified in the genomic sequences o f the different Plasmodium KGDH- \
E2 genes because there was no consensus in-frame methionine initiation codon within |
the predicted intron 2 (highlighted red in figure 5.4B & C). Further analysis o f the
genomic sequences o f Plasmodium KGDH-E2 identified the possible intron/exon
boundaries (highlighted red in figure 5.4D), with their position being conserved in the
sequences o f all the Plasmodium species analysed (highlighted red in figure 5.4B and
C). t
As demonstrated previously in LipDH2B (see section 4.2.1.2) the A/T content o f intron 
sequences was higher than that observed in coding regions. This a common feature o f 
the Plasmodium genome sequences as has been shown by whole genome analyses by
Gardner et al. (Gardner et a l, 1999; Szafranski et a l, 2005). In the P. falciparum  
KGDH-E2B sequence exon 1 was 30 bp long and had an A/T content o f 76.7 %
(highlighted yellow in figure 5.4D), intron 1 was 142 bp in length with an A/T content 
o f 88 %, exon 2 was 106 bp long and had an A/T content o f 76.4 % (highlighted blue in 
figure 5.4D), intron 2 was 124 bp with an A/T content o f 82.7 %, and exon 3 was 1130 
bp in length and had an A/T content o f 72.4 % (highlighted grey in figure 5.4D).
i
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Removal o f both introns resulted in Plasmodium deduced proteins that contained a 
conserved in-frame methionine (data not shown); I named this gene KGDH-E2B (figure 
5.4C and 5.5). ClustalW alignment with the proteins (with the introns spliced out) 
identified in the other Plasmodium species P. berghei, P. yoelii yoelii, P. chabaudi 
displayed amino acid identities o f 73 %, 73 % and 72 %, respectively. BLAST? 
analyses o f the deduced P. falciparum  KGDH-E2 amino acid sequence displayed 
greatest identity to homologous proteins from other apicomplexa (such as Theileria 
parva; 50 % identity), slime mould {Dictyostelium discoideum; 46 % identity), yeast {S. 
cerevisiae; 45 % identity) and fungi {Aspergillus nidulans; 45 % identity).
The P. falciparum succinyl transferase gene {KGDH-E2B) was encoded by 1532 bp 
(including the two predicted introns). The predicted full-length protein was 421 amino 
acids in length with a predicted molecular mass o f 47.6 kDa. The KGDH-E2B protein 
can be divided into three domains that are separated by flexible linker regions; the 
lipoyl domain, subunit- binding domain and the catalytic/inner core domain. The lipoyl 
domain runs from residues 46 to 125 and contains the consei’ved lysine residue (residue 
86 in the P. falciparum  protein; highlighted red in figure 5.5) that becomes lipoylated 
via an amide linkage. Another residue that is essential for the lipoylation reaction is 
glycine 97 (in P. falciparum  protein), which is conserved between the organisms 
(highlighted yellow in figure 5.5). The subunit-binding domain is located between 
residues 139 and 172 in the P. falciparum  protein and is responsible for the binding o f  
Eland LipDH. The catalytic domain o f the P. falciparum  protein runs between residues 
197 and 421 and is the site o f self-association and acylation of coenzyme A. Residues 
His392 and Ser340 (highlighted green in figure 5.5) have been implicated in catalysis o f  
the acylation reaction. His392 (highlighted blue in figure 5.5) is thought to act as a base 
catalyst and is located in a conserved motif (DHRXXDG).
Analysis o f the two possible KGDH-E2 amino acid sequences by subcellular 
localisation predictions programs resulted in very different results (table 5.2). The 
KGDH-E2A protein (which uses the in-frame methionine within the identified intron 2) 
was predicted to be mitochondrial, although with a very low level o f confidence o f 3.7 
%. The KGDH-E2B protein, which uses the methionine identified in exon 1 with both 
predicted introns removed, was suggested to be mitochondrial with an 85.2% 
confidence level, although the mitochondrial targeting peptide cleavage site was not 
determined by the algorithms used. This difference in the subcellular localisation 
prediction data suggests that KGDH-E2B is the more likely gene product, although this 
will be further investigated later in this chapter (see sections 5.2.2.1 & 5.2.4).
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Alignment of the P. falciparum KGDH-E2 with its E. coli homologue displays amino 
acid identity from amino acid 44 (highlighted grey in figure 5.5), which suggests that 
the mature protein size (minus the mitochondrial targeting peptide) will be 
approximately 42.5 kDa.
A)
P b e r g
P g a l l
P v iv c ix
P k n o w
P f a l A
P b e r g
P g a l l
P v i v a x
P k n o w
P f a l A
 -------------------------------------------YVLLCVY----- RYFAIYYYIFIYADTLKVPRLGDSI 32
-------------------   IF IIF R R C L IL L IY N IL F Y IIL F Y Y F F F F L D T IK V P R L G D S I 4 2
 ------------- PLHMHLIAYSHPSNADTIKVPRLGDSI 2 7
CHYRNKKRDSPAPCLHLIWTRACMFVGHQCSFLPLFMYLIALSPSLNAETIKVPRLGDSI 60
-------------------------    IC V C IF F F F F L L P F ..............V ETIK V PR LG D SI 27
.*  * * * * * * * * * *
TEGVINEWKKKVGDYVYSDETLAVIDTDKVSVDINSKSSGALYKIFAEAGDTVLVDSPLC 92  
TEGTINEWKKKVGDYVKNDETLAIIDTDKVSVDINSKSSGTLHKIFAEAGDIILVDSPLC 1 0 2  
TEGTISEW KKKVGDYVKVDETITIIDTDKVSVDINSKSSGALSKIFAEAGDIVLVDAPLC 87  
TEGTISEW KKKVGDYVKMDETITIIDTDKVSVDINSQFSGELSNIFAEAGEIVLVDAPLC 1 2 0  
TEGTINEWKKKVGDYVKADETITIIDTDKVSVDINSKVSGGLSKIFADVGDWLVDAPLC 87  * * *  * * * * * * * * * * *  * * * .  . . * * * * * * * * * * * * .  * * * . * * * •  * . . * * * • * * *
B)
P f a l
P b e r g
P g a l l
p v i v a x
P k n o w
C)
5LLHHVKSFNRTFLNHKYNSNANIEGSLKRYFSIETIKVPRLGDSITEGTINEWKKKVG 60  
2LIYNGNNVKRAFFNVEFRQLVNNYITCKRHFSIDTLKVPRLGDSITEGVINEWKKKVG 60
; s l y n l n s v k r t f f s l k s r q n e k y r f v f r r y f s i d t i k v p r l g d s i t e g t i n e w k k k v g  60
PLFYNAKGISR-ILNLECKQCVNCHSTFKRCFSIDTIKVPRLGDSITEGTISEW KKKVG 5 9  
PLFYNAKGISR-ILNLECKQSVKCHSKFKRCFSIETIKVPRLGDSITEGTISEW KKKVG 59
P v i v a x
P k n o w
P f a l
P g a l l
P b e r g
M TQNLVLRLNjPLFYNAKGISR-ILNLECKQCVNCHSTFKRCFSIDTIKVPRLGDSITEG 59  
MTQNLVLRLn I p L FY N A K G ISR -IL iNLECKQSVKCHSKFKRCFSIETIKVPRLGDSITEG 59
m t k n l v f r l n I s l l h h v k s f n r t f l n h k y n s n a n i e g s l k r y f s i e t i k v p r l g d s i t e g  60
MTQNLILRLn I s SLYNLNSVKRTFFSLKSRQNEKYRFVFRRYFSIDTIKVPRLGDSITEG 60
m n q t l in r l n | q l iy n g n n v k r a f f n v e f r q l v n n y i t c k r h f s i d t l k v p r l g d s i t e g  60  
* : .* "  * * * * « . * . . .  . • . *  * * * . * .* * * * * * * * * * * *
P v i v a x
P k n o w
P f a l
P g a l l
P b e r g
TISEW KKKVGDYVKVDETITIIDTDKVSVDINSKSSGALSKIFAEAGDIVLVDAPLCEID 1 1 9  
TISEW KKKVGDYVKM DETITIIDTDKVSVDINSQFSGELSNIFAEAGEIVLVDAPLCEID 1 1 9  
TINEWKKKVGDYVKADETITIIDTDKVSVDINSKVSGGLSKIFADVGDW LVDAPLCEID 1 2 0  
TINEW KKKVGDYVKNDETLAIIDTDKVSVDINSKSSGTLHKIFAEAGDIILVDSPLCEID 1 2 0  
VINEWKKKVGDYVYSDETLAVIDTDKVSVDINSKSSGALYKIFAEAGDTVLVDSPLCEID 12  0 
* * * * * * * * * * *  * * * .  . . * * * * * * * * * * * * .  * * * . * * * .  * . . * * * • * * * * * *
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D)
DNA: a t g a c a a a g a a t c t t g t a t t t c g a t t a a a t B a a a t a t a t t t a a t a t a t a t t a t g t a t a t g t g t g t c g a a t t a t a t a a a t c g t a
+ 3 :  D K E S C I S I K C K Y I * y i L C I C V S N Y I N R I
+2:  * Q R I L Y F D * M * I Y L I Y I M Y M C V E L Y K S Y
+ 1 : M T K N L V F R L N V N 1  F N I Y Y V Y V C R I  I  * I V
DNA: TTTATCTATTTTTTATTAGTATATATTTTAAAAATGTTGAAAATATATACACATATATAAATATATATTATTTGTTTTATTTTT 
+ 3 :  Y L F F I S I Y F K N V E N I Y T Y I N I Y Y L F Y F Y
+2:  L S I F Y * Y I F * K C * K Y I H I Y K Y I L F V L F L
+ 1 : F I Y F L L V Y I L K M L K I Y T H I * I Y I I C F I F
DNA: a t H a a a t c c t t a t t a c a t c a t g t c a a a a g t t t t a a t a g a a c a t t t t t a a a c c a t a a g t a t a a t t c a a a t g c a a a t a t t g a a g g
+ 3 :  R N P Y Y I M S K V L I E H F * T I S I I Q M Q I L K D
+ 1:  I E I L I T S C Q K F * * N I F K P * V * F K C K Y * R
DNA: a t c a c t t a a g a g a t a t t t t t c c a t a g B a a a t a t t t g a a a a a a a a a g g a c g t t t c t a a g t t a t a a a t a t g g g a a a t a t a t a t a t
+ 3 :  H L R D I F P *  V N I * K K K D V S K L * I W E I Y I Y
K Y L K K K G R F * V I N M G N I Y I  
+ 1:  I T * E I F F H R * I F E K K R T F L S Y K Y G K Y I Y
DNA 
+ 3 
+  2 
+  1
DNA 
+ 3 
+  2 
+  1
a t a t a t a t a t a t a t a t a t a t a t g t g t g t g t g t a t t t t t t t t t t t t t t t t t t t g t t a c c c t t t g t H a a a c c a t t a a a g t a c c t a
l Y I Y I Y M C V C I F F F F F L L P F V E T I K V P R
Y I Y I Y I Y V C V Y F F F F F F V T L C R N H * S T *
I Y I Y I Y 1 C V C V F F F F F F C Y P L * K P L K Y L
GACTTGGTGATTCAATCACAGAAGGTACAATAAATGAATGGAAAAAAAAAGTGGGAGATTATGTTAAGGCGGATGAAACGATAA 
L G D S I T E G T I N E W  K K K V G D Y V K A D E T I T  
T W * F N H R R Y N K * M E K K S G R L C * G G * N D N  
D L V I Q S Q K V Q * M N G K K K W E I M L R R M K R *
F igure  5.4 -  D eterm in ing  th e  in tro n /ex o n  b o u n d a r ie s  of KGDH-E2
N-term ina! sec tions of C lustalW  alignm en ts of the Plasmodium falciparum KGDH-E2 with 
hom o logues identified in o ther Plasmodium sp ec ies  P. wVax (Pvivax), P. knowlesi (Pknow), P. 
falciparum (Pfal), P. gallinecium (Pgall) and P. berghei (Pberg). T he a lignm en t d isp lays only the 
N-term inal sec tions and show s identical residues (*), conserved residues (:) and hom o logous 
residues (.). P ane l A) The p re sen ce  of an  intron w as predicted from alignm ent of the KGDH- 
E2A am ino acid seq u en ce  open reading fram es identified in o ther Plasmodium species. This 
identified tha t the  in-frame m ethionine (m arked in green) w as not conserved  in all species. The 
predicted intron/exon boundary is highlighted in grey. Pane l B) ClustalW  alignm en t of the open 
reading fram es tha t resu lted from the removal of the intron (intron 2) identified in pane l A 
d isp lays tha t there  m ust be ano ther intron within this gene. This w as b ecau se  the exon did not 
con tain an  in-frame m ethionine in any of the Plasmodium genes. The predicted intron/exon 
boundary (for intron 1) is m arked in red. P an e l C) ClustalW  alignm ent of Plasmodium KGDH-E2 
se q u e n c e s  with both introns removed; the intron 1 boundary is m arked in red and the intron 2 
boundary is m arked in grey. P an e l D) The genom ic DNA seq u en ce  from the KGDH-E2 g en e  
highlights the intron/exon boundaries (red), exon 1 (yellow), exon 2 (blue) and exon 3 
(con tinues for the  rest of the  am ino acid sequence ; highlighted in grey).
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DNA: 
+ 1:
DNA; 
+ 1:
DNA: 
+ 1:
DNA: 
+ 1:
DNA: 
+ 1;
DNA: 
+ 1:
DNA: 
+ 1 :
DNA: 
+ 1:
DNA: 
+ 1:
DNA: 
+ 1:
DNA: 
+ 1:
DNA: 
+ 1:
DNA: + 1 :
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1:
ATGACAAAGAATCTTGTATTTCGATTAAATAAATCCTTATTACATCATGTCAAAAGTTTT
M T K N L V L N K S H H V K
AATAGAACATTTTTAAACCATAAGTATAATTCAAATGCAAATATTGAAGGATCACTTAAG
N R T F L N H K Y N S N A N I E G S L K
AGATATTTTTCCATAGAAACCATTAAAGTACCTAGACTTGGTGATTCAATCACAGAAGGT
R Y F S I E T I K V P R L G D S I T E G
ACAATAAATGAATGGAAAAAAAAAGTGGGAGATTATGTTAAGGCGGATGAAACGATAACA
T I N E W K K K V G D Y V K A D E T I T
ATTATCGATACAGATAAAGTTAGTGTTGATATAAATTCTAAAGTAAGTGGAGGGTTATCC
I  i d t d | v s v d i n s k v s g g l s
AAAATTTTTGCGGATGTAGGAGATGTTGTTTTGGTAGATGCACCTTTATGTGAAATTGAT
k i f a d v g d v v l v d | p l c e i d
ACATCTGTAGAACCACCTGAAGATATTTGTAAAACTAAAGAGGAAGTAGGAGAAAGTAAA
T S V E P P E D I C K T K E E V G E S K
AATAATGAAAATAATTATACATTTAATCAATTAAATAGAGATATTAAAGATGAAGCACAT
n n e n n y t f n q l n r d i k d e a h
ATAAAAGATGAAGTTAGTAAAAATGAAAAAGATATTTTTGTAAAAGATCCTATATGTTTT
I K D E V S K N E K D I F V K D P I C F
GGAAATGATTATGAATCAATAAATGAAAGAACAGAAAGAAGAGTCCGTATGTTACCTATA
g n d y e s i n e r t e r r | r m l p i
AGAAAAAGAATTGCAGAACGATTAAAGGAATCACAAAATACATGTGCTTTATTAACAACA
R K R I A E R L K E S Q N T C A L L T T
TTTAATGAATGTGATATGTCAAAGGCAATGTTATTAAGAAGTGAATTAAATGATATATTT 
F N E C D M S K A M L L R S E L N D I  F
CAAAAAAAATATTCATGTAAATTAGGATTTGTATCATTATTTATGTATGCATCAACATTG
K K F V S M Y A S T L
GCTTTAAAAAAAATGCCAAATGTAAATGCATATATAGAAAATGATGAAATTGTATATAAA
A L K K M P N V N A Y V Y K
AATTATATAGATATATCTGTAGCAGTAGCTACACCAAATGGCTTAACCGTTCCAGTTATA
V A V A T N G L T V P V
AGAAATTGTCAAAATAAAAATTTACCACAATTAGAATTAGCTTTATCTGATTTAGCTACA
R N C Q N K N L P Q L E L A L S D L A T
AAAGCACGATCAAATAAATTATCGATTGATGATTTTAGTGGTGGTACATTTACAATATCT
K A R S N K L S I D D F S G G T F T l I
AATGGAGGTGTTTTTGGTAGTATGTTAAGTACTCCTATTATTAATATGCCACAGTCAGCT 
N G G V F G S M L S T P I  I N M P Q S A
ATTCTAGGAATGCATACAATAAAAAATAGACCAGTAGTTGTCAATAATGAAATTGTTATT
I L G M H T I K N R P V V V N N E I V I
AGACCAATTATGTACCTTGCCCTTACATATGATCATAGATTATTAGACGGAAGAGAAGCC
r p i m y l a l t y d | r l l d g r e a
GTACAATTTTTATGTGCAATAAGAGATTATATAGAAAACCCTAATCTAATGTTAATTGAT
V Q F L C A I R D Y I E N P N L M L I D
TGTTAA 
C *
60
20
120
40
1 80
60
2 4 0
80
3 0 0
100
3 6 0
120
4 2 0
140
48 0
160
54 0
180
60 0
20 0
66 0
22 0
72 0
24 0
78 0
26 0
84 0
28 0
900
30 0
960
32 0
10 2 0
34 0
10 8 0
36 0
1 1 4 0
3 80
12 0 0
4 0 0
12 6 0
4 2 0
1266
4 2 2
F igure  5.5 -  Plasmodium falciparum  KGDH-E2B
The com p lem en tary DNA seq u en ce  (with both introns removed) is disp layed with the resulting 
am ino acid seq u en ce  shown below. The initiator m ethionine is included in the  num bering and 
the term ination codon is m arked with an as terisk  (*). The predicted site of mitochondrial 
targeting peptide c leavage (S44) is highlighted in grey. The last am ino acid of the N-term inal 
sec tions used  to produce the  GFP-fusion pro teins is m arked in pink, with the KGDH-E2A 
construct using the residue equivalen t to valine 195 and both KGDH-E2B cons tructs (C & G) 
using a lanine 114, The conserved  lysine residue (K86) that is the site of lipoylation is 
highlighted in red, with ano ther residue (G97) tha t is essen tia l for lipoylation to occur highlighted 
in yellow. R esidues involved in the acylation reaction in the catalytic dom ain a re  highlighted blue 
(H392) and green (S340).
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5.2.1.3 Branched chain a  - keto acid dehydrogenase alpha subunit
The branched chain a  -  keto acid dehydrogenase alpha subunit (BCKDH E l a) 
displayed 49 % amino acid sequence identity with the human protein (012694). The P. 
falciparum  gene I identified was located on chromosome 13 and was later annotated 
PF13_0070 in PlasmoDB (www.plasmodb.org) . ClustalW alignment with homologues 
identified in the other Plasmodium species P. berghei, P. yoelii yoelii, P. chabaudi 
confirmed the predicted start site o f the open reading frame and the deduced amino acid 
sequences displayed identities o f 73 %, 65 % and 66 %, respectively (data not shown). 
Therefore it was assumed that the P, falciparum branched chain a  - keto acid 
dehydrogenase alpha gene contained a single open reading firame o f 1290 bp, which 
encoded a protein consisting o f 430 amino acids with a predicted molecular mass o f  
49.9 kDa. BLASTP analyses o f the predicted amino acid sequence displayed greatest 
amino acid identity to homologous proteins from other apicomplexa such as Theileria 
parva  (52 %) and fungi such as Yarrowia lipolytica (44 %) and Neurospora crassa (45 
% ).
Comparison o f the BCKDH-Ela amino acid sequence with those previously studied 
from other organisms has identified a number of important residues involved in protein 
function (Fisher et a l, 1991; Denoya et a l, 1995; Aevarsson et a l, 1999; Ono et a l, 
2001). Residues responsible for the binding o f the thiamine pyrophosphate co-factor are 
present in the Plasmodium protein in a conserved motif (GDGXzgNN; highlighted grey 
in figure 5.6). A consei-ved leucine residue (Leu 191; highlighted red in figure 5.6) is 
involved in orientation o f the TPP co-factor into a V-conformation, while a conserved 
histidine residue (His 318; highlighted green in figure 5.6) acts as a proton donor to one 
of the sulphur atoms o f the lipoyl-arm of BCKDH-E2 (while a conserved histidine in 
BCKDH-Eip acts as a proton donor to the other; see section 5.2.4). Of the two 
phosphoiylation sites present in mammalian BCKDH-Ela, only the first is conserved in 
the P. falciparum  amino acid sequence (Ser 319; highlighted yellow in figure 5.6) with 
the other being replaced by a proline (Pro 329). A conserved tyrosine residue (Y422; 
highlighted blue in figure 5.6) has been shown to be essential for formation o f the 
hetero-tetramer in human BCKDH (Fisher et a l, 1991).
Analysis of the BCKDH-Ela with subcellular prediction programs identified that the 
protein was likely to be mitochondrially localised with high levels o f confidence (99.4 
%) and a predicted mitochondrial targeting peptide cleavage site at amino acid 21
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(highlighted pink in figure 5.6; table 5.2); this would result in a predicted mature protein 
size of 47.5 kDa.
DNA: + 1:
DNA: + 1 :
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1 :
DNA: + 1:
DNA: + 1:
DNA: + 1:
DNA: + 1 :
DNA: + 1:
DNA: + 1 :
DNA: + 1:
DNA: 
+ 1:
DNA: 
+ 1:
DNA: 
+ 1 :
DNA: 
+  1:
DNA: 
+ 1:
DNA: 
+ 1 :
DNA: 
+ 1:
DNA: 
+ 1:
DNA; 
+  1 :
ATGAGAAATATTGTTCAGAAATACTTACAAAGGAATAGCACAAAGTTATTTAACAGAACA
M R N I V Q K Y L Q R N S T K L F N R T
AGTGTATTCAATTTATATAAAAAATGTAATTTTTCTGGATACAAAATTTACAGTGACGGA
I  V F N L K K C N D G
CTAGTTCACTCTGAATTTTCTACTGAGTTAAAAACTGTAAATGAAGTTATAAAAATGCCT
L V H S E F S T E L K T V N E V I K M P
ATTTATAGAATATTGGATACGAATGGACATTTATTAGACGGTCATGAAGCGCCATTTAAG
l Y R I L D T N G H L L D G H E A P F K
GATGAAGAAGTATTAAAAATTTACAAGGATATGGTTGAATTTTCTATATGGGATGAAATA
D E E V L K I Y K D M V E F S I W D E I
TTTTATGGAATACAAAGACAAGGTAGAATATCATTTTATATAGTTAATGAAGGAGAAGAA
F Y G I Q R Q G R I S F Y I V N E G E E
GGTTTACAATTTGGTATGGGTAAAGCATTAAGTGTTGATGATCATTTATATTGTCAATAT
G L Q F G M G K A L S V D D H L Y C Q Y
AGAGAAACAGGTGTTTTATTATCCAGAGGTTTTACATACACTGATATATTAAATCAATTA
R E T G V L L S R G F T Y T D I L N Q L
TTCGGTACCAAATATGATGAAGGTAAAGGTAGACAAATGTGTATATGCTATACTAAAAAA
F G T K Y D E G K G R Q M C I C Y T K K
GATTTAAATATTCATACTATTACTACACCATTAGGATCTCAATTATCACATGCTGCCGGT
H T P I  G H A A G
TGTGGTTATGCATTAAAACTAAAAAATCAAAAAGCTGTTGCTGTTACTTATTGTGGTGAT
C G Y A L K L K N Q K A V A V T Y C G D
GGTTCTTCATCAGAAGGAGATTTTTATGCTGCTCTAAATTTTGCTTCTGTAAGACAATCA
g s s s e g d f y a a l n f a s v r q s
CAAACCATGTTTGTATGCAAAAATAATTTGTATGCTATATCCACATCTATTAAAGATCAA
Q T M F V C K N N L Y A T S K D
TATAGAGGTGATGGTATTGCACCAAGAGCATTAGCCCTAGGAATAGAATCCATAAGAGTA
Y R G D G I A P R A L A L G I E S I R V
GATGGAAATGATTTATTCGCAAGTTATCTAGCTACAAAAAAATTAAGAGATATTTGTATT
D G N D L F A S Y L A T K K L R D I C I
CAAGAATCAAAACCAGTTTTTATTGAATTCATGTCCTATAGATATGGTCACCATAGTACT
q e s k p v f i e f m s y r y g h | s t
TCTGATGATTCTAGTTTGTACAGACCAAAAGAAGAAAATGAAGCTTGGAGACAAGAAGGA
S D D S S L Y R P K E E N E A W R Q E G
GTACACCCAATTAGTAGAATCTTTTTATATCTCAAGAATAAAAACTTATATAGTGAAAAA
L Y K N K N L Y
GAAGATCAAGAACACAGAAAAAGTGTCAAAGAAAATGTATTAAAAGAATTAAAAAAATAT
E D Q E H R K S V K E N V L K E L K K Y
GAAAGTGTTAAAAGATATAATATTGTTGGTGGATTATTTGAAGATGTATATCATGAAGAA
V K R Y N V G V Y H
GACTGGAACATTAAAGAACAAAGAGAAAACTTTGAGCAGTTTTTCAAAGAAAATAAACAT
K E N K H
60
20
120
40
180
60
24 0
80
30 0
100
360
120
4 2 0
140
4 8 0
16 0
54 0
18 0
60 0
2 00
66 0
220
7 20
2 40
7 80
2 60
8 40
2 80
9 00
3 0 0
9 6 0
320
1 0 2 0
34 0
1 0 8 0
36 0
1 1 4 0
38 0
12 0 0
4 0 0
12 6 0
4 2 0
AATTATGATACATCAAAATTTGAGCGATGA
N I  D T S K
1 3 1 0
4 3 0
F igure  5.6 -  Plasmodium falciparum  BCKDH-E1 a
T he DNA seq u en ce  of the BCKDH-E1a  g en e  is displayed with the resulting am ino acid 
seq u en ce  shown below it. The pred icted m itochondrial targeting peptide c leavage site is 
highlighted in pink, while the th iam ine pyrophospha te  binding motif is highlighted in grey. A 
conserved  histidine residue (His318) residue tha t ac ts a s  a  proton donor to the  lipoic acid 
a ttached  to the BCKDH-E2 is highlighted green. Leucine 191 is responsib le  for the  V- 
conformation of the bound th iam ine pyrophospha te  and is highlighted red. A single 
phosphorylation site (Ser319) is highlighted in yellow, and a residue (Tyr422) tha t is essen tia l 
for formation of the hetero-tetram er is highlighted in blue.
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5.2.1.4 Branched chain a  - keto acid dehydrogenase beta subunit
The P. falciparum  branched chain a  -  keto acid dehydrogenase beta subunit (BCKDH- 
E ip) displayed 61 % amino acid sequence identity with the human protein (P21953). 
The P. falciparum  gene I identified was located on chromosome 5 and was later 
annotated PFE0225w in PlasmoDB (www.plasmodb.ore). The 1146 bp BCKDH-El f  
gene coded for a protein o f 382 amino acids with a predicted molecular size o f 43.0 
kDa. Alignment with homologues from other Plasmodium species P. yoelii yoelii and P. 
berghei confirmed the predicted start site o f the open reading frame and displayed 
amino acid identities o f 82 % and 77 %, respectively (data not shown). BLASTP 
analyses o f the predicted amino acid sequence o f P. falciparum  BCKDH-Eip displayed 
greatest amino acid identities to homologous proteins o f mammals such as Bos taurus 
(Cow; 61 % identity), Gallus gallus (chicken; 62 % identity), Rattus norvegicus (rat; 61 
% identity) and Mus mus cuius (house mouse; 61 % identity).
Comparison o f the P. falciparum  BCKDH-El p amino acid sequence with those from 
organisms previously investigated identified some o f the conserved and important 
residues (Aevarsson et a l, 1999). The active site histidine that acts as a proton donor to 
one of the sulphurs from the lipoyl-arm o f the BCKDH-E2 was conseived identified in 
the P. falciparum  sequence (His 186; highlighted red in figure 5.7). Two residues 
involved in binding o f the TPP co-factor were also conserved; the conseived tyrosine 
(Tyr 142) and glycine (Gly 118) are involved in the binding o f the aminopyrimidine 
ring o f the TPP co-factor (highlighted blue in figure 5.7).
Analysis o f the BCKDH-El p amino acid sequence with subcellular localisation 
prediction programs suggested that the protein was mitochondrial with a high level o f  
confidence (99.5 %), although a mitochondrial targeting peptide cleavage site was not 
predictable by the programs used (table 5.2). Alignment of the P. falciparum  BCKDH- 
E l p with its E. coli homologue displayed amino acid identity starting from amino acid 
57 (highlighted yellow in figure 5.7), which suggests that the possible mature protein 
(minus the mitochondrial targeting peptide) was about 36.2 kDa in size.
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DNA: ATGATGAGACTATTAAGAAATAACGTAAAAAATATGTTCTTAAAAAATTGCTTTCTTGTG 60  
+ 1 : M M R L L R N N V K N M F L K N C F L V  2 0
DNA: AGGAATACAAATGTAAAATGTTGGAGAACCGATAGGTTTCATAATTACAATATGTGGAAT 1 2 0  
+ 1 :  R N T N V K C W R T D R F H N Y N M W N  4 0
DNA: ACTGTTGAAAATAATGGCATTCGTGGTTTTTCTTCCTCTAGTTTTGAAGAGATAAAAAAA 1 8 0  
+ 1 :  T V E N N G I R G F S S S S F E E I K K  60
DNA: ATGAATATGTTTACAGCAATAAATTCAGCTATGCATAATGTATTTGAAAGTAACCCTAAT 24  0 
+ 1 :  M N M F T A I N S A M H N V F E S N P N  80
DNA: TCTGTATTATTAGGAGAAGATGTTGCTTTCGGAGGTGTGTTTAGATGTTCTTTAGATTTA 3 0 0  
+ 1 :  S V L L G E D V A F G G V F R C S L D L  1 0 0
DNA: TTAAAAAAATATGGAAACATGAGAGTTTTCAATACTCCCTTATGTGAACAAGGAATTATA 3 6 0  
+ 1 : L K K Y G N M R V F N T P L C E Q | i  I  1 2 0
DNA: GGATTTGCTATAGGTCTAGCTGAAAATGGATTTACAACAATAGCAGAAATACAATTTGGT 4 2 0  
+ 1 :  G F A I G L A E N § F T T I A E I Q F G  1 4 0
DNA: GATTACATATTTCCAGCnTTGATCAAATAGTAAATGATGTAGCTAAATATAGATATAGA 4 80  
+ 1 : D |  I  F P A F D Q  I V N D V A K Y R Y R  1 6 0
DNA: TCAGGTAGTAGTTTCGATGTAGGTAAATTAACTATAAGATCGACGTGGGGTGCTGTTGGT 54  0 
+ 1 : S G S S F D V G K L T I R S T W G A V G  1 8 0
DNA: AAAATTATTGTACCAAGTGATGCATATAAAGCTAAAGGATTGTTATTGTCAGCTATTAAT 6 6 0  
+ 1 : K I I V P S D A Y K A K G L L L S A I N  2 2 0
DNA: GATCCGAACCCATGCTTATTTTTTGAACCCAAAATTTTATATAGATCATCAGTGTGCGAT 7 2 0  
+ 1 :  D P N P C L F F E P K I L Y R S S V C D  2 4 0
DNA: GTACCTACGGGACCATATCAATTAGAATTGGGTAAGGCAGATGTTGTAAGACAAGGTTCA 7 8 0  
+ 1 : V P T G P Y Q L E L G K A D V V R Q G S  2 6 0
DNA: GATGTGACTATAGTAACATGGGGATCTTTAGTACATAAAATGAAAAATGCTGCAGAGATT 84 0 
+ 1 :  D V T I V T W G S L V H K M K N A A E I  2 8 0
DNA: TTATCCAAAAAACATAATATCGAATGTGAAGTTATTGATCTACAATCTATCATACCATGG 9 0 0  
+ 1 :  L S K K H N I E C E V I D L Q S I I P W  3 0 0
DNA: GATATTGAAACTGTACAAAAATCTGTCGAAAAAACGGGAAGACTTTTAATTACACATGAA 9 6 0  
+ 1 :  D I E T V Q K S V E K T G R L L I T H E  3 2 0
DNA: GCTCAGCTAACCAATGGTTTTGGAGCTGAAATTGCAGCAAAAATTCAAGAAAGATGTTTC 1 0 2  0 
+ 1 :  A Q L T N G F G A E I A A K I Q E R C F  3 4 0
DNA: TATAATTTGCATACACCTATAAAAAGAGTCTGTGGTTATGATACTCCTTTCCCCCATGTC 1 0 8 0  
+ 1 :  Y N L H T P I K R V C G Y D T P F P H V  3 6 0
DNA: TACGAGCCATTTTACATGCCCGATGCACATAAAGTTATATACGAAGTCAAAAAAATGATG 1 1 4  0 
+ 1 :  Y E P F Y M P D A H K V I Y E V K K M M  3 8 0
DNA: AAGTAA 1 1 4  6
+ 1 :  K * 3 8 2
F igure  5.7 -  Plasmodium falciparum  BCKDH-Eip
The DNA seq u en ce  of the BCKDH-E1 p  gene  is disp layed with the resulting am ino acid 
seq u en ce  shown below it. The first am ino acid of the predicted m a ture protein (G lu57) is 
highlighted in yellow. An active site Histidine (His186) tha t ac ts a s  a  proton donor to the E2 
bound lipoic acid is highlighted in red. Two residues (Tyr142 and G ly118) tha t are  involved in 
the binding of thiam ine pyrophospha te  are  highlighted in blue. The last am ino acid (Gly 130) of 
the N-term inal sec tion used to construct the BCKDH-Eip GPP fusion protein is highlighted in 
green.
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5.2.1.5 Branched chain acvl transferase
The P. falciparum  BCKDH-E2 protein displayed 34 % sequence identity with the 
human protein (PI 1182). The P. falciparum  gene I identified was located on 
chromosome 3 and was later annotated PECO 170c in PlasmoDB (www.plasmodb.org). 
The 1347 bp gene coded for a protein o f 449 amino acids with a theoretical molecular 
size o f 51.0 kDa. Alignment with homologues from other Plasmodium species 
confirmed the predicted start site and displayed 59 %, 57 % and 57 % amino acid 
identity to the P. chabaudi, P. berghei and P. vivax homologues, respectively. BLASTP 
analyses o f the predicted P. falciparum  BCKDH-E2 amino acid sequence displayed 
greatest amino acid identity to homologous proteins from the nematode Caenorhabditis 
elegans (32 % identity), gammaproteobacteria {Idiomarina loihiensis; 30 % identity) 
and plant Oryza sativa (30 % identity).
ClustalW alignment of the P. falciparum  BCKDH-E2 with mitochondrial isoforms from 
other organisms displayed that the protein can be divided into three domains that are 
separated by flexible linker regions; the lipoyl-domain, the subunit-binding domain and 
the catalytic/inner core domain. The position o f these domains in the P. falciparum  
BCKDH-E2 amino acid sequence was identified by alignment with proteins from 
organisms that have been previously investigated (Griffin et a l, 1990; Wexler et a l, 
1991; Meng et a l, 1994; Ono et a l, 2001). The lipoyl-domain runs between residues 15 
and 102 and contains the lysine residue (residue 74 in the P. falciparum  protein; 
highlighted in red in figure 5.8) that is the site of lipoylation. The subunit-binding 
domain runs between residues 144 and 189 and is the site o f E l and LipDH association. 
The catalytic domain is the site o f self-association and acylation o f coenzyme A and 
runs between residues 212 and 449. Residues His 418 and Ser 358 (highlighted in 
yellow in figure 5.8) have been implicated in acylation reaction, with His 418 
(highlighted in blue in figure 5.8) acting as an acid/base catalyst. Analysis o f the 
flexible linker domains displays that the BCKDH-E2 linkers are not rich in proline and 
alanine residues as observed in mammalian proteins, but are rich in asparagines, 
glutamates and aspartate residues (figure 5.8).
Analysis o f BCKDH E2 amino acid sequence with subcellular localisation prediction 
programs identified that the protein was predicted to be mitochondrially localised with 
high confidence levels (92.2 %) and a mitochondrial targeting peptide cleavage site was 
suggested after amino acid 14 (highlighted green in figure 5.8; table 5.2); this would 
correspond to a mature protein size o f 49.5 kDa.
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DNA: ATGTTTGTGAAGAATGTACTAAACGTGCTTAGGAGAATCGAGGGAAAATCATTTAAAGGG 60  
+ 1 : M F V K N V L N V L R R i | g K S F K G  20
DNA: CGCCATTACCTGAACACGAGTGCAATACATTTTAAGATTGTGAAATGCAAATTATTTGAT 1 2 0  
+ 1 :  R H Y L N T S A I H F K I V K C K L F D  4 0
DNA: ATAGGGGAAGGGATATCAGAAGTGGAAATTACCAAGTGGCATAAAAATGAAGGTGATCAA 1 8 0  
+ 1 :  I G E G I S E V E I T K W H K N E G D Q  60
DNA: GTAAGTGAAATGGAGAGTTTGTTGACTGTACAAAGTGACAAAGCTGCTGTAGATATAACT 2 4  0 
+ 1 :  V S E M E S L L T V Q S D | a A V D I T  80
DNA: AGTAAATATAATGGTGTATTGGTAAAAAAATATTTAAATGAAAATGATATGTTAAAAGTT 3 0 0  
+ 1 : S K Y N G V L V K K Y L N E N D M L K V  1 0 0
DNA: GGATCATATTTCTGTGAGATAGATACAGATGATGATATTATTGAAAGAGATGAAGAAGAA 3 60  
+ 1 :  G S Y F C E I D T D D D I I E R D E E E  1 2 0
DNA: GTAGAAAAGGAGGAAAATAATAAAAAAGAAGAAGATGGTGAAAGTGATTTAAGTTTAAAT 4 2  0 
+ 1 :  V E K E E N N K K E E D G E S D L S L N  1 4 0
DNA: GATGATATTAGCAATAATGATTATATTAAAGCATCTCCAGGTGTTAAAAGAAAAGCCAAA 4 80 
+ 1 :  D D I S N N D Y I K A S P G V K R K A K  1 6 0
DNA: GAATATAAAGTAAATTTAAATAAAGTTGGTGATTATTTTAATAAAGTTAATATAAGCTTA 54 0 
+ 1 : E Y K V N L N K V G D Y F N K V N I S L  1 8 0
DNA: GAAGATTTGGAATTATATTATAATAATGTTGTTAAAAATGAATATAGTAATAATATAAAT 6 0 0  
+ 1 : E D L E L Y Y N N V V K N E Y S N N I N  2 0 0
DNA: AATAATGATATGGATATTATTGAAGAAGTATCATTAAAAGGTATAAAATTAGCTATGTGT 6 6 0  
+ 1 :  N N D M D I I E E V S L K G I K L A M C  2 2 0
DNA: AAAAGTATGAATGAATCTTTACAAGTACCATTATTTCATTTAAATGAAATGTGTATTATA 7 2 0  
+ 1 : K S M N E S L Q V P L F H L N E M C I  I  2 4 0
DNA: AATAATTTAATAAAAATGAGAAAAGAATATAAAGAACAACAAAAAAATTTACAAACAAAA 7 8 0  
+ 1 :  N N L I K M R K E Y K E Q Q K N L Q T K  2 6 0
DNA: GAAACTAATATAACTATTACATGTATACTTATAAAATTAATATCTAATGTATTAAAAGAA 84 0 
+ 1 :  E T N I T I T C I L I K L I S N V L K E  2 8 0
DNA: TTCCCAATTTTAAATTCCAAATTTAATTTTAAAACTAATACTTATACTATGTATAAGAAT 9 0 0
+ 1:  F L N K F N F K T N T Y T M Y K N 3 0 0
DNA: CATAATATATCTATAGCTGTTGATACTCCTCATGGATTATTAGTACCAAATATAAAAAAT 9 6 0  
+ 1 : H N I S I A V D T P H G L L V P N I K N  3 2 0
DNA: GTTCAGAATAAAAATATTTTAGATATTCAAAAAGATTTATTATCATTACGTGATAAAGCA 1 0 2 0  
+ 1 :  V Q N K N I L D I Q K D L L S L R D K A  3 4 0
DNA: AATAATATGCAACTTGATAAAAGTGATATTACTAATGGTACAATAACTGTTAGTAATTTT 1 0 8 0  
+ 1 :  N N M Q L D K S D I T N G T I T V S N F  3 6 0
DNA : GGAGCCATATCAGGAACCTTTGCTACTCCTATAGTATTTGATAATCAAGCATGTATAATA 1 1 4  0 
+ 1 :  G A I S G T F A T P I V F D N Q A C I  I  3 8 0
DNA: GGTATAGGCAAAATGGAAAAAAAATTGCTTTTAAAAGATGAATCTAATAACTTAAATTCT 1 2 0 0  
+ 1 :  G I G K M E K K L L L K D E S N N L N S  4 0 0
DNA: TTAAATGATATATTAGTTGCTGATACTATAAACTTCACCTTTGGAGCTGACCATAGGTAT 1 2 6 0  
+ 1 :  L N D I L V A D T I N F T F G A D | r Y 4 2 0
DNA: ATAGATGGAGCAACCTTAGCTCAGTTTTCTAAAATGTTAAAAATGAATATTGAAAATTGT 1 3 2 0  
+ 1 : I D G A T L A Q F S K M L K M N I E N C  4 4 0
DNA: GCATCCCTAGGACCACTATTGGAATAA 
+ 1 : A S L G P L L E *
F igure  5.8 -  Plasmodium falciparum  BCKDH E2
1 3 4 7
4 4 9
T he DNA seq u en ce  of the BCKDH E2 g en e  is disp layed with the  resulting am ino acid seq u en ce  
shown below it. The predicted m itochondrial targeting peptide c leavage site (Glu14) is 
highlighted in green. The conserved  lysine residue (Lys74) that is the site of lipoic acid 
a ttachm en t to the protein is highlighted in red. Two residues, Ser358 and His418, which are  
involved in the acylation reaction a re  highlighted in yellow and blue, respectively.
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5.2.1.6 Pyruvate dehydrogenase alpha subunit
The pyruvate dehydrogenase alpha {PDH-El ot) gene displayed 32 % identity with the 
human amino acid sequence (P08559). The P. falciparum  gene I identified was located 
on chromosome 11 and was later amiotated PFl 1 0256 in PlasmoDB 
(www.plasniodb.org). The 1824 bp gene is intron-less and encodes a protein o f 608 
amino acids with a predicted molecular size o f 70.9 kDa. ClustalW alignment with 
homologues identified in other Plasmodium species confirmed the predicted start site o f  
the protein and displayed 73 %, 66 % and 65 % amino acid identity to the P. berghei, P. 
chabaudi and P. yoelii yoelii proteins, respectively. BLASTP analyses of the predicted 
amino acid sequence o f PDH-El a displayed greatest amino acid identity to homologous 
proteins fiom the cyanobacteria Thermosynechococcus elongatus (46 % identity) and 
Crocoshpaera watsonii (44 % identity) and the red algae Cyanidium caldarium (48 % 
identity) and Porphyra purpurea (44 % identity).
Comparison o f the P. falciparum  PDH-El a  amino acid sequence with those previously 
studied in other organism identified a number o f key residues (Diefenbach et a l, 1992; 
Russell et a l, 1992; Ciszak et a l, 2003). The TPP co-factor binding motif 
(GDGX26NN) was observed in the sequence between residues 364 and 395 (highlighted 
grey in figure 5.9). One o f the phosphorylation sites observed in the mammalian 
proteins was conserved in the P. falciparum  sequence (Ser 467; highlighted yellow in 
figure 5.9). The active site histidine residue that acts as a proton donor to one the 
sulphms o f a lipoyl-aim from the PDH-E2 was conserved (His 466; highlighted blue in 
figure 5.9).
The Plasmodium PDH-El a  deduced amino acid sequence possessed a long N-terminal 
extension compared to those PDH-El a  from other organisms. Analysis of the PDFI-
■El a  subunit amino acid sequence with subcellular prediction programs identified a 
typical signal peptide o f 17 or 23 amino acids at its A-terminus (depending on the 
prediction program used; highlighted red in figure 5.9), which was followed by a stretch 
o f hydrophilic amino acids. Using the prediction program PlasmoAP it was found that 
this hydrophilic stretch o f amino acids possibly could confer transit into the parasite’s 
apicoplast (++; table 5.2). These results therefore suggest that PDH possesses a typical 
bipartite tai'geting sequence responsible for the transfer o f Plasmodium proteins to the ;
apicoplast (Foth et a l, 2003). Given that the parasite genome only contains genes 
encoding for the components of a single PDH this predicted localisation appears rather
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unusual and will be investigated in more detail later. Prediction of the possible mature 
PDH-El a  was not possible using any of the prediction programs. Also it is impossible 
to draw any conclusions from comparison with the E. coli counterpart because the 
bacterial PDH contains a homodimeric El rather than a hetero-dimeric tt2p2 El found in 
eukaryotes (de Kok et a l, 1998).
DNA: ATGCTGTTAGTAATATGGTTAAACATTTTTTGGTTCATCCCTTATTATTGTTTTAATTAC 60  
+ 1 :  M L L V I W L N I F W F I P Y y | f N Y  20
DNA: GTnTATGTGTAGGGAATAAAAATGACATGCTTTTTGTAAAAAATAAAAATCTAATATAT 12  0 
+ 1 :  V l | v G N K N D M L F V K N K N L I Y  4 0
DNA: CCTTATAATGATATGAATAGAATAAGGAGACATAAAGGGGTGGAACTAAGCAGAAAGATG 1 8 0  
+ 1 :  P Y N D M N R I R R H K G V E L S R K M  60
DNA: GTTGCTGAGAATATTCAAATGAGAAATATGAAGAGTAACAATAATAGTAATAATGTTCAT 2 4  0 
+ 1 :  V A E N I Q M R N M K S N N N S N N V H  80
DNA: GAGAATAATAATATTGATCATAGTAACAATTATAATAATAATTTATATTTATCATGTAGT 3 0 0  
+ 1 : E N N N I D H S N N Y N N N L Y L S C S  1 0 0
DNA: AATAAAAAAAAAGGAAAAGATGTACAATCATTGTGTGCCATAAAACACGGCAACGTACTG 3 6 0  
+ 1 : N K K K G K D V Q S L C A I K h | n V L  1 2 0
DNA: ATCAAAAATATAAATGAAGAAGAAAAAGAAAAGGGAATTAAGAAAAATGATACAGATAAA 4 2 0  
+ 1 :  I K N I N E E E K E K G I K K N D T D K  1 4 0
DNA: TTAGAATCAAAAAATGATAATGAACATAAAAATGAAGAGAATAATTTCGTTTTTTCATAT 4 80  
+ 1 :  L E S K N D N E H K N E E N N F V F S Y  1 6 0
DNA: GATAAAAAATTAAATAATTATTCTGAATTTAATATATATATGGAAAATAATAATATAGAA 54 0 
+ 1 :  D K K L N N Y S E F N I Y M E N N N I E  1 8 0
DNA: GAATATATATCCGATGTAAATATTAGTAGAGAAGAAATATGTACCTTATATGAAGATATG 6 0 0  
+ 1 :  E Y I S D V N I S R E E I C T L Y E D M  2 0 0
DNA: TATTTAGGACGACTTTTTGAGAACTTAGTAGCCAAATTATATTATAATAAACGAGTTAAT 6 6 0  
+ 1 : Y L G R L F E N L V A K L Y Y N K R V N  2 2 0
DNA: GGTTTTGTTCATTTATATAATGGTCAAGAAGCTGTAAGTACAGGTATTATTAAAAATTTA 7 2 0  
+ 1 : G F V H L Y N G Q E A V S T G I I K N L  2 4 0
DNA: AAAAATTCAGATTTTGTTACAAGTACTTATAGAGATCATGTTCATGCTCTAAGTAAAGGT 7 8 0  
+ 1 : K N S D F V T S T Y R D H V H A L S K G  2 6 0
DNA: GTGCCTGCACATAAAATATTAAATGAATTATATGGAAATTATTATGGTAGTACAAATAAA 84  0 
+ 1 :  V P A H K I L N E L Y G N Y Y G S T N K  2 8 0
DNA: GGGAAAGGTGGTTCTATGCATATTTATTCAAAAGAAAATAATnTATAGGAGGTTTTGGT 9 0 0  
+ 1 :  G K G G S M H I Y S K E N N F I G G F G  3 0 0
DNA: TTTATTGGTGAACAAATACCTATTGCTGTTGGATTAGCATATAGTATCTTATATAAAAAT 9 6 0  
+ 1 : F I G E Q I P I A V G L A Y S I L Y K N  3 2 0
DNA : GAATTTCACTATAATCCAAAAAATACCTCTTTTACATCTACTAAAAATAAAAATAATTAT 1 0 2 0  
+ 1 :  E F H Y N P K N T S F T S T K N K N N Y  3 4 0
DNA: ATACAAGAAAATGAAAATATGATACATATGAATAATTCTCAAAACGTAGATGTTGTAGTA 1 0 8 0  
+ 1 :  I Q E N E N M I H M N N S Q N V D V V V  3 6 0
DNA: TGTTTCTTAGGTGATGGTACTACTAATATTGGACAATTCTTTGAATCATTAAATCTTGCT 1 1 4  0 
+ 1 : C F L G D G T T N I G Q F F E S L N L A  3 8 0
DNA: TCTTCTTACAACTTACCAATAATATTTGTTATAGAAAATAATAATTGGGCTATAGGTATG 1 2 0 0  
+ 1 : S S Y N L P I I F V I E N N N W A I G M  4 0 0
DNA : GAAAGTTCTAGAAGCTCATCTGATGATCTTATGAATAATTATTCCAAAGGAAAAGCTTTT 1 2 6 0  
+ 1 :  E S S R S S S D D L M N N Y S K G K A F  4 2 0
DNA : AATATAGATACTTTTAAAGTAGATGGAAATGATGTTCTTACTATATATAAACTAGCCAAA 1 3 2  0 
+ 1 :  N I D T F K V D G N D V L T I Y K L A K  4 4 0
DNA: AAGAAAATTCAACAAATTAGAAATAGAACATCCGGACCAATAATTATAGAAGCTATTACA 1 3 8 0  
+ 1 :  K K I Q Q I R N R T S G P I I I E A I T  4 6 0
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DNA : TATCGAGCTAAAGGACATTCTTTAGCAGATCCAGATGAACTTCGTATCAAAGAAGAAAAA 1 4 4 0  
+ 1 :  Y R A K G | s L A D P D E L R I K E E K  4 8 0
DNA: ACTTCATGGAAAAAAAGAGACCCTATTTTATTCTTATCTAGTTATATGAAGAAATATAAT 1 5 0 0
+ 1:  T S W K K R D P I L F L S S Y M K K Y N 5 0 0
DNA: TTAGTACAAGAATCATACTTCGAACAAGTTAAAAAAAATACACAAACATTATTACAACAA 1 5 6 0
+ 1 : L V Q E S Y F E Q V K K N T Q T L L Q Q 5 2 0
DNA: GCAGAATTAGATGCTGAACAAAATACAAAGAAAGGGGAACATATAGATATATGTAATGTA 1 6 2 0
+ 1 : A E L D A E Q N T K K G E H I D I C N V 5 4 0
DNA: ATTCAACAAAATATATTCGCCCCATCAAAATCTACTCCATATCAAAGTGAATATGAAAAT 1 6 8 0
+ 1 :  I Q Q N I F A P S K S T P Y Q S E Y E N 5 6 0
DNA: TATAAACAATTTGACGACATTTCTAATGACGAATTAAAAGAATATTATCAAGAAGTACTT 1 7 4  0 
+ 1 :  Y K Q F D D I S N D E L K E Y Y Q E V L  5 8 0
DNA: AAAGAAATTCAAAGAAAAAAAGAAAAGAAAAAACTTGATCCGAACGACAAATTTGATCAA 1 8 0 0
+ 1 : K E I Q R K K E K K K L D P N D K F D Q 6 0 0
DNA: AAAAAGTTACCCTTAATAATAGATTAA 
+ 1 :  K K L P L I I D *
1 8 2 7
6 0 9
F igure  5.9 -  Plasmodium falciparum  PD H -E1a
The DNA seq u en ce  of the PDH-E1 a  gene is disp layed with the resulting am ino acid seq u en ce  
shown below it. Two signal peptide c leavage sites w ere predicted (Cys17 or Cys23) and both 
a re  highlighted in red. The last am ino acid (G ly117) in the N-term inal sec tion (amino acids 1 -  
117) used  to construct the  GFP-fusion protein is highlighted in green. The th iam ine 
pyrophospha te-binding motif (GDGXaeNN) is highlighted in grey. An ac tive site histidine 
(His466) tha t ac ts a s  a  proton donor to the PDH-E2 bound lipoamide is highlighted in blue. The 
ad jacen t residue (Ser467) is a  site of PDH control by phosphorylation with pyruvate 
d ehydrogenase  kinase and is highlighted in yellow.
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5.2.1.7 Pyruvate dehydrogenase beta subunit
The pyruvate dehydrogenase beta {PDH-ElJ3) gene displayed 35 % identity with the 
human amino acid sequence (PI 1177). The P. falciparum gene I identified was located 
on chromosome 14 and was later annotated PF14 0441 in PlasmoDB 
(www.plasmodb.org) . ClustalW alignment with homologues identified in other 
Plasmodium species confirmed the predicted start site of the P. falciparum PDH- 
E l (3 open reading frame and displayed 82 % and 77 % amino acid identity to the P. 
yoelii yoelii and P. berghei proteins, respectively. BLASTP analyses o f the predicted P. 
falciparum  PHD-Elp amino acid sequence displayed greatest amino acid identity to 
homologous proteins from the cyanobacteria Gleobacter violaceus (58 % identity), 
Anabena variabilis (57 % identity) and Prochlorococcus marinus (57 % identity) and 
the red algae Gracilaria tenuistipitata (57 % identity) and Porphyra purpurea (57 % 
identity). The 1248 bp gene coded for a protein of 416 amino acids with a predicted 
molecular size o f 47.0 kDa.
Comparison o f the predicted PDH-Elp amino acid sequence with those previously 
studied in other organisms (Ciszak et a l, 2003) identified a number o f important 
residues conserved in the P. falciparum  protein. The active site histidine residue that 
acts as a proton donor to a sulphur on a lipoyl-arm of the PDH-E2 was identified (His 
217; highlighted red in figure 5.10). Two conserved residues, a phenylalanine (Phe 151) 
and a valine (Val 202) both involved in producing the V-conformation o f the bound 
TPP co-factor (highlighted green in figure 5.10) were also conserved in the parasite 
protein.
Similar to PDH-El a it was found that the PDH-El |3 deduced amino acid sequence 
contained a signal peptide at its V-terminus followed by a hydrophilic stretch o f amino 
acids both possibly comprising a bipartite apicoplast targeting peptide. PlasmoAP 
analyses supported this suggestion with high confidence (++; table 5.2). However, as 
opposed to PDH-El a, the prediction programs did not suggest a potential cleavage site 
o f the signal peptide . Similar to PDH-El a prediction o f the possible mature PDH-Elp 
was not possible as the bacterial PDH contains a homodimeric El rather than a 
heterodimeric a 2p2 E l and a precise cleavage o f a potential apicoplast transit peptide 
cannot be made.
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DNA: ATGGGGAGAAAAAGAAACAATATTGTAAACATTAGATATAATTTTTTCTTGATTTATTTT 60  
+ 1 : M G R K R N N I V N I R Y N F F L I Y F  20
DNA: TGGGTGATATTTATGTATCCATGCGAGACAAATAAAGGAAATGTGAAGCCACTAAATTTT 1 2 0  
+ 1 :  W V I F M Y P C E T N K G N V K P L N F  4 0
DNA: ATAAATGGAATTGAAACTATATCGAATGTTGAGAACAAAAATATTTTGAATGATACAAAT 24  0 
+ 1 :  I N G I E T I S N V E N K N I L N D T N  80
DNA: TATATAAATGAAATGAAGAATATAAAGGTTAGAAGAAATATAAGTGAAGCTTTACATATG 3 0 0  
+ 1 :  Y I N E M K N I K V R R N I S E A L H M  1 0 0
DNA: GCCATATATGAAGAAATGAAAAAAGATAAAGGTGTATATGTACTTGGAGAAGATGTAGGA 3 6 0  
+ 1 :  A I Y E E M K K D K G V Y V L G E D V G  1 2 0
DNA: TTGTATGGAGGTTCGTATAAAGTTACTAAAAATTTAGCTCACTTTTTTGGTTTTTCTAGA 4 2 0  
+ 1 : L Y G G S Y K V T K N L A H F F G F S R  1 4 0
DNA: GTTTTAGATACACCCATATGTGAAAATGCCTTCATGGGATTAGGTATAGGTTCTGCAATT 4 80  
+ 1 : V L D T P I C E N A | m G L G I G S A I  1 6 0
DNA: AACGACTTAAGACCTATTATTGAAGGTATGAATTTGTCTTnTTAAnTTAGCATTTAAT 54  0 
+ 1 :  N D L R P I I E G M N L S F L I L A F N  1 8 0
DNA: CAAATATCAAATAATGCTTGTATGATGAGATATATGTGTGATGGTCAATTTAATATTCCT 6 0 0  
+ 1 : Q  I  S N N A C M M R Y M C D G Q F N  I  P  2 0 0
DNA: ATTGTTATTAGAGGTCCAGGAGGTATAGGGAAACAATTAGGTCCTGAACATTCTCAAAGA 6 6 0  
+ 1 : I | i R G P G G I G K Q L G P E | s Q R  2 2 0
DNA: ATTGAATCGTATTTAATGAGTATACCAGGTATTAAAATCGTTTCATGCTCAACACCTTTT 7 2 0  
+ 1 :  l E S Y L M S I P G I K I V S C S T P F  2 4 0
DNA: AATGCTAGAGGATTATTAAAATCAGCAATTAGAGATAATAACCCTATATTATTTATAGAA 7 8 0  
+ 1 :  N A R G L L K S A I R D N N P I L F I E  2 6 0
DNA: CATGTTTTATTATATAATTATGAACAGGAAATTCCTCTTTTACCTTACACCTTACCTATT 84 0 
+ 1 :  H V L L Y N Y E Q E I P L L P Y T L P I  2 8 0
DNA: GATAAAGCAGAAGTTGTTAAAAATGGAAAAGATCTAACCGTTTTATCCTATGGAATAACA 9 0 0  
+ 1 :  D K A E V V K N G K D L T V L S Y G I T  3 0 0
DNA: AGACATTTAGCTTCCGAAGCAGCAAAAGAATTAACGAAATTTAATATAGATATAGAAGTA 9 6 0  
+ 1 :  R H L A S E A A K E L T K F N I D I E V  3 2 0
DNA: ATTGATTTAATTTCTTTAAAACCATTTGATATGGAAACTATAGAAAAATCTCTTAAAAAA 1 0 2 0  
+ 1 : I D L I S L K P F D M E T I E K S L K K  34  0 f
DNA: ACCAAGAAATGTTTAATTTTGGATGAGTCAGCTGGTTTTGGGGGTATAGGAGCTGAATTA 1 0 8 0  
+ 1 :  T K K C L I L D E S A G F G G I G A E L  3 6 0
DNA: TATACACAAGTTATAGAAATGTTTTCTTCATACTTAATAACCAAACCTATTAGATTATGT 1 1 4 0  
+ 1 : Y T Q V I E M F S S Y L I T K P I R L C  3 8 0
DNA: ACCAAGGATATACCTATAGCTTATTCAAATAAATATGAAGACGCATGTATTATCAAAAAG 1 2 0 0  
+ 1 : T K D I P I A Y S N K Y E D A C I I K K  4 0 0
DNA: GAGGACATTGTATATATGTCTACTTATCTTCATTCGCTATCATCTTGA 1 2 4  8
+ 1 : E D I V Y M S T Y L H S L S S *  4 1 6
F igure  5.10 -  Plasmodium falciparum  PD H -E l p
The DNA seq u en ce  of the PDH-E1agene  is disp layed with the resulting am ino acid seq u en ce  
shown below it. An active site histidine residue tha t ac ts a s  a  proton donor to the  lipoamide 
bound to PDH-E2 is highlighted in red. Two residues (Phe151 and Val202) tha t are  involved in 
the formation of the bound thiam ine pyrophospha te  into a  V-conformation are  highlighted in 
green.
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5.2.1.8 Acetyl transferase
The P. falciparum acetyl transferase gene (PDH-E2) identified had been previously 
annotated PF10_0407 in PlasmoDB (www.plasmodb.org). The predicted protein had 26 
% and 23 % identity with the human (PI0515) and yeast (PI2695) amino acid 
sequences, respectively. The 3192 bp P. falciparum PDH-E2 gene was found to contain 
10 predicted introns (table 5.1); the predicted intron/exon boundaries are displayed in 
figure 5.11 (highlighted red) with the resulting exons highlighted in grey (figui'e 5.11). 
As observed for LipDH2, KGDH-El and KGDH-E2 genes, the PDH-E2 intron 
sequences had a higher A/T content (average of 87.5 % in the PDH E2  introns; table 
5.1) than the exon sequences (average o f 72.9 % in the PDHE2  exons; table 5.1).
The predicted full-length protein consisted o f 641 amino acids with a theoretical 
molecular size o f 73.9 kDa. BLASTP analyses o f the PDH-E2 deduced amino acid 
sequence displayed greatest amino acid identity to homologous proteins from 
cyanobacteria Crocosphaera watsonii (30 % identity), Anabena variabilis (28 % 
identity) and Thermosynechococcus elongates (28 % identity).
The P. falciparum  PDH-E2 predicted amino acid sequence can be divided into three 
domains; the lipoyl-domain, the subunit-binding domain and the catalytic domain. The 
position o f these domains in the P. falciparum  amino acid sequence was identified by 
alignment with proteins from organisms that have been previously investigated 
(Thekkumkara c / 1988; Russell c/ a/., 1992; Hams e/a/., \991).T hs P. falciparum  
protein contains two lipoyl-domains that run between residues 52 and 336. Both 
domains contain the essential lysine residue (residues 93 and 223) that is the site o f  
lipoylation (highlighted red in figure 5.12). The subunit-binding domain was identified 
to be between residues 354 and 385 and is responsible for the binding o f E l and LipDH 
proteins. The catalytic domain was identified to be between residues 414 and 641 and is 
the site o f self-association and acétylation o f CoA. The catalytic domain contains 
conserved histidine (His 612) and tyrosine (Tyr 559) residues that are involved in the 
acétylation reaction (highlighted grey in figure 5.12). Similar to the other 
dihydrolipoamide acyl transferase from Plasmodium, the flexible linker regions 
connecting the domains are not proline (P) and alanine (A) rich as found in the human 
acetyl transferase but are rich in lysine (K) and asparagines (N).
As found for PDH-El a and PDH-El (3 analysis o f the deduced PDH-E2 amino acid 
sequence with subcellular localisation predictions programs suggested that the protein
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might be targeted to the parasite’s apicoplast with confidence (++). The deduced amino 
acid sequence was predicted to contain a hydrophobic signal peptide with a potential 
cleavage site after amino acid 17 (table 5.2; highlighted blue in figure 5.12). The 
probable length of the apicoplast transit peptide was predicted by aligning the P. 
falciparum PDH-E2 protein sequence with its E. coli homologue; this displayed that 
amino acid identity began around amino acid 51 (highlighted yellow in figure 5.12), 
which would correspond to a mature protein (minus apicoplast bipartite targeting 
peptide) size of 67.2 kDa.
DNA 
+3 
+2 
+ 1
ATGTTATACAACTTAATTATATTAATTTTTTATTTAAGATTTTCTAAATGT
V I Q L N Y I N F L F K I F * M Y
C Y T T * L Y * F F I * D F L N V
M L Y N L I I L I F Y L R F S K C
DNA: ATTTCTAAGAACAATAATTACGGTTACATCAACTTCGGTACCTTTTCAAAT 
+ 3 :  F * E Q * L R L H Q L R Y L F K C
+2 :  F L R T I I T V T S T S V P F Q M
+ 1 - . I S K N N N Y G Y I N F G T F S N
DNA 
+3 
+2 
+ 1
GTTGTAAACAACAGTAATAATTTAAGAAATAGAAAAAATGTTGTTTTTTCA 
C K Q Q *  * F K K * K K C C F F K  
L * T T V I I * E I E K M L F F Q  
V V N N S N N L R N R K N V V F S
E x o n  1
DNA: AAAATAGAAATAAAAATGCCAGCTCTATCTAGTACCATGACGACAGGCAAA 
+ 3 :  N R N K N A S S I * Y H D D R Q N
+2 :  K * K * K C Q L Y L V P * R Q A K
+ 1 : K I E I K M P A L S S T M T T G K
DNA : ATTGTTAAATGGAATAAAAATATAGGAGATTATGTAAA'd^AGGATAATAA 
+ 3 :  C * M E * K Y R R L C K C R I I K
+2 ;  L L N G I K I * E I M * M * D N K  
+ 1 : I V K W N K N I G D Y V N V G *  *
DNA: AAGGGATTCCTTAAAAAAAAAAAAAAAAAATATATATATATATATATATAA 
+ 3 :  G I P * K K K K K I Y I Y I Y I I
+2 :  R D S L K K K K K N I Y I Y I Y N
+ 1 : K G F L K K K K K K Y I Y I Y I  *
DNA: TAAATATATGTATAATAAATATATGTATAATAAATATATGTATAATAAATA 
+ 3 :  N I C I I N I C I I N I C I I N I
+2 :  K Y M Y N K Y M Y N K Y M Y N K Y
+ 1:  * I Y V * * I Y V * * I Y V * * I
I n t r o n  1
DNA: TATGTATAATAAATATATGTATAATAAATATATGTATAATAAATATATGTA 
+ 3 :  C I I N I C I I N I C I I N I C I
+2 :  M Y N K Y M Y N K Y M Y N K Y M Y
+ 1:  Y V * * I Y V * * I Y V * * I Y V
+3 :  F F F F F F F F F F F F F * L G D
+2 :  I F F F F F F F F F F F F L A R *
+ 1:  Y F F F F F F F F F F F F F S * V
E x o n  2
DNA: ATATTATAATGACCGTTGAAAGTGATAAAGCAGACATGGACGTGGAAGCAT 
+ 3 :  I I M T V E S D K A D M D V E A F
+2 :  Y Y N D R * K *  * S R H G R G S I
+ 1 : I L *  * P L K V I K Q T W T W K H
DNA : t t g a t g a a g W a t a a c a a t t t t a a t a a a g a t a a a a t t a t t c c a t c t t a t t a  
+ 3 :  D E G I T I L I K I K L F H L I S
+2 :  * * R Y N N F N K D K I I P S Y *
+ 1:  L M K V * Q F *  * R * N Y S I L L
DNA 
+3 
+2 
+  1
GTCCGATAAAAAAAAATATATTTATTTATATACATATGTGTTGTTACCTAT
P I K K N I F I Y I H M C C Y L L
S D K K K Y I Y L Y T Y V L L P I
V R * K K I Y L F I Y I C V V T Y
I n t r o n  2
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DNA : t a t t t t g t i B s c t t t t t a a g g g t t a a g c g t t t a g a a g a t g g a t g t g a a g c
+ 3 : F C * A F * G  L S V * K M D V K Q
+2 :  I L L G F L R  V K R L E D G C E A  
+ 1 : Y F V R L F  K G  * A F R R W M  * S
DNA: AAATGTTGGAGATGTCCTAGGAGTTTTAACTACAGAGGAAAACGAAAATAT 
+ 3 :  M L E M S * E F * L Q R K T K I W
+2 :  N V G D V L G V L T T E  E N E N M  
+ 1:  K C W R C P R S F N Y R G K R K Y
DNA 
+3 
+2 
+ 1
GGATGAAAAGAAATATAATGATGGGGACATTAACAAGACAGAGAACGAAAT
M K R N I M M G T L T R Q R T K *
D E K K Y N D G D I N K T E N E I
G * K E I * * W G H * Q D R E R N
DNA 
+3 
+2 
+  1
AAAAGTATTGAATCCTGATAAAGACAAAAGTGAACAAATTATAAAAGAAGA 
K Y * I L I K T K V N K L * K K I  
K V L N P D K D K S E Q I I K E D  
K S I E S *  * R Q K * T N Y K R R
E x o n  3
DNA: TATTCATTTTGTAAAGAAGCATATAAATGATGATGTAAATGAAGAGAAAAT 
+ 3 :  F I L * R S I * M M M * M K R K Y
+2:  I H F V K K H I N D D V N E E K I
+ 1 ; Y S F C K E A Y K *  * C K * R E N
DNA: ATTTATTCCTTTTATAAAGTGTAAAAAAAAGAAAGCAAAAATAAATAAATG 
+ 3 :  L F L L * S V K K R K Q K * I N G
+2 :  F I P F I K C K K K K A K I N K W
+ 1 : I Y S F Y K V * K K E S K N K * M
DNA: GTTAAAAAATGAGAATGATTTTGTAAAGAAGAATGATTTGTTACTTTATGT 
+ 3 :  * K M R M I L * R R M I C Y F M *
+2 :  L K N E N D F V K K N D L L L Y V
+ 1:  V K K * E * F C K E E * F V T L C
DNA : AGAGGATGATAAAAGCACCATAGAAGTGGAAAGTCCATATTCTgH aATAA 
+ 3 :  R M I K A P * K W K V H I L V I T
+2 :  E D D K S T I E V E S P Y S G N N
+ 1 : R G * * K H H R S G K S I F W * *
DNA: CCCTTTGAAGTATATATGATCAAATCATATAAACAAAATGTATACATATAT 
+ 3 :  L * S I Y D Q I I * T K C I H I Y
+2 :  P L K Y I  * S N H I N K M Y T Y I
+ 1:  P F E V Y M I K S Y K Q N V Y I Y
I n t r o n  3
DNA: ATATATATATATATATATTTTTTTTTGTGTTGAATTTTTCCTTTATTTAAT 
+ 3 :  I Y I Y I F F F V L N F S F I * F
+2 :  Y I Y I Y I F F C V E F F L Y L I
+ 1:  l Y I Y I Y F F L C *  I F P L F N
DNA : TTG i B g TATAATAAAAAAATTATTAGTCAAGGAAGGACAGTTCGTAGATT 
+ 3 :  V G I I K K L L V K E G Q F V D L
+2 :  C R Y N K K I I S Q G R T V R R F
+ 1:  L * V * * K N Y * S R K D S S * I
DNA : TAGACAAAGAAGTTGCCATCATCTCAATAACAGAgH gAGATATACAAATA 
+ 3 :  D K E V A I I S I T E V R Y T N I
+2 :  R Q R S C H H L N N R G E I Y K Y
+ 1:  * T K K L P S S Q * Q R * D I Q I
E x o n  4
DNA
+ 3 : N T F Y K F Y I L Y Y I * * F F Y
+2 :  K Y F L * I L Y S L L Y M M I F L
+ 1 : *  I  L S  I N S  I  F F  I  l Y D D F F
DNA: ATTTTTGTTTAC§|^3AAAAAGATAATGAAAAAGAAAAAATAGAAGAACCTT 
+ 3 :  F C L Q E K D N E K E K I E E P F
+2 :  F L F T G K R *  * K R K N R R T F
+ 1:  I F V Y R K K I M K K K K * K N L
DNA : t t a a a a a t a a W a a a g a a a t a t a t t a a g t t t g a t a a t a t a t a t a t a t a t a t
+ 3 :  K N K * R N I L S L I I Y I Y I Y
+2 :  * K * V K K Y I K F D N I Y I Y I
+ 1 : L K I S K E I Y * V * * Y I Y I Y
I n t r o n  4
E x o n  5
DNA: 
+3 : 
+ 2 : 
+ 1 :
l Y I F F F L Y I  I N C Y Y F M D  
Y I Y F F F S L Y Y * L L L F Y G  
l Y I F F F F F I L L I V I I L W
I n t r o n  5
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DNA : ATTATcH a GAAGATGAAGAAATAAATCGAGATAATATATTAATACATTAT 
+ 3 :  Y Q R R * R N K S R * Y I N T L Y
+2 :  L S E K M K K * I E I I Y * Y I I
+ 1 : 1  I R E D B E I N R D N I L I H Y
DNA: ATAAATAAAATCAAGAAAAGTGAAGAGGGAAGAAAGTTTTTAAAAAATTTA 
+ 3 :  K * N Q E K * R G K K V F K K F K
+2 :  * I K S R K V K R E E S F * K I *
+ 1 : I N K I K K S E E G R K F L K N L
DNA : AgH a CTCATAAAGTTTTACAATTGTTTATAAATGGGATGTTATATATATA 
+ 3 :  V L I K F Y N C L * M G C Y I Y I
+2 :  G T H K V L Q L F I N G M L Y I Y
+ 1:  R Y S *  S F T I V Y K W D V I Y I
E x o n  6
DNA: TATATATATATATTTATTTATTTATTTATTTATTTATTTTTATTATTATTT 
+ 3 :  Y I Y I Y L F I Y L F I F I I I F
+2 :  l Y I Y L F I Y L F I Y F Y Y Y F
+ 1 : Y I Y I F I Y L F I Y L F L L L F
DNA : TTTTTTTTTATATATATATa H tGAACAAGAAGAAAAAACACTGGAAGAGA 
+ 3 :  F F Y I Y I S E Q E E K T L E E R
+2 :  F F L Y I Y K * T R R K N T G R E
+ 1:  F  F F I  Y I  * V N K K K K H W K R
I n t r o n  6
DNA: GGCTCAAATTAAATTATGAGAAATACAATAAAATTTCCAATGATCTATTCA 
+ 3 :  L K L N Y E K Y N K I S N D L F R
+2 :  A Q I K L * E I Q * N F Q * S I Q
+ 1 : G S N *  I M R N T I K F P M I Y S
DNA : gH a TATGACATATGCATAATATATACTCAATATTTAATATTCTTATAAAA 
+ 3 :  Y M T Y A * Y I L N I * Y S Y K N
+2 :  V Y D I C I I Y T Q Y L I F L * K
+ 1 : G I * H M H N I Y S I F N I L I K
E x o n  7
I n t r o n  7
DNA: ATGTTGAAATTTATTTATTTATTTATTTATTTATTTTTTTTTATTATTATT 
+ 3 :  V E I Y L F I Y L F I F F Y Y Y S
+2 :  C * N L F I Y L F I Y F F L L L F
+ 1 : M L K F I Y L F I Y L F F F I I I
DNA : cM g t c t a g t g a a a g t a c a a a a g a t t a t g t a t t a a a a g a a a a g g a a W a a a  
+ 3 :  G L V K V Q K I M Y * K K R K * I
+2 :  R S S E S T K D Y V L K E K E V N
+ 1 : Q V *  * K Y K R L C I K R K G S K
E x o n  8
DNA: TACACAGAAAGATGAATATATAAATAAATTTGCAAAAATATTTTCATATAT 
+ 3 :  H R K M N I  + I N L Q K Y F H I Y
+2 :  T Q K D E Y I N K F A K I F S Y I
+ 1:  Y T E R *  l Y K *  I C K N I F I Y
DNA: ATATATATATATATCATATATTTTTTTCATTTGTTTGTATCTAlfBAATGA 
+ 3 :  l Y I Y H I F F S F V C I Y R M R
+2 :  Y I Y I S Y I F F I C L Y L * N E
+ 1 : I Y I Y I I Y F F H L F V S I E *
I n t r o n  8
DNA: GAGCCAATATGAAATGGTGTTACCATCTGCATCAGAGTTGATGAGACAAAA 
+ 3 :  A N M K W C Y H L H Q S * * D K T
+2 :  S Q Y E M V L P S A S E L M R Q N
+ 1:  E P I * N G V T I C I R V D E T K
DNA : CAAATTAAATCCAAAGGATATAACHaATATATATATATATATTTATATTT 
+ 3 :  N * I Q R I * R N I Y I Y I Y I Y
+2 :  K L N P K D I T * Y I Y I Y L Y L
+ 1 : Q I K S K G Y N V I Y I Y I F I F
DNA : ATATATATTTATATATTTATATTTATACCTTTTA1®AAACAGGAAAACAC 
+ 3 :  l Y L Y I Y I Y T F Y R N R K T P
+2 :  Y I F I Y L Y L Y L L * K Q E N T
+ 1:  l Y I Y I F I F I P F I E T G K H
E x o n  9
I n t r o n  9
DNA 
+3 
+2 
+ 1
CCAATCGTATAACCTATGAAGACGTTGATGCATTTTTAAATGGACATAAAA
N R I T Y E D V D A F L N G H K N
Q S Y N L * R R * C I F K W T * K
P I V * P M K T L M H F * M D I K
Exon 10
DNA: ATAATTCTACTAATGTTACTTACTGCGAAAAACCAAAAGTTGAAACAATTG 
+ 3 :  N S T N V T Y C E K P K V E T I E
+2 :  * F Y * C Y L L R K T K S * N N *
+ 1 : 1  I L L M L L T A K N Q K L K Q L
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DNA: AATATGGAGATCCAAAAACTGTCGATATGACAAATATACAGAAATCAATAA 
+ 3 :  Y G D P K T V D M T N I Q K S I K
+ 2:  I W R S K N C R Y D K Y T E I N K  
+ 1 : N M E  I Q K L S  I  * Q I Y R N Q *
DNA 
+3 
+2 
+ 1
AAAATAATATGATGCTTACCTTAACCGTTCCAGTGTTCCGTGTTACTCATT
N N M M L T L T V P V F R V T H L
K * Y D A Y L N R S S V P C Y S F
K I I * C L P * P F Q C S V L L I
DNA: TAATAAAAACAAACGAATTACTGAAATTATATGAAAAAGTAAAACAAAAAA 
+ 3 :  I K T N E L L K L Y E K V K Q K I
+2 :  N K N K R I T E I I * K S K T K N
+ 1 : *  * K Q T N Y * N Y M K K * N K K
DNA: TTAGTATGAGTGTTATAATAAATAAATGTGTATCATCTGTACTATTAAATC 
+ 3 :  S M S V I I N K C V S S V L L N H
+2 :  * Y E C Y N K * M C I I C T I K S
+ 1:  L V * V L *  * I N V Y H L Y Y *  I
E x o n  10
DNA
+3
+2
+1
ATCCCTTGATATACTCTACTTATATTGATAAAGATAATGGAAAAATATTAT 
P L I Y S T Y I D K D N G K I L Y  
S L D I L Y L Y *  * R * W K N I I  
I P * Y T L L I L I K I M E K Y Y
DNA: ATAATAAGGATGTTAATATAGGAAATGCATTAGGATTACCAGATTCTCTAT 
+ 3 :  N K D V N I G N A L G L P D S L L
+2 :  * * G C * Y R K C I R I T R F S I
+ 1 : 1  I R M L I  * E M H * D Y Q I L Y
DNA: TAACTCCTGTGTTAAAAAAAGTTGATAAAAAGGATATATATACATTGGCCA 
+ 3 :  T P V L K K V D K K D I Y T L A N
+2 :  N S C V K K S *  * K G Y I Y I G Q
+ 1 : *  L L C  * K K L I K R I Y I H W P
DNA : ATGAATGGAAGHt TGTAAAATGCGTATATAAATTGAATTATATATATCCA 
+ 3 :  E W ^ .  K V C K M R I  * l E L Y I S  I
+2 :  * M  E G L * N A Y I N * I I Y I H
+ 1 : M N G R F V K C V Y K L N Y I Y P
+3 :  F F N I * K V Y K K Y C L H V * L
+2 :  F F * Y I K S L * E I L S S C I I
+ 1 : F F L I Y K K F I R N I V F M Y N
DNA: TATGAACAATTTTCATCTTCCACGTAAACGGTGCACCACAATATTATATAT 
+ 3 :  * T I F I F H V N G A P Q Y Y I Y
+2 :  M N N F H L P R K R C T T I L Y I
+ 1 : Y E Q F S S S T * T V H H N I I Y
I n t r o n  10
DNA: ATATATATATATGTATATGTATATTTACATTTATATTTATTTTTTAATATG 
+ 3 :  I Y I C I C I F T F I F I F * Y V
+2 :  Y I Y M Y M Y I Y I Y I Y F L I C
+ 1 : I Y I Y V Y V Y L H L Y L F F N M
DNA 
+3 
+2 
+ 1
Y Y Y Y Y Y Y Y Y F F F F F F F F
L L L L L L L L L F F F F F F F F
F I I I I I I I I I F F F F F F F
DNA : TTTTTTTTTTTTCCAATTTTG'i B aTACTAGTTGAGAAAGGTAAAAATGGT 
+ 3 :  F F F S N F V D T S * E R * K W S
+2 :  F F F F Q F C R Y * L R K V K M V
+ 1 : F F F F P I L *  I L V E K G K N G
DNA: CTCTTAAGTTCTAATGATATGACAGGTAGTAATTTTTACATTTCCAATTTG 
+ 3 :  L K F * * Y D R * * F L H F Q F G
+2 :  S * V L M I * Q V V I F T F P I W
+ 1 : L L S S N D M T G S N F Y I S N L
DNA: GGAATGTTCAATACTTACCAATTTGATGCAATATTGCCAAAGAATTCATCA 
+ 3 :  N V Q Y L P I * C N I A K E F I M
+2 :  E C S I L T N L M Q Y C Q R I H H
+ 1 : G M F N T Y Q F D A I L P K N S S
E x o n  11
DNA: TGTATCTTATCAATCGGCACAAATATTGGAAGTATTGATAACCTGGAAGAC 
+ 3 :  Y L I N R H K Y W K Y * * P G R L
+2 :  V S Y Q S A Q I L E V L I T W K T
+ 1 : C I L S I G T N I G S I D N L  E __D
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DNA
+3
+2
+1
TTAAAAATACAAAAGGGAATGATGATGACTTTGACATGTGACCACAGACAT 
K N T K G N D D D F D M  * P Q T Y  
* K Y K R E *  * * L * H V T T D I
L K I Q K G M M M T L T C D H R H
DNA: ATCTATGGATCCCATGCAGCAGCGTTTATGAATGATTTATCAAAATTTATT 
+ 3 :  L W I P C S S V Y E * F I K I Y *
+2 :  S M D P M Q Q R L * M I Y Q N L L
+ 1 : I Y G S H A A A F M N D L S K F I
DNA: GAAAAGGATATTATGAAAATATTTTTATAG 
+ 3 :  K G Y Y E N I F I
+2 :  K R I L * K Y F Y
+ 1 : K K D I M K I F L *
E x o n  11
F igure  5.11 -  T he In tron /exon  b o u n d a r ie s  o f P. falciparum  PDH-E2
The genom ic DNA seq u en ce  of the PDH-E2  g en e  is disp layed with the  resulting am ino acid 
seq u en ce  shown in th ree  fram es below it. The pred icted intron/exon boundaries from the 
P lasm oDB anno ta tion (PF10_0407) are  disp layed in red, with resulting exons highlighted in 
grey.
Number Length (bp)
Exon 1 243 77.0
Intron 1 209 9 2 3
Exon 2 67 61.2
Intron 2 104 82.7
Exon 3 390 72.1
Intron 3 115 83.5
Exon 4 80 68.8
Intron 4 81 84.0
Exon 5 47 83.0
Intron 5 100 90.0
Exon 6 96 80.2
Intron 6 122 91.0
Exon 7 81 71.6
Intron 7 110 86.4
Exon 8 37 78.4
Intron 8 102 85.3
Exon 9 80 6 6 3
Intron 9 64 93.8
Exon 10 484 73.3
Intron 10 268 8 5 3
Exon 11 312 69.9
T ab le  5.1 -  in tro n /ex o n  b o u n d a r ie s  o f PDH E2
ATT content (%)
The PDH E2 g en e  is predicted to contain ten introns tha t produce a g en e  product coded for by 
e leven exons. The size of the introns and exons are  shown above along with the  A/T content, 
and this disp lays tha t the intron se q u e n c e s  have a higher A/T con ten t tha t the exon seq u en ces .
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DNA: ATGTTATACAACTTAATTATATTAATTTTTTATTTAAGATTTTCTAAATGTATTTCTAAG 60  
+ 1 : M L Y N L I I L I F Y L R F S K | i S K  2 0
DNA: AACAATAATTACGGTTACATCAACTTCGGTACCTTTTCAAATGTTGTAAACAACAGTAAT 1 2 0  
+ 1 :  N N N Y G Y I N F G T F S N V V N N S N  4 0
DNA: AATTTAAGAAATAGAAAAAATGTTGTTTTTTCAAAAATAGAAATAAAAATGCCAGCTCTA 1 8 0  
+ 1 : N L R N R K N V V F S K I E I K M P A L  60
DNA: TCTAGTACCATGACGACAGGCAAAATTGTTAAATGGAATAAAAATATAGGAGATTATGTA 2 4  0 
+ 1 :  S S T M T T G K I V K W N K N I G D Y V  80
DNA : AATCTAGGTGATATTATAATGACCGTTGAAAGTGATAAAGCAGACATGGACGTGGAAGCA 3 0 0  
+ 1 :  N L G D I  I M T V E S d | a D M D V E A  1 0 0
DNA: TTTGATGAAGGCTTTTTAAGGGTTAAGCGTTTAGAAGATGGATGTGAAGCAAATGTTGGA 3 6 0  
+ 1 :  F D E G F L R V K R L E D G C E A N V G  1 2 0
DNA: GATGTCCTAGGAGTTTTAACTACAGAGGAAAACGAAAATATGGATGAAAAGAAATATAAT 4 2  0 
+ 1 :  D V L G V L T T E E N E N M D E K K Y N  1 4 0
DNA: GATGGGGACATTAACAAGACAGAGAACGAAATAAAAGTATTGAATCCTGATAAAGACAAA 4 80  
+ 1 : D g J i N K T E N E  I K V L N P D K D K  1 6 0
DNA: AGTGAACAAATTATAAAAGAAGATATTCATTTTGTAAAGAAGCATATAAATGATGATGTA 5 4 0  
+ 1 : S E Q I  I K E D I H F V K K H I N D D V  1 8 0
DNA: AATGAAGAGAAAATATTTATTCCTTTTATAAAGTGTAAAAAAAAGAAAGCAAAAATAAAT 6 0 0  
+ 1 : N E E K I F I P F I K C K K K K A K I N  2 0 0
DNA: AAATGGTTAAAAAATGAGAATGAmTGTAAAGAAGAATGATTTGTTACTTTATGTAGAG 6 6 0  
+ 1 :  K W L K N E N D F V K K N D L L L Y V E  2 2 0
DNA: GATGATAAAAGCACCATAGAAGTGGAAAGTCCATATTCTGGTATAATAAAAAAATTATTA 7 2 0  
+ 1 :  D D | s T I E V E S P Y S G I I K K L L  2 4 0
DNA: GTCAAGGAAGGACAGTTCGTAGATTTAGACAAAGAAGTTGCCATCATCTCAATAACAGAG 7 8 0  
+ 1 :  V K E G Q F V D L D K E V A I I S I T E  2 6 0
DNA: GAAAAAGATAATGAAAAAGAAAAAATAGAAGAACCTTTTAAAAATAAAGAAGATGAAGAA 84 0 
+ 1 :  E K D N E K E K I E E P F K N K E D E E  2 8 0
DNA: ATAAATCGAGATAATATATTAATACATTATATAAATAAAATCAAGAAAAGTGAAGAGGGA 9 0 0  
+ 1 : I N R D N I L I H Y I N K I K K S E E G  3 0 0
DNA: AGAAAGTTTTTAAAAAATTTAAGTGAACAAGAAGAAAAAACACTGGAAGAGAGGCTCAAA 9 6 0  
+ 1 :  R K F L K N L S E Q E E K T L E E R L K  3 2 0
DNA: TTAAATTATGAGAAATACAATAAAATTTCCAATGATCTATTCAGGTCTAGTGAAAGTACA 1 0 2 0  
+ 1 :  L N Y E K Y N K I S N D L F R S S E S T  3 4 0
DNA: AAAGATTATGTATTAAAAGAAAAGGAAAATGAGAGCCAATATGAAATGGTGTTACCATCT 1 0 8 0  
+ 1 :  K D Y V L K E K E N E S Q Y E M V L P S  3 6 0
DNA : GCATCAGAGTTGATGAGACAAAACAAATTAAATCCAAAGGATATAACAAACAGGAAAACA 1 1 4  0 
+ 1 :  A S E L M R Q N K L N P K D I T N R K T  3 8 0
DNA: CCCAATCGTATAACCTATGAAGACGTTGATGCATTTTTAAATGGACATAAAAATAATTCT 12 00  
+ 1 :  P N R I T Y E D V D A F L N G H K N N S  4 0 0
DNA: ACTAATGTTACTTACTGCGAAAAACCAAAAGTTGAAACAATTGAATATGGAGATCCAAAA 1 2 6 0  
+ 1 :  T N V T Y C E K P K V E T I E Y G D P K  4 2 0
DNA : ACTGTCGATATGACAAATATACAGAAATCAATAAAAAATAATATGATGCTTACCTTAACC 1 3 2  0 
+ 1 :  T V D M T N I Q K S I K N N M M L T L T  4 4 0
DNA: GTTCCAGTGTTCCGTGTTACTCATTTAATAAAAACAAACGAATTACTGAAATTATATGAA 1 3 8 0  
+ 1 :  V P V F R V T H L I K T N E L L K L Y E  4 6 0
DNA: AAAGTAAAACAAAAAATTAGTATGAGTGTTATAATAAATAAATGTGTATCATCTGTACTA 1 4 4  0 
+ 1 : K V K Q K I S M S V I  I N K C V S S V L  4 8 0
DNA: TTAAATCATCCCTTGATATACTCTACTTATATTGATAAAGATAATGGAAAAATATTATAT 1 5 0 0  
+ 1 : L N H P L I Y S T Y I D K D N G K I L Y  5 0 0
DNA: AATAAGGATGTTAATATAGGAAATGCATTAGGATTACCAGATTCTCTATTAACTCCTGTG 1 5 6 0  
+ 1 : N K D V N I G N A L G L P D S L L T P V  5 2 0
DNA: TTAAAAAAAGTTGATAAAAAGGATATATATACATTGGCCAATGAATGGAAGATACTAGTT 1 6 2 0  
+ 1 :  L K K V D K K D I Y T L A N E W K I L V  5 4 0
DNA: GAGAAAGGTAAAAATGGTCTCTTAAGTTCTAATGATATGACAGGTAGTAATTTTTACATT 1 6 8 0  
+1:  E K G K N G L L S S N D M T G S N F Y I  5 6 0
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DNA: TCCAATTTGGGAATGTTCAATACTTACCAATTTGATGCAATATTGCCAAAGAATTCATCA 1 7 4  0 
+ 1 : S N L G M F N T Y Q F D A I L P K N S S  5 8 0
DNA : TGTATCTTATCAATCGGCACAAATATTGGAAGTATTGATAACCTGGAAGACTTAAAAATA 1 8 0 0  
+ 1 :  C I L S I G T N I G S I D N L E D L K I  6 0 0
DNA: CAAAAGGGAATGATGATGACTTTGACATGTGACCACAGACATATCTATGGATCCCATGCA 1 8 6 0  
+ 1 :  Q K G M M M T L T C D H R H I Y G S H A  6 2 0
DNA : GCAGCGTTTATGAATGATTTATCAAAATTTATTGAAAAGGATATTATGAAAATATTTTTA 1 9 2 0  
+ 1 :  A A F M N D L S K F I E K D I M K I F L  6 4 0
DNA: 
+ 1:
TAG 1 9 2 3
6 4 1
F igure  5.12 -  Plasmodium falciparum  PDH-E2
The com p lem en tary DNA seq u en ce  of the PDH-E2  gene is displayed with the resulting am ino 
acid seq u en ce  shown below it. The pred icted signal peptide c leavage site (Cys17) is highlighted 
in blue, with the possib le m a ture protein w as predicted to start around Ser51 (highlighted in 
yellow). The last am ino acid (Asp166) in the N-term inal section (amino acids 1-166) used  to 
construct the GFP-fusion protein is highlighted in green. The two sites of lipoylation (Lys93 and 
Lys223) are  highlighted in red. Two residues (Tyr559 and His612) involved in the acylation 
reaction are  highlighted in grey.
Gene Chromosome Prediction Score* Cleavage
P D H E la 11 Apicoplast 17 or 23'
PD H E ip 14 Apicoplast n.d.
PDH E2 10 Apicoplast 17d
BCKDH E la 13 Mitochondrial 99.4%" 21"
BCKDH E lp 5 Mitochondrial 99.5%" n.d.
BCKDH E2 3 Mitochondrial 92.2%" 14"
KGDH E l 8 Mitochondrial 73.8%" n.d.
KGDH E2A 13 Mitochondrial 3.7%" n.d.
KGDH E2B 13 Mitochondrial 85.2%" n.d.
T ab le  5.2 -  S u b c e llu la r lo ca lisa tio n  p re d ic tio n s  of KADH c o m p o n e n ts
The seq u en ce  ana ly ses  of the KADH pro teins identified in the P. falciparum genom e predicted 
the subcellular localisation of the KGDH and BCKDH to the m itochondrion and PDH to the 
apicop last. a. Predictions w ere perform ed using PLASMIT, TARGETP, SIGNALP and 
PLASMOAP. b. Predc tions perform ed by PLASMOAP with the resu lts b ased  on a  sco re  of 
be tw een + (poor prediction) and +++ (high confidence of apicop last targeting), c . Predictions 
perform ed in PLASMIT and TARGETP w ere given a  confidence limit, and mitochondrial 
targeting peptide c leavage site predictions w here possib le, d. Signal peptide c leavage w as 
predicted using SIGNALP.
I
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5.2.2 Subcellular localisation of KADH
The results of the sequence analyses predicted that the components of the KGDH and 
BCKDH would be localised in the mitochondrion and the single PDH identified would 
be localised in the apicoplast. These subcellular localisation predictions were 
experimentally investigated by producing over-expression constructs using the N- 
terminal targeting peptides of the KADH  genes and fusing them in frame with the green 
fluorescent protein (GFP) gene. The transfection of these constructs into erythrocytic 
stages of P. falciparum  resulted in the expression of GFP-fusion proteins, which should 
be targeted to the respective location of the respective protein whose targeting sequence 
was fused to GFP. This technique has been used frequently to analyse subcellular 
locations of numerous proteins in P. falciparum  and other organisms and is thought to 
be a useful tool to obtain insights into the distribution and location of proteins within a 
cell (Foth et a l, 2003; Sato et a l, 2004; Tonkin et a l, 2004). P. falciparum  parasites 
were electroporated to introduce the recombinant DNA into the parasites as described in 
section 2.2.1.5 and the transfectants were selected for using the pyrimethamine 
derivative WR99210 (Fidock et a l, 1997). The transfected plasmids were expected to 
be maintained by the parasites episomally as long as selective pressure with the drug 
was maintained and as a result express the GFP-fusion protein (driven by the FISP86 
promoter). After transfection it usually took between 6 to 12 weeks before the first 
transfectants were observed in Giemsa stained blood smears. Once parasites reached a 
high enough parasitemia, they were incubated with a mitochondrial marker 
(MitoTracker CMXRos) as described in section 2.2.1.6 and analysed by fluorescent 
light microscopy.
5.2.2.1____ g-Ketoglutarate dehydrogenase complex
The subcellular localisation of the KGDH was investigated using GFP-fusion 
constructs of the KGDH-E2 (figure 5.13). The localisation of the KGDH-E2-GFP 
fusion protein was investigated using three different constructs to analyse which parts of 
the A-terminus would be sufficient to target the fusion protein to its cellular location.
1. KGDH E2A-GFP was constructed using the in-frame methionine contained in 
intron 2. This resulted in a 165 amino acid long sequence being fused to GFP, 
with the last amino acid before the GFP protein being equivalent to Valine 195 
in the KGDH-E2B sequence (highlighted pink in figure 5.5).
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2. KGDH-E2B (C)-GFP was constructed using the KGDH-E2B initiator 
methionine and was amplified from cDNA. This resulted in a 114 amino acid 
long sequence being fused to GFP, with the last amino acid before the GFP 
protein being alanine 114 (highlighted pink in figure 5.5).
3. KGDH E2B (G)-GFP was constructed using the KGDH E2B initiator 
methionine and was amplified from gDNA. This construct resulted in the fusion 
of 608 bp of genomic sequence with the KGDH E2 ORF in-frame with GFP. 
This construct contains both possible initiation sites and would allow the 
parasite to splice the construct as necessary. The last amino acid before the GFP- 
fusion protein was equivalent to alanine 114 in the KGDH-E2B sequence 
(highlighted pink in figure 5.5).
The KGDH-E2A-GFP, which used the in-frame methionine located in the predicted 
intron 2 of the gene showed targeting to an organelle in the parasites that contained the 
MitoTracker staining identifying it as the mitochondrion (figure 5.13A). This was 
surprising because the analyses of the N-terminal amino acid sequence of KGDH-E2A 
did not predict the presence of a mitochondrial targeting peptide with very high 
confidence (3.7%). It has to be noted though that most of the parasites that were 
transfected with this particular construct showed no fluorescence and it appeared that 
only a very small number of parasites expressed the GFP-fusion protein. This low level 
of expression was also observed by Western blotting (with Anti-GFP antibodies) where 
protein samples that were extracted from parasites transfected with the KGDH-E2A- 
GFP construct displayed no detectable expression of GFP. This is in contrast to protein 
samples extracted from LipDHl-GFP transfected parasites that clearly expressed GFP 
(figure 5.13B).
However, the fact that those parasites that displayed GFP-fluorescence actually 
contained the fusion protein within an organelle which co-stained with the 
mitochondrial marker suggests that the targeting of a protein in P. falciparum to the 
mitochondrion is not only governed by its A-terminal targeting sequence but that also 
other parts of the amino acid sequence may be responsible for the targeting of the 
protein to this organelle. Similar results were described in Chapter 4 on the localisation 
of a LipDH2-GFP fusion protein that apparently did not contain a strong mitochondrial 
targeting sequence (section 4.2.4).
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Transfection o f f .  falciparum erythrocytic stages and expression of KGDH-E2B-GFP 
containing a construct amplified from parasite cDNA resulted in targeting of the fusion 
protein to a parasite organelle that was co-stained with MitoTracker (figure 5.13A). 
Compared with the expression of the fusion protein of KGDH-E2A, this construct 
appeared to confer expression of the GFP-fusion protein in a greater number of parasites 
than KGDH-E2A-GFP and the fluorescence observed seemed more consistent and 
stronger than in the parasites expressing KGDH-E2A-GFP. Transfection of the parasites 
with KGDH-E2B-GFP generated from genomic DNA also showed targeting of the 
fusion protein to the mitochondrion as shown by co-staining of the organelle with 
MitoTracker. The image of the localisation of KGDH-E2B-GFP (G) (figure 5.13 A) 
shows an erythrocyte infected with two trophozoites. Both parasites clearly display the 
staining with the mitochondiial marker MitoTracker, whereas GFP-fluorescence is only 
clearly visible in one of the two parasites infecting this particular erythrocyte. This 
image was chosen because it demonstrates a number of points that need to be made 
about the expression of GFP-fusion proteins in P. falciparum erythrocytic stages.
Firstly, the intensity of GFP fluorescence which is likely to represent the level of 
expression of the fusion protein varies between different parasites and secondly, it 
seems to happen that parasites smwiving the selective pressure apparently do not 
express the GFP-fusion protein at all. The latter observation suggests that the parasites 
might have some means to sustain the expression of the selectable marker at sufficiently 
high levels but at the same time limit the expression of the GFP-fusion protein. Further 
analyses of the episomes would have been necessary to further address the question 
what the mechanisms of this differential expression pattern are.
These results provide experimental evidence that the P. falciparum KGDH is localised 
in the mitochondrion and thus confirm the predictions made using various prediction 
programs (as outlined in section 2.2.2.3). Concomitantly, the mitochondrial localisation 
of KGDH-E2 also suggests that LipDH2, which was also found to be targeted to the 
parasite’s mitochondrion, is the LipDH-component of this protein complex.
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KGDH E2A
KGDH E2B (Q
KGDH E2B (G)
B)
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F igure  5.13 -  S u b c e llu la r lo ca lisa tio n  of KGDH-E2
P an e l A. The subcellular localisation of KGDH-E2 w as investigated by th ree different G FP- 
fusion proteins. KGDH-E2A used  the in-frame m ethionine within the second  intron, and 
con tained the first 165 amino acids from KGDH-E2A. KGDH-E2B (0) used  the m ethionine in 
exon 1, had the introns rem oved and con tained the first 114 am ino acids of KGDH-E2B. KGDH- 
E2B (G) used  the m ethionine a t the s tart of exon 1, con tained both introns and therefore the in­
fram e methionine. This would allow the KGDH-E2 (G) construct to be spliced a s  required by the 
parasite . P arasites mitochondria w ere selectively stained with M itotracker CMXRos and im ages 
of live cells w ere ob tained by p h ase  con trast (LIVE) or in the GFP/FITC (GFP) or rhodam ine 
(MITO) fluorescen t channe ls. Overlays of the im ages ob tained from each  channe l are  disp layed 
for determ ination of co-localisation (MERGE). All cons tructs produced co-localisation of G FP 
with m itotracker, although the im age d isp layed for KGDH-E2B (G) con tains two p arasites in a 
single erythrocy te with only one of the p arasites expressing the GFP-fusion protein to a 
sufficiently high level to be de tectab le. P an e l B d isp lays a  w estern blot, using anti-GFP 
an tibodies, of pro teins ex trac ted from parasites transfec ted with e ither LipDHI-GFP (lane 1) or 
KGDH-E2A-GFP (lane 2). 10 pg of ex trac ted pro teins w ere loaded on a 4 -1 2  % gradien t gel, 
with precision all blue protein s tan d ard s (Biorad) a s  a  molecular m ass  m arker and disp lays tha t 
there  w as no de tectab le  KGDH-E2A-GFP expression; LipDHI-GFP ex trac ts w ere loaded a s  a 
positive control.
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5.2.2.2 Branched chain g-keto acid dehydrogenase complex
The subcellular localisation of the P, falciparum  BCKDH was analysed by expressing a 
GFP-fusion constructs of the first 130 and 106 amino acids of the BCKDH E l (3 and 
BCKDH E2 proteins, respectively (figure 5.14). Upon fluorescent light microscopical 
analyses it was found that the expressed fusion proteins co-localised with the 
mitochondrion of the parasites that were stained with MitoTracker as described 
previously (section 2.2.1.6; figure 5.14). However, GFP-fluorescence was not 
exclusively observed to co-localise with the parasite’s mitochondrion but was also 
found in an area that most likely represents the parasite’s food vacuole (dark area in the 
live image of figure 5.14B; although this needs to be experimentally confirmed). This 
possible food vacuole targeting was observed not only in the parasites expressing 
BCKDH-Elp GFP-fusion protein, but also in other GFP-fusion proteins investigated in 
our laboratory (data not shown).
These results give experimental evidence that supports the prediction that P. falciparum 
BCKDH is localised in the mitochondrion of the parasites and suggested that LipDH2 
acts as a component of the complex in the organelle. These results therefore also 
suggested that the single mitochondrial LipDH forms part of both KADH present in the 
mitochondrion of the parasites.
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LIVE GFP MITO MERGE
B
D I V
F igure  5.14 -  S u b c e llu la r lo ca lisa tio n  of BCKDH
The subcellular localisation BCKDH w as investigated by expressing G FP fusion pro teins of the 
E1p and E2 com ponen ts of the com p lex in the  erythrocytic s tag e  P. falciparum. The BCKDH- 
E ip  (p a n e ls  A an d  B) con tained the first 130 am ino acids in fram e with GFP, while the BCKDH 
E2 (p a n e ls  C an d  D) fusion protein con tained the first 106 am ino acids in fram e with GFP. 
P arasites mitochondria w ere selectively stained with M itotracker CMXRos and im ages of live 
cells w ere ob tained by p h ase  con trast (LIVE) or in the GFP/FITC (GFP) or rhodam ine (MITO) 
fluorescen t channe ls. Overlays of the im ages ob tained from each  channe l are  disp layed for 
determ ination of co-localisation (MERGE). All fusion proteins display co-localisation of the G FP 
with m itotracker, although panel B a lso disp lays a  G FP staining asso c ia ted  with the food 
vacuole.
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S.2.2.3 Pyruvate dehydrogenase complex
The subcellular localisation of the components of the PDH was analysed by expressing 
GFP-fusions with N-terminal sequences corresponding to the first 117 and 166 amino 
acids of PDH-Ela and PDH-E2, respectively (figure 5.15 and figure 5.16). Expression 
of both fusion proteins led to the green fluorescent staining of a single organelle within 
the transfected parasites, which was clearly distinct from the mitochondrion but 
appeared to be closely associated with it. This particular localisation pattern was 
previously observed when GFP-fusion proteins with apicoplast targeting sequences 
were analysed by fluorescent light microscopy (Foth et al., 2003; Tonkin et al., 2004; 
van Dooren et a l, 2005). These results together with the in silica analyses described in 
section 5.2.2.3 led me to believe that the components of the single parasite PDH were 
located in the apicoplast rather than the mitochondrion of Plasmodium. This result also 
suggests that LipDH 1, which was also found to be in an organelle closely associated 
with the parasite’s mitochondrion form part of this apicoplast localised PDH complex.
UVE GFP MITO MERGE
PDH E la
PDHE2
Figure 5.15 -  Subcellular localisation of PDH
The subcellular localisation of PDH w as investigated by GFP fusion of P D H -E la  and PDH-E2. 
The GFP-fusion pro teins of P D H -E la  (first 117 am ino acids) and PDH-E2 (first 166 am ino 
acids) w ere ex p ressed  in the erythrocytic s tag e  of the parasites. P arasites mitochondria w ere 
selectively stained with M itotracker CMXRos and im ages of live cells w ere ob tained by p h ase  
con tras t (LIVE) or in the GFP/FITC (GFP) or rhodam ine (MITO) fluorescen t channe ls. Overlays 
of the im ages ob tained from each  channe l are  disp layed for determ ination of co-localisation 
(MERGE). Both P D H -E la  and PDH-E2 disp layed a GFP-staining tha t w as closely asso c ia ted  
with the m itochondria, which w as consisten t with localisation of the G FP to the apicop last.
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5.2.3 Organelle development during the erythrocytic stages
The potential apicoplast localisation of the single PDH of Plasmodium was further 
corroborated by following the organelle’s development through the erytlirocytic 
developmental cycle of the parasites. This was done by analysing the changes of GFP- 
fluorescence in parasites that were expressing the PDH-Ela-GFP (figure 5.16A - D )  
and LipDH 1-GFP (figure 5.16E -  J) fusion proteins, respectively. In parallel the 
development of the mitochondrion through the parasite’s erythrocytic cycle was 
followed using the mitochondrial marker MitoTracker. Thus both the mitochondrion 
and the apicoplast display selective fluorescence when analysed by fluorescence light 
microscopy.
In the early stages of parasite development both organelles are small and rounded and 
appeared to be closely associated (~ between 0 and 15 hours after invasion; figure 
5.16A - B). Both organelles elongated during the development to the trophozoite stage 
(~ between 15 and 28 hours after invasion). In the early trophozoite parasites that were 
analysed, it was observed that the mitochondrion elongated prior to the apicoplast as 
demonstrated in figure 5.16 (panels C and D). There also appeared to be less points of 
contact between the elongating organelles, with commonly only a single point of 
association (figure 5.16E - F). In the later trophozoites both organelles are elongated 
and began to branch in preparation for schizogony, with these branched structures 
exhibiting many points of association (figure 5.16G - H). In schizogony, which occurs 
between 28 and 48 hours after invasion, the parasite prepares to divide and the branched 
organelles appear to be “packaged” into the developing daughter merozoites. It is 
thought that the multiple associations between the two branched structures ensures that 
each daughter merozoite is equipped with a single mitochondrion and an apicoplast 
after division (figure 5.161 -  J).
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Figure 5.16 -  Organelle developm en t  during the  erythrocy tic s ta g e s
The development of the apicoplast and mitochondria was analysed through the different stages 
of the erythrocytic life cycle. Both organelles were small and rounded during the ring stage 
parasites (between 0 and 16 hours after infection) displayed in p a n e ls  A an d  B; during the 
trophozoite stage (between 16 and 28 hours) the organelles began to elongate and eventually 
branching in late trophozoite stages (p a n e ls  C -  H); During schizogony (between 28 and 48 
hours) the organelles are packaged into the individual daughter cells (p a n e ls  I -  J). Apicoplast 
development was followed by GFP-staining from the PDH-Ela (p a n e ls  A -  D) or LipDH 1 fusion 
proteins (p a n e ls  E -  J). Development of the mitochondria was followed by staining the 
organelle with Mitotracker CMXRos. Images of live cells were obtained by phase contrast 
(LIVE), the GFP/FITC (GFP) or rhodamine (MITO) fluorescent channels. Overlays of the images 
from each channel are shown to display interactions between the two organelles (MERGE).
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5.2.4 Components of the KADH are expressed in erythrocytic stages
In order to test whether the components of the three KADH identified in the P. 
falciparum  genome are actually expressed during the erythrocytic life cycle of the 
parasites, I analysed the transcription and translation of the KADH components by 
reverse transcriptase PCR (RT-PCR) and western blot analyses.
The transcription of the genes encoding the components of the parasite KGDH,
BCKDH and PDH was confirmed by RT-PCR performed on total RNA isolated from 
cultured parasites (figme 5.17A; lanes marked with +). All PCR products amplified 
were cloned into TOPO TA and their authenticity was confirmed by DNA sequencing. 
This experiment also allowed me to confirm the respective start-sites of LipDH2, 
KGDH-E2 and PDH-E2 and thus the correct annotation of the introns in these genes. 
Negative controls showed that there was no contamination of the RNA preparation with 
genomic DNA (figure 5.17A; lanes marked with -).
The protein expression of two components of the parasite KADH during their 
erythrocytic development was analysed by western blots of proteins isolated from 
cultured parasites. The antibodies utilised in these analyses were polyclonal rabbit anti- 
KGDH-E2 and anti-BCKDH-E2 antibodies raised against recombinantly expressed 
proteins (section 5.2.5 and S. Müller, unpublished data). The KGDH-E2 antibodies 
identified a single band o f an estimated molecular size of 42 kDa, which was in good 
agreement with the predicted mature protein size of 43 kDa (figure 5.17B; table 5.2). 
The BCKDH-E2 antibodies identified two bands with estimated molecular sizes of 50 
kDa and 30 kDa, respectively. The size of the larger major band was in good agreement 
with the predicted mature protein size of 49 kDa and the 30 kDa band might either 
represent a cross reacting protein or a degradation product of BCKDH-E2 that is 
recognised by the antiserum used (figure 5.17B; table 5.2).
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F igure  5.17 -  E x p re ss io n  o f KADH in P. falciparum  e ry th ro cy tic  s ta g e s
The transcription and translation of both LipDH g en es  in the erythrocytic s ta g e s  w as 
investigated by reverse  transcrip tase (RT-PCR) (Pane l A) and w estern blot (Pane l B). P an e l A 
d isp lays the resu lts of RT-PCR on total RNA iso lated from cultured parasites, with PCR 
perform ed in the  p re sen ce  (+) or a b se n c e  (-) of reverse  transcrip tase. Sam p les amplified in the  
a b se n c e  of reverse  transcrip tase (-) w ere used  a s  negative controls, in order to tes t for genom ic 
DNA contam ination in RNA prepara tions. This disp lays that all the com ponen ts of the KADH 
identified a re  transcribed. The produc ts w ere ana lysed  by DNA sequencing and confirmed the 
p re sen ce  of the predicted introns. P an e l B d isp lays the resu lts of w estern blot an a ly ses  on lOpg 
of parasite  protein ex trac t using polyclonal an tibodies raised agains t recombinantly ex p ressed  
KGDH-E2 (Lane 1) and BCKDH-E2 (Lane 2). The KGDH-E2 blot identified a  single m ajor band 
of approxim ately 42 kDa in size, and the BCKDH E2 blot identified two bands of 50 kDa and 30 
kDa. The m o lecular weight m arkers used  w ere precision plus all blue m arkers (Biorad).
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5.2.5 Recombinant expression and purification of KGDH-E2
In order to start characterising the different components of the KADH and to generate 
antibodies against them it was attempted to recombinantly express them in E.coli 
expression systems; I started with the expression of recombinant KGDH-E2.
The recombinant expression construct of KGDH-E2 was designed so that the 
hydrophobic N-terminal mitochondrial targeting peptide was excluded. The rationale 
for this was that the mitochondrial targeting peptide potentially could cause the 
production of insoluble protein in the E.coli expression system used. However, the 
cleavage site for the potential mitochondrial targeting peptide of KGDH-E2B had not 
been predicted by any of the prediction programs used earlier (table 5.2). This led me to 
design an expression construct starting at exon 3, which was based on the boundary of 
homology with KGDH-E2 proteins from other species (data not shown). This construct 
was amplified by PCR from genomic DNA, cloned into TOPO TA for sequence 
verification and subsequently sub-cloned into the E. coli expression vector pET28 
(figure 5.18). Cloning of this 1128 bp expression construct into pET28, which attaches a 
N-terminal His^-tag, would result in an expressed protein consisting of 399 amino acids 
with a predicted size of 44.6 kDa (including the tag).
k b M
Figure 5.18 -  Overview of KGDH-E2 cloning for recombinant expression
The KGDH-E2 expression construct w as amplified from gDNA by Taq superm ix (Invitrogen) 
using specific o ligonucleo tides (table 2.1). Lane M con tains 1 kb ladder (Prom ega); Lane 1 
con tains the 1.1 kb PCR product; Lane 2 con tains the TOPO TA clone used  for seq u en ce  
verification; Lane 3 con tains the pET28 c loned expression construct. Both the TOPO TA and 
pET28 c lones w ere digested  with Nhe 11 Hind III to rem ove the  insert.
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Test expressions of pET28 cloned KGDH-E2 were carried out to determine the 
parameters required for optimal recombinant expression. The expression plasmid was 
transformed into E. coli BLR(DE3) cells (Novagen) and test expressions were carried 
out at two different temperatures of incubation (37°C or 25°C) for varying lengths of 
expression (between 0 hours and overnight; after induction of expression with 1 mM 
IPTG). After the respective times of incubation, bacteria were harvested and pellets 
were lysed using “Bugbuster”. Soluble protein and insoluble fractions were separated 
by centrifugation and recombinant expression of KGDH-E2 was analysed by western 
blotting using an anti-His-tag antibody. Figure 5.19 shows the western blots of the 
different samples and it can be seen that the major protein band that is recognised by the 
anti-His antibody corresponds to an approximately 45 kDa protein. Regardless of the 
temperature used after induction of recombinant protein expression, it was found that 
the highest levels of KGDH-E2 expression occurred four hours after induction. Both 
western blots also displayed proteins reacting with the anti-His-antibodies of higher 
molecular masses suggesting that KGDH-E2 forms multimers that were not dissolved 
by the treatment with SDS-sample buffer. This is not unusual given that the E2 subunits 
of KADH are known to form trimers/multimers, which are the building blocks of the 
KADH core (Mooney et al., 2002).
A) B)
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F igure  5.19 -  T e s t  e x p re s s io n s  o f KGDH-E2
T es t expressions of pET28 KGDH-E2 w ere ana lysed  by w estern blot an a ly ses  using anti His- 
tag an tibodies. T es t expressions w ere se t up with incubation after induction a t either 37°C 
(P ane l A) or 25°C (P ane l B). Sam p les w ere taken every hour after induction (Oh) for four hours 
(1h -  4h) and again following overnight expression (on). Lane M con tains M agicmark protein 
s tan d ard s (Invitrogen): Lane + con tains recom binan t PfTrxR a s  a His-tag positive control.
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In order to generate sufficient recombinant protein for purification and further 
characterisation, large-scale expressions were performed at 37°C for four hours 
following induction of expression. Bacteria were harvested and the recombinantly 
expressed protein was purified by Ni-NTA batch purification, with the protein eluting 
between 100 and 250 mM imidazole in elution buffer (figui’e 5.20). The fractions of the 
Ni-NTA purification were analysed by SDS-PAGE and western blotting. The SDS- 
PAGE of the elution fractions (lane 6 to 10) showed the presence o f several protein 
bands of the following sizes: -1 0 0  kDa, 53 kDa, 48 kDa and 45 kDa. The 45 kDa band 
probably corresponds to the recombinantly expressed KGDH-E2 protein. Western blot 
analysis of the elution fraction obtained with 250 mM imidazole in elution buffer shows 
that only a single band was reactive with the anti-His-tag antibody (lane 3) suggesting 
that KGDH-E2 co-purified with non-His-tagged proteins present in the E. coli extract 
(figure 5.20A & B). This result led me to hypothesise that recombinantly expressed 
KGDH-E2 may be able to form complexes with E. coli proteins which cannot be 
resolved by this purification method. It is known that recombinantly expressed proteins, 
if not properly folded in the E. coli system, may form complexes with bacterial 
chaperones to enhance their solubility. However, the sizes of the co-purifying proteins 
may correspond to KGDH components of E. coli -  the 100 kDa band possibly 
represents KGDH-El, the 53 kDa band may potentially be LipDH and the 48 kDa band 
could be KGDH-E2 from E. coli. This suggested that the P. falciparum  KGDH-E2 
recombinant protein might form a KGDH complex with E. coli KGDH-El, E2 and 
LipDH proteins.
This theory was tested by applying the Ni-NTA elution fraction (250 mM imidazole) to 
a gel filtration column (Sephadex S-200 16/60) to attempt to separate the recombinantly 
expressed protein from the co-eluting proteins. It was expected that the recombinant 
KGDH-E2 should form multimers (most likely a 24mer) and therefore elute in the 
column’s void volume (peak 1 in figure 5.21 A; Black line). The void volume peak 
sample was analysed by SDS-PAGE (figure 5.21B, Lane 1) and still displayed the same 
protein profile as the originally loaded sample, (figure 5.21, Lane 10). However, a 
number of other peaks were obseiwed in the elution profile of the protein corresponding 
to the following sizes: 417 kDa (peak 2), 200 kDa (peak 3) and 47 kDa (peak 5).
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F igure  5.20 -  P u rifica tion  of KGDH-E2 by NI-NTA b a tch  bind ing
The purification profile for recombinantly ex p re ssed  KGDH-E2 w as loaded on to SDS-PAGE. 
P an e l A d isp lays a coom asie  stained gel of the following sam p les; E. coli so lub le fraction (Lane 
1), unbound/flow through (lane 2), w ash es  with 10 mM imidazole (Lanes 3 & 4), w ash with 20 
mM imidazole (Lane 5), 50 mM imidazole elution (Lane 6), 100 mM imidazole elution (Lane 7), 
150 mM imidazole elution (Lane 8), 200 mM imidazole elution (Lane 9) and  250 mM imidazole 
elution (Lane 10). Lane M con tains benchm ark protein s tandards (Invitrogen), The 250 mM 
elution sam p le  con tains four main bands a t 100 kDa, 53 kDa, 47 kDa and 45 kDa tha t 
correspond to E. coli E l (Ec E l), E. coli LipDH (Ec LipDH), E. coli E2 (Ec E2) and 
recom binantly ex p ressed  P. falciparum E2 (P f E2), respectively. P an e l B d isp lays a  w estern 
blot on purification sam p les, using H is-tag an tibodies (BD biosciences). The w estern con tains a 
his-tagged protein a s  a positive control (Lane 1; recom binan t PfTrxR), flow through fraction 
(Lane 2) and 250 mM imidazole elution (Lane 3). This displays tha t recom binan tly ex p re ssed  P. 
falciparum KGDH-E2 is con tained in the  elution fraction and m ost likely corresponds to the 45 
kDa band in panel A.
An attempt was made to separate the complex by methods used previously to resolve 
individual proteins from purified KADH complexes (Pettit et a i, 1973). Ni-NTA 
elutions were incubated with O.IM Glycine / IM NaCl and subsequently run on a 
Sephadex S-200 16/60 gel filtration column (red line in figure 5.21 A). The resulting 
void volume peak (peak 1 of red line on figure 5.21 A) was analysed by SDS-PAGE, 
which displayed that two of the co-eluting proteins (the predicted E. coli a  -  
ketoglutarate dehydrogenase and dihydrolipoamide dehydrogenase) were removed by 
this treatment (figure 5.2IB, Lane 2). It was also observed that the resulting elution 
trace contained an extra peak (peak 4 of the red line in figure 5.21 A) with a molecular 
mass of 107 kDa, which may represent the E. coli LipDH dimer released from the 
complex. 1 could not experimentally prove that all the components of the E. coli 
complex had been removed by this treatment and therefore another method to separate 
the recombinantly expressed protein from the complex formed was necessary.
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F igure  5.21 -  S e p a ra tio n  o f KGDH c o m p le x e s  by G lyc ine /sa lt tre a tm e n t
The possib le formation of a  com p lex consisting of the recombinantly ex p re ssed  KGDH E2 and 
com ponen ts of the E. coli KGDH w as ana lysed  by gel filtration chrom atography. P an e l A 
d isp lays the elution profile of Ni-NTA purified KGDH E2 run on the  sep h ad ex  8200  16/60 gel 
filtration column. The black line disp lays the  run carried out in 50 mM po tassium  phospha te , 150 
mM sodium chloride pH 7.6. The red line disp lays the run carried ou t in 0.1 mM Glycine, 1.0 M 
sodium chloride pH 9.0. Protein elution w as followed by abso rbance  a t 280 nm and resu lted in 
peaks a t > 1 MDa (peak 1, void volume), 417 kDa (peak 2), 200 kDa (peak 3), 107 kDa (peak 4) 
and 47 kDa (peak 5) P an e l B d isp lays the elution fraction from the gel filtration void volume 
fraction (peak 1 in pane l A) run on SDS-PAGE. Lane 1 corresponds to the void volum e from the 
po tassium  phospha te  run (black line in pane l A) and Lane 2 corresponds to the void volum e 
from the glycine/salt run (Red line in pane l A); Lane M con tains benchm ark protein s tan d ard s 
(Invitrogen). This figure show s tha t the possib le E.coli E l and E3 bands w ere rem oved from the 
protein com plex following trea tm en t with O.IM Glycine, IM NaCI.
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To fuiTher substantiate my suggestion that the recombinant P. falciparum protein would 
form complexes with the endogenous E. coli KGDH components, two of the co-eluted 
proteins (the 100 kDa and the 47 kDa proteins) were analysed by tryptic digestion 
followed by mass spectrometry. This identified the 100 kDa and 47 kDa co-eluting 
bands as the a-ketoglutarate dehydrogenase and succinyl transferase proteins from E. 
coli. These results therefore strongly suggest that the parasite KGDH-E2 indeed forms 
complexes with the bacterial KGDH components during the recombinant expression 
process. Since not all of the co-eluting bands were analysed by mass spectrometry 
finger printing it cannot be excluded that the recombinant protein not only forms 
complexes with the bacterial KGDH but possibly also with other KADH such as PDH 
and BCKDH. In the void volume elution fractions from the gel filtration column, bands 
of 66 kDa and 44 kDa could well represent components of the bacterial PDH and 
BCKDH proteins (PHD-E2 is a 66 kDa protein and BCKDH-E2 is a 44 kDa protein; 
faint bands in figure 5.21). The smaller bands observed at approximately 37 kDa and 25 
kDa cannot be attributed to any of the bacterial KADH complexes.
The difficulty to obtain pure recombinant KGDH-E2 protein led me to use denaturing 
Ni-NTA affinity chi'omatography to purify the recombinant protein. Initially the 
denaturing purification of P. falciparum  KGDH-E2 was carried out using a batch 
procedure. The denatured protein was eluted by a step-wise pH-gradient as shown in the 
SDS-PAGE (figure 5.22A). The elution fraction containing the recombinant protein 
was dialysed against non-denaturing Ni-NTA agarose loading buffer and applied to a 5 
ml Ni-NTA agarose column attached to an ÂKTA FPLC system. The column was 
washed and the protein was eluted using a linear gradient between 10 mM and 500 mM 
imidazole (figure 5.22B).
Unfortimateiy it was not possible to continue with a biochemical characterisation of 
KGDH-E2 due to time constraints. However, it is anticipated that the refolding of 
denatured recombinant proteins fiom the KADH will be possible (Hanemaaijer et a l, 
1989; Faure et al, 2000) and thus the denaturing purification might present a way to 
obtain pure recombinant KGDH-E2 protein for future analyses.
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F ig u re  5.22 -  P urifica tion  o f KGDH E2 by d e n a tu r in g  Ni-NTA purifica tion
The purification of recom binan t KGDH E2 w as carried out under denaturing conditions in order 
to elim inate the  com ponen ts of the E. coli KGDH from the purification. P an e l A d isp lays a  SDS- 
PAGE of the s tep  elutions of pET28 KGDH E2 by batch Ni-NTA purification. The majority of the 
recom binan t protein eluted in the pH 4.4 elutions. P ane l B; Following dialysis the pH 4.4 
elutions w ere further purified by native Ni-NTA purification over a  linear gradien t of imidazole 
(10mM -  500 mM imidazole). Lane 1 con tains the  d ialysed sam p le  from dena turing Ni-NTA 
elution a t pH 4.4; lane 2 con tains the flow through fraction; lane 3 con tains a  10 mM imidazole 
w ash; lanes 4 - 7  w ere be tw een 10 mM and 200 mM imidazole; lane 8 w as a  peak  a t 200 mM 
imidazole; lane 9 w as a peak a t 250 mM imidazole. Lane M in both pane l A and B con tains 
benchm ark protein s tan d ard s (Invitrogen).
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5.3 Discussion
5.3.1 Three KADH identified in the P. falciparum  genome
I have identified genes encoding all the components of three a-ke to acid dehydrogenase 
complexes in the P. falciparum  genome; a a-ketoglutarate dehydrogenase complex, a 
branched chain a-ke to acid dehydrogenase complex and pyruvate dehydrogenase 
complex. Three of the genes identified (KGDH-El, KGDH-E2 & PDH-E2) contained 
introns, with the PDH E2 gene containing ten in total. These introns utilised the 
canonical intron/exon boundaries (GT-AG) and also exhibited a higher A/T content in 
the intron sequences when compared to the exon sequences as reported previously 
(Gardner et al, 2002; Szafranski et a l, 2005). It was observed that all the intron 
containing genes that were investigated in this study (including LipDHl in chapter 4) 
contained introns primarily at the 5’ end of the gene (except PDH E2), which resulted in 
the separation of the organelle targeting sequences from those of the mature gene 
product. This may allow for alternative splicing to occur, which could result in the 
targeting of proteins to different subcellular localisations. Although there have been no 
reports of differential splicing causing changes in the subcellular localisation of proteins 
in P. falciparum, genes have been identified that share a targeting sequence (van 
Dooren et a l, 2002). It was also observed during my studies that the inti'on/exon 
boundaries were mostly conserved between the Plasmodium species (van Lin et a l,
2001) and this was utilised to aid the coiTect prediction of intron/exon boundaries.
The presence of the genes encoding for components of all tln'ee KADH poses the 
question as to when these protein complexes are actively expressed in the parasites. To 
address this question I have performed RT-PCR analyses and found that all components 
of the three KADH are transcribed during the erythrocytic development of the parasites. 
This was somewhat surprising given that microaiTay analyses of P. falciparum  
throughout the erythi'ocytic cycle suggested that these genes would not be expressed or 
if  so would only be expressed at extremely low levels through these developmental 
stages of the parasites (Bozdech et a l, 2003; Le Roch et a l, 2003). Proteome analyses 
of these parasite stages more or less conoborated the microarray data suggesting a 
minor role of the protein complexes during the erythrocytic life of the parasites (Florens 
et a l,  2002). However, analyses of protein levels of various proteins comprising KADH 
in the parasites (by Foth et a l, 2005 and this study) suggest that the genes of KADH 
components are not only transcribed but also present at reasonable protein levels in the
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parasites (as they were detectable by Western blotting) implying a role in parasite 
metabolism in the erythrocytic stages of P. falciparum (Foth et a l, 2005).
Analyses of the deduced amino acid sequences displayed N-terminal extensions of 
various lengths, which upon in silica analyses suggested that the KGDH and BCKDH 
were mitochondrial proteins whereas the single PDH was targeted to the apicoplast of 
the parasites. This was a surprising finding given that in other eukaryotes all three 
complexes usually are mitochondrial, apart from plants which contain two distinct PDH 
that are mitochondrial and plastid localised (Mooney et a l, 2002).
5.3.2 KGDH and BCKDH are mitochondrially localised
The presence of the BCKDH and KGDH in the mitochondria, as experimentally 
determined in this study by expressing GFP fusion proteins in the parasites, was 
consistent with the observed localisation of these complexes in other organisms. The 
observed mis-targeting of some GFP-fusion proteins to the food vacuole has however, 
not been reported previously by other groups. We postulate that this may be due to the 
constitutive over-expression of the fusion protein in the parasites flooding the 
mitochondrial import machinery, which may result in mis-targeting and degradation of 
the GFP-fusion proteins. We have observed this mis-targeting only in mitochondrially 
localised proteins and it may be that the mitochondrion is more susceptible to mis- 
targeting than the apicoplast. The mis-targeting may also he caused by the incorrect 
folding of the GFP-fusion protein and it may be possible to rectify this by designing a 
fusion protein with a shorter leader sequence or by taking into account the domain 
structure of the KADH proteins.
The P. falciparum KGDH could provide substrates (NADH and succinyl CoA) for a 
number of biochemical processes including haem biosynthesis, residual TCA cycle 
activity, and oxidative phosphorylation. Studies with recombinantly expressed P. 
falciparum KGDH-E2 protein demonstrated that the protein formed complexes with the 
components of the E. coli KGDH. This phenomenon has not been previously reported 
and may be due in part to the association of the recombinant P. falciparum KGDH-E2 
with the E. coli KGDH-E2. This may have been due to the reasonably high levels of 
amino acid sequence identity (52 % identity) in the catalytic domains (where self­
association occurs) of the two proteins, which would produce a complex core that 
contained both E2 proteins. The association of E l and LipDH proteins may have been 
due to the presence of E. coli KGDH-E2 in the core, as the lipoyl and subunit binding
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domains of recombinant P. falciparum KGDH-E2 displayed much lower levels of 
sequence identity to the same domains of the E. coli KGDH-E2 (24 % identity). 
Although further investigations will be necessary to conclusively prove the reason for 
the binding of the KGDH to the recombinantly expressed P. falciparum  KGDH-E2.
The P. falciparum  BCKDH would be involved in the degradation of branched chain 
amino acids isoleucine, valine and leucine; producing a-methylbutyryl-CoA, 
isobutyryl-CoA and isovalyryl-CoA from the substrates a-keto-p-methylvalerate, a- 
ketoisovalerate and a-ketoisocaproic acid, respectively. These products may eventually 
lead to the production of acetyl CoA and/or succinyl CoA that could be used within the 
TCA cycle (Ward et a l,  1999; Holecek, 2002). However, the activity of the BCKDH in 
the parasites may be limited, as no homologue of branched chain amino acid 
transaminase (EC 2.6.1.42), the protein responsible for providing the BCKDH with its a  
-  keto acid substrates, has yet to be identified in P. falciparum genome. Also a P. 
falciparum  acyl CoA dehydrogenase homologue (EC 1.3.99.10), the protein that acts on 
the acyl CoA products of the BCKDH reaction, has also yet to be identified in the 
genome.
The BCKDH in other organisms comes under the regulation of a branched chain a  -  
keto acid dehydrogenase kinase (EC 2.7.1.115) and phosphatase (EC 3.1.3.52). The P. 
falciparum BCKDH E2 contains a single phosphorylation site (Ser 319) although 
searches of the P. falciparum  genome have yet to identify homologues for either the 
kinase or the phosphatase.
5.3.3 The single PDH of P. falciparum  is apicoplast localised
I have identified a single pyruvate dehydrogenase complex in the P. falciparum genome 
and have confirmed its apicoplast localisation by expressing GFP-fusion proteins in 
erythrocytic stage parasites. The P. falciparum  PDH lacked a protein X component that 
is required in the mitochondrial PDH for binding of the LipDH protein (Sanderson et 
al, 1996). This was consistent with the apicoplast localisation of the PDH, as plastid 
localised PDH do not contain a protein X component (Mooney et al, 2002). Another 
difference between the mitochondrial and plastid localised PDH, is that plastid PDH are 
not regulated by phosphorylation/dephosphorylation (Randall et a l, 1989). 
Mitochondrial PDH activity is regulated by phosphorylation of the E la  subunit by 
pyruvate dehydrogenase kinase (EC 2.7.1.99). This phosphorylation leads to 
inactivation of PDH and is implicated in control mechanisms such as glucose
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homeostasis (Lydell et a l,  2002; Sugden et a l, 2003). The déphosphorylation of E l a  
by pyruvate dehydrogenase phosphatase (EC 3.1.3.43) activates the PDH E la  again. 
Mitochondrial PDH contain three possible sites of phosphorylation (Yeaman et al,
1978) and although one of the phosphorylation sites is conserved in the P. falciparum  
PDH (Ser 467 in P. falciparum PDH E la ; figure 5.9) and plastid PDH (Johnston et al, 
1997), homologues of the kinase or phosphatase have not been identified (in either P. 
falciparum  or plastids). It is therefore likely that the activity of plastid PDH is 
controlled either at the transcription/translation level, by changes in the biochemical 
environment (Reid et al, 1975) or by product inhibition (Camp et al, 1985; Camp et 
al, 1988).
A recent study (Foth et a l, 2005) has further investigated the P. falciparum  PDH with 
respect to phylogeny, subcellular localisation, expression in erythrocytic stages and 
enzyme activity. Foth et a l observed that the components of the P, falciparum  PDH 
were consistently grouped with plastidic and cyanobacterial PDH proteins during 
phylogenetic analyses, confirming that they were originally encoded for in the genome 
of the endosymbiont that eventually became the apicoplast. Foth et a l also 
independently confirmed the apicoplast localisation of P. falciparum PDH by GFP 
fusion and immuno-fluorescence studies that demonstrated co-localisation with an 
apicoplast marker protein (Foth et a l, 2003; van Dooren et al, 2005). The activity of 
the catalytic domain of the PDH-E2 was also investigated, demonstrating that this was 
active and had comparable kinetic parameters to other PDH-E2 catalytic domains tested 
(Yangefa/., 1997).
5.3.4 Consequences of KADH localisation on P. falciparum  biochemistry
The localisation of KADH in both the mitochondrion and the apicoplast requires that P. 
falciparum  has organelle specific LipDH proteins, which has been investigated and 
discussed in chapter 4. Another consequence of this localisation is the requirement for 
organelle-specific lipoylation pathways; as in order for the complexes to be active the 
E2 proteins are required to have a lipoyl moiety covalently attached. Studies in our (and 
others) laboratory have identified two separate pathways for the lipoylation of the E2 
proteins of KADH; a mitochondrially localised salvage pathway and an apicoplast 
localised biosynthesis pathway (Thomsen-Zieger et a l, 2003; Wrenger et a l, 2004).
The major role of the apicoplast localised PDH would be to produce acetyl Co A and 
NADH for the type II fatty acid biosynthesis (FAS) that is performed in this organelle
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(Waller et al, 1998). Fatty acid biosynthesis has been shown to be essential in 
erythrocytic stages (Waller et al, 1998; Surolia et a l, 2001; Waller et al, 2003; Surolia 
et al, 2004), and therefore any disruption of PDH activity should be lethal to the 
parasites. The presence of a mitochondrial PDH in humans requires any antimalarial 
inhibitors to be active specifically against the plastidic form, although at present no such 
inhibitors have been identified.
The absence of a mitochondrially localised PDH has wide ranging consequences on 
parasite biochemistry, as the mitochondrial PDH is usually the link between glycolysis 
and the tricarboxylic acid cycle (TCA cycle). This raises the question of what role does 
the TCA cycle play within the erythrocytic cycle? It has been generally accepted that 
erythrocytic stage P. falciparum  do not rely on the TCA cycle for energy production, 
but metabolise the majority of their glucose into lactic acid by glycolysis (Bryant et al, 
1964). The TCA cycle must however be at least partially active in order to drive 
oxidative phosphorylation, which has been shown to be essential for parasite sui-vival in 
these stages (Uyemura et a l, 2004). Although pyruvate cannot be used as a carbon 
source for the TCA cycle it may be possible that the TCA cycle is partially active with 
substrates supplied by anapleurotic reactions.
Amino acid degradation may play a key role in providing the TCA cycle with 
substrates, as only 20 % of the amino acids degraded during haemoglobin digestion are 
then used for protein synthesis (Krugliak et a l, 2002), suggesting that the other 80 % 
may be degraded for other cellular processes . The activity of the BCKDH is one 
possible source, as the degradation of valine, leucine and isoleucine (amino acids that 
are highly represented in haemoglobin) can ultimately provide the mitochondrion with 
sources of acetyl Co A and succinyl Co A. Another source of substrates for the TCA 
cycle would be the conversion of glutamate and oxaloacetate to a  -  ketoglutarate and 
aspartate via the activity of an aspartate aminotransferase that has been identified in the 
P. falciparum  genome (Berger et a l, 2001; Gardner et al, 2002). Glutamate can also be 
utilised to produce a  -  ketoglutarate via the activity of glutamate dehydrogenase, 
although the precise location of the three predicted glutamate dehydrogenase proteins 
has yet to be verified (Wagner et a l, 1998; Gardner et a l, 2002; Werner et a l, 2005). 
Another source of substrates that may be able to drive oxidative phosphorylation is the 
transfer of malate that has been produced from phosphoenolpyruvate (PEP), via 
oxaloacetate (OAA) by the activity of PEP-carboxylase (Gardner et a l, 2002) and a 
cytosolic malate dehydrogenase (Lang-Unnasch, 1992; Tripathi et a l,  2004). Once 
transported into the mitochondrion the malate can be acted on by a malateiquinone
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oxidoreductase which is likely to feed electrons into oxidative phosphorylation 
(Gardner et a l, 2002; Uyemura et a l, 2004).
TCA cycle substrates may also be imported into the mitochondrion from the cytosol and 
a number of transporters have been identified that may transport a  -  ketoglutarate or 
acetyl CoA. A dicarboxylate transporter may act as an a  -  ketoglutarate transporter and 
it may be possible that acetyl CoA produced in the apicoplast could be transfeiTed to the 
mitochondrion via an acetyl CoA transporter (NP_700833) that has been identified in 
the P. falciparum  genome. The precise location o f this transporter has not been 
determined, and the transfer o f acetyl CoA would need to span the multiple membranes 
of the two organelles. If this transfer were to occur, it would fm-ther confirm the 
metabolic co-dependence theory that is thought to drive the close association observed 
between the mitochondria and the apicoplast.
5.3.5 Why are the mitochondrion and apicoplast closely associated?
Van Dooren et al have undertaken a study into the structure o f the apicoplast and 
mitochondrion during the erythrocytic stages o f the parasite, with similar results to 
those observed in my study (van Dooren et a l, 2005). Studies into organelle ultra­
structure using electron microscopy were the first to demonstrate a close association 
between the Plasmodium mitochondrion and apicoplast (Aikawa, 1966; Prensier et a l ,  
1986; Hopkins et a l ,  1999). This close association o f the organelles has been proposed 
to arise from a metabolic co-dependence (Hopkins et a l, 1999; Ralph et a l, 2004) and 
the requirement for co-segregation of the organelles into merozoites (van Dooren et a l, 
2005).
The possible metabolic co-dependence can be demonstrated by localisation o f proteins 
from the haem biosynthesis pathway in the mitochondrion and the apicoplast (Sato et 
a l, 2004). This confirmed the prediction that different steps o f the haem biosynthesis 
pathway would occur in both organelles, which suggests that metabolites must be 
transferred between the two organelles for the pathway to be active (Gardner et a l,
2002). The co-segregation o f both organelles into the merozoites is essential, as both the 
mitochondrion and the apicoplast have been shown to be necessary for parasite survival. 
The mitochondrion has been proven necessary as several antimalarial drugs target 
mitochondrial proteins. Atovaquone has been demonstrated to inhibit the parasite’s 
oxidative phosphorylation, by inhibiting complex III (Kessl et a l, 2003), destroying the 
organelles membrane potential (Srivastava et a l, 1997). Artesunate, a derivative o f
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artemisinin has been suggested to inhibit Complex IV activity (Zhao et a l, 1986). Other 
compounds such as Primaquine and Artemether have been suggested to act specifically 
against the mitochondrion by causing morphological changes (Kawai et a l, 1993; 
Vaidya et a l, 1993). Studies have demonstrated that parasites that lack an active 
apicoplast display a “delayed death”, whereby they can readily develop within and 
escape from host cells, but are unable to re-infect to continue their life cycle (He et a l, 
2001). Although the mechanism o f this delayed death is not fully understood, this 
confirms the apicoplast as being essential for parasite survival. Inhibitors o f apicoplast 
located pathways such as non-mevalonate isoprenoid biosynthesis (Fosmidomycin) and 
type II fatty acid biosynthesis (Triclosan) have also been demonstrated to be potent 
antimalarials (Jomaa et al., 1999; Lell et a l ,  2003; Waller et a l ,  2003). Studies by 
Striepen et a l  in the related apicomplexan Toxoplasma gondii have demonstrated that 
the apicoplast divides by association with centromeres (Striepen et a l, 2000). If division 
occurs by this manner in Plasmodium it will be further complicated by the number o f  
daughter cells produced during schizogony, and this needs to be further investigated; 
along with the mode o f division o f the Plasmodium mitochondrion.
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5.4 Conclusions
I have identified the genes that encode the a-keto acid dehydrogenase complexes in the 
Plasmodium falciparum  genome. A number o f the genes were predicted to contain 
introns and these were experimentally verified (by DNA sequencing) following 
amplification from total RNA. All of the genes identified were amplified from total 
RNA, which confirmed that they were transcribed in the erythrocytic stages of 
infection. Protein expression during these stages was also confirmed by western blotting 
analyses for LipDH2, BCKDH E2 and KGDH E2.
In silico analyses had predicted that the KGDH and BCKDH would be located in the 
mitochondrion and that the single PDH identified would be located to the apicoplast. 
These predicted localisations were confirmed by expressing GFP-fusion proteins in 
erythrocytic stage parasites, and work is ongoing to further confirm these results by 
immuno-fluorescence studies with organelle-specific markers. The biochemical 
consequences o f the parasites lacking a mitochondrial PDH have been discussed and 
warrant further investigation. By utilising the PDH-GFP fusion proteins it was possible 
to visualise the development o f the mitochondrion and apicoplast during the 
erythrocytic stages. This confirmed the pattern o f close association, elongation and co­
separation obseiwed in other studies.
Analysis o f the recombinantly expressed KGDH-E2 protein identified that it formed 
complexes with components o f the E. coli KGDH. The recombinant protein was 
purified to homogeneity by denaturing purification and will allow me to further analyse 
the recombinant protein at a later date.
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“Here with a Loaf o f Bread beneath the Bough, 
A Flask o f Wine, a Book o f Verse - and Thou 
Beside me singing in the Wilderness - 
And Wilderness is Paradise now.”
Poem by Edward Fitzgerald
